

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF OHIO
EASTERN DIVISION**

IN RE NATIONAL PRESCRIPTION
OPIATE LITIGATION

This document relates to:

*The County of Summit, Ohio, et al. v. Purdue
Pharma L.P., et al.*, Case No. 18-OP-45090

*The County of Cuyahoga v. Purdue Pharma
L.P., et al.*, Case No. 18-OP-45004

MDL No. 2804

Case No. 17-md-2804

Hon. Dan Aaron Polster

TEVA, CEPHALON AND ACTAVIS GENERIC DEFENDANTS' EXHIBIT LIST

Defendants Teva Pharmaceutical Industries LTD¹, Teva Pharmaceuticals, USA, Inc. (“Teva”), Cephalon, Inc. (“Cephalon”), Watson Laboratories, Inc., Actavis LLC, Warner Chilcott Company, LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., Actavis South Atlantic LLC, Actavis Elizabeth LLC, Actavis Mid Atlantic LLC, Actavis Totowa LLC, Actavis Kadian LLC, Actavis Laboratories UT, Inc. f/k/a Watson Laboratories, Inc. – Salt Lake City, Actavis Laboratories FL, Inc., f/k/a Watson Laboratories, Inc. – Florida (collectively, the “Actavis Generic Defendants”) hereby submit the following Exhibit List for trial in this matter. The Teva, Cephalon and Actavis Generic Defendants submit this trial exhibit list subject to the following reservation of rights:

1. To withdraw at any time any exhibit identified on these lists;
2. To use admissible exhibits identified or used by Plaintiffs or any other party;

¹ Teva Pharmaceutical Industries LTD, is an Israeli corporation that is not subject to and contests personal jurisdiction. It joins these exhibits out of an abundance of caution and does not waive and expressly preserves its personal jurisdiction challenge.

3. To supplement and/or amend these lists upon receipt of Plaintiffs' exhibit list(s), witness list(s) and/or amendments and changes to Plaintiffs' or Defendants' deposition designations or counter-designations;

4. To supplement and/or to amend these lists in the event that additional relevant documents or materials are produced in this action, identified in subsequent supplemental expert reports, or are discovered subsequent to the date of service of these exhibit lists;

5. To supplement these lists with any medical or scientific literature, other data, or regulatory findings or communications issued or published after the date of this submission;

6. To supplement and/or to amend these exhibit lists to use additional unlisted documents and/or data at trial as required for rebuttal, cross examination, demonstrative purposes, impeachment purposes, or to cure an evidentiary objection, or to the extent Plaintiffs proffer any documents which Plaintiffs have not listed or to the extent that Plaintiffs purport to pursue claims or theories not set forth in their pleadings to date;

7. To object to the introduction and/or admissibility of any document listed on the exhibit lists;

8. That the inclusion of any exhibit on any exhibit list does not waive or affect any prior confidentiality designations in this litigation;

9. That the inclusion of a particular document on the Teva, Cephalon and Actavis Generic Defendants' exhibit list is not intended to be a waiver of the right to object to the introduction and/or admissibility of that document for any purpose;

10. To use alternative copies of exhibits where appropriate, including but not limited to physical, color, redacted, and/or native documents, or copies, without deposition exhibit stickers;

11. To use trial demonstrative exhibits, including without limitation: charts, graphs, photographs, animations, timelines, objects, models, PowerPoint slides, drawings, graphics, and other demonstrative aids;

12. To offer enlargements of any exhibits on the lists or on any party's exhibit lists;

13. To supplement and/or to amend these lists in response to rulings of the Court on pretrial motions, including any Daubert motions, Motions for Summary Judgment, or motions in limine, or any other Court decisions that affect the scope of evidence in this trial; and

14. To supplement and/or amend these lists as necessary based on the Court's order regarding the severing of particular party and/or as necessary based on future severance, settlement, and/or dismissal of any other party.

Dated: September 25, 2019

Respectfully submitted,

/s/ Wendy West Feinstein

Wendy West Feinstein
MORGAN, LEWIS & BOCKIUS LLP
One Oxford Centre
301 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 560-7455
Facsimile: (412) 560-7001
wendy.feinstein@morganlewis.com

Steven A. Reed
Eric W. Sitarchuk
Rebecca J. Hillyer
MORGAN, LEWIS & BOCKIUS LLP
1701 Market St.
Philadelphia, PA 19103-2921
Tel: (215) 963-5603
steven.reed@morganlewis.com
eric.sitarchuk@morganlewis.com
rebecca.hillyer@morganlewis.com

Brian Ercole
MORGAN, LEWIS & BOCKIUS LLP
200 South Biscayne Boulevard, Suite 5300
Miami, FL 33131
Telephone: (305) 415-3000
Facsimile: (305) 415-3001
brian.ercole@morganlewis.com

*Attorneys for Teva Pharmaceuticals USA, Inc.,
Watson Laboratories, Inc., Actavis LLC, Actavis
Pharma, Inc. f/k/a Watson Pharma, Inc., Warner
Chilcott Company, LLC, Actavis South Atlantic
LLC, Actavis Elizabeth LLC, Actavis Mid Atlantic
LLC, Actavis Totowa LLC, Actavis Kadian LLC,
Actavis Laboratories UT, Inc. f/k/a Watson
Laboratories, Inc.-Salt Lake City, and Actavis
Laboratories FL, Inc., f/k/a Watson Laboratories,
Inc.-Florida*

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-1	09/15/2006	Watson Infoalert (notification of generic Actiq)	TEVA_MDL_A_00695612	TEVA_MDL_A_00695615							
AC-2	09/10/2018	Buprenorphine Naloxone Journal Advertisement	TEVA_MDL_A_02914335	TEVA_MDL_A_02914335							
AC-3	07/01/2010	Fentanyl Reservoir System Mailer	TEVA_MDL_A_02914336	TEVA_MDL_A_02914339							
AC-4	08/01/2014	Hydrocodone Bitartrate and Acetaminophen Availability Announcement	TEVA_MDL_A_02914340	TEVA_MDL_A_02914344							
AC-5	06/01/2004	Oxymorphone Hydrochloride availability announcement	TEVA_MDL_A_02914345	TEVA_MDL_A_02914347							
AC-6	01/05/2015	Attached Action Stat for Oxycodone HCL ER Tablets, CII	Acquired_Actavis_00835648	Acquired_Actavis_00835648							
AC-7		Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2016-Q1.17	TEVA_MDL_A_02419960	TEVA_MDL_A_02419960							
AC-8		Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2015	TEVA_MDL_A_02419963	TEVA_MDL_A_02419963							
AC-9		Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2013-2014	TEVA_MDL_A_02419969	TEVA_MDL_A_02419969							
AC-10		Direct sales data for Jan 2011 to March 2017	TEVA_MDL_A_02419962	TEVA_MDL_A_02419962							
AC-11		Opioids Direct Sales (2003-2017)	TEVA_MDL_A_02416205	TEVA_MDL_A_02416205							
AC-12		Opioids Indirect Sales (2011-2017)	TEVA_MDL_A_02416206	TEVA_MDL_A_02416206							
AC-13		Actavis/Watson Indirect Sales	TEVA_MDL_A_07869902	TEVA_MDL_A_07937356							
AC-14		SAP Transactional data for Watson 2004-2005	TEVA_MDL_A_08637278	TEVA_MDL_A_08637278							
AC-15		Direct Sales data 2006 through Q1 2017	TEVA_MDL_A_08637279	TEVA_MDL_A_08637279							
AC-16		Indirect Sales data (Model N) Q2 2014 though Q1 2017	TEVA_MDL_A_08637273	TEVA_MDL_A_08637277							
AC-17		QAD data September 1996-April 2013	TEVA_MDL_A_13742900	TEVA_MDL_A_13742900							
AC-18		SAP transactional data May 2004-March 2017	TEVA_MDL_A_13742901	TEVA_MDL_A_13742901							
AC-19		SAP Unique Customer & NDC Codes	TEVA_MDL_A_13742989	TEVA_MDL_A_13742989							
AC-20		Model N (Chargeback Data)	Acquired_Actavis_01996162	Acquired_Actavis_02001522							
AC-21	03/11/2019	Actavis Inc. Health Care Compliance Guide	Acquired_Actavis_01169151	Acquired_Actavis_01169210							
AC-22	07/17/2002	Watson Pharmaceuticals, Inc. Promotional and Marketing Policies	Acquired_Actavis_01648317	Acquired_Actavis_01648341							
AC-23	03/04/2009	Corporate Structure Operating Procedure	Acquired_Actavis_00211536	Acquired_Actavis_00211549							
AC-24	06/24/2011	Handling of DEA Controlled Substances	Acquired_Actavis_00477630	Acquired_Actavis_00477659							
AC-25	10/19/2012	Potential Sources of Medical Inquiries	Acquired_Actavis_00622914	Acquired_Actavis_00622931							
AC-26	01/23/2013	Glossary of Terms Relating to Adverse Events	Acquired_Actavis_00622941	Acquired_Actavis_00622955							
AC-27	12/30/2011	Managing Watson Pharmacovigilance Work Instructions	Acquired_Actavis_00623183	Acquired_Actavis_00623187							
AC-28	02/23/2009	Fentanyl Patch Outsource of SADR, PC and MI to Prosar	Acquired_Actavis_00963852	Acquired_Actavis_00963858							
AC-29	12/07/2019	Corporate Guidelines for HR Policies	Acquired_Actavis_01167403	Acquired_Actavis_01167438							
AC-30	11/23/2010	Global Anti-Corruption Policy	Acquired_Actavis_01168623	Acquired_Actavis_01168636							
AC-31	07/11/2019	Internal Investigation Procedure and Guidelines	Acquired_Actavis_01169131	Acquired_Actavis_01169138							
AC-32	07/11/2019	Actavis Inc. Compliance and Integrity "Speaking Up" Policy	Acquired_Actavis_01169139	Acquired_Actavis_01169142							
AC-33	09/07/2011	SOP MA-006 US Medical Affairs - Elizabeth (USMA-E) Exchange of Cases with Pharmacovigilance Drug Safety Europe (PhVDSE/RoW)	Acquired_Actavis_01169213	Acquired_Actavis_01169213							
AC-34	03/27/2009	Tracking and Trending of Deviations and CAPAs	Acquired_Actavis_01169958	Acquired_Actavis_01169964							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-35	11/13/2019	Actavis Code of Conduct	Acquired_Actavis_01190118	Acquired_Actavis_01190144							
AC-36	11/01/2013	Global Ethics & Compliance Charitable Grants and Donations	Acquired_Actavis_01190347	Acquired_Actavis_01190361							
AC-37	01/20/2009	Quality Organisation	Acquired_Actavis_01344058	Acquired_Actavis_01344064							
AC-38	04/26/2012	Safety Signal Detection and Risk Management	Acquired_Actavis_01358902	Acquired_Actavis_01358910							
AC-39		Trending of Suspected Adverse Reactions	Acquired_Actavis_01385293	Acquired_Actavis_01385296							
AC-40	01/01/2009	Actavis Business Conduct Policy	Acquired_Actavis_01389427	Acquired_Actavis_01389433							
AC-41	07/03/2013	Global Pharmacovigilance Quality System	Acquired_Actavis_01437838	Acquired_Actavis_01437848							
AC-42	05/17/2011	Management of Suspected Adverse Drug Reaction Reports	Acquired_Actavis_01440105	Acquired_Actavis_01440134							
AC-43	12/10/2013	Adverse Event and Product Complaint Procedure	Acquired_Actavis_01440558	Acquired_Actavis_01440567							
AC-44	12/13/2013	Guidelines for Forwarding Adverse Events, Potential Safety Information, and Quality Defect Complaints	Acquired_Actavis_01440569	Acquired_Actavis_01440589							
AC-45	09/03/2013	Distribution of Medicinal Products	Acquired_Actavis_01444274	Acquired_Actavis_01444278							
AC-46	01/03/2011	Business Partner - Evaluation & Handling of Pharmacovigilance Performance	Acquired_Actavis_01444371	Acquired_Actavis_01444373							
AC-47	06/07/2012	CAPAs Related to Inspection and Audit Findings and Compliance Management in Pharmacovigilance	Acquired_Actavis_01444374	Acquired_Actavis_01444380							
AC-48	03/14/2008	Use of Oracle Adverse Event Reporting System (AERS) in US Medical Affairs	Acquired_Actavis_01444415	Acquired_Actavis_01444429							
AC-49	11/27/2012	Crisis Management Standard Operating Procedure	Acquired_Actavis_01444438	Acquired_Actavis_01444444							
AC-50	11/27/2012	Handling of Safety Issues	Acquired_Actavis_01444450	Acquired_Actavis_01444457							
AC-51	02/14/2013	Documenting GMP Contacts with Regulatory Agencies	Acquired_Actavis_01445237	Acquired_Actavis_01445239							
AC-52	10/31/2006	Managing Customer Complaints/ Adverse Drug Events	Acquired_Actavis_01445623	Acquired_Actavis_01445634							
AC-53	08/30/2006	Management of Medical Inquiries	Acquired_Actavis_01447862	Acquired_Actavis_01447868							
AC-54	03/11/2015	Actavis Compliance: General Training	Acquired_Actavis_01493361	Acquired_Actavis_01493411							
AC-55	10/04/2011	Actavis Compliance Program: Speak Up Policy/Actavis Alertline	Acquired_Actavis_01501576	Acquired_Actavis_01501582							
AC-56	11/01/2011	Regional Meetings: Generic Kadian Sales Team Training	Acquired_Actavis_01325827	Acquired_Actavis_01325827							
AC-57	06/16/2011	Advertisement & Approval Review/Approval – Oxymorphone ER Journal Ad w/ Summary	Acquired_Actavis_01372605	Acquired_Actavis_01372609							
AC-58	07/25/2007	SOP RA-003 Review and Approval of Drug Advertising for All ANDA Prescription Drug Products (July 25 2007)	Acquired_Actavis_01389540	Acquired_Actavis_01389544							
AC-59	02/27/2012	Advertisement & Approval Review/Approval – Morphine Sulfate ER Caps – Electronic Sellsheet with PI attached	Acquired_Actavis_02228429	Acquired_Actavis_02228433							
AC-60	06/28/2011	Advertisement & Approval Review/Approval – Oxymorphone HCL Extended Release Tabs – Sellsheet	Acquired_Actavis_02230003	Acquired_Actavis_02230005							
AC-61	11/05/2012	Infolert: Watson/Actavis Acquisition	Acquired_Actavis_02231065	Acquired_Actavis_02231066							
AC-62	09/03/2013	GQP-08-02 Global Quality Policy: Advertising and Promotion	Acquired_Actavis_01444248	Acquired_Actavis_01444250							
AC-63	01/03/2016	ANDA Approval	TEVA_MDL_A_02922022	TEVA_MDL_A_02922025							
AC-64	07/11/2013	ANDA Approval	Acquired_Actavis_00677901	Acquired_Actavis_00677905							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-65	11/17/2017	ANDA Approval	TEVA_MDL_A_08981645	TEVA_MDL_A_08981651							
AC-66	09/14/2011	SOP RA-003 Review and Approval of Drug Advertising For Prescription Drugs—Actavis—2011	ALLERGAN_MDL_00626198	ALLERGAN_MDL_00626203							
AC-67	08/01/2011	Email RE: Generic equivalent to Opana ER now available from Actavis, pp. 3–4	ALLERGAN_MDL_00401025	ALLERGAN_MDL_00401029							
AC-68	07/11/2019	Introduction of Oxymorphone Hydrochloride Extended-Release Tablets, CII: Sales Training Class	ALLERGAN_MDL_00401500	ALLERGAN_MDL_00401518							
AC-69	03/08/2012	Email from M. Killion re Generic Oxymorphone Update	ALLERGAN_MDL_00445923	ALLERGAN_MDL_00445923							
AC-70	11/11/2019	Availability Announcement for Generic Kadian (morphine sulfate extended-release)	ALLERGAN_MDL_00478888	ALLERGAN_MDL_00478889							
AC-71	06/14/2011	Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use for Buprenorphine Hydrochloride and Naloxone Hydrochloride - Form FDA 356h	Acquired_Actavis_00187844	Acquired_Actavis_00187846							
AC-72	05/13/2008	Supplement to ANDA #77-062 for Fentanyl Transderman System with attached Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use - Form FDA 356h	Acquired_Actavis_00188237	Acquired_Actavis_00188249							
AC-73	02/08/2012	Email from Jinping McCormick, Director of Marketing, Actavis, to Nathalie Leitch and Terrence Fullem	Acquired_Actavis_02472861	Acquired_Actavis_02472863							
AC-74	06/12/2019	NAM/MSL Engagement Training	Acquired_Actavis_00448595	Acquired_Actavis_00448609							
AC-75	07/25/2007	SOP RA-003 Review and Approval of Drug Advertising for All ANDA Prescription Drug Products	Acquired_Actavis_00985705	Acquired_Actavis_00985722							
AC-76	07/22/2011	Full Product Catalog Review, and Generic Return Goods Policy	Acquired_Actavis_01063667	Acquired_Actavis_01063689							
AC-77	12/23/2013	GCPOL-014US Policy on Contracting with Healthcare Professionals	Acquired_Actavis_01190024	Acquired_Actavis_01190031							
AC-78	05/04/2011	Compliance Policies on Interacting with Health Care Professionals and Other Customers	Acquired_Actavis_01190039	Acquired_Actavis_01190109							
AC-79	12/23/2013	U.S. Policy on Promotion, Non-Promotional, and Off-Label Interactions and Materials	Acquired_Actavis_01190436	Acquired_Actavis_01190449							
AC-80	03/06/2009	SOP C0-001 Product Recall Procedure	Acquired_Actavis_01403294	Acquired_Actavis_01403312							
AC-81	07/07/2005	Corporate Quality Policy: Drug Product Recalls and Market Withdrawals	Acquired_Actavis_01495263	Acquired_Actavis_01495270							
AC-82	01/07/2019	C-260 Watson Pharmaceuticals, Inc. Human Resources Policy and Procedures Manual: Speaking Engagements	Acquired_Actavis_01495791	Acquired_Actavis_01495791							
AC-83	01/28/2013	Actavis - SOM System Logic	TEVA_MDL_A_01038898	TEVA_MDL_A_01038942							
AC-84	03/21/2016	Actavis - Power Point re SOM Program	TEVA_MDL_A_01038978	TEVA_MDL_A_01038993							
AC-85	10/18/2013	Actavis - Controlled SOM Procedure	TEVA_MDL_A_01039097	TEVA_MDL_A_01039100							
AC-86	03/11/2014	Actavis - SOM program overview after merger with Watson.	TEVA_MDL_A_01039190	TEVA_MDL_A_01039190							
AC-87	10/04/2011	Watson - Investigation Summary Suspicious Order TOP RX, Inc.	TEVA_MDL_A_01039670	TEVA_MDL_A_01039671							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-88	05/17/2012	Watson - PowerPoint titled Global Security & DEA Affairs Audit Summary: Top RX, Inc.	TEVA_MDL_A_01039672	TEVA_MDL_A_01039672							
AC-89	05/30/2012	Watson - Letter to Top RX, Inc. re Restoration of Business Relationship After Audit	TEVA_MDL_A_01039673	TEVA_MDL_A_01039673							
AC-90	07/19/2011	Watson - cSOP – 11-004 – Revision 004 – Suspicious Orders of Controlled Drugs (July 19 2011)	TEVA_MDL_A_01130615	TEVA_MDL_A_01130619							
AC-91		Watson - DEA Affairs Organizational Overview (2009-2010)	TEVA_MDL_A_01159593	TEVA_MDL_A_01159603							
AC-92	09/27/2012	Email RE: Order(s) on Hold - Cardinal SD# 574340	ALLERGAN_MDL_04173111	ALLERGAN_MDL_04173113							
AC-93	01/11/2016	Email RE: Bell Medical	ALLERGAN_MDL_03431731	ALLERGAN_MDL_03431739							
AC-94	01/31/2011	E-mail from Rachelle Galant to Kelly Smith (re: Ox., IR Tabs Suspicious Order SOP revised 1-28-2011).	ALLERGAN_MDL_00493795	ALLERGAN_MDL_00493795							
AC-95	09/12/2012	E-mail from Rachelle Grant to Nancy Baran (re: Last question I promise).	Acquired_Actavis_00099564	Acquired_Actavis_00099564							
AC-96	09/25/2012	E-mail from Michael Clarke to Nancy Baran, et. al (re: SOM meeting).	ALLERGAN_MDL_01641955	ALLERGAN_MDL_01641956							
AC-97	02/14/2012	E-mail from Jinping McCormick to Michael Perfetto and Rachelle Galant (re: RE: safe and secure).	ALLERGAN_MDL_01725016	ALLERGAN_MDL_01725019							
AC-98	03/08/2012	E-mail from Nancy Baran to Michael Clarke, et. al (re: SOM PROJECT TEAM WEEKLY STATUS- Following our meeting on Tuesday, 3/6).	ALLERGAN_MDL_01719862	ALLERGAN_MDL_01719862							
AC-99	06/25/2015	E-mail from Thomas Napoli to Tara Brolly re: (ACTION REQUIRED: Information Request from Pinney Associates).	Acquired_Actavis_00930887	Acquired_Actavis_00930890							
AC-100	05/06/2011	E-mail from Nancy Baran to Beth Zelnick-Kaufman, et. al (re: FW: Actavis / BuzzeoPDMA - Customer Services Agreement - SOM Services).	ALLERGAN_MDL_01860386	ALLERGAN_MDL_01860387							
AC-101	09/30/2013	Email from T. Napoli to ABC requesting DEA/SOM Compliance materials and information	TEVA_MDL_A_01037632	TEVA_MDL_A_01037632							
AC-102	09/30/2013	Letter from T. Napoli to ABC requesting DEA/SOM Compliance materials and information	TEVA_MDL_A_01037633	TEVA_MDL_A_01037634							
AC-103	09/30/2013	Actaivs / ABC - Compliance Acknowledgement Form	TEVA_MDL_A_01037635	TEVA_MDL_A_01037635							
AC-104	09/30/2013	Overview of ABC's Diversion Control Program	TEVA_MDL_A_01037636	TEVA_MDL_A_01037638							
AC-105	02/26/2013	Email from Ed. Hazewski to Tom Napoli Attaching Completed Due Diligence Documents	TEVA_MDL_A_01037639	TEVA_MDL_A_01037640							
AC-106	12/27/2011	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_00220379	Acquired_Actavis_00220380							
AC-107	12/27/2011	Actavis Elizabeth, LLC Quota Approval - RK0146806 12-27-2011.pdf	Acquired_Actavis_00456460	Acquired_Actavis_00456461							
AC-108	07/17/2009	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01378198	Acquired_Actavis_01378198							
AC-109	07/17/2009	Watson Laboratories Inc Quota Approval - RW0117261 07-17-09.PDF	Acquired_Actavis_01378199	Acquired_Actavis_01378199							
AC-110	12/31/2009	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01378389	Acquired_Actavis_01378389							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-111	12/31/2009	Watson Laboratories Inc Quota Approval RW0331885 12-23-2009.pdf	Acquired_Actavis_01378390	Acquired_Actavis_01378390							
AC-112	12/31/2009	Watson Laboratories Inc Quota Approval- Florida RA0279946 12-23-2009.pdf	Acquired_Actavis_01378391	Acquired_Actavis_01378391							
AC-113	12/31/2009	Watson Laboratories Inc Quota Approval - Florida RA0297033 12-23-2009.pdf	Acquired_Actavis_01378392	Acquired_Actavis_01378392							
AC-114	12/31/2009	Watson Laboratories Inc Quota Approval - Florida RA0352663 12-23-2009.pdf	Acquired_Actavis_01378393	Acquired_Actavis_01378393							
AC-115	12/31/2009	Watson Laboratories Inc Quota Approval RD0118150 12-23-2009.pdf	Acquired_Actavis_01378394	Acquired_Actavis_01378394							
AC-116	12/31/2009	Watson Laboratories Inc Quota Approval RW0117261 12-23-2009.pdf	Acquired_Actavis_01378395	Acquired_Actavis_01378395							
AC-117	12/31/2009	Watson Laboratories Inc Quota Approval RW0288933 12-23-2009.pdf	Acquired_Actavis_01378396	Acquired_Actavis_01378396							
AC-118	12/30/2010	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01378409	Acquired_Actavis_01378409							
AC-119	12/30/2010	Andrx dba Watson Quota Approval RA0279946 12-29-10.PDF	Acquired_Actavis_01378410	Acquired_Actavis_01378410							
AC-120	12/30/2010	Andrx dba Watson Quota Approval RA0297033 12-29-10.PDF	Acquired_Actavis_01378411	Acquired_Actavis_01378411							
AC-121	12/30/2010	Andrx dba Watson Quota Approval RA0352663 12-29-10.PDF	Acquired_Actavis_01378412	Acquired_Actavis_01378412							
AC-122	12/30/2010	Watson Quota Approval RW0117261 12-29-10.PDF	Acquired_Actavis_01378413	Acquired_Actavis_01378413							
AC-123	12/30/2010	Watson Quota Approval RW0259893 12-2910.PDF	Acquired_Actavis_01378414	Acquired_Actavis_01378414							
AC-124	12/30/2010	Watson Quota Approval RW0288933 12-29-10.PDF	Acquired_Actavis_01378415	Acquired_Actavis_01378415							
AC-125	06/10/2014	Actavis Laboratories Fl, Inc. Quota Approval RA0297033 6-9-2014.pdf	Acquired_Actavis_01378873	Acquired_Actavis_01378873							
AC-126	06/10/2014	Actavis Laboratories, FL, Inc. Quota Approval RA0279946 6-9-2014.pdf	Acquired_Actavis_01378874	Acquired_Actavis_01378874							
AC-127	08/12/2014	Actavis Laboratories Fl, Inc. Quota Approval RS0297033_8-12-2014.pdf	Acquired_Actavis_01379145	Acquired_Actavis_01379145							
AC-128	12/28/2011	Watson Laboratories_Quota Approval RA0297033_12-27-2011pdf.pdf	Acquired_Actavis_01379672	Acquired_Actavis_01379672							
AC-129	12/28/2011	Watson laboratories Quota Approval RA0279946 12-28-2011.pdf	Acquired_Actavis_01379673	Acquired_Actavis_01379673							
AC-130	07/19/2011	DEA Quota Letter.msg	Acquired_Actavis_01379850	Acquired_Actavis_01379850							
AC-131	07/19/2011	Watson Quota Approval RW0117261 7-18-11.PDF	Acquired_Actavis_01379851	Acquired_Actavis_01379851							
AC-132	08/05/2011	DEA Quota Letters.msg	Acquired_Actavis_01379900	Acquired_Actavis_01379900							
AC-133	08/05/2011	Andrx Pharmaceuticals Inc-FL Quota Approval RA0279946 08-05-11.PDF	Acquired_Actavis_01379901	Acquired_Actavis_01379901							
AC-134	08/05/2011	Andrx Pharmaceuticals Inc-FL Quota Approval RA035266 08-05-11.PDF	Acquired_Actavis_01379902	Acquired_Actavis_01379902							
AC-135	09/30/2014	Actavis Laboratories, Inc.-Florida Quota Approval RA0279946_9-26-2014.pdf	Acquired_Actavis_01379975	Acquired_Actavis_01379975							
AC-136	04/28/2016	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01842692	Acquired_Actavis_01842692							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-137	04/28/2016	Actavis Laboratories FL, Inc. Quota Approval RA0352663_4-28-2016.pdf	Acquired_Actavis_01842693	Acquired_Actavis_01842693							
AC-138	04/25/2016	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01842907	Acquired_Actavis_01842907							
AC-139	04/25/2016	Actavis Elizabeth LLC Quota Approval RK0146806_04-25-2016.pdf	Acquired_Actavis_01842908	Acquired_Actavis_01842908							
AC-140	05/16/2006	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01843751	Acquired_Actavis_01843751							
AC-141	05/16/2016	Warner Chilcott Company, LLC Quota Approval RW0456865_5-16-2016.pdf	Acquired_Actavis_01843752	Acquired_Actavis_01843752							
AC-142	09/21/2010	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01673258	Acquired_Actavis_01673258							
AC-143	09/20/2010	Watson Laboratories, Inc. Quota Approval (RW0117261) 09-20-2010.pdf	Acquired_Actavis_01673259	Acquired_Actavis_01673259							
AC-144	02/11/2011	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01673272	Acquired_Actavis_01673272							
AC-145	02/11/2011	Watson Laboratories Inc Quota Approval RW0331885 02-11-11.PDF	Acquired_Actavis_01673273	Acquired_Actavis_01673273							
AC-146	12/27/2011	Watson Laboratories Quota Approval _RW0117261_12-27-2011.pdf	Acquired_Actavis_01674724	Acquired_Actavis_01674724							
AC-147	08/09/2002	Watson Laboratories Inc-FL Quota Approval RA0279946 -08-09-12.pdf	Acquired_Actavis_01674898	Acquired_Actavis_01674898							
AC-148	09/10/2014	Actavis Elizabeth, LLC Quota Approval RK0146806_9-10-2014.pdf	Acquired_Actavis_01674917	Acquired_Actavis_01674917							
AC-149	08/09/2012	Watson Laboratories Inc- Quota Approval FL RA0352663 -08-09-12.pdf	Acquired_Actavis_01674947	Acquired_Actavis_01674947							
AC-150	10/01/2012	Watson Laboratories Quota Approval RW0117261 10-01-2012.pdf	Acquired_Actavis_01675117	Acquired_Actavis_01675117							
AC-151	08/06/2012	Watson Quota Approval RW0117261 8-6-2012.pdf	Acquired_Actavis_01675146	Acquired_Actavis_01675146							
AC-152	09/19/2014	Correspondence with DEA Re: Procurement Quota	Acquired_Actavis_01675402	Acquired_Actavis_01675402							
AC-153	10/22/2014	Actavis Laboratories FL, Inc. Quota Approval RA0352663_10-22-2014.pdf	Acquired_Actavis_01675450	Acquired_Actavis_01675450							
AC-154	09/25/2014	Actavis Laboratories Florida, Inc. Quota Approval RA0352663_9-25-2014.pdf	Acquired_Actavis_01675486	Acquired_Actavis_01675486							
AC-155	09/25/2014	Watson Laboratories, Inc. Quota Approval RW0288933_9-25-2014.pdf	Acquired_Actavis_01675547	Acquired_Actavis_01675547							
AC-156	09/10/2014	Actavis, LLC Quota Approval RA0419552_9-10-2014.pdf	Acquired_Actavis_01675562	Acquired_Actavis_01675562							
AC-157	12/27/2011	Actavis Elizabeth, LLC Quota Approval RK0146806 12-27-2011.pdf	Acquired_Actavis_01696447	Acquired_Actavis_01696448							
AC-158	12/27/2011	Watson Laboratories_Quota Approval RW0117261_12-27-2011.pdf	ALLERGAN_MDL_03737793	ALLERGAN_MDL_03737794							
AC-159	11/30/2012	Watson Laboratories Quota Approval RW0117261 11-30-2012.pdf	ALLERGAN_MDL_03740473	ALLERGAN_MDL_03740473							
AC-160	08/06/2012	Watson Quota Approval RW0117261 8-6-2012.pdf	ALLERGAN_MDL_03740683	ALLERGAN_MDL_03740684							
AC-161	07/30/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03953857	ALLERGAN_MDL_03953857							
AC-162	07/29/2008	Watson DEA Approval letter for Hydrocodone 7-29-08.PDF	ALLERGAN_MDL_03953858	ALLERGAN_MDL_03953858							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-163	09/23/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03953866	ALLERGAN_MDL_03953866							
AC-164	09/22/2008	Andrx Pharmaceuticals hydrocodone letter - FL.PDF	ALLERGAN_MDL_03953867	ALLERGAN_MDL_03953867							
AC-165	12/30/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03953868	ALLERGAN_MDL_03953868							
AC-166	12/29/2008	Watson Laboratories RW0288933 12-29-08.PDF	ALLERGAN_MDL_03953869	ALLERGAN_MDL_03953869							
AC-167	12/29/2008	Watson Laboratories RD0118150 12-29-08.PDF	ALLERGAN_MDL_03953870	ALLERGAN_MDL_03953870							
AC-168	12/29/2008	Watson Laboratories RW0117261 12-2908.PDF	ALLERGAN_MDL_03953871	ALLERGAN_MDL_03953872							
AC-169	12/29/2008	Watson Laboratories RW0259893 12-29-08.PDF	ALLERGAN_MDL_03953873	ALLERGAN_MDL_03953873							
AC-170	12/29/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03953881	ALLERGAN_MDL_03953881							
AC-171	12/29/2008	Andrx Pharmaceuticals Inc dba Watson Laboratories(FL) RA0297033 12-29-08.PDF	ALLERGAN_MDL_03953882	ALLERGAN_MDL_03953882							
AC-172	12/29/2008	Andrx Pharmaceuticals Inc RA0279946 12-29-08.PDF	ALLERGAN_MDL_03953883	ALLERGAN_MDL_03953884							
AC-173	11/17/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03954097	ALLERGAN_MDL_03954097							
AC-174	11/14/2008	Watson Laboratories Inc RD0118150 11-14-08.PDF	ALLERGAN_MDL_03954098	ALLERGAN_MDL_03954098							
AC-175	11/14/2008	Andrx Pharmaceuticals Inc RA0279946 11-14-08.PDF	ALLERGAN_MDL_03954099	ALLERGAN_MDL_03954099							
AC-176	11/14/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03954259	ALLERGAN_MDL_03954259							
AC-177	11/13/2008	Watson Laboratories Inc RW0117261 11-13-08.PDF	ALLERGAN_MDL_03954260	ALLERGAN_MDL_03954260							
AC-178	11/13/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03954938	ALLERGAN_MDL_03954938							
AC-179	04/14/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03955344	ALLERGAN_MDL_03955344							
AC-180	04/14/2008	Sales to DEA.xls	ALLERGAN_MDL_03955345	ALLERGAN_MDL_03955345							
AC-181	11/25/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03956249	ALLERGAN_MDL_03956249							
AC-182	11/25/2008	Watson Laboratories RW0117261 11-25-08.PDF	ALLERGAN_MDL_03956250	ALLERGAN_MDL_03956250							
AC-183	08/20/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03962766	ALLERGAN_MDL_03962766							
AC-184	08/20/2008	Andrx Pharmaceuticals hydrocodone letter.PDF	ALLERGAN_MDL_03962767	ALLERGAN_MDL_03962767							
AC-185	08/20/2008	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_03966301	ALLERGAN_MDL_03966301							
AC-186	05/19/2016	Correspondence with DEA Re: Procurement Quota	ALLERGAN_MDL_04018690	ALLERGAN_MDL_04018690							
AC-187	05/19/2016	Actavis Laboratories FL, Inc. RA0279946_5-19-2016.pdf	ALLERGAN_MDL_04018691	ALLERGAN_MDL_04018691							
AC-188	12/08/2017	Actavis Labs FL Inc RA0279946 12-8-17.pdf	Acquired_Actavis_02340018	Acquired_Actavis_02340018							
AC-189	12/08/2017	Actavis Labs FL Inc RA0352663 12-8-17.pdf	Acquired_Actavis_02340020	Acquired_Actavis_02340020							
AC-190	03/17/2011	Oxy IR Tabs Suspicious Order SOP revised 3-17-2011.doc	ALLERGAN_MDL_00490306	ALLERGAN_MDL_00490307							
AC-191	08/18/2009	Email from Nancy Baran to John LaRocca re: SOM system.	ALLERGAN_MDL_02081243	ALLERGAN_MDL_02081245							
AC-192	11/03/2010	Suspicious Order Report-082009.doc	ALLERGAN_MDL_02128514	ALLERGAN_MDL_02128514							
AC-193	01/11/2016	SOM Order of Interest Eval SOP.docx	ALLERGAN_MDL_02146077	ALLERGAN_MDL_02146080							
AC-194	01/11/2016	SOM Program Overview.docx	ALLERGAN_MDL_02146081	ALLERGAN_MDL_02146081							
AC-195	01/06/2016	SOMPolicyTN(2).docx	ALLERGAN_MDL_02146301	ALLERGAN_MDL_02146307							
AC-196	01/11/2016	SOM Due Diligence Overview.docx	ALLERGAN_MDL_02146314	ALLERGAN_MDL_02146315							
AC-197	05/30/2014	CSOP_011-004,_Suspicious_Orders_of_Controlled_Drugs.pdf	ALLERGAN_MDL_02146521	ALLERGAN_MDL_02146525							
AC-198	06/06/2008	GUROPDCCO 02 Suspicious Orders of Controlled Drugs.doc	Acquired_Actavis_01495929	Acquired_Actavis_01495930							
AC-199	10/18/2013	Know Your Customer Policy.docx	ALLERGAN_MDL_02176554	ALLERGAN_MDL_02176557							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-200	06/08/2009	CSOP_011-004,_Suspicious_Orders_of_Controlled_Drugs.doc	ALLERGAN_MDL_02467151	ALLERGAN_MDL_02467154							
AC-201	06/27/2014	USOM-LIC-4000 License Maintenance.doc	ALLERGAN_MDL_03750135	ALLERGAN_MDL_03750146							
AC-202	09/19/2005	CSOP_Suspicious_Orders_of_Controlled_Drugs.pdf	ALLERGAN_MDL_03951885	ALLERGAN_MDL_03951888							
AC-203	09/19/2005	License Maintenance.doc	ALLERGAN_MDL_03952774	ALLERGAN_MDL_03952793							
AC-204	11/17/2005	OPDLA 01 License Administration 11705.doc	ALLERGAN_MDL_03953044	ALLERGAN_MDL_03953065							
AC-205	09/26/2011	Watson Laboratories Inc RA0352663 - 09-23-11.PDF	TEVA_MDL_A_13737062	TEVA_MDL_A_13737062							
AC-206	09/26/2011	Watson Laboratories Inc RA0279946 - 09-23-11.PDF	TEVA_MDL_A_13737063	TEVA_MDL_A_13737063							
AC-207	05/03/2004	Watson Call Center Operations Master Data / License Admin. Operational Procedure – CII Schedule Drugs and SOMS Blocks Procedure	ALLERGAN_MDL_01175574	ALLERGAN_MDL_01175585							
AC-208	10/26/2012	SOM SOP and Business Procedure DIRECTfinal.docx	ALLERGAN_MDL_01684748	ALLERGAN_MDL_01684752							
AC-209	04/25/2012	Email from Nancy Baran re SOM Project Team Status/Upcoming Steering Committee Meeting	ALLERGAN_MDL_01729077	ALLERGAN_MDL_01729081							
AC-210	06/12/2013	User Requirement Specification	ALLERGAN_MDL_01767369	ALLERGAN_MDL_01767371							
AC-211	05/03/2004	cSOP 11-004 – Watson Call Center Operations SOP re: Suspicious Orders of Controlled Drugs	ALLERGAN_MDL_01839001	ALLERGAN_MDL_01839002							
AC-212	06/14/2002	Suspicious Orders of Controlled Drugs.doc	ALLERGAN_MDL_01844724	ALLERGAN_MDL_01844725							
AC-213	09/03/2001	DEA Excess Controlled Substance New Prod Launch.doc	ALLERGAN_MDL_01844864	ALLERGAN_MDL_01844865							
AC-214	11/13/2013	Actavis - Letter to Supply Chain Customer re Actavis DEA Affairs Efforts To Prevent Diversion	TEVA_MDL_A_01037413	TEVA_MDL_A_01037414							
AC-215	Undated	Actavis - Compliance Acknowledgement Form to Customers	TEVA_MDL_A_01037415	TEVA_MDL_A_01037415							
AC-216	10/26/2012	SOM SOP and Business Procedure INDIRECTfinal.docx	ALLERGAN_MDL_01979834	ALLERGAN_MDL_01979838							
AC-217	02/17/2010	Email Re: REMS – Contact person	Acquired_Actavis_00657205	Acquired_Actavis_00657207							
AC-218	05/14/2009	CSOP_011-004,_Suspicious_Orders_of_Controlled_Drugs.pdf	ALLERGAN_MDL_03641386	ALLERGAN_MDL_03641389							
AC-219	10/16/2012	Letter from Actavis Elizabeth LLC to FDA: REMS Amendment	Acquired_Actavis_01383113	Acquired_Actavis_01383114							
AC-220	12/13/2012	Email RE: Investigation Summary Capital Wholesale	ALLERGAN_MDL_02187194	ALLERGAN_MDL_02187194							
AC-221	11/21/2011	FW: Approved (Not Released) – Buprenorphine Naloxone A303	Acquired_Actavis_01662177	Acquired_Actavis_01662185							
AC-222	04/30/2012	SOM Presentation to Cardinal Health	ALLERGAN_MDL_00277101	ALLERGAN_MDL_00277110							
AC-223	01/01/2012	Opioid REMS Program Agreement	ALLERGAN_MDL_02823086	ALLERGAN_MDL_02823109							
AC-224	Undated	Actavis Customer Due Diligence Documents	TEVA_MDL_A_01037239	TEVA_MDL_A_01042706							
AC-225	Undated	IMS Xponent	ALLERGAN_MDL_03320305	ALLERGAN_MDL_03320305							
AC-226	Undated	IMS Xponent	ALLERGAN_MDL_03320303	ALLERGAN_MDL_03320303							
AC-227	02/02/2013	Approval Letter Buprenorphine HCI and Naloxone HCI Dihydrate Sublingual Tablets	Acquired_Actavis_01373545	Acquired_Actavis_01373584							
AC-228	11/10/2011	Watson Pharmaceuticals Press Release: Watson Launches Generic Kadian	Acquired_Actavis_01935615	Acquired_Actavis_01935616							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
AC-229	06/00/2011	Oxymorphone Hydrochloride Extended Release Tablets, CII Availability Announcement	ALLERGAN_MDL_01040653	ALLERGAN_MDL_01040681							
CE-1	01/01/2017	ACT039 - Overall Efficacy of ACTIQ in Opioid-Tolerant Patients with Breakthrough Cancer Pain	TEVA_MDL_A_01088915	TEVA_MDL_A_01088921							
CE-2	8/00/2011	FENT006 - Analgesic Potency of FENTORA	TEVA_MDL_A_00704446	TEVA_MDL_A_00704450							
CE-3	08/00/2011	FENT014 - Use of Fentora in Opioid Tolerant patients with noncancer chronic pain conditions	TEVA_MDL_A_00704493	TEVA_MDL_A_00704501							
CE-4	09/00/2011	ACT011 - Use of ACTIQ in Opioid-Tolerant Patients with Chronic Non-Cancer Pain	TEVA_MDL_A_00705148	TEVA_MDL_A_00705151							
CE-5	08/00/2011	FENT008 - Overall Efficacy of FENTORA	TEVA_MDL_A_00705333	TEVA_MDL_A_00705337							
CE-6	04/28/2008	Review Process for Investigator Sponsored Studies	TEVA_MDL_A_00552592	TEVA_MDL_A_00552602							
CE-7	10/00/2014	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04213336	TEVA_MDL_A_04213336							
CE-8	03/01/2012	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04213337	TEVA_MDL_A_04213337							
CE-9	04/00/2013	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04213338	TEVA_MDL_A_04213338							
CE-10	04/00/2013	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04213339	TEVA_MDL_A_04213339							
CE-11	12/06/2017	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04213340	TEVA_MDL_A_04213347							
CE-12		Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04251050	TEVA_MDL_A_04251057							
CE-13	04/04/2008	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04251058	TEVA_MDL_A_04251063							
CE-14	07/28/2005	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04251071	TEVA_MDL_A_04253294							
CE-15	09/20/2007	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04253295	TEVA_MDL_A_04260210							
CE-16	12/09/2009	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04260211	TEVA_MDL_A_04262690							
CE-17	01/06/2009	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04262691	TEVA_MDL_A_04270036							
CE-18	06/30/2009	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04270038	TEVA_MDL_A_04270050							
CE-19	09/22/2009	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04270051	TEVA_MDL_A_04271815							
CE-20	01/23/2007	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04271816	TEVA_MDL_A_04274389							
CE-21	03/07/2008	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04274390	TEVA_MDL_A_04275396							
CE-22	01/17/2007	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04275397	TEVA_MDL_A_04278254							
CE-23	10/26/2007	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04278255	TEVA_MDL_A_04278259							
CE-24	01/17/2007	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04278260	TEVA_MDL_A_04281090							
CE-25	10/26/2007	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04281091	TEVA_MDL_A_04281095							
CE-26	10/15/2007	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04281096	TEVA_MDL_A_04288072							
CE-27	11/24/2008	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04288073	TEVA_MDL_A_04294413							
CE-28	Undated	Table of Clinical Studies: Table 2: Fentora (fentanyl buccal tablet)	TEVA_MDL_A_08235305	TEVA_MDL_A_08235315							
CE-29	12/06/2010	ACTIQ ISI Update to Cephalon.com HCP section (Re-approval 1)	TEVA_MDL_A_01151352	TEVA_MDL_A_01151383							
CE-30	12/06/2010	HCP Website ACTIQ 2010 (Re-approval 1)	TEVA_MDL_A_01151384	TEVA_MDL_A_01151412							
CE-31	12/06/2010	ACTIQ ISI Update to Cephalon.com Patient section (Re-approval 1)	TEVA_MDL_A_01151413	TEVA_MDL_A_01151449							
CE-32	12/06/2010	Patient Website ACTIQ 2010 (Re-approval 1)	TEVA_MDL_A_01151450	TEVA_MDL_A_01151470							
CE-33	02/28/2011	Actiq Media Fact Sheet	TEVA_MDL_A_01152460	TEVA_MDL_A_01152464							
CE-34	05/16/2011	ACTIQ.com	TEVA_MDL_A_01153181	TEVA_MDL_A_01153202							
CE-35	07/28/2011	ACTIQ ISI and labeling update for Cephalon.com HCP section (REMS)	TEVA_MDL_A_01153731	TEVA_MDL_A_01153773							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-36	07/28/2011	ACTIQ ISI and links updates to Cephalon.com Patient Section (REMS)	TEVA_MDL_A_01153774	TEVA_MDL_A_01153816							
CE-37	08/02/2011	ACTIQ REMS PLR PI/Med Guide Update (Aug)	TEVA_MDL_A_01154138	TEVA_MDL_A_01154140							
CE-38	08/04/2011	ISI Updates for ACTIQ listing on HCP section of Cephalon.com	TEVA_MDL_A_01154176	TEVA_MDL_A_01154191							
CE-39	08/04/2011	Update to ISI for ACTIQ on patient section of Cephalon.com	TEVA_MDL_A_01154192	TEVA_MDL_A_01154207							
CE-40	08/16/2011	Actiq Med Guide for ActiqandFENTORAREMS.com	TEVA_MDL_A_01154454	TEVA_MDL_A_01154463							
CE-41	09/01/2011	Actiq.com	TEVA_MDL_A_01154573	TEVA_MDL_A_01154593							
CE-42	09/12/2011	ACTIQ Medication Guide (REMS update)	TEVA_MDL_A_01154714	TEVA_MDL_A_01154715							
CE-43	01/04/2010	ACTIQ Fact Sheet	TEVA_MDL_A_01158291	TEVA_MDL_A_01158293							
CE-44	00/00/2006	Actiq A Pain Primer: A Reference for the Rest of Us (2006)	TEVA_MDL_A_00514270	TEVA_MDL_A_00514280							
CE-45	08/31/2005	Actiq Marketing Materials – Promotional	TEVA_MDL_A_02968522	TEVA_MDL_A_02968522							
CE-46	07/28/2005	Actiq Montage Sales Aid	TEVA_MDL_A_01491886	TEVA_MDL_A_01491894							
CE-47	01/17/2019	ACT002 - Analgesic Potency of ACTIQ	TEVA_MDL_A_01088893	TEVA_MDL_A_01088896							
CE-48	01/17/2019	ACT022 - Dosage and Administration of ACTIQ	TEVA_MDL_A_01088907	TEVA_MDL_A_01088914							
CE-49	12/16/2019	Actiq Warning Label/Prescribing Information	TEVA_MDL_A_01089252	TEVA_MDL_A_01089277							
CE-50		Product Fact Sheet for posting on the media resource section of Cephalon.com	TEVA_MDL_A_01158291	TEVA_MDL_A_01158293							
CE-51	10/11/2019	ACT013 - Abuse Potential - Archived in Dec 2011	TEVA_MDL_A_00705196	TEVA_MDL_A_00705200							
CE-52	07/00/2005	Reimbursement Direct Mail	TEVA_MDL_A_00266356	TEVA_MDL_A_00266367							
CE-53	09/00/2005	www.ACTIQ.com w/ revisions to "Contact Us" section	TEVA_MDL_A_00514149	TEVA_MDL_A_00514154							
CE-54	04/00/2006	9/30/2006 ACTIQ Coupon Expiration Stickers	TEVA_MDL_A_00514156	TEVA_MDL_A_00514158							
CE-55	11/00/2006	www.Actiq.com posting generic PI & Med Guide to site	TEVA_MDL_A_00514338	TEVA_MDL_A_00514354							
CE-56	11/00/2000	Pharmacologic Treatment of Cancer Pain - Levy	TEVA_MDL_A_00514736	TEVA_MDL_A_00514749							
CE-57	01/00/2006	Commercial Operations SF Notifications	TEVA_MDL_A_00695218	TEVA_MDL_A_00695224							
CE-58	01/00/2005	ACTIQ E-Detail (Medsite) Wave B	TEVA_MDL_A_00695225	TEVA_MDL_A_00695260							
CE-59	04/00/2003	2003 BTP Counter Card	TEVA_MDL_A_01583982	TEVA_MDL_A_01583999							
CE-60	04/00/2003	2003 Physician FAQ	TEVA_MDL_A_01584000	TEVA_MDL_A_01584014							
CE-61	04/00/2002	Pocket Dosing Guide	TEVA_MDL_A_11115489	TEVA_MDL_A_11115492							
CE-62	4/11/2005	Letter RE: Actiq Promotional Material	TEVA_MDL_A_00266011	TEVA_MDL_A_00266181							
CE-63	01/00/2005	Product Return Sheet (Tear Pad)	TEVA_MDL_A_00266209	TEVA_MDL_A_00266215							
CE-64	5/16/2005	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00266216	TEVA_MDL_A_00266266							
CE-65	9/22/2005	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00266319	TEVA_MDL_A_00266346							
CE-66	03/00/2006	ACTIQ E-detail Wave B Fax & Emails	TEVA_MDL_A_00695335	TEVA_MDL_A_00695343							
CE-67	11/21/2005	Letter RE: Actiq Promotional Material	TEVA_MDL_A_00266546	TEVA_MDL_A_00266621							
CE-68	07/00/2006	ACTIQ DAW Journal Ad	TEVA_MDL_A_00695596	TEVA_MDL_A_00695605							
CE-69	03/00/2002	www.actiq.com	TEVA_MDL_A_00695638	TEVA_MDL_A_00695660							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-70	11/00/2003	Promotional Slide Kit 2004	TEVA_MDL_A_01583675	TEVA_MDL_A_01583973							
CE-71	03/00/2002	www.actiq.com revised	TEVA_MDL_A_01584015	TEVA_MDL_A_01584439							
CE-72	10/00/2004	2005 Promotional Slide Kit	TEVA_MDL_A_01584765	TEVA_MDL_A_01584793							
CE-73	11/00/2004	BTP Assessment Tool with Folder	TEVA_MDL_A_04250078	TEVA_MDL_A_04250080							
CE-74	11/00/2004	BTP Assessment Poster with Folder	TEVA_MDL_A_04250081	TEVA_MDL_A_04250085							
CE-75	4/10/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00695346	TEVA_MDL_A_00695595							
CE-76	03/00/2001	RP/PAP Guide (Reimbursement Program)	TEVA_MDL_A_11110536	TEVA_MDL_A_11110545							
CE-77	5/16/2006	DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material	TEVA_MDL_A_00695606	TEVA_MDL_A_00695610							
CE-78	04/00/2002	Patient Use Tear Sheet	TEVA_MDL_A_11114375	TEVA_MDL_A_11114391							
CE-79	03/00/2001	2001 Actiq Sales Aid	TEVA_MDL_A_11115315	TEVA_MDL_A_11115343							
CE-80		ACTIQ clock	TEVA_MDL_A_01583974	TEVA_MDL_A_01583981							
CE-81	03/00/2002	MD Retention Direct Mail - Jan.	TEVA_MDL_A_11115497	TEVA_MDL_A_11115522							
CE-82	03/00/2002	Christie Reprint - "Dose Titration, Multicenter Study of OTFC for the Treatment of Breakthrough Pain in Cancer Patients Using Transdermal Fentanyl for Persistent Pain"	TEVA_MDL_A_11115546	TEVA_MDL_A_11115609							
CE-83	02/00/2001	Updated Regular PI (3 pg.)	TEVA_MDL_A_11121362	TEVA_MDL_A_11121438							
CE-84	04/00/2003	New Formulation Press Materials for Trade Magazines	TEVA_MDL_A_11121688	TEVA_MDL_A_11121692							
CE-85	6/29/2001	DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material	TEVA_MDL_A_11110212	TEVA_MDL_A_11110363							
CE-86	7/6/2001	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_11110449	TEVA_MDL_A_11110535							
CE-87	9/21/2001	DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material	TEVA_MDL_A_11113986	TEVA_MDL_A_11114049							
CE-88	11/16/2001	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_11114086	TEVA_MDL_A_11114139							
CE-89	4/12/2001	DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material	TEVA_MDL_A_11114488	TEVA_MDL_A_11114503							
CE-90		Revised Patient Leaflet	TEVA_MDL_A_11117171	TEVA_MDL_A_11117181							
CE-91	1/9/2003	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_11121051	TEVA_MDL_A_11121060							
CE-92		ACTIQ Yellow Convention bag	TEVA_MDL_A_11121061	TEVA_MDL_A_11121062							
CE-93	1/14/2003	DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material	TEVA_MDL_A_11121064	TEVA_MDL_A_11121170							
CE-94	5/21/2003	DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material (2003 Pocket Guide & 2003 Reimbursement Guide)	TEVA_MDL_A_11121675	TEVA_MDL_A_11121687							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-95	01/31/2006	Pain Notebook- American Pain Foundation	TEVA_MDL_A_00695261	TEVA_MDL_A_00695297							
CE-96	03/29/2006	ACTIQ E-detail Wave B (ACT 305)(promotional piece distributed to physicians via Medsite)	TEVA_MDL_A_00695298	TEVA_MDL_A_00695334							
CE-97	03/29/2006	Actiq E-Detail Wave B Fax and Email Invitations (ACT 308)	TEVA_MDL_A_00695335	TEVA_MDL_A_00695343							
CE-98	04/10/2006	PDR Pain Mgmt Prescribing Guide (ACT 296)/Triple I ACTIQ Prescription Pad (ACT 302)/ACTIQ Reimbursement Hotline Patient Information (ACT 293a)/ACTIQ E-detail Wave A (ACT 298)/ACTIQ Welcome Kit Direct Mail (ACT 295)/ACTIQ E-detail Wave B (ACT 305)	TEVA_MDL_A_00695346	TEVA_MDL_A_00695595							
CE-99	05/04/2006	Actiq Dispense As Written (DAW) Journal Ad (ACT 312)	TEVA_MDL_A_00695596	TEVA_MDL_A_00695605							
CE-100	05/16/2006	Actiq Unit Dose Barcode Packaging Notification for In-Direct Amounts (ACT 309)/Actiq Unit Dose Barcode Packaging Notification for Direct Accounts (ACT 310)	TEVA_MDL_A_00695606	TEVA_MDL_A_00695610							
CE-101	11/08/2006	ACT 095d Revised Actiq.com Website	TEVA_MDL_A_00695616	TEVA_MDL_A_00695637							
CE-102	12/04/2006	ACT 095 Revised Actiq.com Website	TEVA_MDL_A_00695638	TEVA_MDL_A_00695660							
CE-103	12/21/2009	ACT 2005 Patient Website	TEVA_MDL_A_00695661	TEVA_MDL_A_00695697							
CE-104	12/21/2009	ACT 2001 HCP Website	TEVA_MDL_A_00695698	TEVA_MDL_A_00695742							
CE-105	03/25/2010	ACT 2006 Fact Sheet	TEVA_MDL_A_00695743	TEVA_MDL_A_00695761							
CE-106	05/26/2011	ACT-2011: Actiq Website	TEVA_MDL_A_00695762	TEVA_MDL_A_00695799							
CE-107	09/16/2011	ACT-2021: Actiq.com/ACT 2010: Actiq Media Fact Sheet	TEVA_MDL_A_00695936	TEVA_MDL_A_00695982							
CE-108	03/15/2012	ACT-2026 ACTIQ.com Update/ACT-2026a Patient Child Safety Kit Request/ACT-2026b HCP Child Safety Kit Request	TEVA_MDL_A_00696694	TEVA_MDL_A_00696716							
CE-109	03/26/2012	ACT-2-26 ACTIQ.com Update/ACT-2026a Patient Child Safety Kit Request/ACT-2026b HCP Child Safety Kit Request	TEVA_MDL_A_00696717	TEVA_MDL_A_00696739							
CE-110	05/25/2012	FEN/ACT-0005 RTL-Actiq Conversions	TEVA_MDL_A_00696740	TEVA_MDL_A_00696762							
CE-111	06/01/2012	ACT-2027 Actiq.com Phase 2 Update/ACT-2027b Actiq HCP Child Safety Request Kit (English)/ ACT-2027b Actiq.com HCP Child Safety Request Kit (English)/ACT-2027c Patient Child Safety Request Kit (Spanish)	TEVA_MDL_A_00696763	TEVA_MDL_A_00696786							
CE-112	12/22/2004	Letter from Cephalon to DDMAC re Actiq	TEVA_MDL_A_01584765	TEVA_MDL_A_01584793							
CE-113	01/23/2006	ACTIQ E-detail Wave B (ACT 305)(promotional piece distributed to physicians via Medsite)	TEVA_MDL_A_00695225	TEVA_MDL_A_00695260							
CE-114	01/09/2006	Actiq Sugar-free Notification (ACT 304)	TEVA_MDL_A_00695218	TEVA_MDL_A_00695224							
CE-115	07/01/2010	New Dimen Dialog MD Workshop: Speaker Deck	TEVA_MDL_A_01150009	TEVA_MDL_A_01150052							
CE-116	01/06/2010	Dinner Meeting Fax Invite	TEVA_MDL_A_01150053	TEVA_MDL_A_01150053							
CE-117	07/06/2010	New Dimension in Pain Dialog: Email Confirmation	TEVA_MDL_A_01150074	TEVA_MDL_A_01150074							
CE-118	07/06/2010	New Dimein Pain Dial: Registration form	TEVA_MDL_A_01150078	TEVA_MDL_A_01150078							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-119	01/06/2010	Dinner Meeting Confirmation Letter	TEVA_MDL_A_01150079	TEVA_MDL_A_01150079							
CE-120	07/07/2010	YEARLY REVIEW: Weinstein reprint	TEVA_MDL_A_01150090	TEVA_MDL_A_01150098							
CE-121	07/07/2010	YEARLY REVIEW: 2009 Patient FAQ	TEVA_MDL_A_01150099	TEVA_MDL_A_01150116							
CE-122	01/06/2010	FENTORA flyer	TEVA_MDL_A_01150117	TEVA_MDL_A_01150117							
CE-123	07/08/2010	YEARLY REVIEW: FENTORA ITC CVA DVD Workshop	TEVA_MDL_A_01150118	TEVA_MDL_A_01150165							
CE-124	07/09/2010	Screenshots for Allied Health Web Speaker Training	TEVA_MDL_A_01150166	TEVA_MDL_A_01150178							
CE-125	07/13/2010	Update to FENTORA listing on Cephalon.com Patient Section	TEVA_MDL_A_01150180	TEVA_MDL_A_01150183							
CE-126	01/07/2010	Patient/ Dosing Workshop, ITC	TEVA_MDL_A_01150184	TEVA_MDL_A_01150200							
CE-127	07/13/2010	Update to FENTORA listing on HCP section of Cephalon.com	TEVA_MDL_A_01150201	TEVA_MDL_A_01150204							
CE-128	07/19/2010	New Dimen Pain Dialog: Sales Force Invite	TEVA_MDL_A_01150206	TEVA_MDL_A_01150206							
CE-129	07/19/2010	Pain Week Floor Clings	TEVA_MDL_A_01150207	TEVA_MDL_A_01150209							
CE-130	07/20/2010	New Dimen Pain MD Worksheets	TEVA_MDL_A_01150210	TEVA_MDL_A_01150214							
CE-131	07/22/2010	New Dimen Pain: Fax Invitation	TEVA_MDL_A_01150215	TEVA_MDL_A_01150215							
CE-132	07/22/2010	New Dimen Pain: Fax Confirmation	TEVA_MDL_A_01150216	TEVA_MDL_A_01150216							
CE-133	07/23/2010	YNF Script 1	TEVA_MDL_A_01150217	TEVA_MDL_A_01150228							
CE-134	07/23/2010	YNF Script 2	TEVA_MDL_A_01150229	TEVA_MDL_A_01150239							
CE-135	07/26/2010	YEARLY REVIEW: FEN-2009P-PM-00231 CVA	TEVA_MDL_A_01150240	TEVA_MDL_A_01150246							
CE-136	01/07/2010	CSP Invite	TEVA_MDL_A_01150250	TEVA_MDL_A_01150251							
CE-137	07/28/2010	Registration Form for PAINWeek Product Theatre Luncheon	TEVA_MDL_A_01150253	TEVA_MDL_A_01150253							
CE-138	01/08/2010	Customer Question Workshop, ITC	TEVA_MDL_A_01150254	TEVA_MDL_A_01150258							
CE-139	08/02/2010	Quantia Wave 3	TEVA_MDL_A_01150259	TEVA_MDL_A_01150275							
CE-140	07/30/2010	PAINWeek invitation for Product Theatre Lunch	TEVA_MDL_A_01150276	TEVA_MDL_A_01150276							
CE-141	07/30/2010	Booth handout for PAINWeek Product Theatre Lunch	TEVA_MDL_A_01150277	TEVA_MDL_A_01150277							
CE-142	07/30/2010	Confirmation for PAINWeek Product Theatre Lunch	TEVA_MDL_A_01150278	TEVA_MDL_A_01150278							
CE-143	08/01/2010	PCS August Managers' Meeting FENTORA Workshop	TEVA_MDL_A_01150279	TEVA_MDL_A_01150309							
CE-144	08/01/2010	FENTORA Scenario Resource Cards	TEVA_MDL_A_01150310	TEVA_MDL_A_01150316							
CE-145	08/02/2010	TRAINING GUIDE: FENTORA Dosing Flash Card	TEVA_MDL_A_01150436	TEVA_MDL_A_01150436							
CE-146	03/25/2010	Revised FENTORA Brief Summary	TEVA_MDL_A_01150443	TEVA_MDL_A_01150446							
CE-147	08/03/2010	Yearly Review: Tick Tock Efficacy Rectnagle Convt Panel	TEVA_MDL_A_01150447	TEVA_MDL_A_01150447							
CE-148	08/06/2010	Signage for PAINWeek Product Theatre Lunch Program	TEVA_MDL_A_01150465	TEVA_MDL_A_01150465							
CE-149	08/09/2010	Yearly Review: Fentora Tick Tock Summary Round Convention panel	TEVA_MDL_A_01150466	TEVA_MDL_A_01150466							
CE-150	08/09/2010	Yearly Review: Tick Tock Approp Patient Table Top	TEVA_MDL_A_01150467	TEVA_MDL_A_01150467							
CE-151	08/09/2010	Yearly Review: Tick Tock BTP Round Convention Panel	TEVA_MDL_A_01150468	TEVA_MDL_A_01150468							
CE-152	08/09/2010	Yearly Review: BBW Round Convention Panel	TEVA_MDL_A_01150469	TEVA_MDL_A_01150469							
CE-153	08/09/2010	TRAINING GUIDE: FENTORABreakthrough Pain Flash Card	TEVA_MDL_A_01150470	TEVA_MDL_A_01150470							
CE-154	08/09/2010	TRAINING GUIDE: FENTORA Efficacy Flash Card	TEVA_MDL_A_01150471	TEVA_MDL_A_01150472							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-155	08/09/2010	TRAINING GUIDE: FENTORA PK Flash Card	TEVA_MDL_A_01150473	TEVA_MDL_A_01150473							
CE-156	08/11/2010	Yearly Review:Secure Reprint Carrier Content	TEVA_MDL_A_01150474	TEVA_MDL_A_01150487							
CE-157	08/11/2010	Yearly Review:Secure Reprint Carrier	TEVA_MDL_A_01150488	TEVA_MDL_A_01150498							
CE-158	08/12/2010	PAINWeek E-Newsletter Cover "Story" Ad	TEVA_MDL_A_01150499	TEVA_MDL_A_01150499							
CE-159	08/16/2010	PPLS Annotated PI Cert Exam	TEVA_MDL_A_01150500	TEVA_MDL_A_01150513							
CE-160	08/16/2010	PPLS Module 6: Risk Minimization Action Plan	TEVA_MDL_A_01150514	TEVA_MDL_A_01150557							
CE-161	08/16/2010	New Dimen in Pain: Allied Health Training Deck Revised	TEVA_MDL_A_01150558	TEVA_MDL_A_01150597							
CE-162	08/18/2010	Risk Map Mod 6 Cert Exam	TEVA_MDL_A_01150598	TEVA_MDL_A_01150600							
CE-163	08/20/2010	TRAINING GUIDE: Darwish: Pharmacokinetic Properties of Fentanyl Effervescent Buccal Tablets: A Phase	TEVA_MDL_A_01150601	TEVA_MDL_A_01150602							
CE-164	08/22/2010	PPLS Module 1: Intro to Pain	TEVA_MDL_A_01150603	TEVA_MDL_A_01150668							
CE-165	08/22/2010	PPLS Module 2: Cancer Pain	TEVA_MDL_A_01150669	TEVA_MDL_A_01150700							
CE-166	08/22/2010	PPLS Module 3: OraVescent Technology	TEVA_MDL_A_01150701	TEVA_MDL_A_01150744							
CE-167	08/22/2010	PPLS Module 5: Analgesia Marketplace	TEVA_MDL_A_01150745	TEVA_MDL_A_01150812							
CE-168	08/22/2010	PPLS Module 1: Assessment	TEVA_MDL_A_01150813	TEVA_MDL_A_01150820							
CE-169	08/22/2010	PPLS Module 2: Assessment	TEVA_MDL_A_01150821	TEVA_MDL_A_01150827							
CE-170	08/22/2010	PPLS Module 5: Assessment	TEVA_MDL_A_01150828	TEVA_MDL_A_01150833							
CE-171	08/26/2010	Fentora Reimbursement Kit - Folder	TEVA_MDL_A_01150836	TEVA_MDL_A_01150836							
CE-172	08/26/2010	Fentora Reimbursement Kit - Reimbursement Guide	TEVA_MDL_A_01150837	TEVA_MDL_A_01150845							
CE-173	08/26/2010	Fentora Reimbursement Kit - Patient Consent Form	TEVA_MDL_A_01150847	TEVA_MDL_A_01150848							
CE-174	08/26/2010	Fentora Reimbursement Program - Flashcard	TEVA_MDL_A_01150849	TEVA_MDL_A_01150849							
CE-175	08/30/2010	PPLS Module 4: Assessment	TEVA_MDL_A_01150850	TEVA_MDL_A_01150860							
CE-176	09/03/2010	Y&F: Fentora Intro Letter	TEVA_MDL_A_01150956	TEVA_MDL_A_01150958							
CE-177	09/03/2010	Y&F: Fentora Detail and material letter	TEVA_MDL_A_01150959	TEVA_MDL_A_01150961							
CE-178	09/07/2010	Y&F: Fentora Copay assistance card Letter	TEVA_MDL_A_01150962	TEVA_MDL_A_01150964							
CE-179	09/13/2010	HCP Web-based Speaker Training Invitation	TEVA_MDL_A_01150971	TEVA_MDL_A_01150971							
CE-180	09/13/2010	HCP Web-based Speaker Training Confirmation	TEVA_MDL_A_01150972	TEVA_MDL_A_01150973							
CE-181	09/13/2010	HCP Web-based Speaker Training Registration Form	TEVA_MDL_A_01150974	TEVA_MDL_A_01150974							
CE-182	09/13/2010	Allied Health Evening Teleconference Fax Invite	TEVA_MDL_A_01150975	TEVA_MDL_A_01150975							
CE-183	09/13/2010	Allied Health Evening Teleconference fax Confirmation	TEVA_MDL_A_01150976	TEVA_MDL_A_01150976							
CE-184	09/13/2010	Allied Health Evening Teleconference Confirmation Letter	TEVA_MDL_A_01150977	TEVA_MDL_A_01150977							
CE-185	09/13/2010	FENTORA Evening Teleconference list of medical items from Total Health Rewards	TEVA_MDL_A_01150978	TEVA_MDL_A_01150983							
CE-186	09/17/2010	Allied Health Evening Teleconference Sales Rep Invitation	TEVA_MDL_A_01150984	TEVA_MDL_A_01150985							
CE-187	09/17/2010	HCP Speaker Training Web Screen Shots	TEVA_MDL_A_01150986	TEVA_MDL_A_01150998							
CE-188	09/17/2010	HCP Dinner Program E-mail Invitation	TEVA_MDL_A_01150999	TEVA_MDL_A_01150999							
CE-189	09/17/2010	HCP Dinner Program E-mail Confirmation	TEVA_MDL_A_01151000	TEVA_MDL_A_01151000							
CE-190	09/17/2010	HCP Dinner Program FAX Invitation	TEVA_MDL_A_01151001	TEVA_MDL_A_01151001							
CE-191	09/17/2010	HCP Dinner Program FAX Confirmation	TEVA_MDL_A_01151002	TEVA_MDL_A_01151002							
CE-192	09/17/2010	HCP Dinner Program Sales Rep Invitation	TEVA_MDL_A_01151003	TEVA_MDL_A_01151003							
CE-193	09/20/2010	Module 3 - OraVescent Technology Exam	TEVA_MDL_A_01151004	TEVA_MDL_A_01151007							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-194	09/27/2010	TRAINING GUIDE: Weinstein et al	TEVA_MDL_A_01151008	TEVA_MDL_A_01151009							
CE-195	01/19/2010	PDR Prescribing Guide Content	TEVA_MDL_A_01151010	TEVA_MDL_A_01151021							
CE-196	10/01/2010	2011 Core Visual Aid	TEVA_MDL_A_01151022	TEVA_MDL_A_01151029							
CE-197	10/04/2010	CSP Promotional Slide Deck	TEVA_MDL_A_01151030	TEVA_MDL_A_01151075							
CE-198	10/04/2010	Allied Health Evening Teleconference Program Worksheets	TEVA_MDL_A_01151076	TEVA_MDL_A_01151082							
CE-199	10/15/2010	Dosing Leave Behind	TEVA_MDL_A_01151083	TEVA_MDL_A_01151086							
CE-200	10/15/2010	Stop Look and Listen Leave Behind	TEVA_MDL_A_01151087	TEVA_MDL_A_01151090							
CE-201	10/21/2010	Efficacy Leave Behind	TEVA_MDL_A_01151091	TEVA_MDL_A_01151094							
CE-202	10/21/2010	PK Leave behind	TEVA_MDL_A_01151095	TEVA_MDL_A_01151098							
CE-203	10/27/2010	PAIN Marketplace Grid	TEVA_MDL_A_01151099	TEVA_MDL_A_01151100							
CE-204	10/27/2010	HCP Dinner invite for Sales Reps	TEVA_MDL_A_01151101	TEVA_MDL_A_01151101							
CE-205	10/27/2010	HCP Dinner fax invite	TEVA_MDL_A_01151102	TEVA_MDL_A_01151102							
CE-206	10/27/2010	HCP Dinner Confirmation Fax	TEVA_MDL_A_01151103	TEVA_MDL_A_01151103							
CE-207	10/27/2010	HCP Dinner Program Participant Evaluation	TEVA_MDL_A_01151104	TEVA_MDL_A_01151104							
CE-208	11/03/2010	New Dimensions HCP Deck Update	TEVA_MDL_A_01151105	TEVA_MDL_A_01151137							
CE-209	11/04/2010	Q1 2011 Vouchers	TEVA_MDL_A_01151138	TEVA_MDL_A_01151143							
CE-210	11/10/2010	FENTORA Annotated CVA eLearning Module	TEVA_MDL_A_01151144	TEVA_MDL_A_01151204							
CE-211	11/10/2010	Facilitator Guide - Section 1: Engaging the Customer	TEVA_MDL_A_01151205	TEVA_MDL_A_01151258							
CE-212	11/10/2010	Facilitator Guide - Section 2: Aligning Solutions	TEVA_MDL_A_01151259	TEVA_MDL_A_01151287							
CE-213	11/10/2010	Facilitator Guide - Section 3: Committing to Action	TEVA_MDL_A_01151288	TEVA_MDL_A_01151309							
CE-214	11/10/2010	Facilitator Guide - Section 4: Putting it All Together	TEVA_MDL_A_01151310	TEVA_MDL_A_01151336							
CE-215	11/10/2010	Yearly Re-review: Fentora Copay Assistance Cards	TEVA_MDL_A_01151337	TEVA_MDL_A_01151338							
CE-216	01/22/2010	Oncology Leave Begind	TEVA_MDL_A_01151339	TEVA_MDL_A_01151344							
CE-217	01/22/2010	Promotional PI	TEVA_MDL_A_01151345	TEVA_MDL_A_01151350							
CE-218	12/01/2010	Copay Holder	TEVA_MDL_A_01151351	TEVA_MDL_A_01151351							
CE-219	12/14/2010	FENTORA.com Renewal	TEVA_MDL_A_01151471	TEVA_MDL_A_01151704							
CE-220	12/21/2010	OraVescent Technology PPT	TEVA_MDL_A_01151707	TEVA_MDL_A_01151714							
CE-221	12/21/2010	Appropriate Patient Selection and Dosing	TEVA_MDL_A_01151715	TEVA_MDL_A_01151734							
CE-222	12/22/2010	Training Guide - FENTORA Reimbursement Kit	TEVA_MDL_A_01151735	TEVA_MDL_A_01151736							
CE-223	12/22/2010	Training Guide - FENTORA Assistance Card	TEVA_MDL_A_01151737	TEVA_MDL_A_01151738							
CE-224	12/22/2010	Training Guide - FENTORA Voucher	TEVA_MDL_A_01151739	TEVA_MDL_A_01151740							
CE-225	01/09/2011	Promotional Slide Deck	TEVA_MDL_A_01151741	TEVA_MDL_A_01151778							
CE-226	01/09/2011	REMS Slide Deck	TEVA_MDL_A_01151779	TEVA_MDL_A_01151833							
CE-227	02/25/2011	Patient Case Study Detailer - FOLDER (Re-approval 1)	TEVA_MDL_A_01151834	TEVA_MDL_A_01151838							
CE-228	01/09/2011	Annotated CVA (print version)	TEVA_MDL_A_01151839	TEVA_MDL_A_01151854							
CE-229	02/25/2011	Patient Case Study Detailer - Case Study #1 (Re-approval 1)	TEVA_MDL_A_01151855	TEVA_MDL_A_01151858							
CE-230	02/25/2011	Patient Case Study Detailer - Case Study #2 (Re-approval 1)	TEVA_MDL_A_01151859	TEVA_MDL_A_01151860							
CE-231	02/25/2011	Patient Case Study Detailer - Tearsheet (Re-approval 1)	TEVA_MDL_A_01151861	TEVA_MDL_A_01151861							
CE-232	01/13/2011	Weinstein Reprint 2009	TEVA_MDL_A_01151862	TEVA_MDL_A_01151870							
CE-233	01/13/2011	Darwish Reprint 2007	TEVA_MDL_A_01151871	TEVA_MDL_A_01151880							
CE-234	01/13/2011	Portenoy Reprint 2006	TEVA_MDL_A_01151881	TEVA_MDL_A_01151887							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-235	01/13/2011	Darwish Reprint 2006	TEVA_MDL_A_01151888	TEVA_MDL_A_01151895							
CE-236	01/13/2011	Darwish Reprint 2006	TEVA_MDL_A_01151896	TEVA_MDL_A_01151906							
CE-237	01/18/2011	FENTORA Participant Guide Tab 1	TEVA_MDL_A_01151907	TEVA_MDL_A_01151935							
CE-238	01/18/2011	FENTORA Participant's Guide Tab 2	TEVA_MDL_A_01151936	TEVA_MDL_A_01151946							
CE-239	01/18/2011	FENTORA Participant's Guide Tab 3	TEVA_MDL_A_01151947	TEVA_MDL_A_01151957							
CE-240	01/18/2011	Aligning Solutions Workmat	TEVA_MDL_A_01151958	TEVA_MDL_A_01151959							
CE-241	01/18/2011	FENTORA Participants Guide - Tab 4	TEVA_MDL_A_01151961	TEVA_MDL_A_01151968							
CE-242	01/20/2011	FENTORA Frequently Asked Questions and Responses	TEVA_MDL_A_01151969	TEVA_MDL_A_01151983							
CE-243	01/23/2011	FENTORA.com Enhancements - HCP Site	TEVA_MDL_A_01151984	TEVA_MDL_A_01152044							
CE-244	01/23/2011	FENTORA.com Enhancements - Consumer Site	TEVA_MDL_A_01152045	TEVA_MDL_A_01152117							
CE-245	01/24/2011	Rep Triggered Letter: Dosing	TEVA_MDL_A_01152118	TEVA_MDL_A_01152121							
CE-246	01/24/2011	Rep Triggered Letter: Efficacy	TEVA_MDL_A_01152122	TEVA_MDL_A_01152124							
CE-247	01/24/2011	Rep Triggered Letter: PK	TEVA_MDL_A_01152125	TEVA_MDL_A_01152127							
CE-248	01/24/2011	Rep triggered Letter: Stop, Look and Listen	TEVA_MDL_A_01152128	TEVA_MDL_A_01152130							
CE-249	01/26/2011	FENTORA Summary Panel	TEVA_MDL_A_01152131	TEVA_MDL_A_01152131							
CE-250	01/28/2011	Rep Triggered Envelope	TEVA_MDL_A_01152134	TEVA_MDL_A_01152134							
CE-251	01/28/2011	Rep Triggered Letter:Dosing Actiq convert	TEVA_MDL_A_01152135	TEVA_MDL_A_01152138							
CE-252	02/09/2011	Fentora Convention Panel Efficacy	TEVA_MDL_A_01152169	TEVA_MDL_A_01152169							
CE-253	02/09/2011	Fentora Convention Panel: ISI and Black Box	TEVA_MDL_A_01152170	TEVA_MDL_A_01152170							
CE-254	02/09/2011	Training Guide – Dosing Leave-Behind	TEVA_MDL_A_01152171	TEVA_MDL_A_01152173							
CE-255	01/27/2010	Pain Products Learning System - M4 Update	TEVA_MDL_A_01152176	TEVA_MDL_A_01152287							
CE-256	02/17/2011	Patient with Cancer Definition	TEVA_MDL_A_01152288	TEVA_MDL_A_01152288							
CE-257	01/27/2010	FENTORA Annotated PI	TEVA_MDL_A_01152289	TEVA_MDL_A_01152370							
CE-258	02/23/2011	FENTORA Medication Guide	TEVA_MDL_A_01152382	TEVA_MDL_A_01152384							
CE-259	02/23/2011	FENTORA Prescribing Information	TEVA_MDL_A_01152385	TEVA_MDL_A_01152395							
CE-260	02/25/2011	TRAINING GUIDE - 2011 Pharmacokinetics Leave-Behind	TEVA_MDL_A_01152396	TEVA_MDL_A_01152397							
CE-261	02/25/2011	TRAINING GUIDE - 2011 Efficacy Leave-Behind	TEVA_MDL_A_01152398	TEVA_MDL_A_01152400							
CE-262	02/25/2011	TRAINING GUIDE - Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate (Darwish, March 2007)	TEVA_MDL_A_01152413	TEVA_MDL_A_01152414							
CE-263	02/25/2011	Update to FENTORA listing on Cephalon.com Patient Section	TEVA_MDL_A_01152415	TEVA_MDL_A_01152436							
CE-264	02/25/2011	Update to FENTORA listing on HCP section of Cephalon.com	TEVA_MDL_A_01152437	TEVA_MDL_A_01152457							
CE-265	02/25/2011	2011 Fentora Booth Retrieval questions	TEVA_MDL_A_01152458	TEVA_MDL_A_01152458							
CE-266	02/25/2011	FENTORA Convention Fabric Ring	TEVA_MDL_A_01152459	TEVA_MDL_A_01152459							
CE-267	03/03/2011	Training Guide - Stop, Look, Listen Leave-Behind	TEVA_MDL_A_01152470	TEVA_MDL_A_01152471							
CE-268	03/04/2011	FENTORA Teleconference Series Invitation	TEVA_MDL_A_01152472	TEVA_MDL_A_01152475							
CE-269	03/04/2011	FENTORA Teleconference Series Workbook Cover Letter for Sales Reps	TEVA_MDL_A_01152476	TEVA_MDL_A_01152476							
CE-270	03/04/2011	FENTORA Teleconference Series Workbook Cover Letter for Attendees	TEVA_MDL_A_01152477	TEVA_MDL_A_01152477							
CE-271	02/01/2010	FENTORA NSMM Workshop	TEVA_MDL_A_01152478	TEVA_MDL_A_01152518							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-272	03/07/2011	FENTORA Annotated PI	TEVA_MDL_A_01152519	TEVA_MDL_A_01152600							
CE-273	03/13/2011	FENTORA Phase II Customer Questions & Responses Workshop	TEVA_MDL_A_01152605	TEVA_MDL_A_01152627							
CE-274	03/17/2011	FENTORA.com Screenshots - Updated Med Guide/PI/Boxed Warning	TEVA_MDL_A_01152629	TEVA_MDL_A_01152873							
CE-275	03/18/2011	FENTORA Phase II New Hire Pre-Exam MASTER (PI and Core Visual Aid)	TEVA_MDL_A_01152876	TEVA_MDL_A_01152889							
CE-276	03/18/2011	FENTORA Phase II Marketplace Workshop Facilitator Guide	TEVA_MDL_A_01152914	TEVA_MDL_A_01152932							
CE-277	03/25/2011	FENTORA Phase II Marketplace Workshop Workmats	TEVA_MDL_A_01152933	TEVA_MDL_A_01152935							
CE-278	03/28/2011	FENTORA Phase II Marketplace Workshop 2 Workmat	TEVA_MDL_A_01152936	TEVA_MDL_A_01152936							
CE-279	03/28/2011	Attendee Workbook for FENTORA Teleconference Series	TEVA_MDL_A_01152937	TEVA_MDL_A_01152972							
CE-280	03/28/2011	FENTORA Teleconference Series Participant Evaluation Form	TEVA_MDL_A_01152973	TEVA_MDL_A_01152973							
CE-281	03/28/2011	FENTORA Teleconference Series Fax-back Participant Sign-in Sheet	TEVA_MDL_A_01152974	TEVA_MDL_A_01152974							
CE-282	03/28/2011	FENTORA Placebo	TEVA_MDL_A_01152975	TEVA_MDL_A_01152979							
CE-283	03/29/2011	Pull Through HCP Brochure	TEVA_MDL_A_01152980	TEVA_MDL_A_01152990							
CE-284	03/31/2011	FENTORA Patient Profile 1	TEVA_MDL_A_01152991	TEVA_MDL_A_01152995							
CE-285	03/31/2011	FENTORA Patient Profile 2	TEVA_MDL_A_01152996	TEVA_MDL_A_01153000							
CE-286	03/31/2011	FENTORA Reprint Compendium	TEVA_MDL_A_01153001	TEVA_MDL_A_01153009							
CE-287	04/01/2011	FENTORA PLR PI Update- print format	TEVA_MDL_A_01153010	TEVA_MDL_A_01153012							
CE-288	04/14/2011	Facilitator Guide: Putting it All Together Workshop: May 2011 Area Manager and June 2011 POA Meetings	TEVA_MDL_A_01153023	TEVA_MDL_A_01153065							
CE-289	04/28/2011	TRAINING GUIDE: FENTORA Patient Profile 1 Case Study Leave-Behind (FEN-2286)	TEVA_MDL_A_01153074	TEVA_MDL_A_01153076							
CE-290	04/28/2011	TRAINING GUIDE: FENTORA Patient Profile #2 Case Study Leave-Behind (FEN-2287)	TEVA_MDL_A_01153077	TEVA_MDL_A_01153079							
CE-291	04/30/2011	Facilitator Guide: Applying the Patient Focused Selling Approach (PFSA) to Clinical Papers Workshop	TEVA_MDL_A_01153080	TEVA_MDL_A_01153119							
CE-292	05/02/2011	Participant Guide: Applying Patient Focused Selling Approach (PFSA) to Clinical Reprint Selling Workshop	TEVA_MDL_A_01153120	TEVA_MDL_A_01153137							
CE-293	05/04/2011	Participant Guide: Putting it All Together Workshop: May 2011 Area Manager and June 2011 POA Meetings	TEVA_MDL_A_01153138	TEVA_MDL_A_01153159							
CE-294	05/04/2011	Putting it All Together: FENTORA Promotional Opportunities Action (POA) Map Activity Worksheet – MASTER	TEVA_MDL_A_01153160	TEVA_MDL_A_01153162							
CE-295	05/10/2011	REMS NAMs Slide Deck	TEVA_MDL_A_01153165	TEVA_MDL_A_01153180							
CE-296	05/19/2011	Pain Product Learning System: Disease State Module	TEVA_MDL_A_01153203	TEVA_MDL_A_01153282							
CE-297	05/19/2011	Pain Product Learning System: Marketplace Module	TEVA_MDL_A_01153283	TEVA_MDL_A_01153358							
CE-298	05/19/2011	Marketed ROOs REM Grid	TEVA_MDL_A_01153359	TEVA_MDL_A_01153400							
CE-299	05/19/2011	FENTORA/Actiq REMS FAQ Document	TEVA_MDL_A_01153401	TEVA_MDL_A_01153410							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-300	05/19/2011	Darwish May 2006 Annotated Clinical Reprint-PK properties	TEVA_MDL_A_01153411	TEVA_MDL_A_01153427							
CE-301	05/19/2011	Darwish March 2007 Annotated Clinical Reprint - Absolute and Relative Bioavailability	TEVA_MDL_A_01153428	TEVA_MDL_A_01153443							
CE-302	05/19/2011	Darwish 2006 Annotated Clinical Reprint - Comparison of Equivalent Doses	TEVA_MDL_A_01153444	TEVA_MDL_A_01153456							
CE-303	05/25/2011	New Dimensions in Pain Dialogues: Worksheets (Re-approval 1)	TEVA_MDL_A_01153459	TEVA_MDL_A_01153465							
CE-304	06/07/2011	FENTORA PHASE II PI Workshop	TEVA_MDL_A_01153466	TEVA_MDL_A_01153511							
CE-305	06/07/2011	FENTORA Leveraging Managed Care Resources Workshop	TEVA_MDL_A_01153512	TEVA_MDL_A_01153528							
CE-306	06/13/2011	FENTORA Teleconference Series, Wave #2	TEVA_MDL_A_01153529	TEVA_MDL_A_01153532							
CE-307	06/13/2011	FENTORA Teleconference Evaluation, Wave #2	TEVA_MDL_A_01153533	TEVA_MDL_A_01153533							
CE-308	06/16/2011	Convention Program Ad	TEVA_MDL_A_01153534	TEVA_MDL_A_01153537							
CE-309	06/20/2011	Fentora Speaker Reduction Letter	TEVA_MDL_A_01153538	TEVA_MDL_A_01153538							
CE-310	06/21/2011	RTL 7: Assessing Short Acting opioids	TEVA_MDL_A_01153539	TEVA_MDL_A_01153541							
CE-311	06/23/2011	PHASE II (PLS FENTORA PI & CVA) Pre-Exam, Answer Sheet/Key	TEVA_MDL_A_01153545	TEVA_MDL_A_01153559							
CE-312	06/29/2011	ACTIQ and FENTORA REMS Graphic for Media	TEVA_MDL_A_01153560	TEVA_MDL_A_01153560							
CE-313	06/29/2011	ACTIQ and FENTORA REMS Media Fact Sheet	TEVA_MDL_A_01153561	TEVA_MDL_A_01153564							
CE-314	02/10/2010	FENTORA NSMM Workshop - CVA	TEVA_MDL_A_01153565	TEVA_MDL_A_01153598							
CE-315	07/10/2011	PCS PHASE II FENTORA Post-Exam	TEVA_MDL_A_01153599	TEVA_MDL_A_01153622							
CE-316	07/18/2011	REMS Fact Sheet for Speakers	TEVA_MDL_A_01153625	TEVA_MDL_A_01153629							
CE-317	07/18/2011	REMS Approval Speaker Letter	TEVA_MDL_A_01153630	TEVA_MDL_A_01153633							
CE-318	07/18/2011	KOL REMS Approval Email	TEVA_MDL_A_01153634	TEVA_MDL_A_01153637							
CE-319	07/27/2011	Actiq and FENTORA REMS Enrollment Kit: Housing Unit	TEVA_MDL_A_01153638	TEVA_MDL_A_01153643							
CE-320	07/27/2011	REMS Dear HCP Letter	TEVA_MDL_A_01153644	TEVA_MDL_A_01153647							
CE-321	07/27/2011	REMS Dear Outpatient Pharmacy Letter	TEVA_MDL_A_01153648	TEVA_MDL_A_01153651							
CE-322	07/28/2011	REMS Patient Perscriber Agreement Form	TEVA_MDL_A_01153652	TEVA_MDL_A_01153653							
CE-323	07/28/2011	REMS Dear Inpatient Pharmacy Letter	TEVA_MDL_A_01153654	TEVA_MDL_A_01153657							
CE-324	07/28/2011	REMS Dear Distributor Letter	TEVA_MDL_A_01153658	TEVA_MDL_A_01153659							
CE-325	07/28/2011	Q1 2011 Vouchers (Re-approval 1)	TEVA_MDL_A_01153660	TEVA_MDL_A_01153665							
CE-326	07/28/2011	REMS Enrollment Information Sheet	TEVA_MDL_A_01153666	TEVA_MDL_A_01153671							
CE-327	07/28/2011	REMS Enrollment Kit: Overview/FAQ Insert	TEVA_MDL_A_01153672	TEVA_MDL_A_01153677							
CE-328	07/28/2011	FENTORA ISI and link update for HCP Products List on Cephalon.com (REMS)	TEVA_MDL_A_01153817	TEVA_MDL_A_01153852							
CE-329	07/28/2011	FENTORA ISI and link update on Patient Product Listing for Cephalon.com (REMS)	TEVA_MDL_A_01153853	TEVA_MDL_A_01153888							
CE-330	07/29/2011	Lesson 1: ACTIQ and FENTORA REMS	TEVA_MDL_A_01153889	TEVA_MDL_A_01153973							
CE-331	07/29/2011	Lesson 2: Follow the Patient	TEVA_MDL_A_01153974	TEVA_MDL_A_01154020							
CE-332	07/29/2011	Lesson 3: Presenting ACTIQ and FENTORA REMS to HCPs	TEVA_MDL_A_01154021	TEVA_MDL_A_01154122							
CE-333	08/02/2011	REMS Enrollment Communication Letters:Wave 1	TEVA_MDL_A_01154123	TEVA_MDL_A_01154126							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-334	08/02/2011	REMS Enrollment Communication Letters:Wave 2	TEVA_MDL_A_01154127	TEVA_MDL_A_01154130							
CE-335	08/02/2011	REMS Enrollment Communication Letters:Wave 3	TEVA_MDL_A_01154131	TEVA_MDL_A_01154134							
CE-336	08/02/2011	FENTORA REMS PLR PI/Med Guide Update	TEVA_MDL_A_01154135	TEVA_MDL_A_01154137							
CE-337	08/03/2011	Convention Panel Update REMS	TEVA_MDL_A_01154141	TEVA_MDL_A_01154141							
CE-338	08/03/2011	Convention Panel Update REMS: Efficacy	TEVA_MDL_A_01154142	TEVA_MDL_A_01154142							
CE-339	08/03/2011	Convention Panel REMS Update: ISI Panel	TEVA_MDL_A_01154143	TEVA_MDL_A_01154143							
CE-340	08/04/2011	Update to ISI for FENTORA on products listing (HCP) for Cephalon.com	TEVA_MDL_A_01154144	TEVA_MDL_A_01154159							
CE-341	08/04/2011	Update to ISI for FENTORA for patient section of Cephalon.com	TEVA_MDL_A_01154160	TEVA_MDL_A_01154175							
CE-342	08/05/2011	Table Top Panel Summary: REMS update	TEVA_MDL_A_01154208	TEVA_MDL_A_01154208							
CE-343	08/05/2011	Table Top Panel Efficacy:REMS update	TEVA_MDL_A_01154209	TEVA_MDL_A_01154209							
CE-344	08/05/2011	Envelope: Dear Stakeholder Letters	TEVA_MDL_A_01154210	TEVA_MDL_A_01154210							
CE-345	08/05/2011	FENTORA Booth Lead Retrieval Questions: Fall shows	TEVA_MDL_A_01154211	TEVA_MDL_A_01154211							
CE-346	08/08/2011	FENTORA Promotional Slide Deck (Full)	TEVA_MDL_A_01154212	TEVA_MDL_A_01154250							
CE-347	08/08/2011	Revised FENTORA Promotional Slide Deck (Abbreviated)	TEVA_MDL_A_01154251	TEVA_MDL_A_01154278							
CE-348	08/11/2011	Facilitator Guide: FENTORA Core Visual Aid PHASE II Workshop	TEVA_MDL_A_01154281	TEVA_MDL_A_01154337							
CE-349	08/11/2011	Pre Work Packet: FENTORA Core Visual Aid PHASE II Workshop	TEVA_MDL_A_01154338	TEVA_MDL_A_01154342							
CE-350	02/12/2010	FENTORA NSMM Workshop - Physician Profile Faciliator Guide	TEVA_MDL_A_01154343	TEVA_MDL_A_01154376							
CE-351	08/11/2011	FENTORA Core Visual Aid PHASE II Workshop: Pre-Workmats	TEVA_MDL_A_01154377	TEVA_MDL_A_01154379							
CE-352	08/11/2011	Handouts: FENTORA Core Visual Aid PHASE II Workshop	TEVA_MDL_A_01154380	TEVA_MDL_A_01154402							
CE-353	08/11/2011	Call Feedback Form: FENTORA Core Visual Aid PHASE II Workshop	TEVA_MDL_A_01154403	TEVA_MDL_A_01154405							
CE-354	08/16/2011	Revised PI for FENTORA linked from pt section of Cephalon.com	TEVA_MDL_A_01154406	TEVA_MDL_A_01154421							
CE-355	08/16/2011	Updated PI for link from HCP section of Cephalon.com product listing	TEVA_MDL_A_01154422	TEVA_MDL_A_01154437							
CE-356	08/16/2011	Aug 2011 REMS PLR PI for Fentora.com	TEVA_MDL_A_01154438	TEVA_MDL_A_01154453							
CE-357	08/16/2011	REMS Reference Guide	TEVA_MDL_A_01154464	TEVA_MDL_A_01154563							
CE-358	08/18/2011	Table Top Panel ISI: REMS update	TEVA_MDL_A_01154564	TEVA_MDL_A_01154564							
CE-359	08/26/2011	Fentora Media Fact Sheet	TEVA_MDL_A_01154565	TEVA_MDL_A_01154568							
CE-360	08/26/2011	ACTIQ and FENTORA REMS Media Fact Sheet	TEVA_MDL_A_01154569	TEVA_MDL_A_01154572							
CE-361	09/06/2011	Rems update:Fentora.com Professional site	TEVA_MDL_A_01154594	TEVA_MDL_A_01154671							
CE-362	09/07/2011	FENTORA Medication Guide (REMS update)	TEVA_MDL_A_01154672	TEVA_MDL_A_01154673							
CE-363	09/07/2011	REMS Pharmacy Inpatient Sell Sheet	TEVA_MDL_A_01154674	TEVA_MDL_A_01154679							
CE-364	09/07/2011	REMS Outpatient Pharmacy Sell Sheet	TEVA_MDL_A_01154680	TEVA_MDL_A_01154685							
CE-365	09/07/2011	Disease State Awareness: Pain Evaluation and Diagnosis Phase II Facilitator Guide-Wkshp (FENTORA)	TEVA_MDL_A_01154686	TEVA_MDL_A_01154713							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-366	09/13/2011	FENTORA PHASE II Dosing, Titration & Administration Workshop	TEVA_MDL_A_01154716	TEVA_MDL_A_01154752							
CE-367	09/16/2011	Patient Breakthrough Pain Waiting Room Brochure	TEVA_MDL_A_01154753	TEVA_MDL_A_01154766							
CE-368	09/21/2011	NCPA Convention Hall banner	TEVA_MDL_A_01154767	TEVA_MDL_A_01154767							
CE-369	09/26/2011	NCPA pre-show email	TEVA_MDL_A_01154768	TEVA_MDL_A_01154773							
CE-370	09/28/2011	RTL: Reminder REMS 3 Steps of Enrollment	TEVA_MDL_A_01154774	TEVA_MDL_A_01154777							
CE-371	09/28/2011	RTL: You're Enrolled, integrating into practice	TEVA_MDL_A_01154778	TEVA_MDL_A_01154781							
CE-372	09/30/2011	Pain Products Learning System: FENTORA Annotated PI	TEVA_MDL_A_01154782	TEVA_MDL_A_01154895							
CE-373	10/06/2011	RTL: Reminder Enrollment is Open	TEVA_MDL_A_01154896	TEVA_MDL_A_01154899							
CE-374	10/10/2011	Enrollment Kit: PPAF Tear Pad	TEVA_MDL_A_01154900	TEVA_MDL_A_01154901							
CE-375	10/17/2011	Revised REMS Transition Slide Deck	TEVA_MDL_A_01154902	TEVA_MDL_A_01154956							
CE-376	10/24/2011	Pharmacy Wave 2 REMS enrollment reminder	TEVA_MDL_A_01154957	TEVA_MDL_A_01154960							
CE-377	10/24/2011	Wave 3 Inpatient Pharmacy REMS comm letter	TEVA_MDL_A_01154961	TEVA_MDL_A_01154964							
CE-378	10/24/2011	Wave 3 Outpatient Pharmacy REMS comm letter	TEVA_MDL_A_01154965	TEVA_MDL_A_01154968							
CE-379	10/28/2011	FENTORA Prescription Savings Brochure	TEVA_MDL_A_01154969	TEVA_MDL_A_01154977							
CE-380	04/01/2010	Nurse Education Workshop - Invite Fax	TEVA_MDL_A_01157712	TEVA_MDL_A_01157712							
CE-381	04/01/2010	Nurse Education Workshop - Registration Confirm Email	TEVA_MDL_A_01157713	TEVA_MDL_A_01157713							
CE-382	04/01/2010	Nurse Education Workshop - Registration Confirm Fax	TEVA_MDL_A_01157735	TEVA_MDL_A_01157735							
CE-383	04/01/2010	Nurse Education Workshop - Signage	TEVA_MDL_A_01157736	TEVA_MDL_A_01157736							
CE-384	04/01/2010	Nurse Education Workshop - BTP Survey	TEVA_MDL_A_01157758	TEVA_MDL_A_01157758							
CE-385	04/01/2010	Nurse Education Workshop - Attendee Survey	TEVA_MDL_A_01157759	TEVA_MDL_A_01157759							
CE-386	04/05/2010	FENTORA Core Visual Aid Coaching Guide	TEVA_MDL_A_01157892	TEVA_MDL_A_01157909							
CE-387	04/05/2010	Oncology Leave Behind Implementation Guide	TEVA_MDL_A_01157993	TEVA_MDL_A_01157997							
CE-388	04/05/2010	Oncology Leave Behind Implementation Guide - Cover Letter	TEVA_MDL_A_01157998	TEVA_MDL_A_01157998							
CE-389	04/09/2010	FENTORA Oncology Leave Behind Training	TEVA_MDL_A_01158002	TEVA_MDL_A_01158049							
CE-390	04/09/2010	eDetail Email Invitation and Assistance Card Order Screen	TEVA_MDL_A_01158050	TEVA_MDL_A_01158051							
CE-391	04/14/2010	Nurse Education Workshop - Deck DVD Label	TEVA_MDL_A_01158071	TEVA_MDL_A_01158071							
CE-392	04/15/2010	Patient Assessment Series At a Glance - Cover Letter	TEVA_MDL_A_01158084	TEVA_MDL_A_01158084							
CE-393	04/16/2010	FENTORA Knowledge Assessment #1	TEVA_MDL_A_01158088	TEVA_MDL_A_01158091							
CE-394	04/27/2010	FENTORA May Managers Meeting Workshop	TEVA_MDL_A_01158158	TEVA_MDL_A_01158216							
CE-395	04/29/2010	FENTORA Patient Case Study Training	TEVA_MDL_A_01158217	TEVA_MDL_A_01158263							
CE-396	12/28/2009	BTP Workshop	TEVA_MDL_A_01158264	TEVA_MDL_A_01158271							
CE-397	04/30/2010	Managers Meeting Exam	TEVA_MDL_A_01158272	TEVA_MDL_A_01158279							
CE-398	12/28/2009	OVTech Workshop	TEVA_MDL_A_01158280	TEVA_MDL_A_01158287							
CE-399	12/28/2009	PI Workshop	TEVA_MDL_A_01158288	TEVA_MDL_A_01158290							
CE-400	01/04/2010	FENTORA Fact Sheet	TEVA_MDL_A_01158322	TEVA_MDL_A_01158324							
CE-401	05/10/2010	FENTORA Annual Assessment	TEVA_MDL_A_01158325	TEVA_MDL_A_01158340							
CE-402	05/12/2010	FENTORA Reimbursement Hotline Flashcard	TEVA_MDL_A_01158341	TEVA_MDL_A_01158342							
CE-403	05/17/2010	FENTORA Workshop for June POA, TSS version	TEVA_MDL_A_01158395	TEVA_MDL_A_01158447							
CE-404	12/01/2011	Fentora Frequently Asked Questions	TEVA_MDL_A_00982822	TEVA_MDL_A_00982836							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-405		FDA letter approving labeling for Fentora	TEVA_MDL_A_00263638	TEVA_MDL_A_00263678							
CE-406	05/06/2009	May 2008 Letter providing FENT008	TEVA_MDL_A_01083635	TEVA_MDL_A_01083640							
CE-407	10/14/2019	FENT002 General Information	TEVA_MDL_A_01085033	TEVA_MDL_A_01085044							
CE-408	12/16/2019	Fentora Warning Label/Prescribing Information	TEVA_MDL_A_01089279	TEVA_MDL_A_01089292							
CE-409	08/27/2010	Direct Mail Appeal in Advance of Pain Week Conference	TEVA_MDL_A_01149905	TEVA_MDL_A_01149910							
CE-410	01/22/2010	Fentora Brochure	TEVA_MDL_A_01151339	TEVA_MDL_A_01151344							
CE-411	03/29/2011	Fentora Brochure	TEVA_MDL_A_01152980	TEVA_MDL_A_01152990							
CE-412	03/29/2011	Promotional Letter re Fentora	TEVA_MDL_A_01153539	TEVA_MDL_A_01153541							
CE-413	08/11/2019	FENT009 - Safety Profile of FENTORA	TEVA_MDL_A_00704700	TEVA_MDL_A_00704712							
CE-414	08/11/2019	FENT012 - Potential for Addiction, Abuse, Misuse and Overdose	TEVA_MDL_A_00705427	TEVA_MDL_A_00705432							
CE-415	00/00/2009	How Do I Request Additional Information About FENTORA?	TEVA_MDL_A_00539204	TEVA_MDL_A_00539221							
CE-416	03/01/2015	Media Fact Sheet: FENTORA (FENTANYL BUCCAL TABLET) (2011)	TEVA_MDL_A_00543178	TEVA_MDL_A_00543180							
CE-417	06/01/2010	FENTORA Sales Simulation Project	TEVA_MDL_A_01149671	TEVA_MDL_A_01149676							
CE-418	06/02/2010	New Dimensions in Pain Dialogues: Workshop Deck	TEVA_MDL_A_01149677	TEVA_MDL_A_01149716							
CE-419	06/02/2010	New Dimensions in Pain Dialogues: Presenter Guide	TEVA_MDL_A_01149717	TEVA_MDL_A_01149766							
CE-420	06/16/2010	New Dimensions in Pain Dialogues: Nurse Peer to Peer Brochure	TEVA_MDL_A_01149832	TEVA_MDL_A_01149847							
CE-421	06/17/2010	New Dimensions in Pain Dialogues: Worksheets	TEVA_MDL_A_01149862	TEVA_MDL_A_01149868							
CE-422	06/22/2010	FEN2009PMC00060 - Yearly review - BTP Education brochure	TEVA_MDL_A_01149871	TEVA_MDL_A_01149880							
CE-423	06/22/2010	FEN2009PPM00164 - Yearly Review - FENTORA BTP Flashcard	TEVA_MDL_A_01149881	TEVA_MDL_A_01149882							
CE-424	06/22/2010	FEN2009PPM00371 - Yearly Review - FENTORA Efficacy Flashcard	TEVA_MDL_A_01149883	TEVA_MDL_A_01149884							
CE-425	06/22/2010	FEN2009PPM00373 - Yearly Review - FENTORA HCP FAQ Brochure	TEVA_MDL_A_01149885	TEVA_MDL_A_01149902							
CE-426	06/22/2010	FEN2009PPM00375 - Yearly Review - FENTORA PK Flashcard	TEVA_MDL_A_01149903	TEVA_MDL_A_01149904							
CE-427	06/25/2010	Allied Health Web Speaker Training Invitation	TEVA_MDL_A_01149915	TEVA_MDL_A_01149915							
CE-428	06/25/2010	Allied Health Web Speaker Training Confirmation	TEVA_MDL_A_01149916	TEVA_MDL_A_01149917							
CE-429	06/25/2010	Allied Health Web Speaker Training Registration Form	TEVA_MDL_A_01149918	TEVA_MDL_A_01149918							
CE-430	06/29/2010	New Dimen in Pain Dialog: Attendee Workbook	TEVA_MDL_A_01149924	TEVA_MDL_A_01149972							
CE-431	06/30/2010	New Dimension in Pain Dialog: Email Invitation	TEVA_MDL_A_01149973	TEVA_MDL_A_01149973							
CE-432	07/00/2006	FENTORA.com	TEVA_MDL_A_00025340	TEVA_MDL_A_00025374							
CE-433	07/00/2006	Fentora Full Promotional Slide Kit	TEVA_MDL_A_00025496	TEVA_MDL_A_00025577							
CE-434	03/00/2007	Fentora Revised Journal Ad -Optimize Onset	TEVA_MDL_A_00025865	TEVA_MDL_A_00025871							
CE-435	07/00/2007	FENTORA.com (3039)	TEVA_MDL_A_00026118	TEVA_MDL_A_00026170							
CE-436	07/00/2007	Epocrates Email Wave 2	TEVA_MDL_A_00026224	TEVA_MDL_A_00026239							
CE-437	08/00/2007	Triple I Tamperproof Rx Pad	TEVA_MDL_A_00026340	TEVA_MDL_A_00026356							
CE-438	09/00/2007	Animated Convetion Booth Panels	TEVA_MDL_A_00026357	TEVA_MDL_A_00026462							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-439	10/12/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025238	TEVA_MDL_A_00025279							
CE-440	10/20/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025280	TEVA_MDL_A_00025339							
CE-441	10/00/2007	Epocrates Safety Update	TEVA_MDL_A_00026463	TEVA_MDL_A_00026472							
CE-442	10/31/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025378	TEVA_MDL_A_00025405							
CE-443	11/28/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025406	TEVA_MDL_A_00025424							
CE-444	12/19/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025425	TEVA_MDL_A_00025495							
CE-445	11/00/2007	Updated Promotional Slide Kit	TEVA_MDL_A_00026628	TEVA_MDL_A_00026706							
CE-446	1/26/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025578	TEVA_MDL_A_00025693							
CE-447	2/7/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025746	TEVA_MDL_A_00025805							
CE-448	2/16/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025806	TEVA_MDL_A_00025843							
CE-449	01/00/2008	Chocolate 3pg Journal Ad (300mcg PI)	TEVA_MDL_A_00026707	TEVA_MDL_A_00026714							
CE-450	5/18/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026028	TEVA_MDL_A_00026079							
CE-451	6/22/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026080	TEVA_MDL_A_00026087							
CE-452	10/00/2007	Chocolate FENTORA.com	TEVA_MDL_A_00026952	TEVA_MDL_A_00027115							
CE-453	03/00/2008	SECURE RiskMAP Slim Jim	TEVA_MDL_A_00027232	TEVA_MDL_A_00027238							
CE-454	8/24/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026240	TEVA_MDL_A_00026329							
CE-455	8/31/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026330	TEVA_MDL_A_00026339							
CE-456	10/00/2007	RiskMAP Sales Aid - Cancer	TEVA_MDL_A_00027239	TEVA_MDL_A_00027250							
CE-457	03/00/2008	Making Pain Talk Painless Brochure	TEVA_MDL_A_00027251	TEVA_MDL_A_00027261							
CE-458	06/00/2008	Practice Manager Program Slides	TEVA_MDL_A_00027416	TEVA_MDL_A_00027473							
CE-459	11/1/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026473	TEVA_MDL_A_00026565							
CE-460	11/9/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026566	TEVA_MDL_A_00026617							
CE-461	11/16/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026618	TEVA_MDL_A_00026627							
CE-462	06/00/2008	PK Flashcard	TEVA_MDL_A_00027556	TEVA_MDL_A_00027562							
CE-463	06/00/2008	Core & Comprehensive Slides for Combined Amrix CSPs	TEVA_MDL_A_00027563	TEVA_MDL_A_00027636							
CE-464	2/22/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026715	TEVA_MDL_A_00026761							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-465	3/14/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026773	TEVA_MDL_A_00026793							
CE-466	3/21/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026794	TEVA_MDL_A_00026902							
CE-467	3/28/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00026903	TEVA_MDL_A_00026951							
CE-468	06/00/2008	Revised Pocket Dosing Guide	TEVA_MDL_A_00027637	TEVA_MDL_A_00027645							
CE-469	4/11/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00027116	TEVA_MDL_A_00027147							
CE-470	4/7/2007	Placebo Placebo Card Holder (5 cards)	TEVA_MDL_A_00027148	TEVA_MDL_A_00027151							
CE-471	4/25/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00027152	TEVA_MDL_A_00027169							
CE-472	5/2/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00027170	TEVA_MDL_A_00027215							
CE-473	5/2/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00027216	TEVA_MDL_A_00027231							
CE-474	06/00/2008	Interactive Dosing Guide	TEVA_MDL_A_00027646	TEVA_MDL_A_00027652							
CE-475	09/00/2008	Epocrates DocAlert & Email - PK	TEVA_MDL_A_00027653	TEVA_MDL_A_00027661							
CE-476	12/00/2008	Epocrates Subscription Certificates	TEVA_MDL_A_00027682	TEVA_MDL_A_00027688							
CE-477	5/23/2008	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00027262	TEVA_MDL_A_00027289							
CE-478	07/00/2008	FENTORA.com Riskmap Pages for SNDA resubmission	TEVA_MDL_A_00027729	TEVA_MDL_A_00027836							
CE-479	5/8/2008	FENTORA E-detail	TEVA_MDL_A_00027474	TEVA_MDL_A_00027555							
CE-480	12/00/2008	Mini Pain Assessment Tear Sheet for BTP Ed. Station	TEVA_MDL_A_00028077	TEVA_MDL_A_00028100							
CE-481	11/00/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00028129	TEVA_MDL_A_00028184							
CE-482	07/00/2006	Direct Mail #1 -Now Available	TEVA_MDL_A_00550961	TEVA_MDL_A_00550966							
CE-483	07/00/2006	Direct Mail #2 - Enhanced Bioavailability	TEVA_MDL_A_00550967	TEVA_MDL_A_00550972							
CE-484	07/00/2006	Direct Mail #3 - A pharmacokinetic difference	TEVA_MDL_A_00550973	TEVA_MDL_A_00550980							
CE-485	07/00/2006	Direct Mail #4 -Simple Administration	TEVA_MDL_A_00550981	TEVA_MDL_A_00550988							
CE-486	4/1/2009	Fentora: Website Banner	TEVA_MDL_A_00027702	TEVA_MDL_A_00027709							
CE-487	07/00/2006	AUS DM #1 -Make the switch	TEVA_MDL_A_00550989	TEVA_MDL_A_00550996							
CE-488	3/9/2009	Debit Card Holder (FEN-2009P-PM-00001)	TEVA_MDL_A_00027837	TEVA_MDL_A_00027849							
CE-489	4/20/2009	Nurses Flip Chart (FEN-2009P-PM-00001)	TEVA_MDL_A_00027850	TEVA_MDL_A_00027869							
CE-490	6/19/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00027916	TEVA_MDL_A_00028076							
CE-491	07/00/2006	AUS DM #2 - Enhanced Bioavailability	TEVA_MDL_A_00550997	TEVA_MDL_A_00551002							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-492	7/10/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00028101	TEVA_MDL_A_00028115							
CE-493	7/17/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00028116	TEVA_MDL_A_00028128							
CE-494	07/00/2006	AUS DM #3 - A pharmacokinetic difference	TEVA_MDL_A_00551003	TEVA_MDL_A_00551010							
CE-495	7/27/2009	SECURE Access Pharmacy Action Letter (FEN-2009P-PM-00160)	TEVA_MDL_A_00028192	TEVA_MDL_A_00028215							
CE-496	6/22/2009	SECURE Access Pharmacy Quick Reference Card (FEN-2009P-PM-00161)	TEVA_MDL_A_00028216	TEVA_MDL_A_00028264							
CE-497	8/21/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00028265	TEVA_MDL_A_00028333							
CE-498	8/28/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00028334	TEVA_MDL_A_00028347							
CE-499	9/4/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00028348	TEVA_MDL_A_00028374							
CE-500	5/11/2009	SECURE Access Patient Enrollment Kit (FEN-2009P-PMC-00073)	TEVA_MDL_A_00028375	TEVA_MDL_A_00028380							
CE-501	4/27/2009	SECURE Nonpromotional Patient FAQ (FEN-2009P-PMC-00083)	TEVA_MDL_A_00507507	TEVA_MDL_A_00507618							
CE-502	07/00/2006	AUS DM #4 - Simple Administration	TEVA_MDL_A_00551011	TEVA_MDL_A_00551018							
CE-503	07/00/2006	Portenoy Reprint "A randomized, placebo-controlled study of FEBT for relief of BTP in opioid-tolerant patients with cancer"	TEVA_MDL_A_00551019	TEVA_MDL_A_00551029							
CE-504	12/00/2006	PharmAlert Mailing Revised	TEVA_MDL_A_00551030	TEVA_MDL_A_00551031							
CE-505	07/00/2006	Darwish 1027 Reprint - Pharmacokinetic Properties of Fentanyl Effervescent Buccal Tablets: A Phase I, Open-Label, Crossover Study of Single-Dose 100, 200, 400, and 800 µg in Healthy Adult Volunteers - Mona Darwish, Mary Kirby, Philmore Robertson, William Tracewell and John Jiang	TEVA_MDL_A_00551102	TEVA_MDL_A_00551115							
CE-506	08/00/2006	Darwish 99-11 Reprint - Relative Bioavailability of the Fentanyl effervescent buccal tablet 1080mcg vs. oral transmucosal fentanyl citrate 1600mcg and Dose proportionality of FET 270 to 1300mcg: A single-dose, randomized, open-label, 3-period study in healthy adult volunteers	TEVA_MDL_A_00551116	TEVA_MDL_A_00551130							
CE-507	08/00/2006	Fentora Formulary Kit	TEVA_MDL_A_00551137	TEVA_MDL_A_00551172							
CE-508	09/00/2006	Reimbursement Kit folder	TEVA_MDL_A_00551249	TEVA_MDL_A_00551274							
CE-509	10/00/2006	Medication Guide - Spanish	TEVA_MDL_A_00551275	TEVA_MDL_A_00551276							
CE-510	10/00/2006	Admin Tear Sheet - Spanish	TEVA_MDL_A_00551277	TEVA_MDL_A_00551280							
CE-511	10/00/2006	Patient FAQ - Spanish	TEVA_MDL_A_00551281	TEVA_MDL_A_00551298							
CE-512	11/00/2006	MPR - Fentora Prescribing Alert (Journal Ad)	TEVA_MDL_A_00551317	TEVA_MDL_A_00551326							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-513	12/00/2006	1026 - Comparison of Equivalent Doses of FEBT and Arteriovenous Differences in Fentanyl Pharmacokinetics - Mona Darwish, Mary Kirby, Philmore Robertson, Edward Hellriegel and John Jiang	TEVA_MDL_A_00551329	TEVA_MDL_A_00551340							
CE-514	12/00/2006	1028 - Relative and Absolute Bioavailability of FEBT - Mona Darwish, Mary Kirby, Philmore Robertson, William Tracewell and John Jiang	TEVA_MDL_A_00551341	TEVA_MDL_A_00551354							
CE-515	12/00/2006	1029 - Single-Dose and Steady-State Pharmacokinetics of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers - Mona Darwish, Mary Kirby, Philmore Robertson, Edward Hellriegel and John Jiang	TEVA_MDL_A_00551355	TEVA_MDL_A_00551368							
CE-516	11/00/2006	PDR Pain Mgmt Prescribing Guide	TEVA_MDL_A_00551369	TEVA_MDL_A_00551395							
CE-517	11/00/2006	Fentora Dose Conversion Cling Poster	TEVA_MDL_A_00551396	TEVA_MDL_A_00551400							
CE-518	01/00/2007	"Gap" Core Sales Aid	TEVA_MDL_A_00551447	TEVA_MDL_A_00551466							
CE-519	01/00/2007	AAPM Convention Panel - Now Available	TEVA_MDL_A_00551480	TEVA_MDL_A_00551484							
CE-520	01/00/2007	AAPM Convention Panel - What is BTP?	TEVA_MDL_A_00551485	TEVA_MDL_A_00551489							
CE-521	01/00/2007	AAPM Animated Booth Panels	TEVA_MDL_A_00551490	TEVA_MDL_A_00551501							
CE-522	01/00/2007	AAPM 20 Second Tower Animation	TEVA_MDL_A_00551502	TEVA_MDL_A_00551511							
CE-523	01/00/2007	AAPM E-detail Booth Activity	TEVA_MDL_A_00551512	TEVA_MDL_A_00551530							
CE-524	02/00/2007	Fentora 3-minute Animation (5 minute)	TEVA_MDL_A_00551531	TEVA_MDL_A_00551544							
CE-525	03/00/2007	Fentora Professional Email(3039)	TEVA_MDL_A_00551586	TEVA_MDL_A_00551586							
CE-526	10/00/2010	Starting Fentora	TEVA_MDL_A_00551587	TEVA_MDL_A_00551590							
CE-527	03/00/2007	AMCP Booth Panels - What is BTP	TEVA_MDL_A_00551591	TEVA_MDL_A_00551591							
CE-528	03/00/2007	AMCP Booth Panels - Optimize onset with FENTORA	TEVA_MDL_A_00551592	TEVA_MDL_A_00551592							
CE-529	03/00/2007	APS/ONS Fentora Booth Panel - What is BTP	TEVA_MDL_A_00551593	TEVA_MDL_A_00551593							
CE-530	03/00/2007	APS/ONS Fentora Booth Panel - Optimize Onset	TEVA_MDL_A_00551594	TEVA_MDL_A_00551594							
CE-531	03/00/2007	APS/ONS Fenotra Booth Panel - BBW	TEVA_MDL_A_00551595	TEVA_MDL_A_00551595							
CE-532	03/00/2007	Patient FAQs - Revised	TEVA_MDL_A_00551596	TEVA_MDL_A_00551616							
CE-533	04/00/2007	Pharmacy Flashcard	TEVA_MDL_A_00551617	TEVA_MDL_A_00551622							
CE-534	04/00/2007	3 pg Gap Journal Ad - 2pg PI	TEVA_MDL_A_00551623	TEVA_MDL_A_00551625							
CE-535	04/00/2007	Triple I FENTORA Rx Ad - Optimize Onset	TEVA_MDL_A_00551626	TEVA_MDL_A_00551634							
CE-536	04/00/2007	Fentora Catalina Newsletter	TEVA_MDL_A_00551635	TEVA_MDL_A_00551635							
CE-537	07/00/2007	3039 4-page Journal Ad - redosing line removed	TEVA_MDL_A_00551664	TEVA_MDL_A_00551665							
CE-538	05/00/2007	Promotional Slide Kit - Revised	TEVA_MDL_A_00551666	TEVA_MDL_A_00551743							
CE-539	07/00/2007	3039 3-page Journal Ad - redosing line removed	TEVA_MDL_A_00551747	TEVA_MDL_A_00551749							
CE-540	05/00/2007	3039 DM #1 - A proven response	TEVA_MDL_A_00551750	TEVA_MDL_A_00551759							
CE-541	05/00/2007	3039 DM #2 - Optimize Onset with Fentora	TEVA_MDL_A_00551760	TEVA_MDL_A_00551767							
CE-542	05/00/2007	3039 Efficacy Flashcard	TEVA_MDL_A_00551768	TEVA_MDL_A_00551773							
CE-543	05/00/2007	3039 Physician FAQ	TEVA_MDL_A_00551774	TEVA_MDL_A_00551793							
CE-544	5/7/2007	RiskMAP Speaker Training Slides	TEVA_MDL_A_00551636	TEVA_MDL_A_00551661							
CE-545	6/7/2007	3039 4-page Journal Ad - revised AEs	TEVA_MDL_A_00551662	TEVA_MDL_A_00551663							
CE-546	06/00/2007	Fentora Pocket Folder (new logo)	TEVA_MDL_A_00551815	TEVA_MDL_A_00551822							
CE-547	08/00/2007	Slatkin 3039 Reprint "FBT for relief of BTP in cancer-related chronic pain"	TEVA_MDL_A_00551853	TEVA_MDL_A_00551857							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-548	6/7/2007	3039 3pg Journal Ad - revised Aes	TEVA_MDL_A_00551744	TEVA_MDL_A_00551746							
CE-549	6/7/2007	3039 Patient FAQ	TEVA_MDL_A_00551794	TEVA_MDL_A_00551814							
CE-550	7/7/2007	Enlarged PI (3oomcg version)	TEVA_MDL_A_00551833	TEVA_MDL_A_00551844							
CE-551	1/12/2009	Model Sales Call Behavior Workshop (FEN-2009P-ST-00032)	TEVA_MDL_A_00551870	TEVA_MDL_A_00551872							
CE-552	2/2/2009	FENTORA: Pillars for success (FEN-2009P-ST-00149)	TEVA_MDL_A_00551873	TEVA_MDL_A_00551883							
CE-553	3/30/2009	SECURE Access Prescriber Reference Guide (FEN-2009P-PM-00177)	TEVA_MDL_A_00551889	TEVA_MDL_A_00551894							
CE-554	4/27/2009	SECURE Access Patient Resource Guide (FEN-2009P-PMC-00178)	TEVA_MDL_A_00551895	TEVA_MDL_A_00551896							
CE-555	4/27/2009	SECURE Access Patient Enrollment Letter (FEN-2009P-PM-00191)	TEVA_MDL_A_00551897	TEVA_MDL_A_00551898							
CE-556	4/27/2009	SECURE Access Prescriber Kit Letter (FEN-2009P-PM-00192)	TEVA_MDL_A_00551899	TEVA_MDL_A_00551916							
CE-557	4/27/2009	SECURE Access Pharmacy Action Letter (FEN-2009P-PM-00193)	TEVA_MDL_A_00551917	TEVA_MDL_A_00551918							
CE-558	4/27/2009	SECURE Access Pharmacy Quick Reference Card (FEN-2009P-PM-00194)	TEVA_MDL_A_00551919	TEVA_MDL_A_00551919							
CE-559	6/8/2009	SECURE Access Patient Identification Card (FEN-2009P-PMC-00195)	TEVA_MDL_A_00551920	TEVA_MDL_A_00551921							
CE-560		SECURE Access Prescriber Enrollment Notification Fax (FEN-2009P-PM-00213)	TEVA_MDL_A_00551922	TEVA_MDL_A_00551923							
CE-561	2/9/2009	SECURE Access Institution Enrollment Form (FEN-2009P-PM-00214)	TEVA_MDL_A_00551930	TEVA_MDL_A_00551943							
CE-562	5/4/2009	2009 Core Visual Aid (FEN-2009P-PM-00231)	TEVA_MDL_A_00551944	TEVA_MDL_A_00551949							
CE-563	5/4/2009	Journal of Pain - APS Abstract Supplement Letter (FEN-2009P-PM-00235)	TEVA_MDL_A_00551951	TEVA_MDL_A_00551951							
CE-564	5/4/2009	SECURE Access Patient Resource Guide (FEN-2009P-PMC-00178)	TEVA_MDL_A_00551954	TEVA_MDL_A_00551971							
CE-565	12/8/2008	SECURE Access Patient Identification Card (FEN-2009P-PMC-00195)	TEVA_MDL_A_00551973	TEVA_MDL_A_00551974							
CE-566	10/31/2006	FENT 033 RiskMAP Compendia Letter/FENT 034 RiskMAP HCP Letter/FENT 035 RiskMAP Top 25 Letter/FENT 036 RiskMAP Assoc Letter/FENT 019 Fentora Launch Announcement Letter/FENT 042 Now Available Journal Ad/FENT 095 FENTORA National Tabletop Panels/FENT 096 Convention Booth Panels	TEVA_MDL_A_00025378	TEVA_MDL_A_00025405							
CE-567	03/30/2007	FENT 042b 2-page FENTORA Journal Advertisement	TEVA_MDL_A_00025865	TEVA_MDL_A_00025871							
CE-568	04/13/2007	FENT 130 FENTORA Healthcare Professionals FAQ/FENT 136 FENTORA Patient Administration Tear Sheet/FENT 139 FENTORA Patient FAQ Includes the previously submitted FENT 080 Medication Guide	TEVA_MDL_A_00025942	TEVA_MDL_A_00025982							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-569	10/13/2006	FENT 016 RiskMAP Flashcard/FENT 039 Voucher Books/ FENT 046 Lined Sticky Note Pads/FENT 050 Lunch and Learn Kits/FENT 051 Durfee Repring/FENT 052 Uniball Tamperproof Ink Pen/ FENT 060 Enlarged P1/FENT 078 Portenoy Abstract	TEVA_MDL_A_00025238	TEVA_MDL_A_00025279							
CE-570	08/08/2011	FEN-2320: REMS Fact Sheet/FEN-2321: REMS Approval Speaker Letter	TEVA_MDL_A_00695824	TEVA_MDL_A_00695852							
CE-571	10/25/2006	FENT 011 Product Fact Sheet/FENT 015 Patient Administration Guide/FENT 071 Patient Reimbursement Worksheet/ FENT 009 FENTORA Pocket Folder. FENT 012 Dosing & Titration Guide/ FENT 083 Annotated PI/FENT 018 Healthcare Provider FAQ/FENT 024 Patient FAQ	TEVA_MDL_A_00025280	TEVA_MDL_A_00025339							
CE-572	10/23/2006	FENT 023 Fentora Website/FENT 054 Launch Announcement Email/FENT 043 Pharmacy Corporate Email	TEVA_MDL_A_00025340	TEVA_MDL_A_00025374							
CE-573	10/30/2006	FENT 056 Convention Tote/FENT 048 Element Convention Pen	TEVA_MDL_A_00025375	TEVA_MDL_A_00025377							
CE-574	11/28/2006	FENT 014 Core Sales Aid/FENT 091 Little Blue Book Ad (1 page)/FENT 091a Little Blue Book Ad (2 pages)/FENT 098 Poster direct mailed to physicians and hospitals	TEVA_MDL_A_00025406	TEVA_MDL_A_00025424							
CE-575	12/19/2006	FENT 088 Patient FAQ-Spanish/FENT 055 Tissue Box/FENT 099 Epocrates Email Alert/FENT 032 Portenoy reprint/FENT 113 FENTORA Calendar/ FENT 097, FENT 100, and FENT 101 Prescription pad, Letter accompanying this Prescription Pad, and Folder containing these pieces/FENT 119 PDR FENTORA Addendum/FENT 105 Porentony Reprint Carrier/FENT 087 Administrative Tear Sheet- Spanish/FENT 118 Medsite Fentora E-Newsletter	TEVA_MDL_A_00025425	TEVA_MDL_A_00025495							
CE-576	01/18/2007	FENT 044 Fentora Promotional Slides for Cephalon Speaker Programs/FENT 104 MPR Fentora Monthly Prescribing Alert/FENT 110 Fentora Dose Conversion Cling Poster	TEVA_MDL_A_00025496	TEVA_MDL_A_00025577							
CE-577	01/26/2007	FENT 041b PharmAlert Insert/FENT 087 NAM Slide Kit/FENT 120 Medsite Detailer	TEVA_MDL_A_00025578	TEVA_MDL_A_00025693							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-578	02/02/2007	FENT 025a Direct Mail to Health Care Providers/FENT 026a Direct Mail to Actiq Prescribers/FENT 045 Promotional Reprint-Darwish-"Comparison of Equivalent Doses of FEBT and Ateriovenous Differences in Fentanyl Pharmacokinetics"/FENT 049 Promotional Reprint-Darwish-"Pharmacokinetic Properties of Fentanyl Effervescent Buccal Tablets: A Phase I, Open-Label, Crossover Study of Single-Dose 100, 200, 400, and 800 mg in Healthy Adult Volunteers/FENT 108 Promotional Reprint- Darwish "Comparison of Equiveland Doses of FEBT and Arteriovenous Differences in Fentanyl Pharmacokinetics."	TEVA_MDL_A_00025694	TEVA_MDL_A_00025745							
CE-579	02/07/2007	FENT 025b Direct Mail to Health Care Providers/FENT 026b Direct Mail to Actiq Prescribers/FENT 109 Pain Management Prescribing Guide/FENT 122a Convention BoothPanel-Now Available/FENT 122b Convention Booth Panel- What is Breakthrough Pain?/FENT 123 Animated Convention Booth Panels Displayed on Flat Screens/FENT 124 Animated Convention Booth Header/FENT 126 E-Detail Booth Activity for Health Care Providers with Fentora Questions and Answers.	TEVA_MDL_A_00025746	TEVA_MDL_A_00025805							
CE-580	02/16/2007	FENT 023a Website for Patients and Health Care Providres/FENT 025c Direct Mail to Health Care Providers/FENT 026c Direct Mail to Actiq Prescribers/FENT 054 Fentora Hand Sanitizer Spray/FENT 088 Spanish Medication Guide/FENT 112 Promotional PI Translated in Spanish/FENT 125 US Oncology Webcast Invitations (print)/FENT 125a US Oncology Webcast Invitations (email)	TEVA_MDL_A_00025806	TEVA_MDL_A_00025843							
CE-581	02/26/2007	FENT 025d Direct Mail to Health Care Providers/FENT 026d Direct Mail to Actiq Prescribers	TEVA_MDL_A_00025844	TEVA_MDL_A_00025864							
CE-582	04/06/2007	FENT 061 FENTORA Reimbursement Kit/FENT 069 FENTORA Abbreviated Formulary Kit and CD_ROM/FENT 137a FENTORA Corporate Booth Panel/FENT 137b FENTORA Corporate Booth Panel	TEVA_MDL_A_00025872	TEVA_MDL_A_00025941							
CE-583	04/20/2007	FENT 138a Convention Booth Panel "What is breakthrough pain?"/FENT 138b FENTORA Convention Booth Panel "Optimizing Onset"/FENT 138c FENTORA Convention Booth Panel "Black Box Warning"/FENT 142a FENTORA "Optimizing Onset" 3-page Journal Ad.	TEVA_MDL_A_00025983	TEVA_MDL_A_00025989							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-584	05/02/2007	WLF-FENT 001 WLF Article "Fentanyl Buccal Tablets for the relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study"/FENT 115 Patient Privacy Sign-in Clopboard/FENT 121 FENTORA Core Sales Aid/FENT 141 FENTORA Pharmacy Flashcard	TEVA_MDL_A_00025990	TEVA_MDL_A_00026027							
CE-585	05/18/2007	FENT 107 Promotional Reprint-Relative and Absoltue Bioavailability of FEBT-Darwish/FENT 108 Promotional Reprint- Single-Dose and Steady-State Pharmacokinetics of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers-Darwish/FENT 132a FENTORA case studies booklet includes 132b FENTORA case studies DVD FENT 132c, d, e, f, FENTORA case study leave behinds.	TEVA_MDL_A_00026028	TEVA_MDL_A_00026079							
CE-586	06/22/2007	FENT 111 FENTORA Patient Education DVD/FENT 150 FENTORA 4 page Journal Ad- July Pubs/FENT 152 FENTORA 3 page Journal ad- July Pubs	TEVA_MDL_A_00026080	TEVA_MDL_A_00026087							
CE-587	06/29/2007	FENT 150a FENTORA 4pg Journal Ad- August pubs/FENT 152a FENTORA 3pg Journal Ad- August Pubs	TEVA_MDL_A_00026088	TEVA_MDL_A_00026097							
CE-588	07/02/2007	FENT 144 Triple I Prescription Pad/144a Triple I Prescription Pad Ad/FENT 144b Triple I Prescription Pad Ad.	TEVA_MDL_A_00026098	TEVA_MDL_A_00026106							
CE-589	07/06/2007	FENT 154 FENTORA Efficacy Flashcard	TEVA_MDL_A_00026107	TEVA_MDL_A_00026117							
CE-590	07/20/2007	FENT 023b FENTORA.com (Revised website with updated physician and patient information)/FENT 135 FENTORA Professional E-mail/FENT 147 Fentora Newsletter/FENT 153a FENTORA Direct Mail/FENT 1543b FENTORA Direct Mail	TEVA_MDL_A_00026118	TEVA_MDL_A_00026170							
CE-591	07/30/2007	FENT 143b FENTORA patient placebo pak desk top holder/FENT 143e FENTORA patient placebo pak carton	TEVA_MDL_A_00026171	TEVA_MDL_A_00026180							
CE-592	08/03/2007	FENT 159 FENTORA Pocket Folder	TEVA_MDL_A_00026181	TEVA_MDL_A_00026189							
CE-593	08/10/2007	FENT 156 FENTORA Patient FAQ/FENT 162 FENTORA Enlarged PI	TEVA_MDL_A_00026190	TEVA_MDL_A_00026223							
CE-594	08/17/2007	FENT 163 FENTORA Slatkin Reprint "FBT for relief of BTP in cancer-related chronic pain"/FENT 178 FENTORA Epocrates Email Alert.	TEVA_MDL_A_00026224	TEVA_MDL_A_00026239							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-595	08/24/2007	FENT 121a FENTORA Sales Aid/FENT 128 FENTORA File Card/FENT 143a-f, FENT 158 Patient Starter Kit/FENT 161a Rep Detail Clin-on poster "What is breakthrough pain?"/FENT 161b Rep Detail Cling-on poster "Optimize Onset with FENTORA"/FENT 165 Dosing and Titration Cling Poster/FENT 166 Dosing and Titration Guide/ FENT 167 Pharmacy Flashcard/FENT 170 Tabletop Display Panels/FENT 174 RiskMAP Flashcard/FENT 179a Reimbursement Slim Jim/FENT 155 Health Care Providers Frequently Asked Questions/ FENT 157 FENTORA P.I.	TEVA_MDL_A_00026240	TEVA_MDL_A_00026329							
CE-596	08/31/2007	FENT 175 PHarmAlert Mailing Insert/FENT 182a AAPM&R Convention Booth Panel "Optimize onset with FENTORA"/FENT 182b AAPM&R Convention Booth Panel "What is breakthrough pain in patients with cancer?"/FENT 182c AAPM&R Convention Booth Panel Boxed Warning/FENT 183a AAPM Booth Panel "Optimize onset with FENTORA"/ FENT 183b AAPM Booth Panel "What is breakthrough pain?"/FENT 184a ASPE Booth Panel "Optimize onset with FENTORA"/FENT 184b ASPE Convention Booth Panel "What is breakthrough pain in patients with cancer?"	TEVA_MDL_A_00026330	TEVA_MDL_A_00026339							
CE-597	09/26/2007	FENT 185 FENTORA Prescription pad contains: FENT 185a Optimize Onset Ad, FENT 185b Successful Titration Ad/FENT 185c Sales Representatives Ordering Materials	TEVA_MDL_A_00026340	TEVA_MDL_A_00026356							
CE-598	10/06/2017	FENT 127a FENTORA 3-D Animation Video/FENT 151 FENTORA Promotional Slide Kit/FENT 194 FENTORA Animated Convention Booth Panels	TEVA_MDL_A_00026357	TEVA_MDL_A_00026462							
CE-599	10/25/2007	FENT 204 Epocrates E-mail Alert Fentora Reminders	TEVA_MDL_A_00026463	TEVA_MDL_A_00026472							
CE-600	11/01/2007	FENT 186a FENTORA Medsite E-Detail Wave B/FENT 186b FENTORA Medsite E-Detail Wave C/FENT 186c FENTORA E-detail Invitation	TEVA_MDL_A_00026473	TEVA_MDL_A_00026565							
CE-601	11/09/2007	FENT 195a SciMedica Speaker Program Workbook/FENT 195b SciMedica Speaker Program Invitation/FENT 206 PharmAlert with Safety Message	TEVA_MDL_A_00026566	TEVA_MDL_A_00026617							
CE-602	11/16/2007	FENT 198a FENTORA Safety Messages Card/FENT 198b FENTORA Safety Messages Sticker/FENT 205 FENTORA Safety Letter to Patients	TEVA_MDL_A_00026618	TEVA_MDL_A_00026627							
CE-603	01/25/2008	FENT 214 FENTORA Promotional Slide Kit	TEVA_MDL_A_00026628	TEVA_MDL_A_00026706							
CE-604	02/08/2008	FENT 232 FENTORA Journal Advertisement	TEVA_MDL_A_00026707	TEVA_MDL_A_00026714							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-605	02/22/2008	FENT 172 FENTORA Pain Assessment Tear Sheet/FENT 201 FENTORA Breakthrough Pain Flashcard/ FENT 211 FENTORA Dosing Cling On Poster/FENT 234 FENTORA Efficacy Flashcard/FENT 236 FENTORA Core Sales Aid/FENT 237 FENTORA Health Care Provider FAQ	TEVA_MDL_A_00026715	TEVA_MDL_A_00026761							
CE-606	03/07/2008	FENT 226 FENTORA Voucher FENT 219 Medication Guide	TEVA_MDL_A_00026762	TEVA_MDL_A_00026772							
CE-607	03/14/2008	FENT 203a "Secure" Reprint Carrier/FENT 203b Heit Article: "Urine Drug Testing in Pain Medicine"/FENT 203d FSMB Article: "Model Policy for the Use of Controlled Substances for the Treatment of Pain"/FENT 227 FENTORA Mouse Pad/FENT 228a FENTORA Lanyard Pen Holder FENT 228b FENTORA Pen/FENT 232a 4 Page Journal Advertisement/FENT 235 PharmAlert Direct Mailing/ FENT 238a-f Tabletop Panel(s)	TEVA_MDL_A_00026773	TEVA_MDL_A_00026793							
CE-608	03/21/2008	FENT 150 FENTORA Managed Care Speaker Slide Kit/FENT 190 Nexcura E-Mail to Cancer Pain Patients/FENT 242 Debit Card IVR Hotline Script.	TEVA_MDL_A_00026794	TEVA_MDL_A_00026902							
CE-609	03/28/2008	FENT 233a FENTORA Reimbursement Kit-Folder/FENT 233b FENTORA Reimbursement Kit-Brochure/FENT 233c FENTORA Reimbursement Kit- Consent Form/FENT 233d FENTORA Reimbursement Kit- Magnet/FENT 233f FENTORA Reimbursement Kit- CD-ROM/ FENT 239 FENTORA PDR addendum/FENT 243 FENTORA Pharmacy Flashcard	TEVA_MDL_A_00026903	TEVA_MDL_A_00026951							
CE-610	04/03/2008	Transmittal of Advertisements and Promotional Labeling for Fentora, FENT 200 FENTORA.com (HCP and Patient Content).	TEVA_MDL_A_00026952	TEVA_MDL_A_00027115							
CE-611	04/11/2008	FENT 217 FENTORA Patient FAQ/FENT 222a Catalina Newsletter/FENT 245a Epocrates Doc Alert-patient selection/FENT 245b Epocrates Doc Alert-dosing/FENT 213 99-15 Weinstein Abstract/FENT 252 a, b, c Corporate Convention Booth Panels.	TEVA_MDL_A_00027116	TEVA_MDL_A_00027147							
CE-612	04/11/2008	Transmittal of Advertisements and Promotional Labeling for Fentora, FENT 216d placebo pack/FENT 143 e holder for placebo pack.	TEVA_MDL_A_00027148	TEVA_MDL_A_00027151							
CE-613	04/25/2008	Transmittal of Advertisements and Promotional Labeling for Fentora, FENT 241 FENTORA Enlarged PI/FENT 257 FENTORA Boat Tote.	TEVA_MDL_A_00027152	TEVA_MDL_A_00027169							
CE-614	05/02/2008	Patient Starter Kit.	TEVA_MDL_A_00027170	TEVA_MDL_A_00027215							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-615	05/02/2008	FENT 224 FENTORA Tamperproof RX Pads/FENT 246 FENTORA 5 Minute Animation/FENT 247 PDR Pain Management Prescribing Guide/FENT 254 FENTORA Booth Challenge Game/FENT 255a-c Convention booth panel[s]/FENT 258 Interactive Touchscreen Panels	TEVA_MDL_A_00027216	TEVA_MDL_A_00027231							
CE-616	05/09/2008	FENT 250 FENTORA SECURE Slim Jim Brochure.	TEVA_MDL_A_00027232	TEVA_MDL_A_00027238							
CE-617	05/12/2008	FENT 208 FENTORA SECURE Visual Aid.	TEVA_MDL_A_00027239	TEVA_MDL_A_00027250							
CE-618	05/23/2008	FENT 251 FENTORA Making Pain Talk Painless - Patient Brochure.	TEVA_MDL_A_00027251	TEVA_MDL_A_00027261							
CE-619	05/23/2008	FENT 249 FENTORA Portenoy Reprint Carrier/FENT 259 FENTORA Spanish PI/FENT 260 FENTORA Spanish Medication Guide.	TEVA_MDL_A_00027262	TEVA_MDL_A_00027289							
CE-620	05/30/2008	Transmittal of Advertisements and Promotional Labeling for Fentora, EDU 262 Abuse, Addiction & Diversion Slide Kit.	TEVA_MDL_A_00027290	TEVA_MDL_A_00027415							
CE-621	06/13/2008	FENT 264 FENTORA Practice Management Slide Kit.	TEVA_MDL_A_00027416	TEVA_MDL_A_00027473							
CE-622	07/18/2008	FENT 262 FENTORA E-detail Website.	TEVA_MDL_A_00027474	TEVA_MDL_A_00027555							
CE-623	07/31/2008	FENT 266 FENTORA PK Flashcard.	TEVA_MDL_A_00027556	TEVA_MDL_A_00027562							
CE-624	08/08/2008	FENT 265 FENTORA Promotional Slide Kit.	TEVA_MDL_A_00027563	TEVA_MDL_A_00027636							
CE-625	08/28/2008	FENT 269 FENTORA Dosing and Administration Guide.	TEVA_MDL_A_00027637	TEVA_MDL_A_00027645							
CE-626	09/12/2008	FENT 263 FENTORA Interactive Dosing Guide.	TEVA_MDL_A_00027646	TEVA_MDL_A_00027652							
CE-627	10/31/2008	FENT 275 PK DocAlert & email.	TEVA_MDL_A_00027653	TEVA_MDL_A_00027661							
CE-628	11/21/2008	FENT 276 FENTORA 2009 Wall Calendar.	TEVA_MDL_A_00027662	TEVA_MDL_A_00027668							
CE-629	01/15/2009	Fentora, FENT 277a FENTORA Voucher.	TEVA_MDL_A_00027669	TEVA_MDL_A_00027681							
CE-630	01/30/2009	FENT 280 Epocrates Certificates.	TEVA_MDL_A_00027682	TEVA_MDL_A_00027688							
CE-631	02/20/2009	Transmittal of Advertisements and Promotional Labeling for Fentora, FENT 2009P-PMC-00001 Assistance Cards.	TEVA_MDL_A_00027689	TEVA_MDL_A_00027701							
CE-632	02/27/2009	FENT 2009P-PMC-00080 Website Banner.	TEVA_MDL_A_00027702	TEVA_MDL_A_00027709							
CE-633	04/03/2009	Transmittal of Advertisements and Promotional Labeling for Fentora, FEN 2009P-PMC-00003 Patient profiler	TEVA_MDL_A_00027710	TEVA_MDL_A_00027726							
CE-634	04/08/2009	Response to DDMAC re FENT 023a/FENT 200.	TEVA_MDL_A_00027727	TEVA_MDL_A_00027728							
CE-635	04/13/2009	FENT 200a Website update.	TEVA_MDL_A_00027729	TEVA_MDL_A_00027836							
CE-636	04/29/2009	FEN-2009P-PM 00165 Prescribing Guide.	TEVA_MDL_A_00027837	TEVA_MDL_A_00027849							
CE-637	05/06/2009	FEN-2009P-PM-00388 Interactive Touch Screens.	TEVA_MDL_A_00027850	TEVA_MDL_A_00027869							
CE-638	05/29/2009	FEN-2009P-PM-00231 Core Visual Aid.	TEVA_MDL_A_00027870	TEVA_MDL_A_00027886							
CE-639	06/19/2009	FEN-2009P-PMC-00377 Card Holder/FEN-2009P-PMC-00399 Patient FAQ.	TEVA_MDL_A_00027887	TEVA_MDL_A_00027915							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-640	06/19/2009	FEN-2009P-PM-00164 BTP Flash Card/FEN-2009P-PM-00371 Efficacy Flash Card/FEN-2009P-PM-00372 Logo Pocket Folder/FEN-2009P-PM-00373 HCP FAQ/FEN-2009P-PM-00374 Journal Ad/FEN-2009P-PM-00375 PK Flashcard/FEN-2009P-PM-00378 Dosing Cling-on/FEN-2009P-PM-0466 Spread Journal Ad/FEN-2009P-PM-00380 Slide Kit/FEN-2009P-PM-00396 Slide Kit/FEN-2009P-M-00397 Efficacy Epocrates	TEVA_MDL_A_00027916	TEVA_MDL_A_00028076							
CE-641	06/26/2009	FENT-279a Tear Sheet/FEN-2009P-PMC-00060 Brochure/FEN-2009P-PMC-00376 Voucher.	TEVA_MDL_A_00028077	TEVA_MDL_A_00028100							
CE-642	07/10/2009	FENT-2009P-PM-00599 Fax Invitation/FENT-2009P-PM-00600 Fax Flyer.	TEVA_MDL_A_00028101	TEVA_MDL_A_00028115							
CE-643	07/17/2009	FEN-2009P-PM-00523 Table Top Panel/FEN-2009PM-00524 Table Top Panel/FEN-2009P-PM-00525 Table Top Panel/FEN-2009P-PM-00526 Table Top Panel/FEN-2009P-PM-00573 Email	TEVA_MDL_A_00028116	TEVA_MDL_A_00028128							
CE-644	07/28/2009	FEN-2009P-PM-00059 Education Station/FEN-2009P-PM-00520 Convention Panel/FEN-2009P-PM-00521 Convention Panel/FEN-2009P-PM-00574 Convention Panel/FEN-2009P-PM-00575 Convention Panel/FEN-2009P-PM-00576 Convention Panel/FEN-2009P-PM-00577 Convention Panel/FEN-2009P-PM-00308 Workbook	TEVA_MDL_A_00028129	TEVA_MDL_A_00028184							
CE-645	08/05/2009	FEN-2009P-PM-00426 Invitation.	TEVA_MDL_A_00028185	TEVA_MDL_A_00028191							
CE-646	08/14/2009	FEN-2009P-PM-00797 Workbook.	TEVA_MDL_A_00028192	TEVA_MDL_A_00028215							
CE-647	08/21/2009	FEN-2009P-PMC-00682 Website	TEVA_MDL_A_00028216	TEVA_MDL_A_00028264							
CE-648	08/21/2009	FEN-2009P-PM-00681 Website/FEN-2009P-PM-00643 DVD/FEN-2009P-PM-00644 DVD/FEN-2009P-PM-00645 DVD	TEVA_MDL_A_00028265	TEVA_MDL_A_00028333							
CE-649	08/28/2009	FEN-2009P-PM-00794 Screensaver/FEN-2009P-PM-00795 Room Drop/FEN-2009P-PM-00886 Belly Band	TEVA_MDL_A_00028334	TEVA_MDL_A_00028347							
CE-650	09/04/2009	FEN-2009P-PM-00715 Sign/FEN-2009P-PM-00716 Room Drop/FEN-2009P-PM-00757 Flashcard/FEN-2009P-PM-00766 Touchscreens/FEN-2009P-PM-00936 E-mail/FEN-2009P-PM-00937 Screenshots	TEVA_MDL_A_00028348	TEVA_MDL_A_00028374							
CE-651	09/18/2009	FEN-2009P-PMC-00480 CD	TEVA_MDL_A_00028375	TEVA_MDL_A_00028380							
CE-652	09/25/2009	FEN-2009P-PMC-00898 Leave Behind	TEVA_MDL_A_00028381	TEVA_MDL_A_00028387							
CE-653	10/15/2009	FEN-2009P-PM-01153 Letter/FEN-2009P-PM-01154 Letter/FEN-2009P-PM-01155 Letter/FEN-2009P-PM-01179	TEVA_MDL_A_00028388	TEVA_MDL_A_00028396							
CE-654	11/13/2009	FEN-2009P-PM-01265 Email/FEN-2009P-PM-01266 Letter	TEVA_MDL_A_00028397	TEVA_MDL_A_00028404							
CE-655	01/05/2010	FEN-2009P-PMC-00377	TEVA_MDL_A_00028405	TEVA_MDL_A_00028417							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-656	01/19/2010	FEN-2001 Quantia Slide Deck/FEN-2013 Dinner Meeting Rep Invite/FEN-2014 DM Fax Invite/FEN-2015 DM Confirmation Fax/FEN-2016 DM Flyer	TEVA_MDL_A_00028418	TEVA_MDL_A_00028449							
CE-657	01/28/2010	FEN 2024 Flash storyboards	TEVA_MDL_A_00028450	TEVA_MDL_A_00028455							
CE-658	02/12/2010	FEN 2027 Promotional P.I.	TEVA_MDL_A_00028456	TEVA_MDL_A_00028462							
CE-659	02/19/2010	FEN 2019 Hospital Invitation	TEVA_MDL_A_00028463	TEVA_MDL_A_00028471							
CE-660	03/25/2010	FEN 2005 Fact Sheet	TEVA_MDL_A_00028472	TEVA_MDL_A_00028481							
CE-661	04/20/2010	FEN 2043 Email Invitation/FEN 2043a Fax Invitation	TEVA_MDL_A_00028482	TEVA_MDL_A_00028491							
CE-662	04/23/2010	FEN 2044 Confirmation Email/FEN 2044a Confirmation Fax/FEN 2056 eDetail Email	TEVA_MDL_A_00028492	TEVA_MDL_A_00028502							
CE-663	04/30/2010	FEN 2025 PDR Content Converter/FEN 2026 Oncology Leave Behind	TEVA_MDL_A_00028503	TEVA_MDL_A_00028527							
CE-664	05/05/2010	FEN-2038 Convention Booth Quiz	TEVA_MDL_A_00028528	TEVA_MDL_A_00028536							
CE-665	05/12/2010	FEN-2028 Detailer-Case Study Folder/FEN-2028a Detailer-Case Study #1/FEN-2028b Detailer-Case Study #2/FEN-2028c Detailer-Tearsheets/FEN-2037 Fentora Brief Summary/FEN-2040 Slide Deck with Speaker Notes/FEN-2040b CD/FEN-2045 Workshop Sign/FEN-2048 Banner/FEN-2054a ONS Booth Sign/FEN-2057 Response Card/FEN-2040a Workbook/FEN-2046 BTP Survey/FEN-2047 Attendee Survey	TEVA_MDL_A_00028537	TEVA_MDL_A_00028650							
CE-666	06/28/2010	FEN-2041 Post Convention Mailer	TEVA_MDL_A_00028651	TEVA_MDL_A_00028657							
CE-667	07/23/2010	FEN-2067 Flashcard	TEVA_MDL_A_00028658	TEVA_MDL_A_00028666							
CE-668	08/05/2010	FEN-2098 Cephalon.com patient section/FEN-2099 HCP section of Cephalon.com	TEVA_MDL_A_00028667	TEVA_MDL_A_00028681							
CE-669	08/13/2010	FEN-2072 Brochure/FEN-2087 Registration Email/FEN-2087a Confirmation Email/FEN-2087b Registration Fax/FEN-2087c Sales Rep Invitation Letter/FEN-2087d Invitation Fax/FEN-2087e Confirmation Fax/FEN-2106 Registration Fax/FEN-2108 Invitation Letter/FEN-2109 Booth Handout/FEN-2110 Confirmation Letter	TEVA_MDL_A_00028682	TEVA_MDL_A_00028715							
CE-670	08/26/2010	FEN-2080 PainWeek Mailer/FEN-2101 Floor Clings/FEN-2082a Pain Week Tweets	TEVA_MDL_A_00028716	TEVA_MDL_A_00028732							
CE-671	09/02/2010	FEN-2069 Slide Deck/FEN-2082 Pain Week e-survey/FEN-2088 MD Slide Deck	TEVA_MDL_A_00028733	TEVA_MDL_A_00028824							
CE-672	09/09/2010	FEN-2088a Worksheet/FEN-2089-PM-00374 Workbook/FEN-2104a E-Newsletter/FEN-2124 Signage	TEVA_MDL_A_00028825	TEVA_MDL_A_00028894							
CE-673	10/01/2010	FEN-2164 ETC Invite/FEN-2165 ETC Fax Confirmation/FEN-2166 ETC Confirmation	TEVA_MDL_A_00028895	TEVA_MDL_A_00028904							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-674	10/08/2010	FEN-2069a Worksheets/FEN-2086 Workbook/FEN-2156 Introduction Letter/FEN-2157 Direct Mail Material Letter/FEN-2159 Co-pay Assistance Card Letter/FEN-2170 HCP Dinner Email Invitation/FEN-2171 HCP Dinner Email Confirmation/FEN-2172 HCP Dinner Fax Invitation/FEN-2173 HCP Dinner Fax Confirmation/FEN-2174 HCP Dinner Sales Rep Invitation/FEN-2168 ETC Sales Rep Invitation	TEVA_MDL_A_00028905	TEVA_MDL_A_00028984							
CE-675	10/29/2010	FEN-2177 Promotional Slide Deck	TEVA_MDL_A_00028985	TEVA_MDL_A_00029031							
CE-676	11/05/2010	FEN-2179 Workbook/FEN-2193 Rep Invitation/FEN-2194 Fax Invitation/FEN-2195 Confirmation Letter/FEN-2196 Evaluation Form	TEVA_MDL_A_00029032	TEVA_MDL_A_00029049							
CE-677	11/12/2010	FEN-2155 Folder/FEN-2155a Prior Authorization CD Guide/FEN-2155b Prior Authorization CD/FEN-2155c Forms/FEN-2155d Flashcard	TEVA_MDL_A_00029050	TEVA_MDL_A_00029070							
CE-678	11/23/2010	FEN-2200 HCP Slide Deck	TEVA_MDL_A_00029071	TEVA_MDL_A_00029110							
CE-679	12/10/2010	FEN-2107 Quantia Slide Deck - Wave 2/FEN-2107a Quantia Slide Deck - Wave 3	TEVA_MDL_A_00029111	TEVA_MDL_A_00029152							
CE-680	01/07/2011	FEN-2122 Fentora.com	TEVA_MDL_A_00029153	TEVA_MDL_A_00029393							
CE-681	01/10/2011	FEN-2201 FENTORA Voucher	TEVA_MDL_A_00029394	TEVA_MDL_A_00029406							
CE-682	01/14/2011	FEN-2176 Core Visual Aid	TEVA_MDL_A_00029407	TEVA_MDL_A_00029421							
CE-683	01/28/2011	FEN-2207 Assistance Card/FEN-2207a Assistance Card Holder	TEVA_MDL_A_00029422	TEVA_MDL_A_00029431							
CE-684	02/18/2011	FEN-2225 Weinstein Reprint 2009/FEN-2226 Darwish Reprint 2007/FEN-2227 Portenoy Reprint 2006/FEN-2228 Darwish Reprint 2006/FEN-2229 Darwish Reprint 2006	TEVA_MDL_A_00029432	TEVA_MDL_A_00029483							
CE-685	03/04/2011	FEN-2183 Dosing Leave Behind	TEVA_MDL_A_00029484	TEVA_MDL_A_00029494							
CE-686	03/11/2011	FEN-2236: Rep-triggered Letter - Efficacy/FEN-2236a: Rep-Triggered Letter Envelope/FEN-2237: Rep-triggered Letter - PK/FEN-2238: Rep-triggered Letter - STL	TEVA_MDL_A_00029495	TEVA_MDL_A_00029511							
CE-687	03/18/2011	FEN-2242: Fentora Summary Panel/FEN-2249: Fentora Efficacy Panel	TEVA_MDL_A_00029512	TEVA_MDL_A_00029520							
CE-688	03/21/2011	FEN-2250: Fentora ISI & Black Box Panel	TEVA_MDL_A_00029521	TEVA_MDL_A_00029528							
CE-689	03/22/2011	FEN-2276: Fentora.com - Update	TEVA_MDL_A_00029529	TEVA_MDL_A_00029774							
CE-690	03/23/2011	FEN-2259: Cephalon.com - Our Products	TEVA_MDL_A_00029775	TEVA_MDL_A_00029797							
CE-691	03/23/2011	FEN-2260: Cephalon.com - Our Products	TEVA_MDL_A_00029798	TEVA_MDL_A_00029819							
CE-692	03/25/2011	FEN-2186: Efficacy Leave Behind/FEN-2187: PK Leave Behind/FEN-2235: RTM Dosing/FEN-2244: RTM Dosing - Actiq Convert	TEVA_MDL_A_00029820	TEVA_MDL_A_00029842							
CE-693	04/01/2011	FEN-2220: Promotional Slide Deck/FEN-2220a: Abbr. Promotional Slide Deck	TEVA_MDL_A_00029843	TEVA_MDL_A_00029914							
CE-694	04/15/2011	FEN-2264: Convention Fabric Ring	TEVA_MDL_A_00029915	TEVA_MDL_A_00029922							
CE-695	04/22/2011	FEN-2271: Teleconference Series Invite	TEVA_MDL_A_00029923	TEVA_MDL_A_00029933							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-696	05/04/2011	FEN-2220b: Telecon Series Workbook/FEN-2273: Telecon Series Cover Letter/FEN-2281: Telecon Series Evaluation Form/FEN-2284: Placebo for demonstration	TEVA_MDL_A_00029934	TEVA_MDL_A_00029983							
CE-697	05/26/2011	FEN-2285: FENTORA HCP Leave Behind/FEN-2286: Patient Profile #1/FEN-2287: Patient Profile #2/FEN-2184: Stop Look Listen Leave Behind	TEVA_MDL_A_00029984	TEVA_MDL_A_00030015							
CE-698	06/09/2011	FEN-2288: FENTORA Reprint Compend./FEN-2289: FENTORA Promotional PI	TEVA_MDL_A_00030016	TEVA_MDL_A_00030028							
CE-699	06/23/2011	FEN-2233 - HCP Product Website Update	TEVA_MDL_A_00030029	TEVA_MDL_A_00030093							
CE-700	07/05/2011	FEN-2234 - Consumer Product Website	TEVA_MDL_A_00030094	TEVA_MDL_A_00030170							
CE-701	07/15/2011	FEN-2271a: Teleconference Series, Wave 2	TEVA_MDL_A_00030171	TEVA_MDL_A_00030178							
CE-702	07/21/2011	FEN-2316: REMS Media Fact Sheet	TEVA_MDL_A_00030179	TEVA_MDL_A_00030202							
CE-703	07/28/2011	FEN-2312: RTL Assessing SAOs/FEN-2313: RTL Assessing LAOs	TEVA_MDL_A_00030203	TEVA_MDL_A_00030212							
CE-704	08/08/2011	FEN-2320: REMS Fact Sheet/FEN-2321: REMS Approval Speaker Letter	TEVA_MDL_A_00030213	TEVA_MDL_A_00030241							
CE-705	08/10/2011	FEN-2322: KOL REMS Approval Email	TEVA_MDL_A_00030242	TEVA_MDL_A_00030270							
CE-706	08/10/2011	Transmittal of advertisements and promotional labeling for Fentora: FEN-2241a: Pain Week Program Ad	TEVA_MDL_A_00030271	TEVA_MDL_A_00030278							
CE-707	09/01/2011	Transmittal of advertisements and promotional labeling for Fentora: FEN-2337 - Convention Panel: Summary/FEN-2338 - Convention Panel: Efficacy/FEN-2339 - Convention Panel: ISI	TEVA_MDL_A_00030279	TEVA_MDL_A_00030299							
CE-708	09/01/2011	FEN-2324 - Dear HCP Letter/FEN-2325 - Dear Outpatient Pharmacy/FEN-2326 - Dear Inpatient Pharmacy/FEN-2327 - Dear Distributer Letter/FEN-2342 - Dear Stakeholder Envelope	TEVA_MDL_A_00030300	TEVA_MDL_A_00030353							
CE-709	09/08/2011	Transmittal of advertisements and promotional labeling for Fentora: FEN-2323: Enrollment Kit Housing Unit/FEN-2323a: PPAF Tear Pad/FEN-2323b: Overview/FAQ/FEN-2328: REMS Enrollment Info Sheet	TEVA_MDL_A_00030354	TEVA_MDL_A_00030375							
CE-710	09/09/2011	FEN-2337a: Table Top Panel - Summary/FEN-2338a: Table Top Panel - Efficacy/FEN-2339a: Table Top Panel - ISI	TEVA_MDL_A_00030376	TEVA_MDL_A_00030396							
CE-711	09/16/2011	FEN-2220c: Full Promotional Slide Deck/FEN-2220d: Abbreviated Promo Slide Deck/FEN-2352: FENTORA Media Fact Sheet	TEVA_MDL_A_00030397	TEVA_MDL_A_00030485							
CE-712	09/16/2011	FEN-2221: REMS Slide Deck/FEN-2353 REMS Media Fact Sheet	TEVA_MDL_A_00030486	TEVA_MDL_A_00030583							
CE-713	10/07/2011	FEN-2334: REMS Enroll Letter-Wave 1/FEN-2357: REMS Inpatient Pharmacy/FEN-2358: REMS Outpatient Pharmacy/FEN-2365: NCPA pre-show email	TEVA_MDL_A_00030584	TEVA_MDL_A_00030644							
CE-714	10/13/2011	FEN-2355: Fentora.com (Professional site)	TEVA_MDL_A_00030645	TEVA_MDL_A_00030740							
CE-715	10/13/2011	FEN-2323c: Enrollment Kit/PPAF Tear Pad	TEVA_MDL_A_00030741	TEVA_MDL_A_00030781							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-716	11/04/2011	FEN-2366: RTL [Representative Triggered Letter] Reminder REMS 3 Steps/FEN-2369: RTL Reminder Enroll is Open	TEVA_MDL_A_00030782	TEVA_MDL_A_00030828							
CE-717	11/11/2011	FEN: 2221b: Rev. REMS Transition Deck	TEVA_MDL_A_00030829	TEVA_MDL_A_00030901							
CE-718	12/02/2011	FEN-2373: Prescription Savings Brochure/FEN-2377: Prescription Savings Card	TEVA_MDL_A_00030902	TEVA_MDL_A_00030929							
CE-719	12/02/2011	FEN-2221a: Rems NAMs Slide Deck	TEVA_MDL_A_00030930	TEVA_MDL_A_00030984							
CE-720	12/09/2011	FEN-2377a: Prescription Savings Website	TEVA_MDL_A_00030985	TEVA_MDL_A_00031008							
CE-721	01/06/2012	FEN-2221c: REMS Transition Deck/FEN-2367: You're Enrolled, Int. ino Pract.	TEVA_MDL_A_00031056	TEVA_MDL_A_00031170							
CE-722	01/13/2012	FEN-2376: REMS Webcast Invitation	TEVA_MDL_A_00031171	TEVA_MDL_A_00031213							
CE-723	01/26/2012	FEN-2382: Core Visual Aid (Update)	TEVA_MDL_A_00031214	TEVA_MDL_A_00031245							
CE-724	01/26/2012	FEN-2376b: REMS Webcast Invite (e-mail)/FEN/ACT-0002: PPAF Leave-Behind	TEVA_MDL_A_00031246	TEVA_MDL_A_00031295							
CE-725	02/17/2012	FEN-2370: Pharmacy REMS Reminder/FEN-2371: Inpatient Pharm. REMS letter/FEN-2371a: REMS Letters Envelope/FEN-2372: Outpatient Pharm. REMS Letter/FEN-2376c: REMS On-Demand Webcast	TEVA_MDL_A_00031296	TEVA_MDL_A_00031403							
CE-726	02/24/2012	FEN-2370: Pharmacy REMS Reminder/FEN-2376c: REMS Webcast Registration	TEVA_MDL_A_00031404	TEVA_MDL_A_00031449							
CE-727	03/02/2012	FEN-2405: BTP Speaker Program Invite/FEN-2408: REMS Speaker Program Invite	TEVA_MDL_A_00031450	TEVA_MDL_A_00031472							
CE-728	03/09/2012	FEN-2401 WIP Table Display/FEN-2409 FENTORA.com Update	TEVA_MDL_A_00031473	TEVA_MDL_A_00031491							
CE-729	03/15/2012	FEN-2415 BTP Speaker Program Invite/FEN-2416 REMS Speaker Program Invite	TEVA_MDL_A_00031492	TEVA_MDL_A_00031514							
CE-730	03/19/2012	FEN-2409 FENTORA.com Update	TEVA_MDL_A_00031515	TEVA_MDL_A_00031532							
CE-731	03/26/2012	FEN-2409 FENTORA.com Update	TEVA_MDL_A_00031533	TEVA_MDL_A_00031550							
CE-732	03/26/2012	FEN-2409 FENTORA.com Update/FEN-2401 WIP Table Display	TEVA_MDL_A_00031551	TEVA_MDL_A_00031569							
CE-733	04/06/2012	FEN-2417 Efficacy Leave Behind Update	TEVA_MDL_A_00031570	TEVA_MDL_A_00031590							
CE-734	04/13/2012	FEN-2411 Rx Savings Brochure/FEN-2411a Rx Savings Brochure Holder	TEVA_MDL_A_00031591	TEVA_MDL_A_00031615							
CE-735	04/20/2012	FEN-2411 Rx Savings Brochure/FEN-2410 Rx Savings Card/FEN-2412 65 & Over Program Ltr & Cert/FEN-2414 Rx Savings Program Envelope	TEVA_MDL_A_00031616	TEVA_MDL_A_00031652							
CE-736	04/20/2012	FEN-2441 FENTORA ISI Panel	TEVA_MDL_A_00031653	TEVA_MDL_A_00031670							
CE-737	04/27/2012	FEN-2421 Rx Savings Rep Triggered Mail	TEVA_MDL_A_00031671	TEVA_MDL_A_00031690							
CE-738	05/03/2012	FEN-2429 Touch Screen Panels	TEVA_MDL_A_00031691	TEVA_MDL_A_00031725							
CE-739	05/18/2012	FEN-2418 Dosing Leave Behind/FEN-2447 Hotline Card Update	TEVA_MDL_A_00031726	TEVA_MDL_A_00031746							
CE-740	05/25/2012	FEN-2442 Portenoy Reprint Carrier/FEN-2443 Weinstein Reprint Carrier/FEN/ACT-0005 RTL-Actiq Conversions	TEVA_MDL_A_00031747	TEVA_MDL_A_00031782							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-741	06/01/2012	FEN-2464 ISI Panel Update/FEN-2446 HCP Brochure Update	TEVA_MDL_A_00031783	TEVA_MDL_A_00031820							
CE-742	07/06/2012	FEN-2456 FentoraSavings.com	TEVA_MDL_A_00031821	TEVA_MDL_A_00031838							
CE-743	07/06/2012	FEN-2456 FentoraSavings.com	TEVA_MDL_A_00031839	TEVA_MDL_A_00031856							
CE-744	07/20/2012	FEN-2362 Patient Brochure	TEVA_MDL_A_00031857	TEVA_MDL_A_00031887							
CE-745	07/27/2012	FEN-2455 FENTORA Digital Sales Aid for iPad (July Pilot)/FEN-2457 FENTORA Dosing Digital Sales Aid for iPad (July Pilot)	TEVA_MDL_A_00031888	TEVA_MDL_A_00031973							
CE-746	09/18/2012	Case-Based Promotional Slide Deck/Breakthrough Cancer Pain Speaker Program Invite Template	TEVA_MDL_A_00031974	TEVA_MDL_A_00032058							
CE-747	09/20/2012	FEN-2438/FEN-2444 FENTORA.com Website Pages (Consumer)	TEVA_MDL_A_00032059	TEVA_MDL_A_00032085							
CE-748	09/20/2012	FEN-2437/FEN-2444 FENTORA.com Website Pages (HCP)	TEVA_MDL_A_00032086	TEVA_MDL_A_00032111							
CE-749	10/03/2012	FEN-2484 Digital Sales Aid for iPad/FEN-2508 Fingertip Formulary for iPad	TEVA_MDL_A_00032112	TEVA_MDL_A_00032218							
CE-750	10/19/2012	FEN-2490 Sales Aid/FEN-2491 HCP Slim Jim/FEN-2497 Hotline Form	TEVA_MDL_A_00032219	TEVA_MDL_A_00032280							
CE-751	11/16/2012	FEN-2509 BTP Speaker Program Invite Template/FEN-2509a BTP Speaker Program Invite Envelope	TEVA_MDL_A_00032281	TEVA_MDL_A_00032300							
CE-752	12/07/2012	FEN-2493 Dosing Leave Behind	TEVA_MDL_A_00032301	TEVA_MDL_A_00032319							
CE-753	12/20/2012	FEN-2492 Tri-fold Leave Behind	TEVA_MDL_A_00032320	TEVA_MDL_A_00032338							
CE-754	01/04/2013	FEN-2452a FENTORA abbreviated case-based promotional slide deck	TEVA_MDL_A_00032339	TEVA_MDL_A_00032398							
CE-755	01/10/2013	FEN-2484a Digital Sales Aid for iPad	TEVA_MDL_A_00032399	TEVA_MDL_A_00032500							
CE-756	02/01/2013	FEN-2510 Rx Savings Brochure/FEN-2519 Rx Savings Card	TEVA_MDL_A_00032501	TEVA_MDL_A_00032524							
CE-757	01/15/2013	FEN-2522 Table Top Panels/FEN-2522a Table Cloth for Table Top Display	TEVA_MDL_A_00032525	TEVA_MDL_A_00032546							
CE-758	01/22/2013	FEN-2526 Rx Savings RTM/FEN-2527 Clinical Data RTM/FEN-2534 Dosing RTM	TEVA_MDL_A_00032547	TEVA_MDL_A_00032573							
CE-759	03/01/2013	FEN-2535 Digital Sales Aid for iPad/PAIN-2094 Breakthrough Pain Animation/FEN-2523 Webkey Splash Page/FEN-2532 Webkey RTM/FEN-2533 Webkey Card/FEN-2526a RTM Envelope/FEN-2533a Webkey Brochure	TEVA_MDL_A_00032574	TEVA_MDL_A_00032694							
CE-760	03/08/2013	FEN-2529 Touchscreen Convention Panels/FEN-2530 Convention ISI Panel	TEVA_MDL_A_00032695	TEVA_MDL_A_00032760							
CE-761	04/02/2013	FEN-40019 AAPM Backlit logo/AMR-40006 AAPM Hanging Sign	TEVA_MDL_A_00032761	TEVA_MDL_A_00032779							
CE-762	04/03/2013	FEN-2516 eNewsletter 1	TEVA_MDL_A_00032780	TEVA_MDL_A_00032783							
CE-763	04/05/2013	FEN-2536a Copay Coupon	TEVA_MDL_A_00032784	TEVA_MDL_A_00032803							
CE-764	04/19/2013	FEN-40007 Horizontal Touchscreen Panels/FEN-40009 ISI Poster	TEVA_MDL_A_00032804	TEVA_MDL_A_00032915							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-765	04/24/2013	ONC-40163 Multi Brand Projection Screen Full Version	TEVA_MDL_A_00032916	TEVA_MDL_A_00032943							
CE-766	04/26/2013	FEN-40011 30x40 Backlit Panel/FEN-40017 eNewsletter 2	TEVA_MDL_A_00032944	TEVA_MDL_A_00032950							
CE-767	05/03/2013	FEN-40028 Vertical Convention Panel Update/FEN-40021 Sublingual Administration Leave Behind	TEVA_MDL_A_00032951	TEVA_MDL_A_00033008							
CE-768	05/10/2013	FEN-40005 Digital Sales Aid for iPad	TEVA_MDL_A_00033009	TEVA_MDL_A_00033092							
CE-769	06/21/2013	FEN-40047 Over 65 Program Letter and Certification Update/FEN-40048 BTP Patient Brochure	TEVA_MDL_A_00033093	TEVA_MDL_A_00033117							
CE-770	07/12/2013	FEN-40044 FENTORA.com HCP Site	TEVA_MDL_A_00033118	TEVA_MDL_A_00033126							
CE-771	07/19/2013	FEN-40050 Managing Breakthrough Pain in the Oncology Setting Slide Deck	TEVA_MDL_A_00033127	TEVA_MDL_A_00033166							
CE-772	08/23/2013	TEVA_MDL_A_00033167	TEVA_MDL_A_00033167	TEVA_MDL_A_00033214							
CE-773	09/06/2013	FEN-40074 Perspectives in Oncology: Managing Breakthrough Pain (Participant Guide)	TEVA_MDL_A_00033215	TEVA_MDL_A_00033252							
CE-774	09/13/2013	FEN-40066 Oncology Speaker Program Invite 7x7 size	TEVA_MDL_A_00033253	TEVA_MDL_A_00033257							
CE-775	09/27/2013	FEN-40056 Rx Savings RTL with Brochure and Copay Coupons/FEN-40078 Speaker Program Invite/FEN-40084 eNewsletter	TEVA_MDL_A_00033263	TEVA_MDL_A_00033275							
CE-776	10/18/2013	FEN-40029 Fentora eDetail	TEVA_MDL_A_00033276	TEVA_MDL_A_00033328							
CE-777	11/08/2013	FEN-40102 HCP Connect Program Invitation/FEN-40037 Cover My Meds Landing Page	TEVA_MDL_A_00033329	TEVA_MDL_A_00033343							
CE-778	11/22/2013	FEN-40101 Reimbursement Form/FEN-40114 Reimbursement Form (fax version)	TEVA_MDL_A_00033344	TEVA_MDL_A_00033362							
CE-779	12/04/2013	FEN-40099 Savings Program - Patient Savings Offer/FEN-40112 Savings Program - SAVINGS CARD	TEVA_MDL_A_00033363	TEVA_MDL_A_00033371							
CE-780	12/04/2013	FEN-40111 Pain Program Guidebook/FEN-40110 Oncology Program Guidebook	TEVA_MDL_A_00033372	TEVA_MDL_A_00033466							
CE-781	12/10/2013	FEN-40108 Savings Program - CARRIER	TEVA_MDL_A_00033467	TEVA_MDL_A_00033471							
CE-782	06/17/2010	New Dimensions in Pain Dialogues: Nurse to Patient Communication Tool	TEVA_MDL_A_01149848	TEVA_MDL_A_01149859							
CE-783	06/17/2010	New Dimensions in Pain Dialogues: Nurse to Patient Communication tool- Patient Tear Sheet	TEVA_MDL_A_01149860	TEVA_MDL_A_01149861							
CE-784	06/24/2010	SYP.com Journal Ad	TEVA_MDL_A_01149914	TEVA_MDL_A_01149914							
CE-785	01/06/2010	Dinner Meeting Sales Rep Invite	TEVA_MDL_A_01149919	TEVA_MDL_A_01149919							
CE-786	06/29/2010	Breakthrough Cancer Pain Podcast Series - Program Intro	TEVA_MDL_A_01149920	TEVA_MDL_A_01149921							
CE-787	06/29/2010	Breakthrough Pain Podcast Series - Letter to Third Party Organizations	TEVA_MDL_A_01149922	TEVA_MDL_A_01149922							
CE-788	06/29/2010	Breakthrough Pain Podcast - Audio News Release	TEVA_MDL_A_01149923	TEVA_MDL_A_01149923							
CE-789	07/01/2010	ShareYourPain.com Nurses' Section	TEVA_MDL_A_01149974	TEVA_MDL_A_01150008							
CE-790	07/06/2010	ShareYourPain.com Article_MayoClinic_Prescription Drug Abuse	TEVA_MDL_A_01150054	TEVA_MDL_A_01150073							
CE-791	07/06/2010	YEARLY REVIEW: BTP Patient Education Brochure	TEVA_MDL_A_01150080	TEVA_MDL_A_01150089							
CE-792	07/12/2010	SYP Material Cover Letter	TEVA_MDL_A_01150179	TEVA_MDL_A_01150179							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-793	07/27/2010	Pain Week: Door Drop	TEVA_MDL_A_01150247	TEVA_MDL_A_01150248							
CE-794	07/29/2010	Quantia Wave 2	TEVA_MDL_A_01150317	TEVA_MDL_A_01150334							
CE-795	08/02/2010	TRAINING GUIDE - A Randomized, Placebo-Controlled Study of Fentanyl Buccal Tablet for Breakthrough Pain in Opioid-Treated Patients With Cancer	TEVA_MDL_A_01150337	TEVA_MDL_A_01150338							
CE-796	08/02/2010	Vodcasts - ShareYourPain.com	TEVA_MDL_A_01150339	TEVA_MDL_A_01150435							
CE-797	08/04/2010	Breakthrough Pain Vodcast Program Mat Release	TEVA_MDL_A_01150448	TEVA_MDL_A_01150448							
CE-798	09/01/2010	Vodcast_Model Dialogue for Improving Patient and Physician Communication	TEVA_MDL_A_01150861	TEVA_MDL_A_01150955							
CE-799	01/26/2011	2011 Convention Door Drop	TEVA_MDL_A_01152132	TEVA_MDL_A_01152133							
CE-800	01/26/2010	Muscle Spasms Fact Sheet	TEVA_MDL_A_01152139	TEVA_MDL_A_01152139							
CE-801	01/27/2010	Breakthrough Pain in Patients with Cancer Fact Sheet	TEVA_MDL_A_01152140	TEVA_MDL_A_01152140							
CE-802	01/27/2010	Drug Scheduling Fact Sheet	TEVA_MDL_A_01152168	TEVA_MDL_A_01152168							
CE-803	01/27/2010	Glossary: Cancer-Related Breakthrough Pain	TEVA_MDL_A_01152174	TEVA_MDL_A_01152175							
CE-804	02/18/2011	Pain Marketplace Guide	TEVA_MDL_A_01152371	TEVA_MDL_A_01152372							
CE-805	02/18/2011	Rapid Onset Opioids (ROOs)	TEVA_MDL_A_01152373	TEVA_MDL_A_01152374							
CE-806	02/18/2011	Pure Short Acting Opioids	TEVA_MDL_A_01152375	TEVA_MDL_A_01152375							
CE-807	02/18/2011	Combination Short Acting Opioids	TEVA_MDL_A_01152376	TEVA_MDL_A_01152377							
CE-808	02/18/2011	Long Acting Opioids (LAOs)	TEVA_MDL_A_01152378	TEVA_MDL_A_01152380							
CE-809	02/18/2011	Centrally Acting Analgesics	TEVA_MDL_A_01152381	TEVA_MDL_A_01152381							
CE-810	02/28/2011	Breakthrough Pain in Cancer Media Fact Sheet	TEVA_MDL_A_01152465	TEVA_MDL_A_01152465							
CE-811	02/28/2011	Drug Scheduling Media Fact Sheet	TEVA_MDL_A_01152466	TEVA_MDL_A_01152466							
CE-812	02/28/2011	Breakthrough Pain Glossary for Media	TEVA_MDL_A_01152467	TEVA_MDL_A_01152468							
CE-813	03/18/2011	ABSTRAL New Product Bulletin	TEVA_MDL_A_01152890	TEVA_MDL_A_01152897							
CE-814	04/08/2011	Marketed ROO Product Grid	TEVA_MDL_A_01153013	TEVA_MDL_A_01153022							
CE-815	04/15/2011	BTP Patient Assessment Tool	TEVA_MDL_A_01153066	TEVA_MDL_A_01153073							
CE-816	05/06/2011	Training Guide: BTP Patient Assessment Tool	TEVA_MDL_A_01153163	TEVA_MDL_A_01153164							
CE-817	05/25/2011	New Dimensions in Pain Dialogues: Nurse to Patient Communication tool- Patient Tear Sheet (Re-approval 1)	TEVA_MDL_A_01153457	TEVA_MDL_A_01153458							
CE-818	06/21/2011	RTL 6: Assessing Long Acting Opioids	TEVA_MDL_A_01153542	TEVA_MDL_A_01153544							
CE-819	07/15/2011	Pain Week Door Drop	TEVA_MDL_A_01153623	TEVA_MDL_A_01153624							
CE-820	04/01/2010	Nurse Education Workshop - Invite Email	TEVA_MDL_A_01157706	TEVA_MDL_A_01157707							
CE-821	04/05/2010	ShareYourPain.com	TEVA_MDL_A_01157910	TEVA_MDL_A_01157992							
CE-822	04/13/2010	BTP Education Station BRC	TEVA_MDL_A_01158052	TEVA_MDL_A_01158053							
CE-823	04/14/2010	Breakthrough Cancer Pain Podcast Series Interview #4: Pain Awareness Month	TEVA_MDL_A_01158054	TEVA_MDL_A_01158058							
CE-824	04/14/2010	Breakthrough Cancer Pain Podcast Series Interview #6: Clinical Perspective	TEVA_MDL_A_01158059	TEVA_MDL_A_01158064							
CE-825	04/14/2010	Breakthrough Cancer Pain Podcast Series Interview #8 - Healthcare Reform	TEVA_MDL_A_01158065	TEVA_MDL_A_01158070							
CE-826	04/16/2010	ShareYourPain.com Mapped!	TEVA_MDL_A_01158085	TEVA_MDL_A_01158087							
CE-827	04/23/2010	ShareYourPain.com Article: National Cancer Institute - Addiction and Chronic Pain Myths	TEVA_MDL_A_01158119	TEVA_MDL_A_01158119							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-828	04/23/2010	ShareYourPain.com Article: National Cancer Institute - Pain(PDQ)	TEVA_MDL_A_01158120	TEVA_MDL_A_01158126							
CE-829	04/26/2010	ShareYourPain.com Article: Leukemia and Lymphoma Society - Pain Management	TEVA_MDL_A_01158132	TEVA_MDL_A_01158145							
CE-830	04/26/2010	ShareYourPain.com Article: National Cancer Institute - Cancer Pain Can Be Managed	TEVA_MDL_A_01158146	TEVA_MDL_A_01158146							
CE-831	04/26/2010	ShareYourPain.com Article: National Pain Foundation - Glossary	TEVA_MDL_A_01158147	TEVA_MDL_A_01158155							
CE-832	05/12/2010	SYP.com In Office Leave Behind	TEVA_MDL_A_01158343	TEVA_MDL_A_01158345							
CE-833	05/13/2010	Breakthrough Pain Patient/Physician Model Dialogue Video Script	TEVA_MDL_A_01158346	TEVA_MDL_A_01158361							
CE-834	07/00/2006	Making Pain Talk Painless: A Guide to Help You Talk with Your Doctor About Pain Management (Jul. 2006)	TEVA_MDL_A_00514263	TEVA_MDL_A_00514266							
CE-835	08/30/2004	Unbranded brochure “Breakthrough Pain: Do you still have pain?”	TEVA_MDL_A_01403602	TEVA_MDL_A_01403609							
CE-836	03/02/2006	Email from Michael Richardson, Senior Director, Worldwide Product Planning, Cephalon, to Terrence Terifay, Associate Product Director, Pain Franchise, (re: Pain as the Fifth Vital Sign campaign language)	TEVA_MDL_A_01488890	TEVA_MDL_A_01488892							
CE-837	12/00/2006	Portenoy 3042 - "Fentanyl Buccal Tablets for the treatment of breakthrough pain in opioid-treated patients with chronic low back pain"	TEVA_MDL_A_00507463	TEVA_MDL_A_00507479							
CE-838	07/00/2006	Revised Abuse, Addiction & Diversion Speaker Slide Kit Module 1	TEVA_MDL_A_00514038	TEVA_MDL_A_00514094							
CE-839	07/00/2006	Revised Abuse, Addiction & Diversion Speaker Slide Kit Module 2	TEVA_MDL_A_00514095	TEVA_MDL_A_00514137							
CE-840	07/00/2006	2006 Pain Management Glossary "Making Pain Talk Painless"	TEVA_MDL_A_00514263	TEVA_MDL_A_00514266							
CE-841	09/00/2006	CME Invitation - "The Clinical Management of Breakthrough Pain Current and Emerging Perspectives"	TEVA_MDL_A_00514284	TEVA_MDL_A_00514285							
CE-842	07/00/2006	Abuse, Addiction and Diversion Speaker Program Invitation	TEVA_MDL_A_00514326	TEVA_MDL_A_00514329							
CE-843	07/00/2006	CME Invitation – “Treating Patients with Chronic Pain: Addressing Clinical and Regulatory Challenges”	TEVA_MDL_A_00514333	TEVA_MDL_A_00514336							
CE-844	3/7/2007	Portenoy 3042 - "Fentanyl Buccal Tablets for the treatment of breakthrough pain in opioid-treated patients with chronic low back pain"	TEVA_MDL_A_00025990	TEVA_MDL_A_00026027							
CE-845	6/8/2008	Abuse, Addiction & Diversion Slide Kit	TEVA_MDL_A_00027290	TEVA_MDL_A_00027415							
CE-846	5/7/2007	3041 Simpson - ""FENTANYL BUCCAL TABLET FOR THE RELIEF OF BTP IN OPIOID-TOLERANT ADULT PATIENTS WITH CHRONIC NEUROPATHIC PAIN: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY.”	TEVA_MDL_A_00507442	TEVA_MDL_A_00507462							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-847	07/00/2006	Three Step Analgesic Ladder for Mgmt of Cancer Pain	TEVA_MDL_A_00514359	TEVA_MDL_A_00514380							
CE-848	11/00/2005	BTP Catalina Newsletter - You may have BTP	TEVA_MDL_A_01400560	TEVA_MDL_A_01400560							
CE-849	04/00/2005	HR Newsletter - BTP Messages	TEVA_MDL_A_01400562	TEVA_MDL_A_01400562							
CE-850	01/00/2005	BTP Booth Panel - BTP a distinct clinical problem	TEVA_MDL_A_01405992	TEVA_MDL_A_01405992							
CE-851	01/00/2005	BTP Booth Panel - BTP a need for independent assessment	TEVA_MDL_A_01405993	TEVA_MDL_A_01405993							
CE-852	02/00/2006	10x20' BTP Booth Panel	TEVA_MDL_A_01405994	TEVA_MDL_A_01405994							
CE-853	01/00/2005	BTP Booth Panel - Just when you think	TEVA_MDL_A_01405995	TEVA_MDL_A_01405995							
CE-854	03/00/2007	Shareyourpain.org Postcard	TEVA_MDL_A_02029712	TEVA_MDL_A_02029713							
CE-855	02/00/2007	BTP Catalina Newsletter #2	TEVA_MDL_A_02274928	TEVA_MDL_A_02274928							
CE-856	7/5/2005	Opioid Glossary (2005 Version)	TEVA_MDL_A_02022516	TEVA_MDL_A_02022518							
CE-857	REMOVED	REMOVED	REMOVED	REMOVED							
CE-858	00/00/2008	Cephalon Corporate Integrity Agreement (2008)	TEVA_MDL_A_06380925	TEVA_MDL_A_06380989							
CE-859	00/00/2012	Speakers Bureau Business Rationale Application	TEVA_MDL_A_00702968	TEVA_MDL_A_00702968							
CE-860	12/16/2004	Cephalon Board of Directors Meeting (Annual Compliance Update Section included)	TEVA_MDL_A_00667543	TEVA_MDL_A_00667754							
CE-861	01/20/2010	Compliance Overview Initial Training Class Presentation conducted by Karen Lowney, Compliance Senior Director (Jan. 2010)	TEVA_MDL_A_00381967	TEVA_MDL_A_00381989							
CE-862	07/01/2018	Cephalon Employee Conduct Policy (HR-510)	TEVA_MDL_A_00552247	TEVA_MDL_A_00552248							
CE-863	01/26/2009	Field Force Ride-Along Program (GC-220), (Jan. 2009)	TEVA_MDL_A_00552273	TEVA_MDL_A_00552275							
CE-864	06/01/2008	Cephalon Good Business Practices Field Guide (“GBP”) (June 2008)	TEVA_MDL_A_00552305	TEVA_MDL_A_00552363							
CE-865	01/26/2009	Cephalon Incident Management (GC-300) (Jan. 2009)	TEVA_MDL_A_00552368	TEVA_MDL_A_00552373							
CE-866	02/09/2007	Cephalon Patient Safety Policy	TEVA_MDL_A_00552453	TEVA_MDL_A_00552453							
CE-867	07/01/2008	Cephalon Reporting and Investigations of Misconduct (C-150) (July 1 2008)	TEVA_MDL_A_00552585	TEVA_MDL_A_00552588							
CE-868	01/26/2009	Targeting Assessment and Call Activity (GPO-130)	TEVA_MDL_A_00552695	TEVA_MDL_A_00552698							
CE-869	07/01/2008	US Sales and Marketing Policy (GPO-100)	TEVA_MDL_A_00552786	TEVA_MDL_A_00552818							
CE-870	10/06/2006	Adverse Drug Experience, Product Complaint, and MIRF to PSMI	TEVA_MDL_A_00552829	TEVA_MDL_A_00552839							
CE-871	03/07/2019	Policy on Gifts, Meals, and Entertainment for Physicians and Other Healthcare Practitioners	TEVA_MDL_A_00552891	TEVA_MDL_A_00552900							
CE-872	10/06/2019	Policy re Sample Management	TEVA_MDL_A_00552901	TEVA_MDL_A_00552901							
CE-873	10/06/2019	Policy on Preceptorships	TEVA_MDL_A_00553012	TEVA_MDL_A_00553026							
CE-874	06/01/2007	Marketing Policy, WLF: Dissemination of Peer-Reviewed Reprints and Reference Textbooks	TEVA_MDL_A_00553036	TEVA_MDL_A_00553047							
CE-875	11/22/2013	Cephalon CIA Annual Report Year 5	TEVA_MDL_A_00559116	TEVA_MDL_A_00559117							
CE-876	11/21/2012	Cephalon CIA Annual Report Year 4	TEVA_MDL_A_00560833	TEVA_MDL_A_00560834							
CE-877	11/20/2009	Cephalon CIA Annual Report Year 1	TEVA_MDL_A_00561764	TEVA_MDL_A_00561765							
CE-878	11/23/2010	Cephalon CIA Annual Report Year 2	TEVA_MDL_A_00562291	TEVA_MDL_A_00562292							
CE-879	11/18/2011	Cephalon CIA Annual Report Year 3	TEVA_MDL_A_00562862	TEVA_MDL_A_00562863							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-880	01/21/2009	Compliance Overview Initial Training Class Presentation conducted by Karen Lowney, Compliance Senior Director	TEVA_MDL_A_00801578	TEVA_MDL_A_00801603							
CE-881	01/09/2019	Charter of Cephalon's Global Compliance Committee	TEVA_MDL_A_00819644	TEVA_MDL_A_00819645							
CE-882	01/27/2010	2009 Global Compliance Report Summary	TEVA_MDL_A_00820941	TEVA_MDL_A_00820947							
CE-883	04/06/2006	Training Process for Members of the Sales Organization	TEVA_MDL_A_01249224	TEVA_MDL_A_01249228							
CE-884	10/04/2007	Cephalon Standards of Business Conduct	TEVA_MDL_A_06880695	TEVA_MDL_A_06880710							
CE-885	01/28/2009	2008 Global Compliance Report Executive Summary	TEVA_MDL_A_04321674	TEVA_MDL_A_04321676							
CE-886	07/30/2009	Effectiveness of Cephalon's Global Compliance Program Board Update	TEVA_MDL_A_04321682	TEVA_MDL_A_04321687							
CE-887	10/06/2019	Policy on Gifts, Meals, and Entertainment for Physicians and Other Healthcare Practitioners	TEVA_MDL_A_04756815	TEVA_MDL_A_04756821							
CE-888	00/00/2000	Cephalon Corporate Compliance Program Policy (2000)	TEVA_MDL_A_05508657	TEVA_MDL_A_05508678							
CE-889	07/29/2004	Memorandum: Mid-Year Compliance Update	TEVA_MDL_A_06377159	TEVA_MDL_A_06377181							
CE-890	06/13/2011	Year Two CIA Specific New Hire Course	TEVA_MDL_A_00007783	TEVA_MDL_A_00007864							
CE-891	07/01/2008	Cephalon Political Activities and Lobbying Policy	TEVA_MDL_A_00552458	TEVA_MDL_A_00552460							
CE-892	09/30/2009	Training Summary	TEVA_MDL_A_00561907	TEVA_MDL_A_00561909							
CE-893	11/02/2009	Ernst & Young Report on Independent Review Organization's Engagement	TEVA_MDL_A_00561910	TEVA_MDL_A_00562007							
CE-894	11/17/2010	Ernst & Young Report on Independent Review Organization's Engagement	TEVA_MDL_A_00562363	TEVA_MDL_A_00562428							
CE-895	01/01/2008	Cephalon MIRF Monitoring Procedure	TEVA_MDL_A_01086224	TEVA_MDL_A_01086225							
CE-896	04/23/2007	Cephalon Management Readiness Program	TEVA_MDL_A_01105624	TEVA_MDL_A_01105632							
CE-897	08/21/2009	Submission of Medical Information Requests WMRO 116	TEVA_MDL_A_00770359	TEVA_MDL_A_00770362							
CE-898	04/03/2013	April 2013 Letter from OIG to Tricia Glover re: Site Inspection Summary	TEVA_MDL_A_00782034	TEVA_MDL_A_00782037							
CE-899	07/29/2008	Cephalon Global Compliance New Employee Orientation	TEVA_MDL_A_00786858	TEVA_MDL_A_00786858							
CE-900	00/00/2008	Cephalon Global Compliance Department	TEVA_MDL_A_01251327	TEVA_MDL_A_01251352							
CE-901	01/26/2009	Medical Information Request Monitoring (C-300)	TEVA_MDL_A_03070586	TEVA_MDL_A_03070587							
CE-902	01/28/2009	Cephalon 2008 Global Compliance Report (Jan. 28 2009)	TEVA_MDL_A_13583946	TEVA_MDL_A_13583978							
CE-903	00/00/2004	2004 Cephalon Code of Conduct	TEVA_MDL_A_09624030	TEVA_MDL_A_09624698							
CE-904	02/13/2009	inVentiv Health Care Compliance Training Interactions with Health Care Professionals	TEVA_MDL_A_11426483	TEVA_MDL_A_11426483							
CE-905	09/29/2004	Policy on Providing Reimbursement Information to Customers	TEVA_MDL_A_11892838	TEVA_MDL_A_11892839							
CE-906	09/29/2004	Policy on Advertising and Promotional Materials and Activities	TEVA_MDL_A_11892858	TEVA_MDL_A_11892861							
CE-907	10/04/2019	Gifts, Meals and Entertainment for Physicians and Other Healthcare Practitioners	TEVA_MDL_A_11892871	TEVA_MDL_A_11892874							
CE-908	09/29/2004	Policy Re: Sample Management	TEVA_MDL_A_11892875	TEVA_MDL_A_11892875							
CE-909	09/29/2004	Policy on Preceptorships	TEVA_MDL_A_11892883	TEVA_MDL_A_11892886							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-910	09/29/2004	Policy on Funding to Support Independent, Third-Party Educational or Scientific Meetings	TEVA_MDL_A_11892887	TEVA_MDL_A_11892899							
CE-911	09/29/2004	Policy on Grants or Support that are not for Independent Medical Education	TEVA_MDL_A_11892900	TEVA_MDL_A_11892903							
CE-912	09/29/2004	Policy Re: Employee Reporting of Adverse Events, Product Complaints, Tampering, Adulteration and/or Diversion	TEVA_MDL_A_11892904	TEVA_MDL_A_11892906							
CE-913	06/07/2019	Policy on Gifts, Meals, and Entertainment for Physicians and Other Healthcare Practitioners	TEVA_MDL_A_00552906	TEVA_MDL_A_00552909							
CE-914	02/26/2009	Implementation Report	TEVA_MDL_A_00560071	TEVA_MDL_A_00560071							
CE-915	01/22/2008	Cephalon 2008 Organizational Chart	TEVA_MDL_A_00456349	TEVA_MDL_A_00456409							
CE-916	01/01/2009	Cephalon 2009 Organizational Chart	TEVA_MDL_A_00456410	TEVA_MDL_A_00456463							
CE-917	01/01/2010	Cephalon 2010 Organizational Chart	TEVA_MDL_A_00456464	TEVA_MDL_A_00456516							
CE-918	10/01/2006	Cephalon Policy on Third-Party Funding Requests to Support Independent Medical Education Program, (Oct. 2006).	TEVA_MDL_A_06880639	TEVA_MDL_A_06880655							
CE-919	09/11/2006	Grant to American Chronic Pain Association for patient brochure and radio media tour regarding breakthrough pain	TEVA_MDL_A_01089593	TEVA_MDL_A_01089596							
CE-920	08/14/2006	Grant to American Society of Pain Management Nursing for meeting regarding recent advances in pain management	TEVA_MDL_A_01089865	TEVA_MDL_A_01089870							
CE-921	08/12/2004	Grant for enhancement of National Pain Foundation's education-oriented website and to help raise funds via NPF's "Triumph Dinner"	TEVA_MDL_A_01171351	TEVA_MDL_A_01171369							
CE-922	02/13/2004	Email from Paula Castagno to Sophie M. Colleau	TEVA_MDL_A_07180634	TEVA_MDL_A_07180635							
CE-923	07/01/2008	Cephalon Charitable Contributions Policy, (July 1 2008)	TEVA_MDL_A_00552042	TEVA_MDL_A_00552044							
CE-924	08/14/2009	Cephalon Charitable Contributions Procedure, (Aug. 14, 2009).	TEVA_MDL_A_00552045	TEVA_MDL_A_00552047							
CE-925	07/01/2008	Cephalon Company Giving Policy	TEVA_MDL_A_00785338	TEVA_MDL_A_00785342							
CE-926	11/21/2006	Educational Grant Approval APS 2007 CME Poster Book Updates in Chronic Pain Management	TEVA_MDL_A_00829238	TEVA_MDL_A_00829239							
CE-927	02/03/2003	Request for Funding for Educational Activity (payee: MediCom)	TEVA_MDL_A_01850590	TEVA_MDL_A_01850597							
CE-928	09/09/2004	AAPM Symposium Proposal for Cephalon (payee: Conexus)	TEVA_MDL_A_01851280	TEVA_MDL_A_01851296							
CE-929	11/30/2005	Educational Grant Draft Request (payee: Fusion)	TEVA_MDL_A_01854921	TEVA_MDL_A_01854944							
CE-930	11/28/2006	Agreement regarding Chronic Pain Management with Opioids Symposium (payee: Boston U School of Medicine)	TEVA_MDL_A_00837109	TEVA_MDL_A_00837132							
CE-931	11/06/2008	Independent Educational Program Grant Agreement (payee: MediCom Worldwide)	TEVA_MDL_A_00502973	TEVA_MDL_A_00502985							
CE-932	01/15/2009	Independent Educational Program Grant Agreement (payee: MediCom Worldwide)	TEVA_MDL_A_00850584	TEVA_MDL_A_00850727							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-933	01/19/2010	Independent Educational Program Grant Agreement (payee: Albert Einstein College of Medicine)	TEVA_MDL_A_01176915	TEVA_MDL_A_01176951							
CE-934	08/12/2011	Independent Educational Program Grant Agreement (payee: AAPM)	TEVA_MDL_A_01176224	TEVA_MDL_A_01176245							
CE-935	12/05/2011	Independent Educational Program Grant Agreement (payee: U Cincinnati)	TEVA_MDL_A_01176639	TEVA_MDL_A_01176665							
CE-936	03/11/2015	First Amendment to Consulting Agreement between Teva and Paul Christo, MD	TEVA_MDL_A_03314704	TEVA_MDL_A_03314705							
CE-937	07/09/2004	Education Grant Draft Request (American Society of Addiction Medicine)	TEVA_MDL_A_06343520	TEVA_MDL_A_06343759							
CE-938	07/24/2004	Education Grant Draft Request (payee: American Society of Addiction Medicine)	TEVA_MDL_A_06343520	TEVA_MDL_A_06343759							
CE-939	09/05/2005	Educational Grant Draft Request (Arizona Geriatrics Society)	TEVA_MDL_A_01852738	TEVA_MDL_A_01852752							
CE-940	08/12/2004	Educational Grant Draft Request (American Pain Foundation)	TEVA_MDL_A_05509299	TEVA_MDL_A_05509312							
CE-941	01/09/2007	Educational Grant Draft Request (American Pain Foundation)	TEVA_MDL_A_01174115	TEVA_MDL_A_01174115							
CE-942	03/06/2007	Unrestricted Educational Grant Agreement between Cephalon and American Pain Foundation)	TEVA_MDL_A_03315373	TEVA_MDL_A_03315375							
CE-943	07/17/2008	Unrestricted Educational Grant Agreement between Cephalon and American Pain Foundation)	TEVA_MDL_A_03315969	TEVA_MDL_A_03315975							
CE-944	03/12/2002	Medical Education Grant (MediCom)	TEVA_MDL_A_06343760	TEVA_MDL_A_06343880							
CE-945	05/07/2003	Educational Grant Request (payee: Postgraduate Institute for Medicine)	TEVA_MDL_A_01850677	TEVA_MDL_A_01850689							
CE-946	11/30/2005	Educational Grant Draft Request (payee: Tufts)	TEVA_MDL_A_01854945	TEVA_MDL_A_01854959							
CE-947	12/06/2006	Educational Grant Agreement (payee: SciMed)	TEVA_MDL_A_01164505	TEVA_MDL_A_01164528							
CE-948	12/16/2008	Educational Grant Agreement (payee: Montefiore)	TEVA_MDL_A_00849962	TEVA_MDL_A_00850031							
CE-949	12/05/2011	Educational Grant Agreement (payee: MediCom)	TEVA_MDL_A_01176720	TEVA_MDL_A_01176751							
CE-950	11/27/2006	Educational Grant Agreement (payee: Advanced Strategies in Medicine)	TEVA_MDL_A_00839940	TEVA_MDL_A_00839996							
CE-951	11/28/2006	Educational Grant Agreement (payee: Advanced Strategies in Medicine)	TEVA_MDL_A_00837375	TEVA_MDL_A_00837408							
CE-952	07/23/2007	Educational Grant Agreement (payee: Advanced Strategies in Medicine)	TEVA_MDL_A_00852665	TEVA_MDL_A_00852716							
CE-953	06/20/2008	Educational Grant Agreement (payee: Advanced Strategies in Medicine)	TEVA_MDL_A_00822382	TEVA_MDL_A_00822414							
CE-954	11/19/2004	Clinical Trial Protocol Work Order (Dr. Donald Taylor)	TEVA_MDL_A_06752819	TEVA_MDL_A_06752824							
CE-955	11/02/2005	Amendment to 11.19.04 Agreement with Dr. Donald Taylor	TEVA_MDL_A_13743712	TEVA_MDL_A_13743712							
CE-956	11/16/2005	Amendment to 11.19.04 Agreement with Dr. Donald Taylor	TEVA_MDL_A_13750148	TEVA_MDL_A_13750148							
CE-957	05/17/2006	Amendment to 11.19.04 Agreement with Dr. Donald Taylor	TEVA_MDL_A_13751007	TEVA_MDL_A_13751009							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-958	06/22/2006	Amendment to 11.19.04 Agreement with Dr. Donald Taylor	TEVA_MDL_A_13745763	TEVA_MDL_A_13745763							
CE-959	06/22/2006	Clinical Trial Protocol Work Order Dr. Donald Taylor	TEVA_MDL_A_06750059	TEVA_MDL_A_06750065							
CE-960	10/27/2006	Amendment to 6.22.06 agreement with Dr. Donald Taylor	TEVA_MDL_A_13744130	TEVA_MDL_A_13744131							
CE-961	03/02/2007	Amendment to 6.22.06 agreement with Dr. Donald Taylor	TEVA_MDL_A_13748753	TEVA_MDL_A_13748754							
CE-962	11/20/2006	IEP Grant Agreement (MediCom Worldwide, Inc.)	TEVA_MDL_A_00503071	TEVA_MDL_A_00503107							
CE-963	12/06/2006	IEP Grant Agreement (Medical Learning Solutions)	TEVA_MDL_A_03315345	TEVA_MDL_A_03315372							
CE-964	04/05/2007	IEP Grant Agreement (SciMed)	TEVA_MDL_A_06755520	TEVA_MDL_A_06755542							
CE-965	08/02/2007	IEP Grant Agreement (CME2)	TEVA_MDL_A_00846329	TEVA_MDL_A_00846390							
CE-966	08/28/2007	IEP Grant Agreement (FSMB)	TEVA_MDL_A_01088845	TEVA_MDL_A_01088857							
CE-967	06/28/2003	Consulting Agreement (Dr. Gerald Aronoff)	TEVA_MDL_A_13591816	TEVA_MDL_A_13591817							
CE-968	05/25/2004	Medical Education Agreement (Scandinavian Association for the Study of Pain)	TEVA_MDL_A_01168727	TEVA_MDL_A_01168736							
CE-969	09/08/2005	Consulting Agreement (Dr. Gerald Aronoff)	TEVA_MDL_A_13599853	TEVA_MDL_A_13599854							
CE-970	11/16/2006	IEP Grant Agreement (Medical Learning Solutions)	TEVA_MDL_A_00835066	TEVA_MDL_A_00835144							
CE-971	02/01/2007	IEP Grant Agreement (Cleveland Clinic Foundation)	TEVA_MDL_A_00843019	TEVA_MDL_A_00843045							
CE-972	04/23/2007	IEP Grant Agreement (Dannemiller Memorial Educational Foundation)	TEVA_MDL_A_00847692	TEVA_MDL_A_00847711							
CE-973	05/01/2007	Managed Care Cephalon Speaker Agreement - Dr. Gerald Aronoff	TEVA_MDL_A_13603675	TEVA_MDL_A_13603685							
CE-974	03/20/2011	Consulting Agreement with Dr. Gerald Aronoff	TEVA_MDL_A_13745185	TEVA_MDL_A_13745197							
CE-975	09/19/2006	Consulting Agreement with Dr. Gerald Aronoff	TEVA_MDL_A_06747131	TEVA_MDL_A_06747144							
CE-976	02/04/2005	Letter of Agreement Medscape LLC	TEVA_MDL_A_00502700	TEVA_MDL_A_00502703							
CE-977	07/24/2006	Medical Education Agreement (Medscape LLC)	TEVA_MDL_A_00502714	TEVA_MDL_A_00502715							
CE-978	11/27/2006	IEP Grant Agreement (Medscape, LLC)	TEVA_MDL_A_03315246	TEVA_MDL_A_03315288							
CE-979	07/19/2007	Amendment to 11/27/06 IEP Grant Agreement with Medscape	TEVA_MDL_A_01169507	TEVA_MDL_A_01169513							
CE-980	05/25/2007	IEP Grant Agreement (Medscape, LLC)	TEVA_MDL_A_00502716	TEVA_MDL_A_00502725							
CE-981	11/25/2008	IEP Grant Agreement (Medscape)	TEVA_MDL_A_06761210	TEVA_MDL_A_06761237							
CE-982	04/01/2009	IEP Grant Agreement (Medscape LLC)	TEVA_MDL_A_06794147	TEVA_MDL_A_06794207							
CE-983	05/22/2009	IEP Grant Agreement (Medscape)	TEVA_MDL_A_06770386	TEVA_MDL_A_06770428							
CE-984	09/02/2009	IEP Grant Agreement (Medscape)	TEVA_MDL_A_06772520	TEVA_MDL_A_06772547							
CE-985	09/02/2009	IEP Grant Agreement (Medscape LLC)	TEVA_MDL_A_06772447	TEVA_MDL_A_06772472							
CE-986	11/27/2006	IEP Grant Agreement (Vital Issues in Medicine)	TEVA_MDL_A_00836297	TEVA_MDL_A_00836324							
CE-987	11/28/2006	IEP Grant Agreement (Univ. of Florida College of Med.)	TEVA_MDL_A_00829004	TEVA_MDL_A_00829027							
CE-988	12/06/2006	IEP Grant Agreement (SciMed)	TEVA_MDL_A_01164505	TEVA_MDL_A_01164528							
CE-989	08/18/2009	IEP Grant Agreement (Global Education Group)	TEVA_MDL_A_00854118	TEVA_MDL_A_00854165							
CE-990	10/22/2009	IEP Grant Agreement (Washington Hospital Center)	TEVA_MDL_A_00854802	TEVA_MDL_A_00854826							
CE-991	03/01/2011	Consulting Agreement - Dr. Perry Fine	TEVA_MDL_A_03314967	TEVA_MDL_A_03314981							
CE-992	10/18/2011	IEP Grant Agreement (Purdue University)	TEVA_MDL_A_01176282	TEVA_MDL_A_01176330							
CE-993	09/12/2006	Preceptorship Agreement - Dr. Russell Portenoy	TEVA_MDL_A_06753556	TEVA_MDL_A_06753563							
CE-994	10/27/2006	IEP Grant Agreement (SciMed)	TEVA_MDL_A_00838658	TEVA_MDL_A_00838687							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-995	11/22/2006	IEP Grant Agreement (U. Kentucky)	TEVA_MDL_A_03315211	TEVA_MDL_A_03315245							
CE-996	07/27/2007	IEP Grant Agreement (U. Kentucky)	TEVA_MDL_A_00825472	TEVA_MDL_A_00825545							
CE-997	02/15/2008	Educational Grant Draft Request - U. Kentucky	TEVA_MDL_A_01163644	TEVA_MDL_A_01163647							
CE-998	03/04/2008	Amendment to 07/27/07 IEP Grant Agreement (U. Kentucky)	TEVA_MDL_A_00823839	TEVA_MDL_A_00823874							
CE-999	10/26/2007	Grant Agreement (Beth Israel Medical Center)	TEVA_MDL_A_00849375	TEVA_MDL_A_00849416							
CE-1000	06/25/2008	IEP Grant Agreement (Dannemiller Memorial Educational Foundation)	TEVA_MDL_A_00824912	TEVA_MDL_A_00824966							
CE-1001	01/15/2009	IEP Grant Agreement (Beth Israel Medical Center)	TEVA_MDL_A_06766836	TEVA_MDL_A_06766852							
CE-1002	03/01/2009	Advisory Board Agreement Dr. Russell Portenoy	TEVA_MDL_A_00784866	TEVA_MDL_A_00784873							
CE-1003	09/09/2009	Advisory Board Agreement Dr. Russell Portenoy	TEVA_MDL_A_09540158	TEVA_MDL_A_09540159							
CE-1004	02/23/2010	IEP Grant Agreement (Beth Israel Medical Center)	TEVA_MDL_A_00855331	TEVA_MDL_A_00855339							
CE-1005	02/11/2011	Advisory Board Agreement Dr. Russell Portenoy	TEVA_MDL_A_07249931	TEVA_MDL_A_07249938							
CE-1006	10/18/2011	IEP Grant Agreement (MediCom Worldwide, Inc.)	TEVA_MDL_A_01176418	TEVA_MDL_A_01176472							
CE-1007	02/24/2006	Letter re CME Symposium AAPM	TEVA_MDL_A_03314982	TEVA_MDL_A_03314983							
CE-1008	09/13/2006	Educational Grant Draft Request ACPA	TEVA_MDL_A_01089593	TEVA_MDL_A_01089596							
CE-1009	09/13/2006	Educational Grant Draft Request APF	TEVA_MDL_A_01089587	TEVA_MDL_A_01089589							
CE-1010	09/13/2006	Educational Grant Draft Request APF	TEVA_MDL_A_01089590	TEVA_MDL_A_01089592							
CE-1011	12/04/2006	Educational Grant Draft Request APS	TEVA_MDL_A_00829238	TEVA_MDL_A_00829239							
CE-1012	11/27/2006	Educational Grant Draft Request ASM	TEVA_MDL_A_01172593	TEVA_MDL_A_01172621							
CE-1013	12/03/2006	Educational Grant Draft Request ASM	TEVA_MDL_A_01173437	TEVA_MDL_A_01173458							
CE-1014	08/21/2006	Educational Grant Draft Request ASPMN	TEVA_MDL_A_01089865	TEVA_MDL_A_01089870							
CE-1015	02/03/2006	Amendment to 11/19/05 Clinical Trial Protocol Work Order Dr. Donald Taylor	TEVA_MDL_A_13746847	TEVA_MDL_A_13746847							
CE-1016	03/14/2006	Amendment to 11/19/05 Clinical Trial Protocol Work Order Dr. Donald Taylor	TEVA_MDL_A_13744145	TEVA_MDL_A_13744146							
CE-1017	06/09/2006	Educational Grant Draft Request FSMB	TEVA_MDL_A_01088810	TEVA_MDL_A_01088820							
CE-1018	11/30/2005	Educational Grant Draft Request Medscape	TEVA_MDL_A_00838506	TEVA_MDL_A_00838511							
CE-1019	11/13/2006	Educational Grant Draft Request Medicom	TEVA_MDL_A_01172729	TEVA_MDL_A_01172759							
CE-1020	01/26/2009	Cephalon Speaker Bureau Management	TEVA_MDL_A_00953748	TEVA_MDL_A_00953754							
CE-1021	07/27/2017	Marketing Speaker Bureau Policy	TEVA_MDL_A_00954145	TEVA_MDL_A_00954169							
CE-1022	06/20/2008	Agreement with Advanced Strategies in Medicine to provide funding for Special Report: Opioid-Based Management of Persistent and Breakthrough Pain	TEVA_MDL_A_00822382	TEVA_MDL_A_00822414							
CE-1023	07/27/2007	Agreement with University of Kentucky Pharmacy and Medicine and Remedica Medical Education and Publishing to provide funding for Advances in Pain Management	TEVA_MDL_A_00825472	TEVA_MDL_A_00825545							
CE-1024	11/27/2006	Agreement with Medscape to provide funding for Pain Education Programs	TEVA_MDL_A_03315246	TEVA_MDL_A_03315288							
CE-1025	10/04/2019	Promotional Meetings Policy	TEVA_MDL_A_11892876	TEVA_MDL_A_11892882							
CE-1026	04/10/2003	CME versus Promotional Guidelines	TEVA_MDL_A_05397081	TEVA_MDL_A_05397081							
CE-1027	05/05/2004	Sales Bulletin - New Process for Educational Grants	TEVA_MDL_A_05484703	TEVA_MDL_A_05484704							
CE-1028	09/29/2006	CSP Planning System User Manual (2006)	TEVA_MDL_A_00583032	TEVA_MDL_A_00583069							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1029	03/26/2007	[Standard] Speaker Agreement (March 2007)	TEVA_MDL_A_00633735	TEVA_MDL_A_00633742							
CE-1030	10/12/2010	Cephalon Pain Franchise Fentora Speaker Training (2010)	TEVA_MDL_A_00666538	TEVA_MDL_A_00666607							
CE-1031	08/12/2006	Cephalon Pain Franchise Speaker Training (Aug 11 2006)	TEVA_MDL_A_00677115	TEVA_MDL_A_00677115							
CE-1032	04/11/2008	Abuse, Addiction, and Diversion of Controlled Substances (Apr. 11 2008)	TEVA_MDL_A_00679713	TEVA_MDL_A_00679713							
CE-1033	07/14/2007	Cephalon Pain Franchise Speaker Training (Jul 14 2007)	TEVA_MDL_A_00681509	TEVA_MDL_A_00681509							
CE-1034	11/06/2008	Independent Educational Program Grant Agreement (AAPM) with MediCom Worldwide	TEVA_MDL_A_00502973	TEVA_MDL_A_00502985							
CE-1035	02/25/2004	2004 Medical Education Agreement for CME Lecture Series	TEVA_MDL_A_00503141	TEVA_MDL_A_00503146							
CE-1036	01/27/2003	MediCom Medical Education Agreement for 2002 Medical Education Programs	TEVA_MDL_A_00503257	TEVA_MDL_A_00503261							
CE-1037	01/01/2008	Cephalon Policy on Third-Party Grant Requests	TEVA_MDL_A_00553027	TEVA_MDL_A_00553029							
CE-1038	09/11/2006	Medical education grant to develop, produce, and distribute a patient-focused book on treatment options titled "Treatment Options for Pain"	TEVA_MDL_A_01089587	TEVA_MDL_A_01089589							
CE-1039	09/11/2006	Grant to support non-branded patient-focused educational pamphlets on chronic pain (Target)	TEVA_MDL_A_01089590	TEVA_MDL_A_01089592							
CE-1040	05/31/2006	Education grant to potentially support a precursor to Responsible Opioid Prescribing (FSMB)	TEVA_MDL_A_01088810	TEVA_MDL_A_01088820							
CE-1041	08/28/2007	Independent Educational Program ("IEP") Grant Agreement (APS) for dissemination of book Responsible Opioid Prescribing: A Physician Guide	TEVA_MDL_A_01088845	TEVA_MDL_A_01088857							
CE-1042	08/12/2004	Medical education grant to support reprinting of "the TARGET Card and TARGET Pain Notebook" and outreach to nonprofit organizations about these materials	TEVA_MDL_A_01166356	TEVA_MDL_A_01166358							
CE-1043	12/15/2006	Educational Grant Draft Request (APF) - Chronic Pain Management with Opioids	TEVA_MDL_A_01169010	TEVA_MDL_A_01169032							
CE-1044	08/12/2011	Independent Educational Program Grant Agreement (AAPM) - Changing Landscape of Opioid Therapy	TEVA_MDL_A_01176224	TEVA_MDL_A_01176245							
CE-1045	12/05/2011	Cephalon entered into an agreement with the University of Cincinnati, Global Education Group, and Educational Awareness Solutions to support an educational program titled "Optimizing Pain Management in the 20-Minute Visit" to be held at the annual AAPM meeting.	TEVA_MDL_A_01176639	TEVA_MDL_A_01176665							
CE-1046	12/05/2011	Cephalon entered into an independent educational program grant agreement with Medicom Worldwide to support Conference Coverage life from APS 2012.	TEVA_MDL_A_01176720	TEVA_MDL_A_01176751							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1047	01/19/2010	Cephalon entered into an agreement with Albert Einstein College of Medicine & Montefiore Medical Center and Asante Communications to support an educational program titled “Multimodal Opioid-Based Therapy for Persistent and Breakthrough Pain: From Phenomenology and Disease Mechanisms to Individualized Care” which includes an interactive showcase held in conjunction with AAPM 2010.	TEVA_MDL_A_01176915	TEVA_MDL_A_01176951							
CE-1048	03/01/2009	Portenoy Advisory Board Agreement	TEVA_MDL_A_00784866	TEVA_MDL_A_00784873							
CE-1049	01/26/2009	Independent Medical Education Grants Policy	TEVA_MDL_A_00785735	TEVA_MDL_A_00785740							
CE-1050	12/06/2006	Educational grant to SciMed for an accredited APS CME Poster Book titled “Updates in Chronic Pain Management”	TEVA_MDL_A_00829261	TEVA_MDL_A_00829268							
CE-1051	12/16/2008	Cephalon entered into an independent educational program grant agreement with Montefiore Medical Center and Asante Communications to support “Persistent and BTP: Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies,” which includes a forum planned to be held at an APS meeting.	TEVA_MDL_A_00849962	TEVA_MDL_A_00850031							
CE-1052	01/15/2009	Cephalon entered into an agreement with Medicom Worldwide to support an educational program titled “Emerging Solutions in Pain” which includes an accredited live AAPM symposia.	TEVA_MDL_A_00850584	TEVA_MDL_A_00850727							
CE-1053	01/23/2003	Cephalon entered into an agreement with MediCom Worldwide to support a medical education program to be held at AAPM in 2003.	TEVA_MDL_A_01850590	TEVA_MDL_A_01850597							
CE-1054	05/02/2003	Cephalon entered into medical education agreement with the Postgraduate Institute of Medicine to support a report titled “Therapeutic Spotlight: Crisis Management of Severe Migraine” summarizing relevant studies from an APS meeting.	TEVA_MDL_A_01850677	TEVA_MDL_A_01850689							
CE-1055	05/30/2006	Cephalon entered into an agreement with Conexus Health to support an educational program titled “Management of Breakthrough Pain” to be held at the AAPM meeting.	TEVA_MDL_A_01851280	TEVA_MDL_A_01851296							
CE-1056	09/28/2005	Medical Education Grant through Fusion Medical Education for AAPM 22nd Annual Meeting	TEVA_MDL_A_01854921	TEVA_MDL_A_01854944							
CE-1057	11/30/2005	Cephalon entered into a medical education agreement with Tufts University School of Medicine and Fusion Medical Education to support a program titled “Practical Issues in Prescribing Opioids: Maximizing Pain Relief and Minimizing Risk” held during an annual APS meeting.	TEVA_MDL_A_01854945	TEVA_MDL_A_01854959							
CE-1058	01/23/2003	Grant Request from Medicom Worldwide Inc. for year-long CME lecture series through 2003	TEVA_MDL_A_02683563	TEVA_MDL_A_02683563							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1059	03/01/2007	Sales Policy Handbook – Policy on Promotional Meetings (“CPS”), (Mar. 2007)	TEVA_MDL_A_06880674	TEVA_MDL_A_06880690							
CE-1060	05/13/2005	Actiq Speaker Training (May 13 2005)	TEVA_MDL_A_07079928	TEVA_MDL_A_07079928							
CE-1061	09/10/2004	Cephalon Speaker Bureau Policy (2004)	TEVA_MDL_A_03206965	TEVA_MDL_A_03206973							
CE-1062	03/12/2015	Cephalon agreed to pay Dr. Paul Christo to participate as a consultant in the “Pain Matters” screening event at the AAPM annual meeting.	TEVA_MDL_A_03314704	TEVA_MDL_A_03314705							
CE-1063	03/01/2001	Perry Fine Consulting Agreement	TEVA_MDL_A_03314967	TEVA_MDL_A_03314981							
CE-1064	03/06/2007	Unrestricted Educational Grant Agreement (APF)	TEVA_MDL_A_03315373	TEVA_MDL_A_03315375							
CE-1065	07/17/2008	Unrestricted Educational Grant Agreement (American Chronic Pain Association)	TEVA_MDL_A_03315969	TEVA_MDL_A_03315975							
CE-1066	01/23/2004	Letter from Cephalon to DDMAC re Actiq	TEVA_MDL_A_04784719	TEVA_MDL_A_04785017							
CE-1067	08/12/2004	American Pain Foundation Educational Grant Request and Agreement for Target Initiative	TEVA_MDL_A_05509299	TEVA_MDL_A_05509312							
CE-1068	10/12/2004	American Pain Society Educational Grant Request and Agreement for Commercial Support of CME Activities	TEVA_MDL_A_05510585	TEVA_MDL_A_05510594							
CE-1069	06/01/2007	Cephalon Marketing Speaker Bureau (CSP) Policy (June 2007)	TEVA_MDL_A_05816085	TEVA_MDL_A_05816117							
CE-1070	07/09/2004	Cephalon entered into a medical education agreement with AAPM to support “Public Policy Statement on the Rights and Responsibilities of Healthcare Professionals in the Use of Opioids for the Treatment of Pain.”	TEVA_MDL_A_06343520	TEVA_MDL_A_06343759							
CE-1071	03/12/2002	Cephalon entered into a medical education agreement with MediCom Worldwide to support a self-study educational program based on lectures and presentations at the APS meeting.	TEVA_MDL_A_06343760	TEVA_MDL_A_06343880							
CE-1072	00/00/2007	Fentora Secure Program (2007)	TEVA_MDL_A_06384952	TEVA_MDL_A_06384966							
CE-1073	10/01/2003	Actiq Speaker Bureau Training Guidelines (Oct. 1 2003)	TEVA_MDL_A_06560910	TEVA_MDL_A_06560912							
CE-1074		Cephalon Speaker Identification and Development	TEVA_MDL_A_06560913	TEVA_MDL_A_06560915							
CE-1075	09/12/2006	Portenoy Preceptor Agreement	TEVA_MDL_A_06753556	TEVA_MDL_A_06753563							
CE-1076	04/07/2007	Cephalon Cogenix LLC Speaker Agreement (Apr. 2007)	TEVA_MDL_A_06756402	TEVA_MDL_A_06756410							
CE-1077	05/02/2008	Cephalon entered into an agreement with MedicCom Worldwide and Medical Learning Solutions to support an educational program titled “2008 Emerging Solutions in Pain lecture in Conjunction with AAPM 2008.”	TEVA_MDL_A_06764039	TEVA_MDL_A_06764083							
CE-1078	02/11/2011	Portenoy Advisory Board Agreement	TEVA_MDL_A_07249931	TEVA_MDL_A_07249938							
CE-1079	09/09/2009	Portenoy collaboration on development and implementation of Burden of Illness Study	TEVA_MDL_A_09540158	TEVA_MDL_A_09540159							
CE-1080	11/04/1998	https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/207471bl.pdf	TEVA_MDL_A_13750961	TEVA_MDL_A_13750989							
CE-1081		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20747s0171bl.pdf	TEVA_MDL_A_13745721	TEVA_MDL_A_13745751							
CE-1082		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020747s0191bl.pdf	TEVA_MDL_A_13744637	TEVA_MDL_A_13744667							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1083		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020747s023lbl.pdf	TEVA_MDL_A_13749671	TEVA_MDL_A_13749763							
CE-1084		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020747s027lbl.pdf	TEVA_MDL_A_13745533	TEVA_MDL_A_13745545							
CE-1085	09/01/2009	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020747s030lbl.pdf	TEVA_MDL_A_13745238	TEVA_MDL_A_13745252							
CE-1086		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020747s029lbl.pdf	TEVA_MDL_A_13748903	TEVA_MDL_A_13748921							
CE-1087	12/20/2011	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020747s033lbl.pdf	TEVA_MDL_A_13744071	TEVA_MDL_A_13744089							
CE-1088	12/01/2016	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020747s043s044lbl.pdf	TEVA_MDL_A_13748191	TEVA_MDL_A_13748216							
CE-1089		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021947lbl.pdf	TEVA_MDL_A_13751010	TEVA_MDL_A_13751050							
CE-1090	12/05/2007	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021947s006lbl.pdf	TEVA_MDL_A_13748837	TEVA_MDL_A_13748878							
CE-1091	04/01/2009	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021947s010lbl.pdf	TEVA_MDL_A_13755545	TEVA_MDL_A_13755573							
CE-1092	01/05/2011	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021947s011lbl.pdf	TEVA_MDL_A_13748710	TEVA_MDL_A_13748723							
CE-1093	07/01/2011	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021947s009lbl.pdf	TEVA_MDL_A_13743152	TEVA_MDL_A_13743161							
CE-1094	12/20/2011	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021947s013lbl.pdf	TEVA_MDL_A_11404718	TEVA_MDL_A_11404855							
CE-1095	12/21/2011	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021947s015lbl.pdf	TEVA_MDL_A_13747680	TEVA_MDL_A_13747695							
CE-1096	03/01/2007	Cephalon Policy Regarding Medical Information Request Forms (MIRFs) (March 2007)	TEVA_MDL_A_04794310	TEVA_MDL_A_04794315							
CE-1097	02/25/2005	Cephalon Handling Unsolicited Medical Communications (SOP-0321-D08) (Feb. 2005)	TEVA_MDL_A_11837123	TEVA_MDL_A_11837129							
CE-1098	01/26/2009	Cephalon Medical Information Request Monitoring (GC-210)	TEVA_MDL_A_00552427	TEVA_MDL_A_00552428							
CE-1099	07/01/2008	Cephalon Submission of Medical Requests (WMRO-116)(July, 2008)	TEVA_MDL_A_00552687	TEVA_MDL_A_00552690							
CE-1100	05/01/2004	Cephalon Guide for Discussions with Physicians, May 2004	TEVA_MDL_A_02678395	TEVA_MDL_A_02678395							
CE-1101	05/06/2008	Fentora sNDA Briefing Book	TEVA_MDL_A_00193936	TEVA_MDL_A_00194048							
CE-1102	11/12/2008	Letter from Penny Levin, Cephalon, to Robert Rappaport, FDA, General Correspondence Information Package – Type A Meeting	TEVA_MDL_A_00199116	TEVA_MDL_A_00199256							
CE-1103	11/23/2010	Letter from Susan Franks, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA	TEVA_MDL_A_00294264	TEVA_MDL_A_00294266							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1104	05/11/2007	Correspondence discussed in Letter from Penny Levin, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA, with sNDA Briefing Package	TEVA_MDL_A_00758548	TEVA_MDL_A_00758820							
CE-1105	04/08/2008	Report from FDA Office of Surveillance & Epidemiology Fentora RiskMAP & Postmarketing Review Team to FDA Anesthetic & Life Support Drugs Advisory Committee Members & FDA Drug Safety & Risk Management Advisory Committee Members	TEVA_MDL_A_07864370	TEVA_MDL_A_07864502							
CE-1106	05/03/2005	Actiq (Oral Transmucosal Fentanyl Citrate, OTFC) Official Correspondence Log	TEVA_MDL_A_08261145	TEVA_MDL_A_08261145							
CE-1107	04/15/2005	Letter from Cephalon to FDA acknowledgment of meeting minutes	TEVA_MDL_A_01584973	TEVA_MDL_A_01584989							
CE-1108	01/01/2006	Cephalon – Launch of FBT MESSAGE MASTER & SHOWFLOW, at pp. 7–8	TEVA_MDL_A_00368662	TEVA_MDL_A_00368675							
CE-1109	04/15/2005	Letter from Cephalon to FDA acknowledgment of meeting minutes	TEVA_MDL_A_01584973	TEVA_MDL_A_01584989							
CE-1110	01/26/2009	Cephalon Activity Review & Evaluation (CARE) Process (Jan. 2009)	TEVA_MDL_A_00552037	TEVA_MDL_A_00552041							
CE-1111	01/26/2009		TEVA_MDL_A_00552513	TEVA_MDL_A_00552525							
CE-1112	12/16/2008	Cephalon Promotional Review Process Training (Dec. 2008)	TEVA_MDL_A_08923233	TEVA_MDL_A_08923298							
CE-1113	04/15/2005	Cephalon's Acknowledgment of DDMAC Meeting Minutes	TEVA_MDL_A_00266190	TEVA_MDL_A_00266206							
CE-1114	10/24/2005	Cephalon Pharmaceutical Operations Organizational Chart (May 2006)	TEVA_MDL_A_02383517	TEVA_MDL_A_02383517							
CE-1115	01/01/2004	Cephalon Marketing Department Organizational Chart (Jan. 2004)	TEVA_MDL_A_02383521	TEVA_MDL_A_02383526							
CE-1116	Undated	ACTIQ New Hire Kit	TEVA_MDL_A_04561246	TEVA_MDL_A_04561247							
CE-1117	Undated	Actiq Breakthrough Pain Learning System	TEVA_MDL_A_05931629	TEVA_MDL_A_05932241							
CE-1118	05/14/1999	Letter to Thomas Willer (FDA) re: NDA 20-747 (05/14/1999); Letter to John Markow (FDA) re NDA 20-747 (04/16/1999)	TEVA_MDL_A_11104032	TEVA_MDL_A_11104588							
CE-1119	REMOVED	REMOVED	REMOVED	REMOVED							
CE-1120	11/16/2000	Actiq Master Plan (2000)	TEVA_MDL_A_00454747	TEVA_MDL_A_00454807							
CE-1121	01/01/2001	Actiq Marketing 2001	TEVA_MDL_A_00454808	TEVA_MDL_A_00454815							
CE-1122	01/01/2002	Actiq 2002 Marketing Plan	TEVA_MDL_A_00454816	TEVA_MDL_A_00454871							
CE-1123	01/01/2003	Actiq 2003 Marketing Plan	TEVA_MDL_A_00454872	TEVA_MDL_A_00454940							
CE-1124	01/01/2004	2004 Actiq Marketing Plan	TEVA_MDL_A_00454941	TEVA_MDL_A_00454999							
CE-1125	01/01/2005	2005 Actiq Marketing Plan	TEVA_MDL_A_00455000	TEVA_MDL_A_00455083							
CE-1126	10/27/2004	Sales Bulletin – Ensuring Appropriate Targeting and Promotion of Actiq	TEVA_MDL_A_04756549	TEVA_MDL_A_04756550							
CE-1127	04/23/2003	Product Promotion Guidelines	TEVA_MDL_A_05896296	TEVA_MDL_A_05896296							
CE-1128	03/05/2002	2002 Actiq Sales Aid	TEVA_MDL_A_11115315	TEVA_MDL_A_11115343							
CE-1129	04/29/2004	Sales Bulletin 14	TEVA_MDL_A_04816393	TEVA_MDL_A_04816394							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1130	02/26/2008	Cephalon, Sales Operations "Do Not Promote/Do Not Call Documentation Policy"	TEVA_MDL_A_00642507	TEVA_MDL_A_00642513							
CE-1131	01/26/2009	Cephalon Targeting Assessment and Call Activity Policy, (June 2009)	TEVA_MDL_A_00552706	TEVA_MDL_A_00552708							
CE-1132	03/01/2007	Cephalon Targeting and "Do Not Detail" Policy (March, 2007)	TEVA_MDL_A_00552880	TEVA_MDL_A_00552883							
CE-1133	02/01/2010	Cephalon Global Pharm Operations Policies	TEVA_MDL_A_00562311	TEVA_MDL_A_00562355							
CE-1134	06/04/2009	Email regarding instituting a new Do Not Compensate (DNC) policy for Fentora.	TEVA_MDL_A_00970646	TEVA_MDL_A_00970648							
CE-1135	03/00/2007	Sales Policy Handbook – Policy on Providing Reimbursement Information to Customers (March 2007)	TEVA_MDL_A_06880691	TEVA_MDL_A_06880694							
CE-1136	10/01/2004	Cephalon Policy on Identifying Called on Universe of Physicians in Connection with Promotional Activities (Oct. 2004)	TEVA_MDL_A_04794307	TEVA_MDL_A_04794309							
CE-1137	01/26/2005	OVF Commercial Strategy Meeting (Jan. 2005)	TEVA_MDL_A_00360974	TEVA_MDL_A_00360974							
CE-1138	08/23/2006	Sales Training on the RiskMAP (2006)	TEVA_MDL_A_00365152	TEVA_MDL_A_00365152							
CE-1139	12/04/2008	Fentora Pre-module: Introduction to Pain (2008)	TEVA_MDL_A_00390332	TEVA_MDL_A_00390409							
CE-1140	08/21/2006	FENTORA Launch Agenda (Aug. 2006)	TEVA_MDL_A_00390728	TEVA_MDL_A_00390728							
CE-1141	04/30/2008	FENTORA 90 Day Plan: "One New Patient per Week," (Apr. 30, 2008)	TEVA_MDL_A_00398705	TEVA_MDL_A_00398705							
CE-1142	03/23/2011	Cephalon Sales Training & Development Phase II Training – CVA Workshop Facilitator's Guide	TEVA_MDL_A_00544344	TEVA_MDL_A_00544433							
CE-1143	03/03/2009	FENTORA 2009 National Sales Meeting: Q2 2009 90-Day Plan (2009)	TEVA_MDL_A_01095930	TEVA_MDL_A_01095944							
CE-1144	11/11/2008	Fentora Questions & Answers for Patients	TEVA_MDL_A_00724412	TEVA_MDL_A_00724429							
CE-1145	01/11/2019	FENTORA Reimbursement Kit	TEVA_MDL_A_00752865	TEVA_MDL_A_00752866							
CE-1146	08/01/2013	US Specialty Medicines: CNS: Fentora 2014 Annual Operating Plan (Aug. 2013)	TEVA_MDL_A_01253817	TEVA_MDL_A_01255558							
CE-1147	05/18/2006	FEBT Launch Playbook: Steering Committee Presentation (May 2006)	TEVA_MDL_A_07360899	TEVA_MDL_A_07360899							
CE-1148	01/05/2010	FENTORA 2011 Brand Plan (Jan. 5 2010)(Draft)	TEVA_MDL_A_00550572	TEVA_MDL_A_00550593							
CE-1149	11/29/2005	FEBT (Fentanyl Effervescent Buccal Tablet) 2005–2006 Marketing Plan (Jun. 2005)	TEVA_MDL_A_00550595	TEVA_MDL_A_00550814							
CE-1150	08/13/2007	Fentora 2008 Brand Plan	TEVA_MDL_A_00550836	TEVA_MDL_A_00550836							
CE-1151	07/08/2009	Fentora 2009 Brand Plan	TEVA_MDL_A_00550838	TEVA_MDL_A_00550881							
CE-1152	01/01/2007	Fentora Marketing Plan 2007	TEVA_MDL_A_00550891	TEVA_MDL_A_00550891							
CE-1153	01/01/2010	Fentora 2010 Brand Plan	TEVA_MDL_A_00550892	TEVA_MDL_A_00550960							
CE-1154	03/05/2015	FENTORA (fentanyl buccal tablet) US Regional Brand Plan (Mar. 5 2015)	TEVA_MDL_A_08794090	TEVA_MDL_A_08794106							
CE-1155	02/10/2010	Fentora 2010 National Sales Meeting – Exploring the CVA Workshop Slides	TEVA_MDL_A_00345610	TEVA_MDL_A_00345644							
CE-1156		Appropriate Prescribing of Fentora: A Focus on REMS	TEVA_MDL_A_01151779	TEVA_MDL_A_01151833							
CE-1157	04/15/2008	Sales Bulletin WLF Policy Update – Ending Use of Reprints	TEVA_MDL_A_00739357	TEVA_MDL_A_00739357							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1158	09/28/2009	PCS Fall 2009 POA Training Workshops	TEVA_MDL_A_01220047	TEVA_MDL_A_01220047							
CE-1159	10/08/2019	Doing What Matters!, Tampa/Phoenix POA	TEVA_MDL_A_01316550	TEVA_MDL_A_01316636							
CE-1160	03/10/2010	2010 Field Action Plan	TEVA_MDL_A_01325583	TEVA_MDL_A_01325583							
CE-1161	02/25/2008	Email from Michael Morreale re National Sales Meeting Follow Up	TEVA_MDL_A_09601972	TEVA_MDL_A_09601973							
CE-1162	07/19/2007	Sales Bulletin	TEVA_MDL_A_00013847	TEVA_MDL_A_00013856							
CE-1163	05/08/2011	Cephalon Pain Care Business Overview	TEVA_MDL_A_00010688	TEVA_MDL_A_00010731							
CE-1164	12/18/2007	Cephalon Reimbursement Process and Procedure Guide	TEVA_MDL_A_00012827	TEVA_MDL_A_00012868							
CE-1165	07/01/2008	Cephalon Reimbursement Process and Procedure	TEVA_MDL_A_00552538	TEVA_MDL_A_00552584							
CE-1166	01/26/2009	Cephalon Targeting Assessment and Call Activity (GPO-130)(Jan. 26 2009)	TEVA_MDL_A_00819289	TEVA_MDL_A_00819292							
CE-1167	07/01/2009	Reimbursement Process and Procedure Guide	TEVA_MDL_A_01188202	TEVA_MDL_A_01188248							
CE-1168	07/16/2004	Cephalon Sales Department Organizational Chart	TEVA_MDL_A_01373059	TEVA_MDL_A_01373150							
CE-1169	04/00/2005	Policy on Providing Reimbursement Information to Customers	TEVA_MDL_A_04756907	TEVA_MDL_A_04756912							
CE-1170	12/12/2003	Memo from Roy Craig to U.S. Sales re “Ensuring Appropriate Targeting And Promotion of ACTIQ,” Dec. 12 2003	TEVA_MDL_A_05445644	TEVA_MDL_A_05445712							
CE-1171	01/31/2006	ACTIQ Reimbursement Hotline flyer	TEVA_MDL_A_08857270	TEVA_MDL_A_08857271							
CE-1172	07/01/2008	Reimbursement Process and Procedure Guide	TEVA_MDL_A_08924132	TEVA_MDL_A_08924178							
CE-1173	01/08/2019	Standards of Global Business Practices (Cephalon Code of Conduct)	TEVA_MDL_A_00552635	TEVA_MDL_A_00552681							
CE-1174	01/01/2009	Cephalon US Sales and Marketing Policy (2009)	TEVA_MDL_A_00552730	TEVA_MDL_A_00552765							
CE-1175	06/07/2019	Marketing Policy Handbook	TEVA_MDL_A_00552840	TEVA_MDL_A_00552849							
CE-1176	06/07/2019	Marketing Policy on Grants	TEVA_MDL_A_00552919	TEVA_MDL_A_00552932							
CE-1177	06/07/2019	Interactions Among MSLs, Cephalon Business Personnel (e.g., Marketing) and HCPs	TEVA_MDL_A_00552942	TEVA_MDL_A_00552944							
CE-1178	09/07/2019	Policy on Providing Reimbursement Information to Customers	TEVA_MDL_A_00553053	TEVA_MDL_A_00553056							
CE-1179	10/06/2019	Policy on Interactions Between MSLs, Cephalon Business Personnel (e.g., Sales, Account Management, and Marketing) and Healthcare Professionals	TEVA_MDL_A_00553057	TEVA_MDL_A_00553058							
CE-1180	02/20/2009	General and Specific Training	TEVA_MDL_A_00560368	TEVA_MDL_A_00560370							
CE-1181	07/01/2008	Email from A. Pyfer to PCS Sales Management	TEVA_MDL_A_00971774	TEVA_MDL_A_00971776							
CE-1182	10/06/2019	Cephalon 2006 Sales Policy Handbook	TEVA_MDL_A_01251767	TEVA_MDL_A_01251777							
CE-1183	03/01/2007	Cephalon Sales Policy Handbook- Mar. 2007	TEVA_MDL_A_06880605	TEVA_MDL_A_06880614							
CE-1184	10/03/2001	Cephalon Review and Approval of Promotional Materials (SOP-0348-R01)	TEVA_MDL_A_04785055	TEVA_MDL_A_04785062							
CE-1185	10/01/2004	Cephalon Sales Policy Handbook- Oct. 2004	TEVA_MDL_A_04794285	TEVA_MDL_A_04794294							
CE-1186	04/01/2005	Exhibit IV Laws and Standards that Affect the Sale and Marketing of Cephalon Products	TEVA_MDL_A_05662727	TEVA_MDL_A_05662730							
CE-1187	06/07/2019	Marketing Policy on Developing Promotional and Advertising Materials	TEVA_MDL_A_00552902	TEVA_MDL_A_00552905							
CE-1188	03/04/2004	Compliance Lecture	TEVA_MDL_A_11137773	TEVA_MDL_A_11137773							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1189		Sales Bulletins	TEVA_MDL_A_05445644	TEVA_MDL_A_05445712							
CE-1190	11/00/2006	CME Program Information and Distribution Announcements	TEVA_MDL_A_07838533	TEVA_MDL_A_07838536							
CE-1191	03/00/2008	Revised PI and HCP Sales Bulletin	TEVA_MDL_A_00402658	TEVA_MDL_A_00402658							
CE-1192	08/00/2007	Policy on Providing Reimbursement Information Sales Bulletin	TEVA_MDL_A_00701428	TEVA_MDL_A_00701436							
CE-1193	09/00/2007	Dear HCP Sales Bulletin	TEVA_MDL_A_00390605	TEVA_MDL_A_00390605							
CE-1194	08/00/2007	Clinical Trial Abstracts Sales Bulletin	TEVA_MDL_A_00739337	TEVA_MDL_A_00739337							
CE-1195	09/00/2006	FENTORA RiskMAP Sales Bulletin	TEVA_MDL_A_07416850	TEVA_MDL_A_07416850							
CE-1196	12/00/2008	Medical Educationa lGrant Requests Sales Bulletins	TEVA_MDL_A_02379242	TEVA_MDL_A_02379244							
CE-1197	02/00/2006	Child Safety Information and Proper Storage & Disposal of Actiq	TEVA_MDL_A_04758223	TEVA_MDL_A_04758226							
CE-1198	07/00/2007	Frequently Asked Questions from Compliance Sales Meeting	TEVA_MDL_A_07353865	TEVA_MDL_A_07353874							
CE-1199	03/07/2019	Policy on Dissemination of Certain Off-Label Peer-Reviewed Reprints and Reference Textbooks (WLF Policy)	TEVA_MDL_A_00553033	TEVA_MDL_A_00553035							
CE-1200	07/27/2010	PCS New Hire Training – Sales Operations Department (July 2010)	TEVA_MDL_A_00681276	TEVA_MDL_A_00681276							
CE-1201	01/01/2004	Cephalon Incentive Compensation Plan Payment Policies for All Cephalon Field Sales Personnel (Jan 2004)	TEVA_MDL_A_00406531	TEVA_MDL_A_00406533							
CE-1202	01/26/2009	Cephalon Employee Compensation Policy (January 26, 2009)	TEVA_MDL_A_00552245	TEVA_MDL_A_00552246							
CE-1203	10/04/2012	Incentive Compensation for Sales Reps - Redline Draft	TEVA_MDL_A_00961784	TEVA_MDL_A_00961793							
CE-1204		Cephalon Management Incentive Compensation Plan	TEVA_MDL_A_09621973	TEVA_MDL_A_09622326							
CE-1205	01/01/2007	3rd Quarter 2007 Incentive Compensation Plan	TEVA_MDL_A_00455140	TEVA_MDL_A_00455141							
CE-1206	02/20/2008	“Dear Healthcare Provider” Letter notifying healthcare provider of completed Fentora labels, (Feb 20 2008)	TEVA_MDL_A_00868502	TEVA_MDL_A_00868504							
CE-1207	09/10/2007	“Dear Healthcare Provider: Important Safety Information for Fentora” Letter (Sept. 10 2007)	TEVA_MDL_A_01009322	TEVA_MDL_A_01009325							
CE-1208	06/01/2009	Cephalon - SOP-0013489	TEVA_MDL_A_01088881	TEVA_MDL_A_01088884							
CE-1209	01/22/2008	Product Bulletin issued by Cephalon regarding updates to Fentora labels (Jan 22 2008)	TEVA_MDL_A_01211330	TEVA_MDL_A_01211330							
CE-1210	04/28/2004	E-mail from Andy Pyfer to Stacey Beckhardt (RE: Associated Press Article: "Increase in abuse reported of narcotic lollipops for cancer patients").	TEVA_MDL_A_04108856	TEVA_MDL_A_04108858							
CE-1211	12/16/2011	Cephalon RC0351178 12-16-11.pdf	TEVA_MDL_A_01463427	TEVA_MDL_A_01463428							
CE-1212	01/31/2012	Cephalon_RC0351178_01-30-2012.pdf	TEVA_MDL_A_02806082	TEVA_MDL_A_02806082							
CE-1213	07/01/2008	Cephalon Reporting of Adverse Events, Product Complaints and Suspected Diversions, (July 1, 2008).	TEVA_MDL_A_00552589	TEVA_MDL_A_00552591							
CE-1214	11/19/2004	Actiq Risk Management Program	TEVA_MDL_A_00270514	TEVA_MDL_A_00270535							
CE-1215	08/01/2001	Actiq Risk Management Program	TEVA_MDL_A_00271190	TEVA_MDL_A_00271221							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1216	08/22/2006	Chronology of FDA-Approved Changes to the Actiq Risk Management Program (Aug 22 2006)	TEVA_MDL_A_00271315	TEVA_MDL_A_00271493							
CE-1217	01/06/2006	Amendment to S-020 (Jan 6 2006)	TEVA_MDL_A_00275953	TEVA_MDL_A_00276034							
CE-1218	12/22/2006	Amendment to S-020 and Request for Meeting to Discuss Revisions to Actiq RMP	TEVA_MDL_A_00277891	TEVA_MDL_A_00277984							
CE-1219	09/17/2008	New Supplement for NDA 20-747: Proposed Risk Evaluation & Mitigation Strategy (REMS) Actiq, (Sept. 16 2008)	TEVA_MDL_A_00285468	TEVA_MDL_A_00285668							
CE-1220	08/06/2010	Actiq Risk Evaluation & Mitigation Strategy, (Aug 6 2010)	TEVA_MDL_A_00294131	TEVA_MDL_A_00294258							
CE-1221	08/06/2010	Summary of Changes – Proposed Actiq REMS, (Aug. 6, 2010)	TEVA_MDL_A_00294259	TEVA_MDL_A_00294260							
CE-1222	11/23/2010	Actiq & Fentora Proposed Risk Evaluation & Mitigation Strategy	TEVA_MDL_A_00294267	TEVA_MDL_A_00294374							
CE-1223	10/13/2007	Fentora sNDA RiskMAP Tools Review Meeting: Pain Care Franchise Marketing (Oct. 12 2007)	TEVA_MDL_A_00376199	TEVA_MDL_A_00376199							
CE-1224	07/20/2011	Actiq and Fentora REMS	TEVA_MDL_A_01010424	TEVA_MDL_A_01010537							
CE-1225	12/15/2003	Carol Marchione, Memorandum on Actions to Respond to Audit Findings Regarding the Actiq Risk Management Program (Quality Assurance Memorandum – 12/02/03),	TEVA_MDL_A_01159549	TEVA_MDL_A_01159553							
CE-1226	11/22/2004	Actiq Prior Approval Supplement: Revised RMP (Nov. 22 2004)	TEVA_MDL_A_01578534	TEVA_MDL_A_01578613							
CE-1227	01/13/2011	Charter Agreement of the TIRF REMS Industry Group (Jan 13 2011)	TEVA_MDL_A_06779361	TEVA_MDL_A_06779384							
CE-1228	12/28/2011	Supplemental Approval for Fentora REMS	TEVA_MDL_A_07679384	TEVA_MDL_A_07679521							
CE-1229	06/30/2010	Summary of Changes – Actiq REMS (June 30 2010)	TEVA_MDL_A_08510383	TEVA_MDL_A_08510384							
CE-1230	02/11/2005	SOP-0001053, for Marketing Support of the Actiq Risk Management Program	TEVA_MDL_A_08531805	TEVA_MDL_A_08531810							
CE-1231	11/06/2018	Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation & Mitigation Strategy (REMS)	TEVA_MDL_A_11087241	TEVA_MDL_A_11087411							
CE-1232	04/01/2007	Fentora Risk Minimization Actiqon Plan (The Secure Program) Quarterly Report	TEVA_MDL_A_00037913	TEVA_MDL_A_00037972							
CE-1233	09/19/2006	Letter from Penny S. Levin, M.S., Associate Director, Regulatory Affairs, Cephalon, to Robert Rappaport, M.D., FDA	TEVA_MDL_A_00265075	TEVA_MDL_A_00265425							
CE-1234	06/05/2012	TIRF REMS Approval Letter	TEVA_MDL_A_00710057	TEVA_MDL_A_00710205							
CE-1235	11/12/1999	Actiq (oral transmucosal fentanyl citrate, OTFC) Risk Management Program – 1st Quarterly Report	TEVA_MDL_A_11105721	TEVA_MDL_A_11105733							
CE-1236	09/22/2005	Actiq Risk Management Program – 25th Quarterly Report	TEVA_MDL_A_00268683	TEVA_MDL_A_00268720							
CE-1237	04/13/2007	Fentora 1st Quarterly Report	TEVA_MDL_A_10313692	TEVA_MDL_A_10313708							
CE-1238	12/09/2019	Fentora 12th Quarterly Report	TEVA_MDL_A_10598611	TEVA_MDL_A_10598668							
CE-1239	08/17/2001	Actiq Risk Management Program – 8th Quarterly Report	TEVA_MDL_A_11113764	TEVA_MDL_A_11113802							
CE-1240	11/12/1999	Actiq Risk Management Program - 1st Quarterly Report	TEVA_MDL_A_11105721	TEVA_MDL_A_11105733							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1241	12/21/1999	Actiq Risk Mangement Program - 2nd Quarterly Report	TEVA_MDL_A_11105746	TEVA_MDL_A_11105761							
CE-1242	03/07/2000	Actiq Risk Management Program - 3rd Quarterly Report	TEVA_MDL_A_11107186	TEVA_MDL_A_11107203							
CE-1243	06/14/2000	Actiq Risk Management Program - 4th Quarterly Report	TEVA_MDL_A_11108180	TEVA_MDL_A_11108198							
CE-1244	10/06/2000	Actiq Risk Management Program - 5th Quarterly Report	TEVA_MDL_A_11108258	TEVA_MDL_A_11108279							
CE-1245	12/05/2000	Actiq Risk Mangement Program - 6th Quarterly Report	TEVA_MDL_A_11108280	TEVA_MDL_A_11108303							
CE-1246	08/17/2001	Actiq Risk Management Program - 7th Quarterly Report	TEVA_MDL_A_11113764	TEVA_MDL_A_11113802							
CE-1247	08/17/2001	Actiq Risk Management Program - 8th Quarterly Report	TEVA_MDL_A_11113764	TEVA_MDL_A_11113802							
CE-1248	09/21/2001	Actiq Risk Management Program - 9th Quarterly Report	TEVA_MDL_A_11113967	TEVA_MDL_A_11113985							
CE-1249	11/30/2001	Actiq Risk Management Program - 10th Quarterly Report	TEVA_MDL_A_11114141	TEVA_MDL_A_11114159							
CE-1250	02/28/2002	Actiq Risk Mangement Program - 11th Quarterly Report	TEVA_MDL_A_08242777	TEVA_MDL_A_08242797							
CE-1251	05/31/2002	Actiq Risk Management Program - 12th Quarterly Report	TEVA_MDL_A_11115637	TEVA_MDL_A_11115661							
CE-1252	08/30/2002	Actiq Risk Mangement Program - 13th Quarterly Report	TEVA_MDL_A_11117191	TEVA_MDL_A_11117223							
CE-1253	12/09/2002	Actiq Risk Management Program - 14th Quarterly Report	TEVA_MDL_A_11117531	TEVA_MDL_A_11117555							
CE-1254	03/24/2003	Actiq Risk Mangement Program - 15th Quarterly Report	TEVA_MDL_A_11118999	TEVA_MDL_A_11119025							
CE-1255	06/13/2003	Actiq Risk Management Program - 16th Quarterly Report	TEVA_MDL_A_11120800	TEVA_MDL_A_11120823							
CE-1256	09/24/2003	Actiq Risk Mangement Program - 17th Quarterly Report	TEVA_MDL_A_11121911	TEVA_MDL_A_11121940							
CE-1257	03/04/2004	Actiq Risk Management Program - 18th Quarterly Report	TEVA_MDL_A_11836580	TEVA_MDL_A_11836602							
CE-1258	04/19/2004	Actiq Risk Mangement Program - 19th Quarterly Report	TEVA_MDL_A_01574944	TEVA_MDL_A_01574987							
CE-1259	08/20/2004	Actiq Risk Management Program - 20th Quarterly Report	TEVA_MDL_A_01576048	TEVA_MDL_A_01576070							
CE-1260	10/05/2004	Actiq Risk Management Program - 21st Quarterly Report	TEVA_MDL_A_08437872	TEVA_MDL_A_08437899							
CE-1261	03/08/2005	Actiq Risk Management Program - 22nd Quarterly Report	TEVA_MDL_A_00267755	TEVA_MDL_A_00267778							
CE-1262	07/19/2005	Actiq Risk Management Program - 23rd and 24th Quarterly Report	TEVA_MDL_A_00268414	TEVA_MDL_A_00268483							
CE-1263	09/22/2005	Actiq Risk Management Program - 25th Quarterly Report	TEVA_MDL_A_00268683	TEVA_MDL_A_00268720							
CE-1264	11/28/2005	Actiq Risk Management Program - 26th Quarterly Report	TEVA_MDL_A_00268778	TEVA_MDL_A_00268805							
CE-1265	02/27/2006	Actiq Risk Management Program - 27th Quarterly Report	TEVA_MDL_A_00276183	TEVA_MDL_A_00276218							
CE-1266	05/31/2006	Actiq Risk Management Program - 28th Quarterly Report	TEVA_MDL_A_00276298	TEVA_MDL_A_00276327							
CE-1267	08/30/2006	Actiq Risk Mangement Program - 29th Quarterly Report	TEVA_MDL_A_00276352	TEVA_MDL_A_00276383							
CE-1268	11/30/2006	Actiq Risk Management Program - 30th Quarterly Report	TEVA_MDL_A_00276445	TEVA_MDL_A_00276469							
CE-1269	03/29/2007	Actiq Risk Management Program - 31st Quarterly Report	TEVA_MDL_A_00283237	TEVA_MDL_A_00283264							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1270	05/31/2007	Actiq Risk Management Program - 32nd Quarterly Report	TEVA_MDL_A_00283269	TEVA_MDL_A_00283297							
CE-1271	08/30/2007	Actiq Risk Management Program - 33rd Quarterly Report	TEVA_MDL_A_00283384	TEVA_MDL_A_00283416							
CE-1272	11/30/2007	Actiq Risk Management Program - 34th Quarterly Report	TEVA_MDL_A_00283443	TEVA_MDL_A_00283488							
CE-1273	02/26/2008	Actiq Risk Management Program - 35th Quarterly Report	TEVA_MDL_A_00285282	TEVA_MDL_A_00285324							
CE-1274	05/29/2008	Actiq Risk Management Program - 36th Quarterly Report	TEVA_MDL_A_00285333	TEVA_MDL_A_00285412							
CE-1275	08/26/2008	Actiq Risk Management Program - 37th Quarterly Report	TEVA_MDL_A_00285413	TEVA_MDL_A_00285467							
CE-1276	11/21/2008	Actiq Risk Management Program - 38th Quarterly Report	TEVA_MDL_A_00285713	TEVA_MDL_A_00285761							
CE-1277	02/27/2009	Actiq Risk Management Program - 39th Quarterly Report	TEVA_MDL_A_00292654	TEVA_MDL_A_00292703							
CE-1278	05/28/2009	Actiq Risk Management Program - 40th Quarterly Report	TEVA_MDL_A_00292892	TEVA_MDL_A_00292940							
CE-1279	09/30/2009	Actiq Risk Management Program - 41st Quarterly Report	TEVA_MDL_A_00292945	TEVA_MDL_A_00292996							
CE-1280	12/07/2009	Actiq Risk Management Program - 42nd Quarterly Report	TEVA_MDL_A_00293428	TEVA_MDL_A_00293478							
CE-1281	02/25/2010	Actiq Risk Management Program - 43rd Quarterly Report	TEVA_MDL_A_00295463	TEVA_MDL_A_00295512							
CE-1282	05/28/2010	Actiq Risk Management Program - 44th Quarterly Report	TEVA_MDL_A_00295557	TEVA_MDL_A_00295611							
CE-1283	08/30/2010	Actiq Risk Management Program - 45th Quarterly Report	TEVA_MDL_A_00295780	TEVA_MDL_A_00295828							
CE-1284	11/24/2010	Actiq Risk Management Program - 46th Quarterly Report	TEVA_MDL_A_00295841	TEVA_MDL_A_00295892							
CE-1285	02/28/2011	Actiq Risk Management Program - 47th Quarterly Report	TEVA_MDL_A_00299921	TEVA_MDL_A_00299960							
CE-1286	05/26/2011	Actiq Risk Management Program - 48th Quarterly Report	TEVA_MDL_A_00300050	TEVA_MDL_A_00300092							
CE-1287	08/29/2011	Actiq Risk Management Program - 49th Quarterly Report	TEVA_MDL_A_00300163	TEVA_MDL_A_00300206							
CE-1288	04/13/2007	Fentora Risk Minimization Plan - 1st Quarterly Report	TEVA_MDL_A_10313692	TEVA_MDL_A_10313708							
CE-1289	07/20/2007	Fentora Risk Minimization Plan - 2nd Quarterly Report	TEVA_MDL_A_10315736	TEVA_MDL_A_10315760							
CE-1290	10/22/2007	Fentora Risk Minimization Plan - 3rd Quarterly Report	TEVA_MDL_A_10316841	TEVA_MDL_A_10316900							
CE-1291	02/26/2008	Fentora Risk Minimization Plan - 4th Quarterly Report	TEVA_MDL_A_10422175	TEVA_MDL_A_10422232							
CE-1292	04/15/2008	Fentora Risk Minimization Plan - 5th Quarterly Report	TEVA_MDL_A_10497915	TEVA_MDL_A_10498256							
CE-1293	06/20/2008	Fentora Risk Minimization Plan - 6th Quarterly Report	TEVA_MDL_A_10502990	TEVA_MDL_A_10503077							
CE-1294	10/24/2008	Fentora Risk Minimization Plan - 7th Quarterly Report	TEVA_MDL_A_10510166	TEVA_MDL_A_10510333							
CE-1295	04/17/2009	Fentora Risk Minimization Plan - 8th Quarterly Report	TEVA_MDL_A_10552587	TEVA_MDL_A_10552662							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1296	04/20/2009	Fentora Risk Minimization Plan - 9th Quarterly Report	TEVA_MDL_A_10552668	TEVA_MDL_A_10552773							
CE-1297	06/11/2009	Fentora Risk Minimization Plan - 10th Quarterly Report	TEVA_MDL_A_10562042	TEVA_MDL_A_10562090							
CE-1298	10/01/2009	Fentora Risk Minimization Plan - 11th Quarterly Report	TEVA_MDL_A_10568672	TEVA_MDL_A_10568718							
CE-1299	12/30/2009	Fentora Risk Minimization Plan - 12th Quarterly Report	TEVA_MDL_A_10598611	TEVA_MDL_A_10598668							
CE-1300	00/00/2010	Fentora Risk Minimization Plan - 13th Quarterly Report	TEVA_MDL_A_00652142	TEVA_MDL_A_00652200							
CE-1301	06/30/2010	Fentora Risk Minimization Plan - 14th Quarterly Report	TEVA_MDL_A_10621200	TEVA_MDL_A_10621254							
CE-1302	09/30/2010	Fentora Risk Minimization Plan - 15th Quarterly Report	TEVA_MDL_A_10635646	TEVA_MDL_A_10635696							
CE-1303	12/22/2010	Fentora Risk Minimization Plan - 16th Quarterly Report	TEVA_MDL_A_10641276	TEVA_MDL_A_10641328							
CE-1304	05/31/2011	Fentora Risk Minimization Plan - 17th Quarterly Report	TEVA_MDL_A_10645019	TEVA_MDL_A_10645067							
CE-1305	06/28/2011	Fentora Risk Minimization Plan - 18th Quarterly Report	TEVA_MDL_A_10657239	TEVA_MDL_A_10657291							
CE-1306	09/28/2011	Fentora Risk Minimization Plan - 19th Quarterly Report	TEVA_MDL_A_10666318	TEVA_MDL_A_10666370							
CE-1307	00/00/2008	"2008 Global Compliance Report,"	TEVA_MDL_A_00360420	TEVA_MDL_A_00360452							
CE-1308	03/29/2007	Actiq Risk Management Program – 31stQuarterly Report, TEVA_MDL_A_00283237–64 at TEVA_MDL_A_00283253, March 29, 2007	TEVA_MDL_A_00283237	TEVA_MDL_A_00283264							
CE-1309	06/00/2007	Marketing Speaker Bureau (CSP) Policy Cephalon Jun-07	TEVA_MDL_A_00552396	TEVA_MDL_A_00552420							
CE-1310	10/00/2006	Sales Policy Handbook, with exhibits and Government Employee Certification Form	TEVA_MDL_A_00552850	TEVA_MDL_A_00552860							
CE-1311	03/00/2007	Promotional Materials and Activities Cephalon Mar-07	TEVA_MDL_A_00552870	TEVA_MDL_A_00552879							
CE-1312	03/00/2007	Medical Information Request Forms Cephalon Mar-07	TEVA_MDL_A_00552884	TEVA_MDL_A_00552890							
CE-1313	06/00/2007	Preceptorships and exhibits Cephalon Jun-07	TEVA_MDL_A_00552945	TEVA_MDL_A_00552958							
CE-1314	06/00/2007	Speaker Bureau (CSP) Cephalon Jun-07	TEVA_MDL_A_00552970	TEVA_MDL_A_00552994							
CE-1315	03/00/2007	Promotional Meetings ("CSPs") Cephalon Mar-07	TEVA_MDL_A_00552995	TEVA_MDL_A_00553011							
CE-1316	01/00/2008	Third Party Grant Requests Cephalon Jan-08	TEVA_MDL_A_00553030	TEVA_MDL_A_00553032							
CE-1317	11/04/1998	Anesta Corporation, and Abbott Laboratories, "Actiq Risk Management Program," November 4, 1998	TEVA_MDL_A_00564336	TEVA_MDL_A_00564365							
CE-1318	09/10/2007	Cephalon, Inc., "Important Safety Information for Fentora," September 10, 2007	TEVA_MDL_A_00970847	TEVA_MDL_A_00970850							
CE-1319		"Actiq TIRF REMS Documentation"	TEVA_MDL_A_00709777	TEVA_MDL_A_00710056							
CE-1320	00/00/2009	"2009 Global Compliance Incident Details Report,"	TEVA_MDL_A_00769186	TEVA_MDL_A_00769186							
CE-1321	03/00/2007	Policy on Promotional Materials and Activities Cephalon Mar-07	TEVA_MDL_A_01251780	TEVA_MDL_A_01251789							
CE-1322	Undated	"Understanding FDA Regulations,"	TEVA_MDL_A_02724063	TEVA_MDL_A_02724063							
CE-1323	11/19/2009	"Report on Independent Review Organization's Engagement,"	TEVA_MDL_A_02939244	TEVA_MDL_A_02939340							
CE-1324	10/00/2004	Policy on Advertising and Promotional Materials and Activities	TEVA_MDL_A_04794303	TEVA_MDL_A_04794306							
CE-1325	10/00/2004	Grants or Support That Are Not For Independent Medical Education	TEVA_MDL_A_04794345	TEVA_MDL_A_04794348							
CE-1326	01/04/2009	Cephalon Compliance Investigations and Disciplinary Actions Report	TEVA_MDL_A_06616796	TEVA_MDL_A_06616855							
CE-1327	00/00/2005	Cephalon Newsletter (Summer 2005),"	TEVA_MDL_A_08272952	TEVA_MDL_A_08272957							
CE-1328	10/00/2004	Medical Information Request Forms Cephalon Oct-04	TEVA_MDL_A_11892865	TEVA_MDL_A_11892870							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
CE-1329	Undated	“Teva Year 4 FENTORA Message Recall Surveys,”	TEVA_MDL_A_00561498	TEVA_MDL_A_00561500							
TE-1	11/05/2016	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04213348	TEVA_MDL_A_04213356							
TE-2	Undated	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04250791	TEVA_MDL_A_04250857							
TE-3	Undated	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04250858	TEVA_MDL_A_04250891							
TE-4	09/30/2014	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04250892	TEVA_MDL_A_04250932							
TE-5	03/14/2018	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04250933	TEVA_MDL_A_04251049							
TE-6	07/31/2015	Actiq and Fentora Clinical Study Reports	TEVA_MDL_A_04251064	TEVA_MDL_A_04251070							
TE-7	12/12/2014	Distribution and Supply Agreement Between Purdue Pharma L.P. and Teva Pharmaceuticals USA, Inc.	TEVA_MDL_A_01459814	TEVA_MDL_A_01459866							
TE-8	11/01/1997	Generic Wholesale Service Agreement Between Cardinal Health and Teva Pharmaceuticals USA	TEVA_MDL_A_02837166	TEVA_MDL_A_02837187							
TE-9	08/02/2016	Quality Agreement Between Allergan PLC and Teva Pharmaceuticals Industries Ltd.	TEVA_MDL_A_03066252	TEVA_MDL_A_03066307							
TE-10	01/17/2012	Risk Evaluation and Mitigation Strategies Amendment Between Cephalon, Inc. and Miami-Luken, Inc.	TEVA_MDL_A_03443993	TEVA_MDL_A_03443998							
TE-11	01/01/2012	Master Distribution Services Agreement Between AmerisourceBergen and Teva Pharmaceuticals USA, Inc.	TEVA_MDL_A_03447808	TEVA_MDL_A_03447847							
TE-12	09/01/2012	Amendment No. 1 to Distribution Services Agreement Between Teva Pharmaceuticals USA, Inc. and Miami-Luken, Inc.	TEVA_MDL_A_03448911	TEVA_MDL_A_03448921							
TE-13	04/03/2015	Distribution Services Agreement Between Teva Pharmaceuticals USA, Inc. and Anda, Inc.	TEVA_MDL_A_03451410	TEVA_MDL_A_03451456							
TE-14	01/01/2015	Master Distribution Services Agreement Between AmerisourceBergen and Teva Pharmaceuticals USA, Inc.	TEVA_MDL_A_03451519	TEVA_MDL_A_03451565							
TE-15	05/01/2015	National Redistribution Center Agreement Between Teva Pharmaceuticals USA, Inc. and McKesson Corporation	TEVA_MDL_A_03462063	TEVA_MDL_A_03462079							
TE-16	12/15/2017	Generic Wholesale Service Agreement Between Cardinal Health and Teva Pharmaceuticals USA, Inc.	TEVA_MDL_A_03464455	TEVA_MDL_A_03464484							
TE-17	02/01/2017	Master Distribution Services Agreement Between AmerisourceBergen and Teva Pharmaceuticals USA, Inc.	TEVA_MDL_A_03464712	TEVA_MDL_A_03464770							
TE-18	12/13/2016	Quality Agreement Between Purdue Pharma L.P. and Teva Pharmaceuticals USA, Inc.	TEVA_MDL_A_04346745	TEVA_MDL_A_04346766							
TE-19	12/18/2014	Distribution and Supply Agreement By and Between Purdue Pharma L.P. and Teva Pharmaceuticals USA, INC.	TEVA_MDL_A_03434545	TEVA_MDL_A_03434611							
TE-20	08/02/2016	Teva Pharmaceutical Industries Ltd and Allergan PLC, Supply Agreement (Teva to Allergan)	TEVA_MDL_A_03504309	TEVA_MDL_A_03504368							
TE-21	02/02/2012	ACTIQ PI Plus Med Guide 25 1/2 x 22	TEVA_MDL_A_01155656	TEVA_MDL_A_01155657							
TE-22	02/02/2012	ACTIQ Medication Guide	TEVA_MDL_A_01155662	TEVA_MDL_A_01155666							
TE-23	02/16/2012	ACTIQ ISI with TIRF REMS	TEVA_MDL_A_01155705	TEVA_MDL_A_01155706							
TE-24	02/28/2012	ACTIQ PI Plus Med Guide 8 1/2 X 11	TEVA_MDL_A_01155753	TEVA_MDL_A_01155765							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-25	02/29/2012	ACTIQ.com Update	TEVA_MDL_A_01155780	TEVA_MDL_A_01155780							
TE-26	03/07/2012	Patient Child Safety Kit Request Form	TEVA_MDL_A_01155812	TEVA_MDL_A_01155812							
TE-27	03/07/2012	HCP Child Safety Kit Request Form	TEVA_MDL_A_01155817	TEVA_MDL_A_01155817							
TE-28	03/19/2012	Actiq.com Phase 2 Update	TEVA_MDL_A_01155825	TEVA_MDL_A_01155825							
TE-29	04/19/2012	Actiq.com Patient Child Safety Request Kit (English)	TEVA_MDL_A_01156006	TEVA_MDL_A_01156006							
TE-30	04/19/2012	Actiq.com HCP Child Safety Request Kit (English)	TEVA_MDL_A_01156007	TEVA_MDL_A_01156007							
TE-31	04/19/2012	Patient Child Safety Request Kit (Spanish)	TEVA_MDL_A_01156008	TEVA_MDL_A_01156008							
TE-32	04/19/2012	RTL-Actiq Conversions	TEVA_MDL_A_01156009	TEVA_MDL_A_01156011							
TE-33	Undated	Actiq (Fentanyl Citrate) Oral Transmucosal Lozenge, CII Standard Response Letters Index	TEVA_MDL_A_00705826	TEVA_MDL_A_00705826							
TE-34	Undated	ACT001 – General Information	TEVA_MDL_A_01086138	TEVA_MDL_A_01086149							
TE-35	Undated	ACT002 – Relative Analgesic Potency	TEVA_MDL_A_01086013	TEVA_MDL_A_01086015							
TE-36	Undated	ACT003 – Analgesic Effects Compared with Other Opioids	TEVA_MDL_A_01086154	TEVA_MDL_A_01086158							
TE-37	Undated	ACT004 – Onset and Duration of Analgesia	TEVA_MDL_A_01086159	TEVA_MDL_A_01086161							
TE-38	Undated	ACT006 – Differences Between ACTIQ and Fentanyl Oralet	TEVA_MDL_A_01086052	TEVA_MDL_A_01086052							
TE-39	Undated	ACT007 – Occurrence of Dental Caries	TEVA_MDL_A_01086162	TEVA_MDL_A_01086164							
TE-40	Undated	ACT008 – Use as Pre-Med or for Acute, Postoperative Pain	TEVA_MDL_A_00705126	TEVA_MDL_A_00705128							
TE-41	Undated	ACT009 – Use in Pediatric Patients	TEVA_MDL_A_01086165	TEVA_MDL_A_01086167							
TE-42	Undated	ACT010 – Occurrence of Mucositis/Stomatitis	TEVA_MDL_A_01085860	TEVA_MDL_A_01085864							
TE-43	Undated	ACT011 – Use for Management of Breakthrough Pain (Opioid-Tolerant/non-cancer)	TEVA_MDL_A_00705148	TEVA_MDL_A_00705151							
TE-44	Undated	ACT012 – Differences in the Amount of Fentanyl in ACTIQ vs. Transdermal Formulation (Duragesic)	TEVA_MDL_A_01085869	TEVA_MDL_A_01085871							
TE-45	Undated	ACT013 – Potential for Drug Abuse, Addiction and Diversion	TEVA_MDL_A_00705196	TEVA_MDL_A_00705200							
TE-46	Undated	ACT015 – Effect on Respiratory Function	TEVA_MDL_A_01086172	TEVA_MDL_A_01086176							
TE-47	Undated	ACT016 – Adverse Effect on Oral Mucosa	TEVA_MDL_A_01085872	TEVA_MDL_A_01085875							
TE-48	Undated	ACT018 – Drug Interaction Profile	TEVA_MDL_A_01086177	TEVA_MDL_A_01086180							
TE-49	Undated	ACT020 – Pharmacokinetic Profile of ACTIQ	TEVA_MDL_A_01086181	TEVA_MDL_A_01086186							
TE-50	Undated	ACT022 – Dosing and Administration	TEVA_MDL_A_01086187	TEVA_MDL_A_01086195							
TE-51	Undated	ACT023 – Overall Safety Profile	TEVA_MDL_A_01086196	TEVA_MDL_A_01086205							
TE-52	Undated	ACT026 – Use in the Treatment of Migraine Headache	TEVA_MDL_A_00705228	TEVA_MDL_A_00705229							
TE-53	Undated	ACT032 – Occurrence of Death	TEVA_MDL_A_00705240	TEVA_MDL_A_00705242							
TE-54	Undated	ACT033 – Occurrence of Accidental Exposure in Children	TEVA_MDL_A_01086211	TEVA_MDL_A_01086214							
TE-55	Undated	ACT039 – Efficacy Profile	TEVA_MDL_A_01086215	TEVA_MDL_A_01086221							
TE-56	Undated	ACT040 – Risk Evaluation and Mitigation Strategy (REMS)	TEVA_MDL_A_01086018	TEVA_MDL_A_01086019							
TE-57	03/10/2017	ACT-40027 ACTIQ Website Update (v2.0)	TEVA_MDL_A_01130696	TEVA_MDL_A_01130696							
TE-58	02/03/2017	ACT-40026 ACTIQ Promotional PI and Med Guide Update (v2.0)	TEVA_MDL_A_01130694	TEVA_MDL_A_01130695							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-59	01/12/2017	ACT-40025 ACTIQ Indication and ISI - Professional (v2.0)	TEVA_MDL_A_01130692	TEVA_MDL_A_01130693							
TE-60	02/16/2017	ACT-40024 ACTIQ Promotional Med Guide Update SPANISH DIGITAL (v2.0)	TEVA_MDL_A_01130687	TEVA_MDL_A_01130691							
TE-61	02/02/2017	ACT-40023 ACTIQ Promotional Med Guide Update DIGITAL (v2.0)	TEVA_MDL_A_01130683	TEVA_MDL_A_01130686							
TE-62	02/01/2017	ACT-40022 ACTIQ Promotional PI and Med Guide Update DIGITAL (v2.0)	TEVA_MDL_A_01130668	TEVA_MDL_A_01130682							
TE-63	02/02/2017	ACT-40021 ACTIQ Promotional Med Guide Update (v2.0)	TEVA_MDL_A_01130664	TEVA_MDL_A_01130667							
TE-64	01/20/2017	ACT-40020 ACTIQ Promotional PI and Med Guide Update (v1.0)	TEVA_MDL_A_01130662	TEVA_MDL_A_01130663							
TE-65	07/27/2016	ACT-40019 ACTIQ Website Update (v1.0)	TEVA_MDL_A_01130661	TEVA_MDL_A_01130661							
TE-66	11/04/2015	ACT-40017 Oral Transmucosal Fentanyl Citrate (OTFC) - Trade Journal Product Announcement Email (v1.0)	TEVA_MDL_A_01130659	TEVA_MDL_A_01130660							
TE-67	11/04/2015	ACT-40016 Oral Transmucosal Fentanyl Citrate - Homepage and New Teva Generic pages (v1.0)	TEVA_MDL_A_01130652	TEVA_MDL_A_01130658							
TE-68	11/04/2015	ACT-40015 Oral Transmucosal Fentanyl Citrate (OTFC) - Trade Pricing Email (v1.0)	TEVA_MDL_A_01130651	TEVA_MDL_A_01130651							
TE-69	11/04/2015	ACT-40014 Oral Transmucosal Fentanyl Citrate (OTFC) - Teva Dose Email (v1.0)	TEVA_MDL_A_01130649	TEVA_MDL_A_01130650							
TE-70	11/04/2015	ACT-40013 Oral Transmucosal Fentanyl Citrate (OTFC) - Pharmacist Corner Email (v1.0)	TEVA_MDL_A_01130647	TEVA_MDL_A_01130648							
TE-71	11/04/2015	ACT-40012 Oral Transmucosal Fentanyl Citrate (OTFC) - Trade Customer Email (v1.0)	TEVA_MDL_A_01130646	TEVA_MDL_A_01130646							
TE-72	11/04/2015	ACT-40011 Oral Transmucosal Fentanyl Citrate (OTFC) - Consumer Email (v1.0)	TEVA_MDL_A_01130641	TEVA_MDL_A_01130645							
TE-73	10/19/2015	ACT-40010 OTFC Healthcare Professional ISI (v1.0)	TEVA_MDL_A_01130639	TEVA_MDL_A_01130640							
TE-74	10/19/2015	ACT-40009 OTFC Consumer ISI (v1.0)	TEVA_MDL_A_01130636	TEVA_MDL_A_01130638							
TE-75	04/12/2013	ACT-40006 RE-APPROVAL: ACTIQ Med Guide [ACT-2024] (v2.0)	TEVA_MDL_A_01130631	TEVA_MDL_A_01130635							
TE-76	04/12/2013	ACT-40005 RE-APPROVAL: ACTIQ PI Plus Med Guide 25 1/2 x 22 [ACT-2023] (v2.0)	TEVA_MDL_A_01130629	TEVA_MDL_A_01130630							
TE-77	04/12/2013	ACT-40004 RE-APPROVAL Actiq.com Patient Child Safety Kit Request Form (Spanish) [ACT-2027c] (v2.0)	TEVA_MDL_A_01130628	TEVA_MDL_A_01130628							
TE-78	04/15/2013	ACT-40003 RE-APPROVAL HCP Child Safety Kit Request Form (English) (v1.0)	TEVA_MDL_A_01130627	TEVA_MDL_A_01130627							
TE-79	04/15/2013	ACT-40002 RE-APPROVAL Patient Child Safety Kit Request Form (English) [ACT-2027a] (v2.0)	TEVA_MDL_A_01130626	TEVA_MDL_A_01130626							
TE-80	04/15/2013	ACT-40001 RE-APPROVAL Actiq.com (v1.0)	TEVA_MDL_A_01130625	TEVA_MDL_A_01130625							
TE-81	11/01/2011	FENTORA REMS On-Demand Webcast Invitation (Print)	TEVA_MDL_A_01154978	TEVA_MDL_A_01154981							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-82	11/01/2011	FENTORA REMS On-Demand Webcast Invitation (Electronic)	TEVA_MDL_A_01154982	TEVA_MDL_A_01154986							
TE-83	11/01/2011	FENTORA REMS On-Demand Webcast Audio Recording	TEVA_MDL_A_01154987	TEVA_MDL_A_01155042							
TE-84	11/01/2011	FENTORA REMS On-Demand Webcast Registration Website	TEVA_MDL_A_01155043	TEVA_MDL_A_01155045							
TE-85	11/07/2011	FENTORA Prescription Savings Card	TEVA_MDL_A_01155046	TEVA_MDL_A_01155046							
TE-86	11/10/2011	REMS Transition Deck with Enrollment Link	TEVA_MDL_A_01155047	TEVA_MDL_A_01155118							
TE-87	11/17/2011	FENTORA Annotated PI	TEVA_MDL_A_01155119	TEVA_MDL_A_01155224							
TE-88	11/17/2011	Certification Exam: FENTORA Annotated PI	TEVA_MDL_A_01155225	TEVA_MDL_A_01155235							
TE-89	11/18/2011	Pharmacy REMS Letters: Envelope	TEVA_MDL_A_01155236	TEVA_MDL_A_01155236							
TE-90	11/20/2011	FENTORA Prescribing Information PHASE II Workshop Pre-Work	TEVA_MDL_A_01155237	TEVA_MDL_A_01155239							
TE-91	11/20/2011	FENTORA Prescribing Information PHASE II Workshop Handouts	TEVA_MDL_A_01155240	TEVA_MDL_A_01155268							
TE-92	11/20/2011	FENTORA Dosing and Administration PHASE II Workshop Pre-Work Worksheets	TEVA_MDL_A_01155269	TEVA_MDL_A_01155277							
TE-93	11/20/2011	FENTORA Dosing and Administration PHASE II Workshop Activity 2 Dosing and Administration Scenario Worksheets	TEVA_MDL_A_01155278	TEVA_MDL_A_01155281							
TE-94	11/20/2011	Certification Exam: Pharmacologic Treatment in the Current Marketplace	TEVA_MDL_A_01155282	TEVA_MDL_A_01155291							
TE-95	11/20/2011	Certification Exam: Pain Physiology, Assessment, and Management	TEVA_MDL_A_01155292	TEVA_MDL_A_01155301							
TE-96	11/21/2011	FENTORA Pain Evaluation and Diagnosis PII Workshop Patient Profile Management Worksheet	TEVA_MDL_A_01155302	TEVA_MDL_A_01155303							
TE-97	11/23/2011	FENTORARxSavings website landing pages	TEVA_MDL_A_01155304	TEVA_MDL_A_01155309							
TE-98	11/29/2011	Fentora Annotated PI Certification Exam	TEVA_MDL_A_01155310	TEVA_MDL_A_01155320							
TE-99	12/08/2011	CVA Update	TEVA_MDL_A_01155321	TEVA_MDL_A_01155334							
TE-100	12/15/2011	2011 Core Visual Aid (Re-approval 1)	TEVA_MDL_A_01155335	TEVA_MDL_A_01155342							
TE-101	12/19/2011	REMS PPAF Mgrs Meeting/Jan 2012 POA Facilitator Guide and Workshop	TEVA_MDL_A_01155343	TEVA_MDL_A_01155368							
TE-102	12/19/2011	"Creating Balance" - Promotional and REMS Activities - Managers Meeting/Jan 2012 POA FENTORA Facilitator Guide and Workshop	TEVA_MDL_A_01155369	TEVA_MDL_A_01155406							
TE-103	12/19/2011	REMS Enrollement Mgrs Meeting/JAN 2012 POA Facilitator Guide and Workshop	TEVA_MDL_A_01155407	TEVA_MDL_A_01155422							
TE-104	12/19/2011	REMS Pharmacy Managers Meeting/JAN 2012 POA Facilitator Guide and Workshop	TEVA_MDL_A_01155423	TEVA_MDL_A_01155448							
TE-105	01/05/2012	PPAF Leave Behind	TEVA_MDL_A_01155449	TEVA_MDL_A_01155454							
TE-106	01/06/2012	Dosing Leave Behind (Re-approval 1)	TEVA_MDL_A_01155455	TEVA_MDL_A_01155458							
TE-107	01/08/2012	Peer Feedback Form Worksheets for Fentora PPAF Workshop	TEVA_MDL_A_01155459	TEVA_MDL_A_01155460							
TE-108	01/08/2012	Rx Savings Card Workshop Worksheets	TEVA_MDL_A_01155461	TEVA_MDL_A_01155464							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-109	01/08/2012	Creating Balance Workshop Worksheets	TEVA_MDL_A_01155465	TEVA_MDL_A_01155466							
TE-110	01/12/2012	"Creating Balance" – Promotional and REMS Activities - JAN 2012 POA FENTORA Powerpoint slides	TEVA_MDL_A_01155467	TEVA_MDL_A_01155504							
TE-111	01/12/2012	"REMS Patient Prescriber Agreement Form Workshop" JAN 2012 POA Workshop Powerpoint Slides	TEVA_MDL_A_01155505	TEVA_MDL_A_01155524							
TE-112	01/12/2012	"REMS Pharmacy Workshop" JAN 2012 POA Powerpoint slides	TEVA_MDL_A_01155525	TEVA_MDL_A_01155552							
TE-113	01/12/2012	FENTORA Rx Savings Card - JAN 2012 POA Workshop Powerpoint slides	TEVA_MDL_A_01155564	TEVA_MDL_A_01155580							
TE-114	01/16/2012	Weinstein Reprint 2009 (Re-approval 1)	TEVA_MDL_A_01155581	TEVA_MDL_A_01155589							
TE-115	01/16/2012	Portenoy Reprint 2006 (Re-approval 1)	TEVA_MDL_A_01155590	TEVA_MDL_A_01155596							
TE-116	01/16/2012	Darwish Reprint 2006 (Re-approval 1)	TEVA_MDL_A_01155597	TEVA_MDL_A_01155607							
TE-117	01/16/2012	OraVescent Technology PPT (Re-approval 1)	TEVA_MDL_A_01155608	TEVA_MDL_A_01155615							
TE-118	01/16/2012	Darwish Reprint 2007 (Re-approval 1)	TEVA_MDL_A_01155616	TEVA_MDL_A_01155625							
TE-119	01/16/2012	Darwish Reprint 2006 (Re-approval 1)	TEVA_MDL_A_01155626	TEVA_MDL_A_01155633							
TE-120	01/16/2012	Rep Triggered Envelope (Re-approval 1)	TEVA_MDL_A_01155634	TEVA_MDL_A_01155634							
TE-121	01/18/2012	WIP Table Display	TEVA_MDL_A_01155651	TEVA_MDL_A_01155651							
TE-122	02/02/2012	FENTORA PI Plus Med Guide 25 1/2 x 22	TEVA_MDL_A_01155654	TEVA_MDL_A_01155655							
TE-123	02/02/2012	FENTORA Medication Guide	TEVA_MDL_A_01155658	TEVA_MDL_A_01155661							
TE-124	02/03/2012	BTP Speaker Program Invite	TEVA_MDL_A_01155667	TEVA_MDL_A_01155669							
TE-125	02/06/2012	FENTORA TIRF ISI	TEVA_MDL_A_01155670	TEVA_MDL_A_01155671							
TE-126	02/09/2012	ACTIQ and FENTORA Combined TIRF ISI	TEVA_MDL_A_01155672	TEVA_MDL_A_01155675							
TE-127	02/13/2012	FENTORA NFM Facilitator Guide	TEVA_MDL_A_01155676	TEVA_MDL_A_01155696							
TE-128	02/13/2012	FENTORA NFM Handout 1	TEVA_MDL_A_01155697	TEVA_MDL_A_01155697							
TE-129	02/13/2012	FENTORA NFM Handout 2	TEVA_MDL_A_01155698	TEVA_MDL_A_01155698							
TE-130	02/15/2012	Training Guide – Dosing Leave-Behind (Re-approval 1)	TEVA_MDL_A_01155699	TEVA_MDL_A_01155701							
TE-131	02/16/2012	REMS Speaker Program Invite	TEVA_MDL_A_01155702	TEVA_MDL_A_01155704							
TE-132	02/23/2012	Fentora.com Update	TEVA_MDL_A_01155708	TEVA_MDL_A_01155708							
TE-133	02/23/2012	Rx Savings Card	TEVA_MDL_A_01155709	TEVA_MDL_A_01155710							
TE-134	02/23/2012	Rx Savings Brochure	TEVA_MDL_A_01155711	TEVA_MDL_A_01155717							
TE-135	02/23/2012	65 & Over Program Letter and Certification	TEVA_MDL_A_01155718	TEVA_MDL_A_01155727							
TE-136	02/23/2012	Prescription Savings Program Envelope	TEVA_MDL_A_01155728	TEVA_MDL_A_01155728							
TE-137	02/23/2012	BTP Speaker Program Invite Update	TEVA_MDL_A_01155729	TEVA_MDL_A_01155731							
TE-138	02/23/2012	REMS Speaker Program Invite Update	TEVA_MDL_A_01155732	TEVA_MDL_A_01155734							
TE-139	02/28/2012	FENTORA PI Plus Med Guide 8 1/2 x 11	TEVA_MDL_A_01155741	TEVA_MDL_A_01155752							
TE-140	02/28/2012	Efficacy Leave Behind Update	TEVA_MDL_A_01155766	TEVA_MDL_A_01155769							
TE-141	02/28/2012	Dosing Leave Behind	TEVA_MDL_A_01155770	TEVA_MDL_A_01155771							
TE-142	03/01/2012	Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate Training Guide	TEVA_MDL_A_01155781	TEVA_MDL_A_01155783							
TE-143	03/01/2012	FENTORA FAQ and Responses	TEVA_MDL_A_01155784	TEVA_MDL_A_01155795							
TE-144	03/07/2012	Rx Savings Rep Triggered Mailer	TEVA_MDL_A_01155818	TEVA_MDL_A_01155820							
TE-145	03/14/2012	Rx Savings Brochure Envelope	TEVA_MDL_A_01155821	TEVA_MDL_A_01155821							
TE-146	03/14/2012	Fentora Patient ISI	TEVA_MDL_A_01155822	TEVA_MDL_A_01155824							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-147	03/21/2012	Rx Savings Brochure Holder	TEVA_MDL_A_01155838	TEVA_MDL_A_01155838							
TE-148	03/26/2012	RX Savings Card Training Guide	TEVA_MDL_A_01155839	TEVA_MDL_A_01155841							
TE-149	03/27/2012	Efficacy Leave Behind Training Guide	TEVA_MDL_A_01155843	TEVA_MDL_A_01155845							
TE-150	03/27/2012	Touch Screen Panels	TEVA_MDL_A_01155874	TEVA_MDL_A_01155891							
TE-151	03/29/2012	FENTORA Convention Fabric Ring (Re-approval 1)	TEVA_MDL_A_01155901	TEVA_MDL_A_01155901							
TE-152	03/29/2012	Fentora Q&A	TEVA_MDL_A_01155904	TEVA_MDL_A_01155910							
TE-153	04/02/2012	FENTORA Placebo (Re-approval 1)	TEVA_MDL_A_01155911	TEVA_MDL_A_01155915							
TE-154	04/03/2012	Fentora.com Phase 2 (HCP)	TEVA_MDL_A_01155916	TEVA_MDL_A_01155921							
TE-155	04/03/2012	Fentora.com Phase 2 (Patient)	TEVA_MDL_A_01155922	TEVA_MDL_A_01155928							
TE-156	04/05/2012	Lead Retrieval System	TEVA_MDL_A_01155929	TEVA_MDL_A_01155929							
TE-157	04/06/2012	FENTORA Annotated CVA	TEVA_MDL_A_01155930	TEVA_MDL_A_01155961							
TE-158	04/09/2012	Fentora ISI Panel	TEVA_MDL_A_01155964	TEVA_MDL_A_01155964							
TE-159	04/12/2012	Portenoy Reprint Carrier	TEVA_MDL_A_01155965	TEVA_MDL_A_01155972							
TE-160	04/12/2012	Weinstein Reprint Carrier	TEVA_MDL_A_01155973	TEVA_MDL_A_01155980							
TE-161	04/12/2012	Rx Savings Program Web Voucher	TEVA_MDL_A_01155981	TEVA_MDL_A_01155983							
TE-162	04/18/2012	HCP Brochure Update	TEVA_MDL_A_01155986	TEVA_MDL_A_01156003							
TE-163	04/18/2012	Hotline Card Update	TEVA_MDL_A_01156004	TEVA_MDL_A_01156005							
TE-164	04/23/2012	PCS ITC Pre-Exam	TEVA_MDL_A_01156012	TEVA_MDL_A_01156026							
TE-165	04/23/2012	Ready for the FENTORA Marketplace Workshop	TEVA_MDL_A_01156027	TEVA_MDL_A_01156054							
TE-166	04/24/2012	Frequently Asked Questions and Responses Workshop	TEVA_MDL_A_01156074	TEVA_MDL_A_01156089							
TE-167	04/24/2012	Case-Based Promotional Slide Deck	TEVA_MDL_A_01156090	TEVA_MDL_A_01156152							
TE-168	04/26/2012	FENTORA Annotated PI - December 2011 Update	TEVA_MDL_A_01156153	TEVA_MDL_A_01156268							
TE-169	04/26/2012	Fentora DSA (July Pilot)	TEVA_MDL_A_01156269	TEVA_MDL_A_01156300							
TE-170	04/26/2012	FentoraSavings.com	TEVA_MDL_A_01156301	TEVA_MDL_A_01156301							
TE-171	04/27/2012	Fentora Dosing DSA (July Pilot)	TEVA_MDL_A_01156302	TEVA_MDL_A_01156338							
TE-172	05/07/2012	PI Workshop for ITC	TEVA_MDL_A_01156339	TEVA_MDL_A_01156383							
TE-173	05/07/2012	ITC FENTORA PI Workshop Class Assignment Sheet	TEVA_MDL_A_01156384	TEVA_MDL_A_01156386							
TE-174	05/07/2012	FENTORA PI ITC Workshop - Master Activity Worksheet	TEVA_MDL_A_01156387	TEVA_MDL_A_01156417							
TE-175	05/10/2012	Clinical Papers Workshop	TEVA_MDL_A_01156423	TEVA_MDL_A_01156455							
TE-176	05/10/2012	Clinical Papers Workshop: Participant's Guide	TEVA_MDL_A_01156456	TEVA_MDL_A_01156482							
TE-177	05/10/2012	FENTORA Pain Marketplac Workshop Facilitator's Guide	TEVA_MDL_A_01156483	TEVA_MDL_A_01156501							
TE-178	05/17/2012	Pain Marketplace Activity 1 Workmat	TEVA_MDL_A_01156502	TEVA_MDL_A_01156503							
TE-179	05/17/2012	Pain Marketplace Activity 2 Workmat	TEVA_MDL_A_01156504	TEVA_MDL_A_01156507							
TE-180	05/22/2012	ISI Panel Update	TEVA_MDL_A_01156517	TEVA_MDL_A_01156519							
TE-181	06/15/2012	Patient ISI Update	TEVA_MDL_A_01156520	TEVA_MDL_A_01156522							
TE-182	06/20/2012	Fentora.com Metadata	TEVA_MDL_A_01156523	TEVA_MDL_A_01156523							
TE-183	06/22/2012	Portenoy Annotated Clinical Reprint	TEVA_MDL_A_01156524	TEVA_MDL_A_01156535							
TE-184	06/22/2012	Weinstein Annotated Clinical Reprint	TEVA_MDL_A_01156536	TEVA_MDL_A_01156549							
TE-185	06/29/2012	iPad Launch Workshop 2	TEVA_MDL_A_01156550	TEVA_MDL_A_01156570							
TE-186	06/29/2012	iPad Launch Workshop 3	TEVA_MDL_A_01156571	TEVA_MDL_A_01156592							
TE-187	06/29/2012	iPad Launch Workshop 4	TEVA_MDL_A_01156593	TEVA_MDL_A_01156619							
TE-188	06/29/2012	iPad Launch Workshop 8	TEVA_MDL_A_01156620	TEVA_MDL_A_01156639							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-189	07/02/2012	July iPad Pilot Training Guide	TEVA_MDL_A_01156653	TEVA_MDL_A_01156667							
TE-190	07/16/2012	Fentora October DSA	TEVA_MDL_A_01156704	TEVA_MDL_A_01156788							
TE-191	08/08/2012	PCS 2012 Semester 2 MBO Assessment	TEVA_MDL_A_01156825	TEVA_MDL_A_01156826							
TE-192	08/13/2012	CVA Update	TEVA_MDL_A_01156828	TEVA_MDL_A_01156844							
TE-193	08/13/2012	Slim Jim Update	TEVA_MDL_A_01156845	TEVA_MDL_A_01156870							
TE-194	08/13/2012	Efficacy Leave Behind Update	TEVA_MDL_A_01156871	TEVA_MDL_A_01156872							
TE-195	08/13/2012	Dosing Leave Behind Update	TEVA_MDL_A_01156873	TEVA_MDL_A_01156874							
TE-196	08/14/2012	Brief Summary	TEVA_MDL_A_01156880	TEVA_MDL_A_01156882							
TE-197	08/22/2012	Hotline Form Update	TEVA_MDL_A_01156888	TEVA_MDL_A_01156889							
TE-198	08/22/2012	Breakthrough Pain Speaker Program Invite Template	TEVA_MDL_A_01156890	TEVA_MDL_A_01156892							
TE-199	08/27/2012	iPad Launch Workshop 2	TEVA_MDL_A_01156893	TEVA_MDL_A_01156912							
TE-200	08/27/2012	iPad Launch Workshop 3	TEVA_MDL_A_01156913	TEVA_MDL_A_01156936							
TE-201	08/27/2012	iPad Launch Workshop 4	TEVA_MDL_A_01156937	TEVA_MDL_A_01156961							
TE-202	08/27/2012	iPad Launch Workshop 8	TEVA_MDL_A_01156962	TEVA_MDL_A_01156981							
TE-203	08/27/2012	iPad Launch Workshop 9	TEVA_MDL_A_01156982	TEVA_MDL_A_01157000							
TE-204	08/29/2012	Rep Triggered Email Weinstein	TEVA_MDL_A_01157001	TEVA_MDL_A_01157001							
TE-205	08/29/2012	Rep Triggered Email Portenoy	TEVA_MDL_A_01157002	TEVA_MDL_A_01157002							
TE-206	09/07/2012	Fentora User Guide October	TEVA_MDL_A_01157033	TEVA_MDL_A_01157059							
TE-207	09/18/2012	Fentora Fingertip Formulary for iPad	TEVA_MDL_A_01157066	TEVA_MDL_A_01157070							
TE-208	09/26/2012	BTP Speaker Program Invite Template Refresh	TEVA_MDL_A_01157071	TEVA_MDL_A_01157072							
TE-209	09/27/2012	Rx Savings Brochure Refresh	TEVA_MDL_A_01157073	TEVA_MDL_A_01157078							
TE-210	09/27/2012	Updated Brochure Holder with Clear Front	TEVA_MDL_A_01157079	TEVA_MDL_A_01157080							
TE-211	09/27/2012	BTP Speaker Program Invite Envelope	TEVA_MDL_A_01157081	TEVA_MDL_A_01157081							
TE-212	10/02/2012	PPLS Update: Marketplace Module	TEVA_MDL_A_01157085	TEVA_MDL_A_01157158							
TE-213	10/02/2012	PPLS Update: Disease State	TEVA_MDL_A_01157159	TEVA_MDL_A_01157238							
TE-214	10/16/2012	FENTORA abbreviated case-based promotional slide deck	TEVA_MDL_A_01157247	TEVA_MDL_A_01157289							
TE-215	10/18/2012	Field Forum Newsletter-First Issue	TEVA_MDL_A_01157290	TEVA_MDL_A_01157292							
TE-216	11/09/2012	Introduction e-mail for newsletter	TEVA_MDL_A_01157330	TEVA_MDL_A_01157330							
TE-217	11/13/2012	PCS ITC FENTORA Exam	TEVA_MDL_A_01157331	TEVA_MDL_A_01157341							
TE-218	11/14/2012	Initial Training Class PCS Dosing Workshop	TEVA_MDL_A_01157342	TEVA_MDL_A_01157367							
TE-219	11/15/2012	Fentora eNewsletter 1	TEVA_MDL_A_01157368	TEVA_MDL_A_01157368							
TE-220	11/19/2012	Rx Savings Card	TEVA_MDL_A_01157369	TEVA_MDL_A_01157369							
TE-221	11/26/2012	Pain Physiology, Assessment and Management Workshop	TEVA_MDL_A_01157370	TEVA_MDL_A_01157393							
TE-222	12/11/2012	Table Top Panels Refresh	TEVA_MDL_A_01157471	TEVA_MDL_A_01157474							
TE-223	12/11/2012	Webkey Splash Page	TEVA_MDL_A_01157489	TEVA_MDL_A_01157489							
TE-224	12/13/2012	Table Cloth for Table Top Display	TEVA_MDL_A_01157490	TEVA_MDL_A_01157490							
TE-225	01/03/2013	Fentora DSA Update	TEVA_MDL_A_01157491	TEVA_MDL_A_01157575							
TE-226	01/08/2013	Rx Savings RTM	TEVA_MDL_A_01157578	TEVA_MDL_A_01157580							
TE-227	01/08/2013	RTM Envelope	TEVA_MDL_A_01157581	TEVA_MDL_A_01157581							
TE-228	01/08/2013	Clinical Data RTM	TEVA_MDL_A_01157582	TEVA_MDL_A_01157584							
TE-229	01/09/2013	Managed Care Module 2 - FENTORA	TEVA_MDL_A_01157585	TEVA_MDL_A_01157602							
TE-230	01/11/2013	Touchscreen Convention Panels	TEVA_MDL_A_01157649	TEVA_MDL_A_01157696							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-231	01/11/2013	Convention ISI Panel	TEVA_MDL_A_01157697	TEVA_MDL_A_01157697							
TE-232	01/11/2013	Webkey RTM	TEVA_MDL_A_01157700	TEVA_MDL_A_01157702							
TE-233	01/11/2013	Webkey Card	TEVA_MDL_A_01157703	TEVA_MDL_A_01157703							
TE-234	02/11/2013	FENTORA iDetail Digital Sales Aid - February 2013	TEVA_MDL_A_01157785	TEVA_MDL_A_01157875							
TE-235	02/14/2013	Fentora NFM Poster	TEVA_MDL_A_01157876	TEVA_MDL_A_01157876							
TE-236	02/21/2013	Fentora Copay Coupon	TEVA_MDL_A_01157878	TEVA_MDL_A_01157880							
TE-237	02/22/2013	FENTORA PI Plus Med Guide 25 1/2 x 22 (Re-approval 1)	TEVA_MDL_A_01157881	TEVA_MDL_A_01157882							
TE-238	05/03/2013	FEN-40043 FAQ and Responses (v1.0)	TEVA_MDL_A_01131144	TEVA_MDL_A_01131156							
TE-239	09/27/2013	FEN-40084 Fentora eNewsletter 3 (v1.0)	TEVA_MDL_A_01131520	TEVA_MDL_A_01131524							
TE-240	10/02/2013	FEN-40095 REAPPROVAL Fentora Slim Jim (v1.0)	TEVA_MDL_A_01131636	TEVA_MDL_A_01131661							
TE-241	03/12/2015	FEN-40264 2015 FENTORA Convention Touchscreen Plasma Panel (v1.0)	TEVA_MDL_A_01133682	TEVA_MDL_A_01133746							
TE-242	12/22/2015	FEN-40346 Guide to FENTORA Messaging (v1.0)	TEVA_MDL_A_01134573	TEVA_MDL_A_01134582							
TE-243	01/01/2013	FENTORA Prescription Savings Card Brochure (2013)	TEVA_MDL_A_01131171	TEVA_MDL_A_01131188							
TE-244	Undated	Fentora (Fentanyl Buccal Tablet) Standard Response Letter Index	TEVA_MDL_A_00706096	TEVA_MDL_A_00706097							
TE-245	Undated	FEN002 – General Information	TEVA_MDL_A_01085242	TEVA_MDL_A_01085255							
TE-246	Undated	FEN003 – Pharmacokinetic (PK) Profile of Fentanyl	TEVA_MDL_A_00704432	TEVA_MDL_A_00704439							
TE-247	Undated	FEN004 – Clinical Data Comparing FENTORA to OTFC	TEVA_MDL_A_00704440	TEVA_MDL_A_00704445							
TE-248	Undated	FEN006 – Analgesic Potency Relative to that of Other Opioid Medications	TEVA_MDL_A_00704446	TEVA_MDL_A_00704450							
TE-249	05/03/2011	FEN008 – Overall Efficacy	TEVA_MDL_A_00705333	TEVA_MDL_A_00705337							
TE-250	02/04/2014	FEN009 – Safety Profile	TEVA_MDL_A_00704700	TEVA_MDL_A_00704712							
TE-251	02/04/2014	FEN010 – Drug Interaction Profile	TEVA_MDL_A_00704475	TEVA_MDL_A_00704477							
TE-252	02/04/2014	FEN011 – Dosing and Administration	TEVA_MDL_A_00704713	TEVA_MDL_A_00704718							
TE-253	08/22/2011	FEN012 – Potential for Drug Abuse, Addiction and Diversion	TEVA_MDL_A_00705427	TEVA_MDL_A_00705432							
TE-254	02/04/2014	FEN013 – Use in Patients with Mucositis (Stomatitis)	TEVA_MDL_A_01085314	TEVA_MDL_A_01085316							
TE-255	02/04/2014	FEN014 – Use for Management of BTP in Opioid-Tolerant Patients with Chronic Noncancer Pain conditions	TEVA_MDL_A_00704493	TEVA_MDL_A_00704501							
TE-256	02/04/2014	FEN016 – Use in Pediatric Patients	TEVA_MDL_A_00704727	TEVA_MDL_A_00704728							
TE-257	02/04/2014	FEN019 – Use in Elderly Patients	TEVA_MDL_A_00704729	TEVA_MDL_A_00704730							
TE-258	02/04/2014	FEN021 – Effect on Respiratory Function	TEVA_MDL_A_00704519	TEVA_MDL_A_00704522							
TE-259	08/22/2011	FEN022 – Use as a Premedication or for the Management of Acute or Postoperative Pain in Adults	TEVA_MDL_A_00705460	TEVA_MDL_A_00705461							
TE-260	02/04/2014	FEN025 – Application Site Reactions in the Oral Mucosa	TEVA_MDL_A_00704735	TEVA_MDL_A_00704737							
TE-261	09/06/2011	FEN027 – Use for the Management of BTP in Opioid-Tolerant Patients with Chronic Lower Back Pain	TEVA_MDL_A_00705556	TEVA_MDL_A_00705563							
TE-262	09/06/2011	FEN028 – Use for the Management of BTP in Opioid-Tolerant Patients with Chronic Neuropathic Pain	TEVA_MDL_A_00705657	TEVA_MDL_A_00705664							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-263	11/04/2010	FEN029 – Occurrence of Death	TEVA_MDL_A_00705681	TEVA_MDL_A_00705683							
TE-264	02/04/2014	FEN033 – Risk Evaluation and Mitigation Strategy (REMS)	TEVA_MDL_A_00704757	TEVA_MDL_A_00704758							
TE-265	02/06/2014	FEN035 – Analgesic Effects Compared to Other Opioids for the Management of Breakthrough Pain in Opioid Tolerant Patients	TEVA_MDL_A_00704560	TEVA_MDL_A_00704569							
TE-266	02/06/2014	FEN0036 – Occurrence of Dental Disorders Coincident with Use of FENTORA	TEVA_MDL_A_00704581	TEVA_MDL_A_00704583							
TE-267	03/29/2018	FEN-40550 Fentora Website Update (v1.0)	TEVA_MDL_A_01136137	TEVA_MDL_A_01136139							
TE-268	01/04/2018	FEN-40549 FENTORA Savings Offer Brochure 2018 (v1.0)	TEVA_MDL_A_01136133	TEVA_MDL_A_01136136							
TE-269	05/18/2017	FEN-40539 - Fentora PI Certification Exam (v1.0)	TEVA_MDL_A_01136101	TEVA_MDL_A_01136113							
TE-270	05/19/2017	FEN-40538 - Fentora PPLS Marketplace Certification Exam (v1.0)	TEVA_MDL_A_01136093	TEVA_MDL_A_01136100							
TE-271	05/26/2017	FEN-40537 - Fentora Pain Product Learning System - Marketplace Module (v1.0)	TEVA_MDL_A_01136028	TEVA_MDL_A_01136092							
TE-272	05/18/2017	FEN-40536 - Fentora PPLS Disease State Certification Exam (v1.0)	TEVA_MDL_A_01136020	TEVA_MDL_A_01136027							
TE-273	05/18/2017	FEN-40535 - Fentora PPLS Disease State Module (v1.0)	TEVA_MDL_A_01135946	TEVA_MDL_A_01136019							
TE-274	05/11/2017	FEN-40534 - FENTORA Pharmacy Leave Behind Instructions for Use Email (v1.0)	TEVA_MDL_A_01135945	TEVA_MDL_A_01135945							
TE-275	04/24/2017	FEN-40522 FENTORA 2017 Patient Brochure (Print) (v1.0)	TEVA_MDL_A_01135921	TEVA_MDL_A_01135930							
TE-276	03/09/2017	FEN-40518 FENTORA HCP Splash Page (v1.0)	TEVA_MDL_A_01135906	TEVA_MDL_A_01135914							
TE-277	03/09/2017	FEN-40517 FENTORA Splash Page: Patient Website (v1.0)	TEVA_MDL_A_01135897	TEVA_MDL_A_01135905							
TE-278	04/07/2017	FEN-40516 FENTORA C.A.R.E. Team Direct Mailer (v1.0)	TEVA_MDL_A_01135895	TEVA_MDL_A_01135896							
TE-279	03/06/2017	FEN-40515 FENTORA 2017 Patient Brochure (Electronic) (v1.0)	TEVA_MDL_A_01135863	TEVA_MDL_A_01135894							
TE-280	04/07/2017	FEN-40514 FENTORA Taking Your Medication Brochure Update (v1.0)	TEVA_MDL_A_01135855	TEVA_MDL_A_01135862							
TE-281	04/24/2017	FEN-40512 FENTORA Patient Brochure Holder Update (v1.0)	TEVA_MDL_A_01135840	TEVA_MDL_A_01135843							
TE-282	02/21/2017	FEN-40509 FENTORA PI Update Email (ISR) (v1.0)	TEVA_MDL_A_01135839	TEVA_MDL_A_01135839							
TE-283	03/06/2017	FEN-40505 Managing Breakthrough Pain in Patients with Cancer (v1.0)	TEVA_MDL_A_01135783	TEVA_MDL_A_01135838							
TE-284	05/17/2017	FEN-40501 FENTORA Rep Pharmacy Leave Behind (v1.0)	TEVA_MDL_A_01135781	TEVA_MDL_A_01135782							
TE-285	03/06/2017	FEN-40498 FENTORA Downloadable Patient Materials (v1.0)	TEVA_MDL_A_01135743	TEVA_MDL_A_01135780							
TE-286	03/07/2017	FEN-40483 FENTORA Reimbursement Assistance Patient Consent Form (v1.0)	TEVA_MDL_A_01135680	TEVA_MDL_A_01135695							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-287	03/16/2017	FEN-40482 FENTORA C.A.R.E. Team Leave-Behind Update (v1.0)	TEVA_MDL_A_01135678	TEVA_MDL_A_01135679							
TE-288	03/30/2017	FEN-40481 FENTORA Sublingual Leave Behind (v1.0)	TEVA_MDL_A_01135675	TEVA_MDL_A_01135677							
TE-289	03/28/2017	FEN-40480 Fentora Dosing Leave Behind (v1.0)	TEVA_MDL_A_01135672	TEVA_MDL_A_01135674							
TE-290	03/30/2017	FEN-40479 FENTORA Patient Profile Detail Piece / Leave Behind (v1.0)	TEVA_MDL_A_01135667	TEVA_MDL_A_01135671							
TE-291	03/17/2017	FEN-40476 FENTORA Savings Offer Brochure 2017 Update (v1.0)	TEVA_MDL_A_01135665	TEVA_MDL_A_01135666							
TE-292	03/21/2017	FEN-40474 FENTORA C.A.R.E. Team Rep Triggered Letter Update (v1.0)	TEVA_MDL_A_01135662	TEVA_MDL_A_01135664							
TE-293	03/21/2017	FEN-40473 FENTORA Dosing and Administration Rep Triggered Letter Update (v1.0)	TEVA_MDL_A_01135659	TEVA_MDL_A_01135661							
TE-294	03/21/2017	FEN-40472 FENTORA Clinical Trial Rep Triggered Letter Update (v1.0)	TEVA_MDL_A_01135655	TEVA_MDL_A_01135658							
TE-295	03/17/2017	FEN-40470 FENTORA Slim Jim Update (v1.0)	TEVA_MDL_A_01135625	TEVA_MDL_A_01135654							
TE-296	02/01/2017	FEN-40469 Fentora PI (FENT-009 12/2016) PRINT (v2.0)	TEVA_MDL_A_01135623	TEVA_MDL_A_01135624							
TE-297	01/31/2017	FEN-40468 Fentora Medication Guide (FENTMG-008 12/2016) DIGITAL (v2.0)	TEVA_MDL_A_01135620	TEVA_MDL_A_01135622							
TE-298	01/31/2017	FEN-40467 Fentora Medication Guide (FENTMG-008 12/2016) PRINT (v2.0)	TEVA_MDL_A_01135617	TEVA_MDL_A_01135619							
TE-299	01/12/2017	FEN-40466 FENTORA ISI - Consumer (v2.0)	TEVA_MDL_A_01135614	TEVA_MDL_A_01135616							
TE-300	01/12/2017	FEN-40465 FENTORA Indication and ISI - Professional (v2.0)	TEVA_MDL_A_01135611	TEVA_MDL_A_01135613							
TE-301	01/30/2017	FEN-40464 Fentora PI (FENT-009 12/2016) DIGITAL (v2.0)	TEVA_MDL_A_01135597	TEVA_MDL_A_01135610							
TE-302	01/19/2017	FEN-40463 Fentora Promotional PI Update PRINT (v1.0)	TEVA_MDL_A_01135595	TEVA_MDL_A_01135596							
TE-303	04/13/2017	FEN-40461 FENTORA 2017 LIS Leave Behind Update (v1.0)	TEVA_MDL_A_01135592	TEVA_MDL_A_01135594							
TE-304	03/21/2017	FEN-40458 FENTORA Patient Website Update [Desktop] (v1.0)	TEVA_MDL_A_01135536	TEVA_MDL_A_01135591							
TE-305	03/22/2017	FEN-40457 FENTORA HCP Website Update [Desktop] (v1.0)	TEVA_MDL_A_01135427	TEVA_MDL_A_01135535							
TE-306	11/22/2016	FEN-40455 FENTORA ISI - Consumer (v1.0)	TEVA_MDL_A_01135424	TEVA_MDL_A_01135426							
TE-307	03/09/2017	FEN-40453 FENTORA Branded DSA 2017 Update (v1.0)	TEVA_MDL_A_01135322	TEVA_MDL_A_01135405							
TE-308	11/15/2016	FEN-40450 FENTORA C.A.R.E. Team Rep Triggered Letter Update (v1.0)	TEVA_MDL_A_01135319	TEVA_MDL_A_01135321							
TE-309	11/15/2016	FEN-40448 FENTORA Savings Offer Brochure 2017 (v1.0)	TEVA_MDL_A_01135302	TEVA_MDL_A_01135303							
TE-310	10/21/2016	FEN-40443 FENTORA C.A.R.E. Team Rep Triggered Letter (v1.0)	TEVA_MDL_A_01135279	TEVA_MDL_A_01135281							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-311	10/21/2016	FEN-40442 FENTORA Dosing and Administration Rep Triggered Letter (v1.0)	TEVA_MDL_A_01135276	TEVA_MDL_A_01135278							
TE-312	10/21/2016	FEN-40441 FENTORA Clinical Trial Rep Triggered Letter (v1.0)	TEVA_MDL_A_01135272	TEVA_MDL_A_01135275							
TE-313	10/17/2016	FEN-40440 FENTORA Direct Mail Newsletter 5 (v1.0)	TEVA_MDL_A_01135270	TEVA_MDL_A_01135271							
TE-314	10/17/2016	FEN-40439 FENTORA eNewsletter 5 [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135268	TEVA_MDL_A_01135269							
TE-315	11/14/2016	FEN-40436 FENTORA Savings & Support Email [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135265	TEVA_MDL_A_01135267							
TE-316	12/07/2016	FEN-40435 FENTORA Savings and Support Direct Mailer (v1.0)	TEVA_MDL_A_01135263	TEVA_MDL_A_01135264							
TE-317	09/12/2016	FEN-40431 FENTORA MedAlert 4 Email [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135250	TEVA_MDL_A_01135251							
TE-318	09/12/2016	FEN-40429 FENTORA Direct Mail Newsletter 4 (v1.0)	TEVA_MDL_A_01135246	TEVA_MDL_A_01135249							
TE-319	09/12/2016	FEN-40428 FENTORA eNewsletter 4 [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135238	TEVA_MDL_A_01135245							
TE-320	08/12/2016	FEN-40427 FENTORA Pharmacokinetics Direct Mailer (v1.0)	TEVA_MDL_A_01135234	TEVA_MDL_A_01135237							
TE-321	08/10/2016	FEN-40426 FENTORA Direct Mail Newsletter 3 (v1.0)	TEVA_MDL_A_01135230	TEVA_MDL_A_01135233							
TE-322	07/28/2016	FEN-40425 FENTORA Patient Profile 2 Direct Mailer (v1.0)	TEVA_MDL_A_01135226	TEVA_MDL_A_01135229							
TE-323	09/01/2016	FEN-40424 FENTORA eNewsletter 3 [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135224	TEVA_MDL_A_01135225							
TE-324	08/03/2016	FEN-40423 FENTORA Sublingual Leave Behind (v1.0)	TEVA_MDL_A_01135222	TEVA_MDL_A_01135223							
TE-325	08/18/2016	FEN-40422 FENTORA MedAlert 3 Email [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135218	TEVA_MDL_A_01135221							
TE-326	09/07/2016	FEN-40421 FENTORA Coverage Email [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135215	TEVA_MDL_A_01135217							
TE-327	06/30/2016	FEN-40420 FENTORA Patient Profile Direct Mailer (v1.0)	TEVA_MDL_A_01135211	TEVA_MDL_A_01135214							
TE-328	06/30/2016	FEN-40419 FENTORA Coverage Direct Mailer (v1.0)	TEVA_MDL_A_01135209	TEVA_MDL_A_01135210							
TE-329	07/08/2016	FEN-40414 FENTORA Direct Mail Newsletter 2 (v1.0)	TEVA_MDL_A_01135201	TEVA_MDL_A_01135202							
TE-330	06/30/2016	FEN-40413 FENTORA eNewsletter 2 [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135199	TEVA_MDL_A_01135200							
TE-331	06/03/2016	FEN-40409 - FENTORA Access Advisor Web PDF (v1.0)	TEVA_MDL_A_01135176	TEVA_MDL_A_01135195							
TE-332	07/08/2016	FEN-40408 FENTORA Reimbursement Folder (v1.0)	TEVA_MDL_A_01135174	TEVA_MDL_A_01135175							
TE-333	09/01/2016	FEN-40407 FENTORA Branded Email Invitation [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135172	TEVA_MDL_A_01135173							
TE-334	09/07/2016	FEN-40402 FENTORA QuantiaMD Interactive Presentation (v1.0)	TEVA_MDL_A_01135055	TEVA_MDL_A_01135164							
TE-335	07/21/2016	FEN-40400 FENTORA MedAlert 1 Email [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01135053	TEVA_MDL_A_01135054							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-336	06/28/2016	FEN-40398 FENTORA Access Advisor Email 5 [Desktop & Mobile] (v1.0)	TEVA_MDL_A_01135051	TEVA_MDL_A_01135052							
TE-337	06/28/2016	FEN-40397 FENTORA Access Advisor Email 4 [Desktop & Mobile] (v1.0)	TEVA_MDL_A_01135049	TEVA_MDL_A_01135050							
TE-338	06/28/2016	FEN-40396 FENTORA Access Advisor Email 3 [Desktop & Mobile] (v1.0)	TEVA_MDL_A_01135047	TEVA_MDL_A_01135048							
TE-339	06/28/2016	FEN-40395 FENTORA Access Advisor Email 2 [Desktop & Mobile] (v1.0)	TEVA_MDL_A_01135045	TEVA_MDL_A_01135046							
TE-340	06/28/2016	FEN-40394 FENTORA Access Advisor Email 1 [Desktop & Mobile] (v1.0)	TEVA_MDL_A_01135043	TEVA_MDL_A_01135044							
TE-341	05/31/2016	FEN-40392 FENTORA Clinical Trials Rep Triggered Email (Desktop and Mobile) (v1.0)	TEVA_MDL_A_01135038	TEVA_MDL_A_01135042							
TE-342	05/31/2016	FEN-40391 FENTORA C.A.R.E. Team Rep Triggered Email (Desktop and Mobile) (v1.0)	TEVA_MDL_A_01135033	TEVA_MDL_A_01135037							
TE-343	05/31/2016	FEN-40390 FENTORA Administration & Dosing Rep Triggered Email (Desktop and Mobile) (v1.0)	TEVA_MDL_A_01135028	TEVA_MDL_A_01135032							
TE-344	04/25/2016	FEN-40389 FENTORA Direct Mail Newsletter 1 (v1.0)	TEVA_MDL_A_01135024	TEVA_MDL_A_01135027							
TE-345	04/28/2016	FEN-40388 FENTORA eNewsletter 1 [Mobile and Desktop] (v1.0)	TEVA_MDL_A_01135020	TEVA_MDL_A_01135023							
TE-346	04/11/2016	FEN-40387 FENTORA CNE Consent Form Carrier (v1.0)	TEVA_MDL_A_01135017	TEVA_MDL_A_01135018							
TE-347	04/28/2016	FEN-40386 FENTORA Low Income Subsidy Direct Mailer (v1.0)	TEVA_MDL_A_01135015	TEVA_MDL_A_01135016							
TE-348	09/12/2016	FEN-40383 FENTORA Downloadable Patient Materials (v1.0)	TEVA_MDL_A_01134979	TEVA_MDL_A_01135014							
TE-349	09/12/2016	FEN-40382 FENTORA Patient 2016 Website Update (v1.0)	TEVA_MDL_A_01134952	TEVA_MDL_A_01134978							
TE-350	04/11/2016	FEN-40381 FENTORA CNE Reimbursement Assistance Patient Consent Form (v1.0)	TEVA_MDL_A_01134938	TEVA_MDL_A_01134951							
TE-351	06/08/2016	FEN-40378 FENTORA Low-Income Subsidy Email [Desktop and Mobile] (v1.0)	TEVA_MDL_A_01134920	TEVA_MDL_A_01134923							
TE-352	03/04/2016	FEN-40374 FENTORA Resource Guide (v1.0)	TEVA_MDL_A_01134894	TEVA_MDL_A_01134903							
TE-353	08/30/2016	FEN-40373 FENTORA.com Patient Website Metadata (2016) (v1.0)	TEVA_MDL_A_01134874	TEVA_MDL_A_01134893							
TE-354	10/21/2016	FEN-40372 FENTORA.com HCP Website Metadata (2016) (v1.0)	TEVA_MDL_A_01134813	TEVA_MDL_A_01134873							
TE-355	05/18/2016	FEN-40371 FENTORA Patient Brochure Holder (v1.0)	TEVA_MDL_A_01134811	TEVA_MDL_A_01134812							
TE-356	03/24/2016	FEN-40370 FENTORA C.A.R.E. Team Direct Mailer (v1.0)	TEVA_MDL_A_01134809	TEVA_MDL_A_01134810							
TE-357	09/01/2016	FEN-40369 FENTORA.com (HCP) 2016 Updates (v1.0)	TEVA_MDL_A_01134736	TEVA_MDL_A_01134808							
TE-358	04/27/2016	FEN-40367 FENTORA Access Advisor Newsletter (v1.0)	TEVA_MDL_A_01134728	TEVA_MDL_A_01134735							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-359	04/27/2016	FEN-40366 FENTORA Access Advisor Cover Letter (v1.0)	TEVA_MDL_A_01134725	TEVA_MDL_A_01134727							
TE-360	09/08/2016	FEN-40360 Web-based On-demand FENTORA promotional presentation (v2.0)	TEVA_MDL_A_01134682	TEVA_MDL_A_01134704							
TE-361	03/03/2016	FEN-40356 Fentora Slim Jim Update (v1.0)	TEVA_MDL_A_01134646	TEVA_MDL_A_01134675							
TE-362	01/25/2016	FEN-40357 FENTORA Kiosk (v1.0)	TEVA_MDL_A_01134606	TEVA_MDL_A_01134610							
TE-363	03/17/2016	FEN-40352 FENTORA MedAlert 1 Omnio (v1.0)	TEVA_MDL_A_01134606	TEVA_MDL_A_01134610							
TE-364	03/01/2016	FEN-40351 MedAlert 1 Email (v1.0)	TEVA_MDL_A_01134605	TEVA_MDL_A_01134605							
TE-365	03/10/2016	FEN-40350 FENTORA Direct Mail Newsletter 1 (v1.0)	TEVA_MDL_A_01134603	TEVA_MDL_A_01134604							
TE-366	03/01/2016	FEN-40349 FENTORA eNewsletter 1 (v1.0)	TEVA_MDL_A_01134603	TEVA_MDL_A_01134604							
TE-367	01/20/2016	FEN-40348 FENTORA LIS Leave Behind Update (v1.0)	TEVA_MDL_A_01134600	TEVA_MDL_A_01134601							
TE-368	12/08/2015	FEN-40347 FENTORA CNE CARE Team Training Slide Deck (v1.0)	TEVA_MDL_A_01134583	TEVA_MDL_A_01134599							
TE-369	12/22/2015	FEN-40346 Guide to FENTORA Messaging (v1.0)	TEVA_MDL_A_01134573	TEVA_MDL_A_01134582							
TE-370	01/25/2016	FEN-40345 FENTORA Touchscreen Panel Update (v1.0)	TEVA_MDL_A_01134508	TEVA_MDL_A_01134572							
TE-371	01/12/2016	FEN-40344 FENTORA ISR Direct Mailer (v1.0)	TEVA_MDL_A_01134506	TEVA_MDL_A_01134507							
TE-372	01/29/2016	FEN-40343 FENTORA Branded DSA Update (v1.0)	TEVA_MDL_A_01134427	TEVA_MDL_A_01134505							
TE-373	12/17/2015	FEN-40340 FENTORA ISR Rep Triggered Letter (v1.0)	TEVA_MDL_A_01134421	TEVA_MDL_A_01134423							
TE-374	12/09/2015	FEN-40338 FENTORA Reimbursement Assistance Patient Consent Form - Faxable (v2.0)	TEVA_MDL_A_01134407	TEVA_MDL_A_01134420							
TE-375	12/07/2015	FEN-40337 FENTORA Patient Brochure - Electronic Version (v2.0)	TEVA_MDL_A_01134377	TEVA_MDL_A_01134406							
TE-376	12/22/2015	FEN-40336 FENTORA C.A.R.E. Team RTL Update (v1.0)	TEVA_MDL_A_01134374	TEVA_MDL_A_01134376							
TE-377	12/09/2015	FEN-40335 2016 FENTORA Savings Offer Brochure (v1.0)	TEVA_MDL_A_01134372	TEVA_MDL_A_01134373							
TE-378	11/12/2015	FEN-40333 FENTORA.com Patient Website Metadata Update (v1.0)	TEVA_MDL_A_01134350	TEVA_MDL_A_01134369							
TE-379	11/12/2015	FEN-40332 FENTORA.com HCP Website Metadata Update (v1.0)	TEVA_MDL_A_01134307	TEVA_MDL_A_01134349							
TE-380	03/07/2016	FEN-40330 FENTORA Branded SEM Update (v3.0)	TEVA_MDL_A_01134295	TEVA_MDL_A_01134306							
TE-381	12/02/2015	FEN-40329 FENTORA ISR Transition Leave Behind (v1.0)	TEVA_MDL_A_01134293	TEVA_MDL_A_01134294							
TE-382	01/25/2016	FEN-40328 FENTORA hcpConnect Digital Brochure (v1.0)	TEVA_MDL_A_01134269	TEVA_MDL_A_01134292							
TE-383	11/16/2015	FEN-40325 CNE FENTORA C.A.R.E. Team Leave Behind (v1.0)	TEVA_MDL_A_01134267	TEVA_MDL_A_01134268							
TE-384	06/28/2016	FEN-40324 FENTORA Managing Breakthrough Cancer Pain (v1.0)	TEVA_MDL_A_01134259	TEVA_MDL_A_01134266							
TE-385	09/22/2015	FEN-40323 Fentora Goodie Bag for FAB (Sales rep ad board) members (v1.0)	TEVA_MDL_A_01134257	TEVA_MDL_A_01134258							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-386	09/16/2015	FEN-40322 Fentora FAB (Sales rep ad board) Thermos (v1.0)	TEVA_MDL_A_01134256	TEVA_MDL_A_01134256							
TE-387	09/22/2015	FEN-40321 Fentora FAB (Sales Rep ad board) cookie (v1.0)	TEVA_MDL_A_01134255	TEVA_MDL_A_01134255							
TE-388	09/16/2015	FEN-40320 Fentora FAB (Sales Rep ad board) Goodie Box (v1.0)	TEVA_MDL_A_01134253	TEVA_MDL_A_01134254							
TE-389	09/03/2015	FEN-40316 FENTORA Indication and ISI - Professional (v1.0)	TEVA_MDL_A_01134240	TEVA_MDL_A_01134241							
TE-390	09/03/2015	FEN-40315 FENTORA Indication and ISI - Consumer (v1.0)	TEVA_MDL_A_01134237	TEVA_MDL_A_01134239							
TE-391	10/15/2015	FEN-40314 FENTORA Perspectives in Palliative Care Live Program Guidebook (v1.0)	TEVA_MDL_A_01134185	TEVA_MDL_A_01134236							
TE-392	10/15/2015	FEN-40313 FENTORA Oncology Live Program Guidebook (v1.0)	TEVA_MDL_A_01134133	TEVA_MDL_A_01134184							
TE-393	08/31/2015	FEN-40311 FENTORA Fall 2015 POA Workshop (v1.0)	TEVA_MDL_A_01134116	TEVA_MDL_A_01134132							
TE-394	08/04/2015	FEN-40310 Fentora Field Advisory Board Trunk Blanket (v1.0)	TEVA_MDL_A_01134115	TEVA_MDL_A_01134115							
TE-395	09/03/2015	FEN-40309 Taking Your Medication Brochure (v1.0)	TEVA_MDL_A_01134105	TEVA_MDL_A_01134114							
TE-396	09/03/2015	FEN-40308 My Daily Breakthrough Cancer Pain Journal (v1.0)	TEVA_MDL_A_01134087	TEVA_MDL_A_01134104							
TE-397	09/03/2015	FEN-40307 FENTORA Reimbursement Assistance Patient Consent Form Update (v1.0)	TEVA_MDL_A_01134085	TEVA_MDL_A_01134086							
TE-398	09/03/2015	FEN-40306 FENTORA Patient Starter Kit Housing Unit (v1.0)	TEVA_MDL_A_01134073	TEVA_MDL_A_01134084							
TE-399	09/03/2015	FEN-40305 LIS Education Leave Behind (v1.0)	TEVA_MDL_A_01134071	TEVA_MDL_A_01134072							
TE-400	08/20/2015	FEN-40303 FENTORA Tote Bag Insert (v1.0)	TEVA_MDL_A_01134070	TEVA_MDL_A_01134070							
TE-401	08/07/2015	FEN-40302 2015 FENTORA Speaker Program Invitation (Palliative Care) (v1.0)	TEVA_MDL_A_01134055	TEVA_MDL_A_01134069							
TE-402	08/07/2015	FEN-40301 2015 FENTORA Speaker Program Invitation (ONC) (v1.0)	TEVA_MDL_A_01134040	TEVA_MDL_A_01134054							
TE-403	08/07/2015	FEN-40300 2015 FENTORA Speaker Program Invitation (BTP) (v1.0)	TEVA_MDL_A_01134025	TEVA_MDL_A_01134039							
TE-404	12/15/2015	FEN-40299 Fentora Interactive PI Hunt Review (v2.0)	TEVA_MDL_A_01133948	TEVA_MDL_A_01134024							
TE-405	08/24/2015	FEN-40298 FENTORA C.A.R.E. Team Leave Behind (v2.0)	TEVA_MDL_A_01133946	TEVA_MDL_A_01133947							
TE-406	08/18/2015	FEN-40297 Field Force Motivation Direct Mail (v1.0)	TEVA_MDL_A_01133942	TEVA_MDL_A_01133945							
TE-407	11/06/2015	FEN-40296 FENTORA Weinstein Annotated Reprint review eModule Activity (v1.0)	TEVA_MDL_A_01133904	TEVA_MDL_A_01133941							
TE-408	11/16/2015	FEN-40295 FENTORA Portenoy Annotated reprint review eModule Activity (v1.0)	TEVA_MDL_A_01133875	TEVA_MDL_A_01133903							
TE-409	07/16/2015	FEN-40294 OraVescent Technology Leave Behind Update (v1.0)	TEVA_MDL_A_01133870	TEVA_MDL_A_01133874							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-410	07/14/2015	FEN-40293 Perspectives in Palliative Care: Managing Breakthrough Pain in Patients w/ Cancer (v1.0)	TEVA_MDL_A_01133812	TEVA_MDL_A_01133869							
TE-411	10/12/2015	FEN-40290 Newsletter 4 Direct Mail (v1.0)	TEVA_MDL_A_01133808	TEVA_MDL_A_01133811							
TE-412	10/06/2015	FEN-40289 eNewsletter 4 (v1.0)	TEVA_MDL_A_01133805	TEVA_MDL_A_01133807							
TE-413	09/11/2015	FEN-40288 eNewsletter 3 Direct Mail (v1.0)	TEVA_MDL_A_01133801	TEVA_MDL_A_01133804							
TE-414	09/02/2015	FEN-40287 eNewsletter 3 (v1.0)	TEVA_MDL_A_01133795	TEVA_MDL_A_01133800							
TE-415	06/12/2015	FEN-40284 Sales Rep Notification Email (v1.0)	TEVA_MDL_A_01133787	TEVA_MDL_A_01133787							
TE-416	07/13/2015	FEN-40283 FENTORA Patient Brochure (v1.0)	TEVA_MDL_A_01133773	TEVA_MDL_A_01133786							
TE-417	05/07/2015	FEN-40281 Fentora Patient Brochure Holder 2015 (v1.0)	TEVA_MDL_A_01133771	TEVA_MDL_A_01133771							
TE-418	05/12/2015	FEN-40280 Large Back Wall (v1.0)	TEVA_MDL_A_01133770	TEVA_MDL_A_01133770							
TE-419	05/12/2015	FEN-40277 FENTORA Back Wall (v1.0)	TEVA_MDL_A_01133763	TEVA_MDL_A_01133763							
TE-420	08/20/2015	FEN-40275 eNewsletter 2 Direct Mail (v1.0)	TEVA_MDL_A_01133757	TEVA_MDL_A_01133758							
TE-421	07/13/2015	FEN-40274 eNewsletter 1 Direct Mail (v1.0)	TEVA_MDL_A_01133755	TEVA_MDL_A_01133756							
TE-422	08/07/2015	FEN-40272 eNewsletter 2 (v1.0)	TEVA_MDL_A_01133752	TEVA_MDL_A_01133752							
TE-423	06/18/2015	FEN-40271 eNewsletter 1 (v1.0)	TEVA_MDL_A_01133750	TEVA_MDL_A_01133751							
TE-424	03/24/2015	FEN-40270 FENTORA C.A.R.E. Team RTL (v1.0)	TEVA_MDL_A_01133747	TEVA_MDL_A_01133749							
TE-425	03/12/2015	FEN-40264 2015 FENTORA Convention Touchscreen Plasma Panel (v1.0)	TEVA_MDL_A_01133682	TEVA_MDL_A_01133746							
TE-426	03/12/2015	FEN-40263 FENTORA Kiosk (v1.0)	TEVA_MDL_A_01133681	TEVA_MDL_A_01133681							
TE-427	02/25/2015	FEN-40256 Fentora Savings Offer Brochure (v1.0)	TEVA_MDL_A_01133671	TEVA_MDL_A_01133672							
TE-428	04/27/2015	FEN-40255 FENTORA eDetail (v1.0)	TEVA_MDL_A_01133616	TEVA_MDL_A_01133670							
TE-429	01/16/2015	FEN-40254 Fentora Field Advisory Journal Book (v1.0)	TEVA_MDL_A_01133615	TEVA_MDL_A_01133615							
TE-430	01/16/2015	FEN-40253 Fentora Field Rep Advisory Messenger Bag (v1.0)	TEVA_MDL_A_01133614	TEVA_MDL_A_01133614							
TE-431	04/09/2015	FEN-40251 ITC Workshop: Putting it All Together (v1.0)	TEVA_MDL_A_01133598	TEVA_MDL_A_01133613							
TE-432	04/20/2015	FEN-40250 ITC Workshop: Marketplace (v1.0)	TEVA_MDL_A_01133568	TEVA_MDL_A_01133597							
TE-433	04/17/2015	FEN-40247 Fentora ITC Workshop: Messaging Resources (v1.0)	TEVA_MDL_A_01133501	TEVA_MDL_A_01133567							
TE-434	02/03/2015	FEN-40246 FENTORA Speaker Program Follow-up RTL (v1.0)	TEVA_MDL_A_01133498	TEVA_MDL_A_01133500							
TE-435	01/20/2015	FEN-40245 Fentora DSA workshop (v1.0)	TEVA_MDL_A_01133471	TEVA_MDL_A_01133497							
TE-436	02/13/2015	FEN-40244 Fentora Slim Jim Update (v1.0)	TEVA_MDL_A_01133441	TEVA_MDL_A_01133470							
TE-437	01/30/2015	FEN-40242 Fentora Table Top Panels Update (v1.0)	TEVA_MDL_A_01133435	TEVA_MDL_A_01133436							
TE-438	03/07/2016	FEN-40241 FENTORA.com HCP site (v1.0)	TEVA_MDL_A_01133385	TEVA_MDL_A_01133434							
TE-439	03/07/2016	FEN-40240 FENTORA.com Patient Website (v1.0)	TEVA_MDL_A_01133369	TEVA_MDL_A_01133384							
TE-440	01/30/2015	FEN-40239 Patient Profile Detail Piece / Leave-Behind (v1.0)	TEVA_MDL_A_01133363	TEVA_MDL_A_01133368							
TE-441	12/03/2014	FEN-40238 Managing Breakthrough Pain in Patients with Cancer (revision) (v2.0)	TEVA_MDL_A_01133311	TEVA_MDL_A_01133362							
TE-442	12/11/2014	FEN-40235 Managing Breakthrough Pain in Patients with Cancer - Live Program Guidebook (v2.0)	TEVA_MDL_A_01133258	TEVA_MDL_A_01133305							
TE-443	01/13/2015	FEN-40234 Fentora DSA Update (v1.0)	TEVA_MDL_A_01133190	TEVA_MDL_A_01133257							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-444	10/21/2014	FEN-40233 Fentora Product Theater Invitation for the Palliative Care in Oncology Symposium (v1.0)	TEVA_MDL_A_01133186	TEVA_MDL_A_01133189							
TE-445	10/03/2014	FEN-40231 Patient Brochure Holder (v1.0)	TEVA_MDL_A_01133185	TEVA_MDL_A_01133185							
TE-446	10/21/2014	FEN-40230 Perspectives in Oncology: Managing Breakthrough Pain Slide Deck (revision) (v1.0)	TEVA_MDL_A_01133126	TEVA_MDL_A_01133184							
TE-447	09/19/2014	FEN-40227 Perspectives in Oncology: Managing Breakthrough Pain Workbook (v1.0)	TEVA_MDL_A_01133067	TEVA_MDL_A_01133118							
TE-448	11/11/2014	FEN-40226 Perspectives in Oncology: Managing Breakthrough Pain hcpConnect Participant Guidebook (v1.0)	TEVA_MDL_A_01133035	TEVA_MDL_A_01133066							
TE-449	10/30/2014	FEN-40225 Managing Breakthrough Pain in Patients with Cancer Slide Deck (v1.0)	TEVA_MDL_A_01132983	TEVA_MDL_A_01133034							
TE-450	08/13/2014	FEN-40224 PAINWeek Event Description Form_FENTORA (v1.0)	TEVA_MDL_A_01132980	TEVA_MDL_A_01132982							
TE-451	08/18/2014	FEN-40223 Fentora Pain Week Product Theater Invitation (v1.0)	TEVA_MDL_A_01132976	TEVA_MDL_A_01132979							
TE-452	09/04/2014	FEN-40222 FENTORA PAINWeek Product Presentation (v1.0)	TEVA_MDL_A_01132925	TEVA_MDL_A_01132975							
TE-453	09/12/2014	FEN-40212 Perspectives in Palliative Care: Managing BTP (Live Program Workbook) (v1.0)	TEVA_MDL_A_01132870	TEVA_MDL_A_01132921							
TE-454	11/05/2014	FEN-40211_FENTORA Rx Peer Insights ClinSite (v1.0)	TEVA_MDL_A_01132859	TEVA_MDL_A_01132869							
TE-455	11/03/2014	FEN-40210_FENTORA Rx Peer Insights Envelope (v1.0)	TEVA_MDL_A_01132858	TEVA_MDL_A_01132858							
TE-456	11/03/2014	FEN-40208_FENTORA Rx Peer Insights Cover Letter (v1.0)	TEVA_MDL_A_01132855	TEVA_MDL_A_01132857							
TE-457	11/07/2014	FEN-40206_FENTORA Rx Peer Insights Email 4 (v1.0)	TEVA_MDL_A_01132854	TEVA_MDL_A_01132854							
TE-458	11/07/2014	FEN-40205_FENTORA Rx Peer Insights Email 3 (v1.0)	TEVA_MDL_A_01132853	TEVA_MDL_A_01132853							
TE-459	11/07/2014	FEN-40204_FENTORA Rx Peer Insights Email 2 (v1.0)	TEVA_MDL_A_01132852	TEVA_MDL_A_01132852							
TE-460	11/07/2014	FEN-40203_FENTORA Rx Peer Insights Email 1 (v1.0)	TEVA_MDL_A_01132851	TEVA_MDL_A_01132851							
TE-461	11/03/2014	FEN-40202_FENTORA Rx Peer Insights Direct Mail Newsletter (v1.0)	TEVA_MDL_A_01132843	TEVA_MDL_A_01132850							
TE-462	08/28/2014	FEN-40201 Brand Book (v1.0)	TEVA_MDL_A_01132795	TEVA_MDL_A_01132842							
TE-463	09/25/2014	FEN-40199 Perspectives in Palliative Care: Managing Breakthrough Pain (Faculty Guide) (v1.0)	TEVA_MDL_A_01132759	TEVA_MDL_A_01132794							
TE-464	09/19/2014	FEN-40198 Perspectives in Palliative Care: Managing Breakthrough Pain (Participant Guide) (v1.0)	TEVA_MDL_A_01132723	TEVA_MDL_A_01132758							
TE-465	08/11/2014	FEN-40197 Palliative Care Speaker Program Invitation (v1.0)	TEVA_MDL_A_01132720	TEVA_MDL_A_01132722							
TE-466	09/02/2014	FEN-40196 OraVescent Technology Leave-Behind (v1.0)	TEVA_MDL_A_01132715	TEVA_MDL_A_01132719							
TE-467	08/11/2014	FEN-40195 Fentora C.A.R.E. Team Patient Assistance Leave Behind (v1.0)	TEVA_MDL_A_01132714	TEVA_MDL_A_01132714							
TE-468	06/02/2014	FEN-40193 Fentora Branded SEM campaign (v1.0)	TEVA_MDL_A_01132709	TEVA_MDL_A_01132713							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-469	07/17/2014	FEN-40192 Fentora 2014 Palliative Care Slide Deck (v1.0)	TEVA_MDL_A_01132651	TEVA_MDL_A_01132708							
TE-470	08/18/2014	FEN-40191 Perspectives in Oncology: Managing Breakthrough Pain Slide Deck (v1.0)	TEVA_MDL_A_01132592	TEVA_MDL_A_01132650							
TE-471	05/28/2014	FEN-40189 Medicare Part D Leave-Behind (v1.0)	TEVA_MDL_A_01132591	TEVA_MDL_A_01132591							
TE-472	05/23/2014	FEN-40188 Fentora CoverMyMeds Landing Page Update (v1.0)	TEVA_MDL_A_01132583	TEVA_MDL_A_01132590							
TE-473	07/17/2014	FEN-40187 FENTORA DSA Content Update (v1.0)	TEVA_MDL_A_01132520	TEVA_MDL_A_01132582							
TE-474	05/23/2014	FEN-40176 Over 65 Program Letter and Certification Update (v1.0)	TEVA_MDL_A_01132501	TEVA_MDL_A_01132504							
TE-475	04/30/2014	FEN-40175 Sublingual Leave-Behind (v1.0)	TEVA_MDL_A_01132499	TEVA_MDL_A_01132500							
TE-476	04/15/2014	FEN-40173 PPLS Disease State Certification Exam (v1.0)	TEVA_MDL_A_01132486	TEVA_MDL_A_01132493							
TE-477	04/10/2014	FEN-40172 PPLS Marketplace Certification Exam (v1.0)	TEVA_MDL_A_01132478	TEVA_MDL_A_01132485							
TE-478	04/10/2014	FEN-40171 Fentora Annotated PI Certification Exam (v1.0)	TEVA_MDL_A_01132467	TEVA_MDL_A_01132477							
TE-479	04/10/2014	FEN-40164 ITC Disease State Workshop (v1.0)	TEVA_MDL_A_01132430	TEVA_MDL_A_01132453							
TE-480	03/18/2014	FEN-40163 ITC Exam (v1.0)	TEVA_MDL_A_01132419	TEVA_MDL_A_01132429							
TE-481	04/23/2014	FEN-40160 Patient Brochure (v1.0)	TEVA_MDL_A_01132399	TEVA_MDL_A_01132418							
TE-482	04/04/2014	FEN-40159 PPLS Disease State Module (v1.0)	TEVA_MDL_A_01132325	TEVA_MDL_A_01132398							
TE-483	03/14/2014	FEN-40158 Fentora Website Savings Card PDF (v1.0)	TEVA_MDL_A_01132322	TEVA_MDL_A_01132324							
TE-484	03/28/2014	FEN-40157 FENTORA C.A.R.E. Team RTL (v1.0)	TEVA_MDL_A_01132319	TEVA_MDL_A_01132321							
TE-485	03/21/2014	FEN-40156 Fentora Patient Savings Offer (v1.0)	TEVA_MDL_A_01132317	TEVA_MDL_A_01132318							
TE-486	03/31/2014	FEN-40151 Pain Product Learning System - Marketplace Module (v1.0)	TEVA_MDL_A_01132236	TEVA_MDL_A_01132311							
TE-487	04/02/2014	FEN-40150 FENTORA Dosing Leave Behind (v1.0)	TEVA_MDL_A_01132234	TEVA_MDL_A_01132235							
TE-488	02/14/2014	FEN-40149 Fentora Annotated DSA (v1.0)	TEVA_MDL_A_01132215	TEVA_MDL_A_01132233							
TE-489	02/12/2014	FEN-40148 questions for FENTORA Annotated DSA (v1.0)	TEVA_MDL_A_01132213	TEVA_MDL_A_01132214							
TE-490	03/28/2014	FEN-40146 Fentora.com Patient Site - C.A.R.E. Team Update (v1.0)	TEVA_MDL_A_01132201	TEVA_MDL_A_01132212							
TE-491	03/28/2014	FEN-40145 Fentora.com HCP Site - C.A.R.E. Team Update (v2.0)	TEVA_MDL_A_01132178	TEVA_MDL_A_01132200							
TE-492	03/28/2014	FEN-40144 Fentora Touchscreen - vertical display (v1.0)	TEVA_MDL_A_01132115	TEVA_MDL_A_01132177							
TE-493	02/18/2014	FEN-40138 Fentora DSA Workshop (v2.0)	TEVA_MDL_A_01132082	TEVA_MDL_A_01132097							
TE-494	01/31/2014	FEN-40136 Fentora C.A.R.E. RTL Label for Envelope (v1.0)	TEVA_MDL_A_01132067	TEVA_MDL_A_01132067							
TE-495	03/07/2014	FEN-40135 Fentora Slim Jim (v1.0)	TEVA_MDL_A_01132037	TEVA_MDL_A_01132066							
TE-496	02/13/2014	FEN-40133 Fentora Managed Care Leave-Behind (v1.0)	TEVA_MDL_A_01132030	TEVA_MDL_A_01132031							
TE-497	01/31/2014	FEN-40130 Fentora C.A.R.E. Team RTL (v1.0)	TEVA_MDL_A_01132027	TEVA_MDL_A_01132029							
TE-498	01/31/2014	FEN-40129 Clinical Trials RTL (v1.0)	TEVA_MDL_A_01132023	TEVA_MDL_A_01132026							
TE-499	04/23/2014	FEN-40128 Administration and Dosing RTL (v1.0)	TEVA_MDL_A_01132020	TEVA_MDL_A_01132022							
TE-500	01/27/2014	FEN-40126 TIRF Product Grid (v1.0)	TEVA_MDL_A_01131989	TEVA_MDL_A_01132019							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-501	01/10/2014	FEN-40125 Fentora Reimbursement Patient Consent Form (electronic version) (v1.0)	TEVA_MDL_A_01131975	TEVA_MDL_A_01131988							
TE-502	01/31/2014	FEN-40124 Table Cloth for Table Top Display (v1.0)	TEVA_MDL_A_01131974	TEVA_MDL_A_01131974							
TE-503	01/31/2014	FEN-40122 FENTORA Table Top Panels Refresh (v1.0)	TEVA_MDL_A_01131967	TEVA_MDL_A_01131970							
TE-504	12/18/2013	FEN-40121 RE-APPROVAL FENTORA Rep Triggered Mail Envelope (old zinc # FEN-2526a) (v2.0)	TEVA_MDL_A_01131965	TEVA_MDL_A_01131966							
TE-505	01/17/2014	FEN-40120 Clinical Trial Data Leave-Behind (v1.0)	TEVA_MDL_A_01131963	TEVA_MDL_A_01131964							
TE-506	02/13/2014	FEN-40119 Portenoy Reprint Carrier (old # FEN-40024) (v1.0)	TEVA_MDL_A_01131957	TEVA_MDL_A_01131962							
TE-507	02/13/2014	FEN-40118 Weinstein Reprint Carrier (old # FEN-40025) (v1.0)	TEVA_MDL_A_01131951	TEVA_MDL_A_01131956							
TE-508	11/22/2013	FEN-40114 Fentora Reimbursement Consent Form (faxable version) (v1.0)	TEVA_MDL_A_01131934	TEVA_MDL_A_01131947							
TE-509	12/04/2013	FEN-40111 FENTORA Pain Program Guidebook (v1.0)	TEVA_MDL_A_01131884	TEVA_MDL_A_01131931							
TE-510	12/04/2013	FEN-40110 FENTORA Oncology Program Guidebook (v1.0)	TEVA_MDL_A_01131840	TEVA_MDL_A_01131883							
TE-511	10/28/2013	FEN-40104 REAPPROVAL Disease State Module (FEN-2512) (v1.0)	TEVA_MDL_A_01131758	TEVA_MDL_A_01131837							
TE-512	02/18/2014	FEN-40103 FENTORA DSA (v1.0)	TEVA_MDL_A_01131696	TEVA_MDL_A_01131757							
TE-513	11/08/2013	FEN-40102 Invitation for the HCP Connect Program (v1.0)	TEVA_MDL_A_01131693	TEVA_MDL_A_01131695							
TE-514	11/22/2013	FEN-40101 Fentora Reimbursement Form (v1.0)	TEVA_MDL_A_01131691	TEVA_MDL_A_01131692							
TE-515	10/04/2013	FEN-40098 ITC Pain Marketplace: Workshop Workmat (v1.0)	TEVA_MDL_A_01131687	TEVA_MDL_A_01131688							
TE-516	10/04/2013	FEN-40097 The Pain Marketplace: Facilitator's Guide (v1.0)	TEVA_MDL_A_01131664	TEVA_MDL_A_01131686							
TE-517	10/02/2013	FEN-40096 REAPPROVAL Fentora Hotline Form (v1.0)	TEVA_MDL_A_01131662	TEVA_MDL_A_01131663							
TE-518	10/02/2013	FEN-40095 REAPPROVAL Fentora Slim Jim (v1.0)	TEVA_MDL_A_01131636	TEVA_MDL_A_01131661							
TE-519	09/19/2013	FEN-40093 REAPPROVAL - FEN-2462 Clinical Reprint Workshop FG FINAL MAY 2012 (v1.0)	TEVA_MDL_A_01131603	TEVA_MDL_A_01131635							
TE-520	10/09/2013	FEN-40092 FENTORA Digital Sales Aid Workshop (DSA) (v1.0)	TEVA_MDL_A_01131561	TEVA_MDL_A_01131602							
TE-521	09/11/2013	FEN-40085 Patient Profiles Workshop (v1.0)	TEVA_MDL_A_01131525	TEVA_MDL_A_01131550							
TE-522	09/27/2013	FEN-40084 Fentora eNewsletter 3 (v1.0)	TEVA_MDL_A_01131520	TEVA_MDL_A_01131524							
TE-523	09/27/2013	FEN-40082 New Hire Dosing Workshop (v1.0)	TEVA_MDL_A_01131494	TEVA_MDL_A_01131519							
TE-524	09/25/2013	FEN-40080 TIRF Marketplace Workshop (v1.0)	TEVA_MDL_A_01131465	TEVA_MDL_A_01131493							
TE-525	09/27/2013	FEN-40078 Speaker Program Invite (v1.0)	TEVA_MDL_A_01131463	TEVA_MDL_A_01131464							
TE-526	09/06/2013	FEN-40074 Perspectives in Oncology: Managing Breakthrough Pain (Participant Guide) (v1.0)	TEVA_MDL_A_01131428	TEVA_MDL_A_01131462							
TE-527	10/04/2013	FEN-40073 Perspectives in Oncology: Managing Breakthrough Pain (Faculty Guide) (v1.0)	TEVA_MDL_A_01131393	TEVA_MDL_A_01131427							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-528	09/13/2013	FEN-40066 Fentora Oncology Speaker Program Invite 7x7 size (v1.0)	TEVA_MDL_A_01131391	TEVA_MDL_A_01131392							
TE-529	08/23/2013	FEN-40057 Oncology Speaker Program Invite (v1.0)	TEVA_MDL_A_01131362	TEVA_MDL_A_01131364							
TE-530	01/13/2014	FEN-40055 Fentora.com HCP Website (v1.0)	TEVA_MDL_A_01131337	TEVA_MDL_A_01131358							
TE-531	01/13/2014	FEN-40054 Fentora.com Patient Website (v1.0)	TEVA_MDL_A_01131325	TEVA_MDL_A_01131336							
TE-532	08/23/2013	FEN-40051 Managing Breakthrough Pain in Patients With Cancer Slide Deck (v1.0)	TEVA_MDL_A_01131283	TEVA_MDL_A_01131324							
TE-533	07/19/2013	FEN-40050 Managing Breakthrough Pain In The Oncology Setting: An Interdisciplinary Approach (v1.0)	TEVA_MDL_A_01131244	TEVA_MDL_A_01131282							
TE-534	05/29/2013	FEN-40049 FENTORA Annotated PI (v2.0)	TEVA_MDL_A_01131189	TEVA_MDL_A_01131243							
TE-535	06/23/2013	FEN-40048 BTP Patient Brochure (v1.0)	TEVA_MDL_A_01131171	TEVA_MDL_A_01131188							
TE-536	06/23/2013	FEN-40047 Over 65 Program Letter and Certification Update (v1.0)	TEVA_MDL_A_01131167	TEVA_MDL_A_01131170							
TE-537	04/26/2013	FEN-40045 Fentora header at AANP (v1.0)	TEVA_MDL_A_01131165	TEVA_MDL_A_01131165							
TE-538	07/15/2013	FEN-40044 Fentora.com 2.0 HCP Site (v1.0)	TEVA_MDL_A_01131157	TEVA_MDL_A_01131164							
TE-539	05/03/2013	FEN-40043 FAQ and Responses (v1.0)	TEVA_MDL_A_01131144	TEVA_MDL_A_01131156							
TE-540	04/12/2013	FEN-40039 RE-APPROVAL Portenoy Reprint [FEN-2227] (v1.0)	TEVA_MDL_A_01131136	TEVA_MDL_A_01131142							
TE-541	11/08/2013	FEN-40037 FENTORA Cover My Meds Landing Page (v1.0)	TEVA_MDL_A_01131127	TEVA_MDL_A_01131135							
TE-542	05/02/2013	FEN-40034 Fentora ISI Convention Panel Update (v1.0)	TEVA_MDL_A_01131126	TEVA_MDL_A_01131126							
TE-543	10/18/2013	FEN-40029 Fentora eDetail (v1.0)	TEVA_MDL_A_01131076	TEVA_MDL_A_01131125							
TE-544	05/02/2013	FEN-40028 Fentora Vertical Touchscreen Convention Panel Update (v1.0)	TEVA_MDL_A_01131024	TEVA_MDL_A_01131075							
TE-545	03/27/2013	FEN-40026 Pharma Finder Stocking Update (v1.0)	TEVA_MDL_A_01131023	TEVA_MDL_A_01131023							
TE-546	04/04/2013	FEN-40025 RE-APPROVAL Weinstein Reprint Carrier (FEN-2443) (v1.0)	TEVA_MDL_A_01131015	TEVA_MDL_A_01131022							
TE-547	04/04/2013	FEN-40024 RE-APPROVAL Portenoy Reprint Carrier (FEN-2442) (v1.0)	TEVA_MDL_A_01131007	TEVA_MDL_A_01131014							
TE-548	05/02/2013	FEN-40021 Sublingual Administration Leave Behind (v1.0)	TEVA_MDL_A_01131005	TEVA_MDL_A_01131006							
TE-549	04/26/2013	FEN-40017 Fentora eNewsletter 2 (v1.0)	TEVA_MDL_A_01131003	TEVA_MDL_A_01131003							
TE-550	03/12/2013	FEN-40014 Darwish_2008_SubLing_1043 (v1.0)	TEVA_MDL_A_01130996	TEVA_MDL_A_01131002							
TE-551	04/16/2013	FEN-40013 Fentora PI Web Format (v1.0)	TEVA_MDL_A_01130984	TEVA_MDL_A_01130995							
TE-552	04/19/2013	FEN-40012 Fentora Sublingual Administration Introductory Letter (v1.0)	TEVA_MDL_A_01130981	TEVA_MDL_A_01130983							
TE-553	04/19/2013	FEN-40009 Fentora ISI Poster (v1.0)	TEVA_MDL_A_01130976	TEVA_MDL_A_01130976							
TE-554	04/19/2013	FEN-40007 Fentora Horizontal Touchscreen Panels (v1.0)	TEVA_MDL_A_01130888	TEVA_MDL_A_01130975							
TE-555	03/22/2013	FEN-40006 Fentora S-008 final PI-MG for website_highlighted (v1.0)	TEVA_MDL_A_01130870	TEVA_MDL_A_01130887							
TE-556	05/13/2013	FEN-40005 Fentora iRep DSA (v1.0)	TEVA_MDL_A_01130789	TEVA_MDL_A_01130869							
TE-557	04/02/2013	FEN-40003 Fentora Med Guide (v1.0)	TEVA_MDL_A_01130785	TEVA_MDL_A_01130788							
TE-558	04/02/2013	FEN-40002 Fentora PI Printer Format (v1.0)	TEVA_MDL_A_01130783	TEVA_MDL_A_01130784							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-559	12/02/2011	FEN-2334a: REMS Enrollent: Wave 2/FEN-2335: REMS Enrollment: Wave 3	TEVA_MDL_A_00031009	TEVA_MDL_A_00031055							
TE-560	09/20/2013	FEN-40091 Overhead logo sign for 20x20 booth/FEN-40089 Overhead banner for 10x10 booth	TEVA_MDL_A_00033258	TEVA_MDL_A_00033262							
TE-561	10/05/2016	TIRF-40017 TIRF REMS Rep Triggered Letter (v1.0)	TEVA_MDL_A_01140787	TEVA_MDL_A_01140790							
TE-562	05/31/2016	TIRF-40016 TIRF Re-enrollment Rep Triggered Email (Desktop and Mobile) (v2.0)	TEVA_MDL_A_01140785	TEVA_MDL_A_01140786							
TE-563	10/01/2014	TIRF-40015 TIRF REMS Re-enrollment Envelope (Reapproval of TIRF-40004) (v1.0)	TEVA_MDL_A_01140784	TEVA_MDL_A_01140784							
TE-564	03/13/2014	TIRF-40014 RE-APPROVAL Pharmacy Finder Internal Stocking Report Update (old zinc # TIRF-0020) (v1.0)	TEVA_MDL_A_01140782	TEVA_MDL_A_01140783							
TE-565	03/26/2014	TIRF-40013 TIRF REMS Prescriber Enrollment Folder (v1.0)	TEVA_MDL_A_01140780	TEVA_MDL_A_01140781							
TE-566	03/25/2014	TIRF-40011 PPAF Patient Education Leave Behind (v1.0)	TEVA_MDL_A_01140768	TEVA_MDL_A_01140779							
TE-567	02/03/2014	TIRF-40010 RE-APPROVAL Pharmacy Finder Mobile Web (v1.0)	TEVA_MDL_A_01140739	TEVA_MDL_A_01140767							
TE-568	12/18/2013	TIRF-40009 RE-APPROVAL Pharmacy Finder Website (v1.0)	TEVA_MDL_A_01140714	TEVA_MDL_A_01140738							
TE-569	12/18/2013	TIRF-40008 RE-APPROVAL Pharmacy Finder Flashcard (old zinc # TIRF-0019) (v1.0)	TEVA_MDL_A_01140712	TEVA_MDL_A_01140713							
TE-570	12/18/2013	TIRF-40007 RE-APPROVAL PPAF Patient Brochure (zinc # TIRF-0018) (v1.0)	TEVA_MDL_A_01140700	TEVA_MDL_A_01140711							
TE-571	12/20/2013	TIRF-40006 RE-APPROVAL - TIRF REMS Enrollment Kit (old zinc # TIRF-0017) (v1.0)	TEVA_MDL_A_01140698	TEVA_MDL_A_01140699							
TE-572	10/25/2013	TIRF-40004 Envelope RTL TIRF Re-enrollment (v1.0)	TEVA_MDL_A_01140697	TEVA_MDL_A_01140697							
TE-573	10/23/2013	TIRF-40003 RTL TIRF Re-enrollment (v1.0)	TEVA_MDL_A_01140693	TEVA_MDL_A_01140696							
TE-574	08/12/2013	REAPPROVAL FEN-2475 Weinstein Annotated Clinical Reprint (v1.0)	TEVA_MDL_A_01140658	TEVA_MDL_A_01140671							
TE-575	08/12/2013	REAPPROVAL - FEN-2474 Portenoy Annotated Reprint (v1.0)	TEVA_MDL_A_01140646	TEVA_MDL_A_01140657							
TE-576	01/16/2012	2011 Convention Door Drop (Re-approval 1)	TEVA_MDL_A_01155635	TEVA_MDL_A_01155636							
TE-577	01/17/2012	TIRF REMS FAQ	TEVA_MDL_A_01155637	TEVA_MDL_A_01155649							
TE-578	01/26/2012	Door Drop AAPM	TEVA_MDL_A_01155652	TEVA_MDL_A_01155653							
TE-579	02/24/2012	TIRF REMS Access Leave Behind	TEVA_MDL_A_01155735	TEVA_MDL_A_01155740							
TE-580	02/28/2012	TIRF REMS Access HCP Letter	TEVA_MDL_A_01155772	TEVA_MDL_A_01155775							
TE-581	02/28/2012	TIRF PPAF Cover Letter	TEVA_MDL_A_01155776	TEVA_MDL_A_01155779							
TE-582	03/06/2012	Triage Matrix	TEVA_MDL_A_01155796	TEVA_MDL_A_01155796							
TE-583	03/06/2012	Call Center FAQ	TEVA_MDL_A_01155797	TEVA_MDL_A_01155807							
TE-584	03/06/2012	Call Center Verbiage- HCP (Post TIRF REMS)	TEVA_MDL_A_01155808	TEVA_MDL_A_01155809							
TE-585	03/06/2012	Call Center Verbiage- Pharmacists (Post TIRF REMS)	TEVA_MDL_A_01155810	TEVA_MDL_A_01155811							
TE-586	03/07/2012	PPAF Rep Triggered Mailer	TEVA_MDL_A_01155813	TEVA_MDL_A_01155816							
TE-587	03/20/2012	PPAF Patient Education Leave Behind	TEVA_MDL_A_01155826	TEVA_MDL_A_01155837							
TE-588	03/27/2012	TIRF REMS Access Leave Behind Training Guide	TEVA_MDL_A_01155842	TEVA_MDL_A_01155842							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-589	03/27/2012	SUBSYS Product Bulletin	TEVA_MDL_A_01155846	TEVA_MDL_A_01155856							
TE-590	03/27/2012	LAZANDA Product Bulletin	TEVA_MDL_A_01155857	TEVA_MDL_A_01155867							
TE-591	03/27/2012	CONCEPT: Unbranded Plasma Screens	TEVA_MDL_A_01155868	TEVA_MDL_A_01155871							
TE-592	03/27/2012	CONCEPT: Unbranded Static Panels	TEVA_MDL_A_01155872	TEVA_MDL_A_01155873							
TE-593	03/29/2012	ONS Door Drop	TEVA_MDL_A_01155902	TEVA_MDL_A_01155903							
TE-594	04/06/2012	PPAF Patient Brochure HOLDER	TEVA_MDL_A_01155962	TEVA_MDL_A_01155963							
TE-595	04/12/2012	APS Door Drop	TEVA_MDL_A_01155984	TEVA_MDL_A_01155985							
TE-596	04/24/2012	Pain Marketplace Guide	TEVA_MDL_A_01156055	TEVA_MDL_A_01156073							
TE-597	05/21/2012	Pharmacy Finder Application (July Pilot)	TEVA_MDL_A_01156508	TEVA_MDL_A_01156516							
TE-598	06/29/2012	iPad Launch Workshop 9	TEVA_MDL_A_01156640	TEVA_MDL_A_01156652							
TE-599	07/02/2012	Pharmacy Finder	TEVA_MDL_A_01156668	TEVA_MDL_A_01156692							
TE-600	07/24/2012	ASPMN Door Drop	TEVA_MDL_A_01156793	TEVA_MDL_A_01156794							
TE-601	08/09/2012	Pain Management Resource Folder	TEVA_MDL_A_01156827	TEVA_MDL_A_01156827							
TE-602	08/29/2012	Rep Triggered Email Pharmacy Finder URL	TEVA_MDL_A_01157003	TEVA_MDL_A_01157003							
TE-603	08/30/2012	Pharmacy Finder Mobile Version	TEVA_MDL_A_01157004	TEVA_MDL_A_01157032							
TE-604	10/01/2012	Pain Care Proactive Talking Points	TEVA_MDL_A_01157082	TEVA_MDL_A_01157084							
TE-605	11/08/2012	Breakthrough Pain Animation	TEVA_MDL_A_01157325	TEVA_MDL_A_01157329							
TE-606	12/11/2012	TIRF REMS Prescriber Enrollment Kit	TEVA_MDL_A_01157475	TEVA_MDL_A_01157476							
TE-607	12/11/2012	PPAF Patient Education Leave Behind	TEVA_MDL_A_01157477	TEVA_MDL_A_01157488							
TE-608	01/07/2013	Pharmacy Finder Card	TEVA_MDL_A_01157576	TEVA_MDL_A_01157577							
TE-609	01/14/2013	Dosing RTM	TEVA_MDL_A_01157708	TEVA_MDL_A_01157711							
TE-610	01/24/2013	Chronic Pain Survey Questionnaire - Patient	TEVA_MDL_A_01157743	TEVA_MDL_A_01157750							
TE-611	01/24/2013	Chronic Pain Survey Questionnaire - Caregiver	TEVA_MDL_A_01157751	TEVA_MDL_A_01157757							
TE-612	02/20/2013	Cover My Meds Brochure	TEVA_MDL_A_01157877	TEVA_MDL_A_01157877							
TE-613	02/26/2013	Pharmacy Finder Internal Stocking Report Update	TEVA_MDL_A_01157890	TEVA_MDL_A_01157891							
TE-614		Chargeback Data for Actiq and Fentora 2011 through April 2018.	TEVA_MDL_A_02401118	TEVA_MDL_A_02401118							
TE-615		Actiq and Fentora AR Transactional Data (All Invoices and Credits Issued) for April 2012 through April 2018.	TEVA_MDL_A_02419961	TEVA_MDL_A_02419961							
TE-616		Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2016	TEVA_MDL_A_02419964	TEVA_MDL_A_02419964							
TE-617		Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for June 2017-2018	TEVA_MDL_A_02419965	TEVA_MDL_A_02419965							
TE-618		Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2008-2010	TEVA_MDL_A_02419966	TEVA_MDL_A_02419966							
TE-619		Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2011-2013	TEVA_MDL_A_02419967	TEVA_MDL_A_02419967							
TE-620		Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2014-2015	TEVA_MDL_A_02419968	TEVA_MDL_A_02419968							
TE-621		Direct Sales data 1/2006-7/2018	TEVA_MDL_A_02416192	TEVA_MDL_A_02416192							
TE-622		Indirect Sales data 5.1.18-7.29.18	TEVA_MDL_A_02416193	TEVA_MDL_A_02416193							
TE-623		Indirect Sales data 2011	TEVA_MDL_A_02416194	TEVA_MDL_A_02416194							
TE-624		Indirect Sales data 2012	TEVA_MDL_A_02416195	TEVA_MDL_A_02416195							
TE-625		Indirect Sales data 2013	TEVA_MDL_A_02416196	TEVA_MDL_A_02416196							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-626		Indirect Sales data 2014	TEVA_MDL_A_02416197	TEVA_MDL_A_02416197							
TE-627		Indirect Sales data 2015	TEVA_MDL_A_02416198	TEVA_MDL_A_02416198							
TE-628		Indirect Sales data 2016	TEVA_MDL_A_02416199	TEVA_MDL_A_02416199							
TE-629		Indirect Sales data 1.1.17-3.31.17	TEVA_MDL_A_02416200	TEVA_MDL_A_02416200							
TE-630		Indirect Sales data 4.1.17-6.30.17	TEVA_MDL_A_02416201	TEVA_MDL_A_02416201							
TE-631		Indirect Sales data 7.1.17-9.30.17	TEVA_MDL_A_02416202	TEVA_MDL_A_02416202							
TE-632		Indirect Sales data 10.1.17-12.31.17	TEVA_MDL_A_02416203	TEVA_MDL_A_02416203							
TE-633		Indirect Sales data 1.1.18-4.30.18	TEVA_MDL_A_02416204	TEVA_MDL_A_02416204							
TE-634	07/01/2012	Reporting and Investigations of Misconduct US Policy - 400	TEVA_MDL_A_00553150	TEVA_MDL_A_00553152							
TE-635	01/01/2012	Teva Employee Conduct Policy	TEVA_MDL_A_00553159	TEVA_MDL_A_00553160							
TE-636	02/27/2006	Teva Code of Business Conduct	TEVA_MDL_A_00553166	TEVA_MDL_A_00553192							
TE-637	11/15/2016	Handling Safety Information on Company Products	TEVA_MDL_A_04243438	TEVA_MDL_A_04243445							
TE-638	07/01/2012	Teva Incident Management (Compliance Procedure-100), (Jul. 2012)	TEVA_MDL_A_00553116	TEVA_MDL_A_00553120							
TE-639	03/22/2017	Onboarding Toolkit COE iMCM Advisor	TEVA_MDL_A_01078522	TEVA_MDL_A_01078522							
TE-640	09/24/2013	September 24, 2013 Government & Public Policy PPT	TEVA_MDL_A_01088049	TEVA_MDL_A_01088074							
TE-641	07/20/2017	Government Affairs and Public Policy at Teva	TEVA_MDL_A_01088358	TEVA_MDL_A_01088358							
TE-642	02/28/2013	Exit Meeting Presentation for OIG – “OIG Site Visit – February 28, 2013 – Compliance Program Overview	TEVA_MDL_A_00774868	TEVA_MDL_A_00774913							
TE-643	08/03/2017	Consultants and Consulting Services Spreadsheet	TEVA_MDL_A_13253980	TEVA_MDL_A_13253988							
TE-644	07/10/2013	Integrity In Focus: Products and Promotion	TEVA_MDL_A_00772936	TEVA_MDL_A_00773149							
TE-645	08/10/2015	Teva U.S. Specialty Medicines Compliance Policy Manual	TEVA_MDL_A_00787206	TEVA_MDL_A_00787332							
TE-646	01/01/2015	Teva 2015 Organizational Chart	TEVA_MDL_A_00537729	TEVA_MDL_A_00538894							
TE-647	02/26/2018	Example of Letter of Independence	TEVA_MDL_A_01090282	TEVA_MDL_A_01090286							
TE-648	09/07/2015	Teva SOP on US Medical Education Grants	TEVA_MDL_A_01090293	TEVA_MDL_A_01090303							
TE-649	08/04/2015	Grant Review Check List	TEVA_MDL_A_01090304	TEVA_MDL_A_01090307							
TE-650	08/01/2013	US Policy-205 – Independent Medical Education Grants	TEVA_MDL_A_01090487	TEVA_MDL_A_01090492							
TE-651	10/27/2014	Template Letter of Agreement - Educational Programs	TEVA_MDL_A_01178682	TEVA_MDL_A_01178683							
TE-652	02/27/2015	Educational grant to support a live program for clinicians about the needs of patients with common pain disorders titled “2015 Essential Tools for Treating the Patient in Pain.”	TEVA_MDL_A_01529685	TEVA_MDL_A_01529685							
TE-653	12/01/2016	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021947s024s0251b1.pdf	TEVA_MDL_A_13747313	TEVA_MDL_A_13747335							
TE-654	12/01/2016	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021947s0191b1.pdf	TEVA_MDL_A_13746820	TEVA_MDL_A_13746846							
TE-655	07/01/2012	Teva Medical Science Liaison Policy (US Policy-210), (Jul. 2012)	TEVA_MDL_A_00553127	TEVA_MDL_A_00553131							
TE-656	07/01/2012	Teva Medical Information Request Monitoring (Compliance Procedure-300)(Jul. 2012)	TEVA_MDL_A_00553125	TEVA_MDL_A_00553126							
TE-657	07/01/2012	Submission of Medical Requests US Policy - 215	TEVA_MDL_A_00553161	TEVA_MDL_A_00553162							
TE-658	12/20/2011	Regulatory Affairs Project Update	TEVA_MDL_A_00990906	TEVA_MDL_A_00990912							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-659	11/13/2018	Transcript of FDA Commissioner Scott Gottlieb's speech on November 13, 2018	TEVA_MDL_A_13743890	TEVA_MDL_A_13743897							
TE-660	REMOVED	REMOVED	REMOVED	REMOVED							
TE-661		Postoperative Opioid Prescribing and the Pain Scores on Hospital Consumer Assessment of Healthcare Providers and Systems Survey, JAMA	TO BE PRODUCED	TO BE PRODUCED							
TE-662	02/10/2015	Letter from Grant Erdel to the Honorable Joseph Crisco and the Honorable Robert Megna re: support for SB 21, An Act concerning health insurance coverage of abuse-deterrent opioid analgesics	TEVA_MDL_A_00694928	TEVA_MDL_A_00694929							
TE-663	07/28/2011	Discussion with the Office of the Vice President of the United States	TEVA_MDL_A_01086959	TEVA_MDL_A_01086988							
TE-664	05/08/2017	US Government Affairs Strategic Plan	TEVA_MDL_A_01087400	TEVA_MDL_A_01087400							
TE-665	07/04/2013	Rx Drug Abuse: Teva Alliance with Cardinal Health and CVS Caremark	TEVA_MDL_A_01088104	TEVA_MDL_A_01088106							
TE-666	02/24/2015	NTE [New Therapeutic Entities] Interview with Ed Silverman	TEVA_MDL_A_01088126	TEVA_MDL_A_01088127							
TE-667	02/06/2014	Issue Brief: Rx Abuse	TEVA_MDL_A_01088297	TEVA_MDL_A_01088303							
TE-668	07/09/2013	Introduction to the "Alliance" (Members: CVS-Caremark, Cardinal Health, Teva, AMA, NCPA)	TEVA_MDL_A_01088400	TEVA_MDL_A_01088400							
TE-669	04/02/2014	Prescription Drug Abuse: Public Health Approach to Addressing the Epidemic and Preserving Access to Treatment for Chronic Pain	TEVA_MDL_A_01088419	TEVA_MDL_A_01088420							
TE-670	03/11/2013	Position Statement: Abuse Deterrence and Generic Market Entry	TEVA_MDL_A_01088574	TEVA_MDL_A_01088574							
TE-671	03/15/2013	Letter from Penny Levin re: Draft guidance for industry on "abuse deterrent opioids - evaluation and labeling"	TEVA_MDL_A_01088619	TEVA_MDL_A_01088622							
TE-672	10/15/2015	Statement for the Record Submitted by Teva Pharmaceuticals: Senate Finance Subcommittee on Health Care Field Hearing: Examining Heroin and Opiate Abuse in Southwestern Pennsylvania	TEVA_MDL_A_01088623	TEVA_MDL_A_01088625							
TE-673	12/06/2015	What Is Teva Doing to Help Address the Opioid Abuse Epidemic in the U.S.? (draft)	TEVA_MDL_A_01088696	TEVA_MDL_A_01088697							
TE-674	09/13/2018	Legal HCP Opioids Commercial_2007 to 2017_All values.xlsx	TEVA_MDL_A_03413816	TEVA_MDL_A_03413816							
TE-675	02/26/2019	Statement from FDA Commissioner Scott Gottlieb, M.D. on the Agencies 2019.pdf	TEVA_MDL_A_13745160	TEVA_MDL_A_13745169							
TE-676	07/29/2019	Deposition by Written Questions of Valli Baldassano									
TE-677	05/17/2007	Board of Directors Meeting	TEVA_MDL_A_06654815	TEVA_MDL_A_06655042							
TE-678	09/00/2012	PCS Home Study Training Guide	TEVA_MDL_A_02396899	TEVA_MDL_A_02396919							
TE-679	04/29/2008	email from M. Morreale	TEVA_MDL_A_07244892	TEVA_MDL_A_07244893							
TE-680		IQVIA data	TEVA_MDL_A_02416209	TEVA_MDL_A_02416209							
TE-681		IQVIA data	TEVA_MDL_A_03413818	TEVA_MDL_A_03413818							
TE-682		IQVIA data	TEVA_MDL_A_08677335	TEVA_MDL_A_08677335							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-683	00/00/2006	Drug Enforcement Administration 2006 Practitioner's Manual	TEVA_MDL_A_13749277	TEVA_MDL_A_13749338							
TE-684	10/06/2010	Role of Authorized Agents in Communicating Controlled Substance Prescriptions to Pharmacies	TEVA_MDL_A_13754779	TEVA_MDL_A_13754783							
TE-685	Undated	Lisa Kohler Deposition Exhibit 5: PowerPoint Slides Entitled "Forensic Medicine and the Community, What is Forensic Medicine and How Does it Enhance our Community"									
TE-686	09/01/2014	Cynthia Weiskittle Deposition Exhibit 7: September 2014 white paper published by Child Welfare Opiate Engagement Project									
TE-687	09/27/2016	Opiate Response Presentation	CLEVE_000187960	CLEVE_000187961							
TE-688	04/17/2014	April 17, 2014 report "Ohio's Prescription Drug Overdose Epidemic: Epidemiology, Contributing Factors and Ongoing Prevention efforts"	CUYAH_001547662	CUYAH_001547725							
TE-689	12/02/2010	Email from Gidley Re: CFHS Minutes and Agenda for December 2, 2010, with Attachment	SUMMIT_001711478	SUMMIT_001711478							
TE-690	10/09/2008	Email from Kathleen Oberlin to Tonya Block, FWD: First Lady FCFC visit challenges and issues	SUMMIT_001714776	SUMMIT_001714776							
TE-691	06/01/2017	June 2017 draft of "Opioid Crisis Coordination Plan"	CUYAH_001714432	CUYAH_001714455							
TE-692	06/01/2012	June 2012 E-Mail Chain Re: ADM Board - Draft Community Plan, with Attachment	SUMMIT_001702355	SUMMIT_001702355							
TE-693	06/20/2018	Narc_Seizures_2005-2017.xlsx	CLEVE_002746115	CLEVE_002746115							
TE-694	00/00/2014	OARRS Training	BOP_MDL072649	BOP_MDL072714							
TE-695	10/30/2012	Email from M. Pallo to E. Griffin	BOP_MDL103450	BOP_MDL103450							
TE-696	10/29/2012	Email from C. Reed to E. Griffin	BOP_MDL103451	BOP_MDL103451							
TE-697	10/01/2016	Order of the Ohio State Board of Pharmacy	BOP_MDL113537	BOP_MDL113551							
TE-698	02/15/2012	Order of the Ohio State Board of Pharmacy	BOP_MDL209035	BOP_MDL209043							
TE-699	08/06/2013	Minutes of the August 6, 2013 Ohio State Board of Pharmacy	BOP_MDL212264	BOP_MDL212275							
TE-700	01/29/2018	OHBOP DEA 106 Forms Jan. 2017-Dec 2017	BOP_MDL417771	BOP_MDL417771							
TE-701	05/08/2013	Minutes of the May 6-8, 2013 Ohio State Board of Pharmacy	BOP_MDL470388	BOP_MDL470426							
TE-702	10/18/2012	Pharmacy Board Insider newsletter	BOP_MDL643725	BOP_MDL643730							
TE-703		Cleveland LERMS database	LERMS000000001	LERMS008914720							
TE-704		Cuyahoga County Medical Examiner Data	CUYAH_000134580	CUYAH_016502694							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-705		Ohio Board of Pharmacy Data	BOP_MDL 1st Production_000001 BOP_MDL_ 2nd Production_000001 BOP_MDL 5th Production_000001 BOP_MDL000001 OBPM_MDL_000000001 Ohio BOP 00000001 OhioPharmMins_0000001	BOP_MDL_ 1st Production_012552 BOP_MDL 2nd Production_012954 BOP_MDL 5th Production_000044 BOP_MDL999749 OBPM_MDL_000000199 Ohio BOP 00012557 OhioPharmMins_0000199							
TE-706		Ohio State Medical Board Data	Ohio_State_Medical_Board_00000001	Ohio_State_Medical_Board_00100791							
TE-707		Summit County Medical Examiner Data	SUMMIT_000016567	SUMMIT_002103713							
TE-708	06/10/2014	Ohio State Board of Pharmacy Settlement Agreement	Ohio BOP 00005186	Ohio BOP 00005188							
TE-709	03/15/2018	Ohio State Board of Pharmacy Order	Ohio BOP 00005576	Ohio BOP 00005581							
TE-710	10/24/2017	Order of the Ohio State Board of Pharmacy	Ohio BOP 00009811	Ohio BOP 00009815							
TE-711	09/17/2009	Order of the Ohio State Board of Pharmacy	Ohio BOP 00010295	Ohio BOP 00010299							
TE-712	10/06/2014	Ohio Board of Pharmacy Meeting Minutes, October 2014	BOP_MDL098390	BOP_MDL098432							
TE-713	03/02/2015	Pharmacy Board meeting minutes, 2015	BOP_MDL177101	BOP_MDL177135							
TE-714	03/02/2015	Pharmacy Board meeting minutes, 2015	BOP_MDL178752	BOP_MDL178785							
TE-715	10/19/2012	Pharmacy Board order finding M. Mastramico, intern, stole drugs from his employer for personal use	BOP_MDL208345	BOP_MDL208351							
TE-716	09/10/2012	Pharmacy Board Meeting Minutes, 2012	BOP_MDL208353	BOP_MDL208392							
TE-717	10/05/2012	Draft pharmacy board meeting minutes, 2012	BOP_MDL208405	BOP_MDL208442							
TE-718	09/10/2012	Pharmacy Board meeting minutes, 2012	BOP_MDL208443	BOP_MDL208476							
TE-719	09/10/2012	OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse	BOP_MDL208707	BOP_MDL208737							
TE-720	01/08/2013	OHBOP order re pharmacist H. Fletcher, drug trafficking	BOP_MDL208873	BOP_MDL208886							
TE-721	09/10/2012	OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse	BOP_MDL208943	BOP_MDL208978							
TE-722	09/10/2012	OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse	BOP_MDL211299	BOP_MDL211304							
TE-723	09/10/2012	OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse	BOP_MDL212128	BOP_MDL212161							
TE-724	09/10/2012	OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse	BOP_MDL212162	BOP_MDL212195							
TE-725	12/06/2004	OHBOP order re pharmacist D. Hart, diversion and drug abuse	BOP_MDL212377	BOP_MDL212400							
TE-726	03/02/2015	OHBOP orders re various pharmacists for diversion and drug abuse	BOP_MDL450035	BOP_MDL450068							
TE-727	07/11/2012	OHBOP packet re various pharmacists, drug abuse and diversion	BOP_MDL465725	BOP_MDL465790							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-728	03/03/2008	OHBOP order re pharmacist R. Colosimo, diversion and drug abuse	BOP_MDL466034	BOP_MDL466070							
TE-729	05/24/2012	OHBOP orders re various pharmacists for diversion and drug abuse	BOP_MDL466266	BOP_MDL466298							
TE-730	Not specified; January 2014	Consent Agreement Ohio Board of Nursing	OBN_MDL 1st Production 040844	OBN_MDL 1st Production 043085							
TE-731	08/13/2012	Letter from the Ohio Board of Nursing to the Compliance Unit Manager/ Supervising Attorney	OBN_MDL 1st Production 045533	OBN_MDL 1st Production 047750							
TE-732	09/20/2013	Consent Agreement Between Lyndsiey Marie Allen, L.P.N, R.N. Applicant and Ohio Board of Nursing	OBN_MDL 1st Production 059516	OBN_MDL 1st Production 062106							
TE-733	12/01/2017	Letter from Ohio State Board of Pharmacy to Amy Wildermuth Re: summary suspension order/notice of opportunity for hearing	Ohio BOP 00003054	Ohio BOP 00003057							
TE-734	07/09/2008	State Medical Board of Ohio Meeting Agenda	Ohio_State_Medical_Board_00007729	Ohio_State_Medical_Board_00009059							
TE-735	12/14/2011	State Medical Board of Ohio Meeting Agendas and Minutes	Ohio_State_Medical_Board_000053026	Ohio_State_Medical_Board_000053913							
TE-736	07/10/2013	State Medical Board of Ohio Meeting Agendas and Minutes	Ohio_State_Medical_Board_000064842	Ohio_State_Medical_Board_000065318							
TE-737	01/08/2014	State Medical Board of Ohio; Agenda; Assigned Committees	Ohio_State_Medical_Board_000067975	Ohio_State_Medical_Board_000068510							
TE-738	08/13/2014	State Medical Board of Ohio; Agenda; Assigned Committees	Ohio_State_Medical_Board_000071371	Ohio_State_Medical_Board_000072096							
TE-739	11/09/2016	State Medical Board of Ohio meeting packet, Assigned Committees	Ohio_State_Medical_Board_000083377	Ohio_State_Medical_Board_000083740							
TE-740	01/11/2017	State Medical Board of Ohio meeting packet, Assigned Committees	Ohio_State_Medical_Board_000084019	Ohio_State_Medical_Board_000084508							
TE-741	02/10/2010	State Pharmacy Board order	BOP_MDL122386	BOP_MDL122394							
TE-742	07/06/1998	OHBOP orders re various pharmacists for diversion and drug abuse	BOP_MDL211669	BOP_MDL212072							
TE-743	12/06/2004	OHBOP order re pharmacist D. Hart, diversion and drug abuse	BOP_MDL212377	BOP_MDL212400							
TE-744	03/05/2001	OHBOP orders re various pharmacists for diversion and drug abuse	BOP_MDL465897	BOP_MDL465935							
TE-745	04/08/2002	OHBOP orders re various pharmacists for diversion and drug abuse	BOP_MDL465936	BOP_MDL465962							
TE-746	08/02/2010	Minutes of the August 2-3, 2010 Ohio State Board of Pharmacy and announcement of settlement agreements re diversion	BOP_MDL466071	BOP_MDL466103							
TE-747	03/08/1999	OHBOP orders re various pharmacists for diversion and drug abuse	BOP_MDL466151	BOP_MDL466181							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-748	07/11/2012	OHBOP Order re pharmacist H. Ridgeway pertaining to prescription drug abuse and diversion	BOP_MDL467172	BOP_MDL467181							
TE-749	04/19/2012	OH Board of pharmacy Summary Suspension Order	BOP_MDL470482	BOP_MDL470490							
TE-750	Undated	Ohio State Dental Board Disciplinary Action	OSDB_MDL 1st Production_004395	OSDB_MDL 1st Production_004398							
TE-751	02/05/2013	Teva Promotion and Ad Review Process SOP BM-RA-102 (Feb. 5 2013)	TEVA_MDL_A_00553140	TEVA_MDL_A_00553149							
TE-752	07/02/2012	Teva Policies and Codes of Conduct	TEVA_MDL_A_00560852	TEVA_MDL_A_00561167							
TE-753	05/16/2018	Summit County Initial Responses to Manufacturer Defendants First Set of Request for Productions									
TE-754	05/16/2018	Cuyahoga County Initial Responses to Manufacturer Defendants First Set of Request for Productions									
TE-755	05/16/2018	Cleveland Initial Responses to Manufacturer Defendants First Set of Request for Productions									
TE-756	05/25/2018	Summit_Akron Initial Responses to Manufacturer Defendants 1st Set of Interrogatories									
TE-757	05/25/2018	Cuyahoga Initial Responses to Manufacturer Defendants 1st Set of Interrogatories									
TE-758	05/25/2018	Cleveland Response to Manufacturer Defendants 1st Set of Interrogatories									
TE-759	05/24/2018	Cuyahoga 1st Amended Responses to Manufacturer Defendant 1st Set of Interrogatories									
TE-760	06/12/2018	Cuyahoga 1st Amended Responses to Manufacturer Defendant 1st Set of Interrogatories									
TE-761	06/12/2018	Summit_Akron 1st Amended Responses to Manufacturer Defendants 1st Set of Interrogatories									
TE-762	07/03/2018	Cleveland 1st Amended Response to Manufacturer Defendants 1st Set of Interrogatories									
TE-763	07/05/2018	Summit_Akron Responses to Manufacturer Defendants 2nd Set of Interrogatories									
TE-764	07/05/2018	Cleveland Response to Manufacturer Defendants 2nd Set of Interrogatories									
TE-765	07/05/2018	Cuyahoga Responses to Manufacturer Defendants 2nd Set of Interrogatories									
TE-766	08/02/2018	Cleveland Responses to Manufactuer Defendants 2nd Set of Request for Productions									
TE-767	08/02/2018	Summit_Akron Responses to Manufactuer Defendants 2nd Set of Request for Productions									
TE-768	08/17/2018	Cleveland 2nd Amended Responses to Manufacturer Defendants 1st Set of Interrogatories									
TE-769	08/17/2018	Summit_Akron 2nd Amended Responses to Manufacturer Defendants 1st Set of Interrogatories									
TE-770	08/20/2018	Cuyahoga 2nd Amended Responses to Manufacturer Defendants 1st Set of Interrogatories									

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-771	08/21/2018	Cleveland Responses to Manufactuer Defendants Amended 2nd Set of Request for Productions									
TE-772	10/08/2018	Summit_Akron 3rd Amended Responses to Manufacturer Defendants 1st Set of Interrogatories									
TE-773	11/02/2018	Cleveland Rogs updated with SM Cohens Discovery Ruling No_ 5									
TE-774	11/02/2018	Cuyahoga Amended Responses to Manufacturer and Retail Pharma Defendants 1st Set of Interrogatories									
TE-775	11/02/2018	Summit_Akron Amended Responses to Manufacturer and Retail Pharma Defendants 1st Set of Rog									
TE-776	11/08/2018	Cleveland Supplemental Response to Manufacturer Defendant Rog. No. 11 and 18									
TE-777	11/27/2018	Cuyahoga Amended Responses to Manufacturer Defendants Rog No. 27									
TE-778	11/27/2018	Summit_Akron Supplemental Responses to Reformulated Suspicious Interrogatories by Manufacturer Defendant									
TE-779	11/28/2018	Cleveland and Cuyahoga Amended Response to Manufacturer Defendant Rog. No. 27									
TE-780	11/30/2018	Cuyahoga Written Response to Rule 30b6 Topic No. 36									
TE-781	12/14/2018	Summit_Akron 4th Amended Response to Manufacturer Dedendant First Set of Interrogatories									
TE-782	12/21/2018	Plaintiffs Supplemental Responses to Manufacturer Defendant Rog. No. 27-28									
TE-783	12/28/2018	Plaintiffs Supplemental Responses to Manufacturer Defendants Rog. No. 28-29									
TE-784	12/31/2018	Plaintiffs Responses to Manufacturer Defendants 3rd Set of Interrogatories									
TE-785	12/31/2018	Plaintiffs Supplemental Amended Responses to Manufacturer Defendants 1st Set of Interrogatories									
TE-786	12/31/2018	Plaintiffs Supplemental Amended to Manufacturers Defendant 1st Set of Rog and DR 13									
TE-787	01/07/2018	Cleveland Written Response to Defendant Rule 30b6 No 7 & 8									
TE-788	01/11/2018	Plaintiffs Response to Supplemental Interrogatory in DR 12									
TE-789	01/18/2018	Plaintiffs Supplement Response to Manufacturer Defendants 1st Set of Interrogatories									
TE-790	01/25/2019	Plaintiffs Amended Response to Discovery Ruling No 12									
TE-791	03/04/2019	Cleveland Supplemental Responses to Manufacturer Defendants Interrogatories									
TE-792	03/04/2019	Cuyahoga Supplemental Responses to Manufacturer Defendants Interrogatories									

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-793	03/04/2019	Plaintiffs Response to Manufacturer Defendants 4th Set of Interrogatories									
TE-794	03/04/2019	Plaintiffs Supplement Response to Manufacturer Defendants Rog No. 1-3_5_8-9_11-13_15_20-21_26-29									
TE-795	03/18/2019	Summit_Akron Plaintiffs Replacement Supplemental Responses and Objections to Manufacturer Defendants Interrogatory No.1_2_3_5_8_9_11_12_13_15_20_21_26_27_28_29									
TE-796	03/18/2019	Cuyahoga Replacement Supplemental Responses to Manufacturer Defendants Interrogatories									
TE-797	03/19/2019	Cleveland Replacement Amended and Supplemental Responses to Manufacturer Defendants Interrogatories									
TE-798	03/28/2019	Plaintiffs Response to Manufacturer Defendants Rog. No. 33									
TE-799	05/14/2019	Summit_Akron Supplemental Response to Manufacturer Defendants Rog. No. 23									
TE-800	05/20/2019	Cuyahoga 3rd Supplemental Responses to Manufacturer Defendants Rog. 3 and 11									
TE-801	05/20/2019	Cuyahoga Supplemental Responses to Manufacturer Defendants Rog No. 24									
TE-802	05/29/2019	Plaintiffs Written Responses to Defendants Rule 30b6 Rule - Topics 4_5_6_19									
TE-803	06/21/2019	Cuyahoga Supplemental Responses and Objections to Manufacturer Defendants' Interrogatories 14, 16 and 26									
TE-804	06/21/2019	Summit_Akron Supplemental Responses and Objections to Manufacturer Defendants' Second Set of Interrogatories 16 and 25									
TE-805	07/23/2018	Cuyahoga Responses Retail Pharma Defendant to 1st Set of Interrogatories									
TE-806	07.23.2018	Cleveland Answers to Retail Pharmacy Defendants to 1st Set of Interrogatories									
TE-807	07.23.2018	Summit_Akron Responses to Retail Pharma to 1st Set of Interrogatories									
TE-808	09.26.2018	Summit_Akron 1st Amended Responses to Retail Pharma to 1st Set of Interrogatories									
TE-809	10.31.2019	Cuyahoga Responses Retail Pharma to 1st Set of Rog and Distributor Defendant to 4th Set of Rogs									
TE-810	10.31.2018	Cuyahoga Amended Responses to Retail Pharma 1st Set of Rog and Distributor Defendants 4th Set of Rog									
TE-811	11.02.2018	Cuyahoga Amended Responses Retail Pharma and Manufacturer Defendant to 1st Set of Interrogatories									
TE-812	11.02.2018	Cleveland Response to Manufacturer and Retail Pharma Defendants 1st Set of Interrogatories									

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-813	11.02.2018	Summit_Akron Amended Responses to Manufacturer and Retail Pharma Defendants 1st Set of Rog									
TE-814	06.27.2019	Summit_Akron Amended Supplemental Responses to National Retail Pharmacy Defendants Interrogatory No. 6									
TE-815	06.27.2019	Summit_Akron Amended Supplemental Responses to National Retail Pharmacy Defendants Interrogatory No. 4, 7, 15, 16, & 19									
TE-816	07.26.2019	Cuyahoga Amended Supplemental Responses and Objections to Pharmacy Defendants Interrogatory No. 6									
TE-817	12.28.2018	Cuyahoga Supplemental Response to Distributor Defendants Rog No. 3									
TE-818	12.28.2018	Cleveland Supplemental Response to Distributor Defendant Rog. No. 3									
TE-819	12.21.2018	Summit_Akron Supplemental Responses to Distributor Defendants Rog. No. 3									
TE-820	12.17.2018	Akron Supplemental Responses to Distributor Defendants Interrogatories No. 24-27									
TE-821	12.14.2018	Plaintiffs Supplemental Responses to Distributor Defendants Interrogatories Nos 24-27									
TE-822	12.14.2018	Plaintiffs Supplemental Response to Distributor Defendants Rog. Nos. 24-27									
TE-823	11.30.2018	Akron 2nd Supplemental Responses to Distributor Defendants to Rog No. 18									
TE-824	11.30.2018	Cuyahoga 2nd Supplemental Responses to Distributor Defendants Rog. No. 18									
TE-825	11.30.2018	Cleveland 2nd Supplemental Response Distributor Defendant Rog No. 18									
TE-826	11.05.2018	Akron Supplemental Responses to Distributor Defendants Rog. 18									
TE-827	11.05.2018	Cleveland Supplemental Responses to Distributor Defendants 3rd Set of Interrogatories									
TE-828	11.05.2018	Cuyahoga Supplemental Responses to Distributors Defendants Rog. No. 18									
TE-829	10.31.2018	Cuyahoga Amended Responses to Retail Pharma 1st Set of Rog and Distributor Defendants 4th Set of Rog									
TE-830	10.31.2018	Cuyahoga Responses Retail Pharma to 1st Set of Rog and Distributor Defendant to 4th Set of Rogs									
TE-831	10.15.2018	Cleveland Response to Distributor Defendant 5th Set of Interrogatories									
TE-832	10.15.2018	Summit_Akron Responses to Distributor Defendants 5th Set of Interrogatories									
TE-833	10.15.2018	Cuyahoga Responses to Distributors Defendant 5th Set of Interrogatories									

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-834	08.31.2018	Summit_Akron 2nd Amended Responses to Distributor Defendants 2nd Set of Interrogatories									
TE-835	08.31.2018	Cuyahoga Responses to Distributors Defendant 4th Set of Interrogatories									
TE-836	08.31.2018	Summit_Akron Responses to Distributor Defendants 4th Set of Interrogatories									
TE-837	08.30.2018	Summit_Akron 1st Amended Responses to Distributor Defendants 2nd Set of Interrogatories									
TE-838	08.13.2018	Cleveland Amended Response to Distributor Defendant Rog. No. 13									
TE-839	08.13.2018	Cuyahoga 1st Amended Responses Distributor Defendants 3rd Set of Interrogatories									
TE-840	08.13.2018	Summit_Akron 1st Amended Responses to Distributor Defendants 3rd Set of Interrogatories									
TE-841	08.10.2018	Clevelands Amended Responses and Objections to Distributor Defendants Request for Production No. 13-17 and 19-22									
TE-842	08.08.2018	Cleveland Amended Reponses to Distributor Defendant Rog. No. 17									
TE-843	07.25.2018	Cuyahoga Responses to Distributor Defendant to 3rd Set of Interrogatories									
TE-844	07.24.2018	Summit_Akron Responses to Distributor Defendants Second Set of Request for Production									
TE-845	07.24.2018	Summit_Akron Responses to Distributor Defendants 3rd Set of Interrogatories									
TE-846	07.23.2018	Cleveland Response to Distributor Defendants 3rd Set of Interrogatories									
TE-847	07.02.2019	Cleveland Response to Distributor Defendants 2nd Set of Interrogatories									
TE-848	07.02.2018	Cuyahoga Responses to Distributor Defendant to 2nd Set of Interrogatories									
TE-849	07.02.2018	Summit_Akron Responses to Distributor Defendants 2nd Set of Interrogatories									
TE-850	06.20.2018	Cuyahoga 1st Amended Response to Distributor Defendants 1st Set of Interrogatories									
TE-851	06.20.2018	Summit_Akron 1st Amended Responses to Distributor Defendants 1st Set of Interrogatories									
TE-852	06.18.2018	Cleveland 1st Amended Response to Distributor Defendants 1st Set of Interrogatories									
TE-853	05.14.2019	Summit_Akron Supplemental Responses to Distributor Defendants Rog. No. 10-12									
TE-854	05.20.2019	Cuyahoga Supplemental Responses to Distributor Defendants Rog. No. 10_11_12									

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-855	03/04/2019	Cleveland Supplemental Amended Response to Retail Pharmacy Defendants 1st Set of Interrogatories									
TE-856	03/04/2019	Cuyahoga Supplemental Responses to Retail Pharmacy 1st Set of Interrogatories									
TE-857	03/04/2019	Summit_Akron Supplemental Responses to Retail Pharma Defendnants to Rog No. 4_7_15_16_19									
TE-858	03/04/2019	Cleveland Amended and Supplemental Response to Distributor Defendant Interrogatories									
TE-859	03/04/2019	Cuyahoga Supplemental Response to Distributor Defendant Interrogatories									
TE-860	03/04/2019	Summit_Akron Supplemental Responses to Distributor Defendants Rog. No. 2-4_8_12_14-17_23_27_27_29									
TE-861	03/04/2019	Distributor Defendants Report in Support of Partial Objection to Discovery Ruling No. 17 Regarding SACWIS DATA									
TE-862	10/27/2005	ACTIQ 2006 Marketing Plan	TEVA_MDL_A_03235020	TEVA_MDL_A_03235128							
TE-863	05/19/2014	Teva DNC Exemption Process (5/19/2014)	TEVA_MDL_A_00977184	TEVA_MDL_A_00977186							
TE-864	04/15/2014	Teva Do Not Call (DNC) Form Pain Care	TEVA_MDL_A_01086432	TEVA_MDL_A_01086433							
TE-865	07/01/2012	Targeting Assessment and Call Activity US Policy - 165	TEVA_MDL_A_00553163	TEVA_MDL_A_00553165							
TE-866	01/16/2014	Email removing prescriber	TEVA_MDL_A_00977857	TEVA_MDL_A_00977859							
TE-867	05/01/2012	FENTORA Brand Review (May, 2012)	TEVA_MDL_A_02970485	TEVA_MDL_A_02970485							
TE-868	01/01/2013	Fast Start Meeting (Jan. 2013).	TEVA_MDL_A_00978659	TEVA_MDL_A_00978659							
TE-869	01/19/2012	A Brand New Day: TEVA Pain Care 180-Day Plan, January – June 2012	TEVA_MDL_A_01108365	TEVA_MDL_A_01108365							
TE-870	00/00/2012	2012 FENTORA Brand Plan	TEVA_MDL_A_02767253	TEVA_MDL_A_02767266							
TE-871	02/22/2008	2008 National Sales Meeting Presentation	TEVA_MDL_A_03222359	TEVA_MDL_A_03222408							
TE-872	01/08/2007	PCS Sales Leadership Kick-Off Meeting (Jan 2007)	TEVA_MDL_A_03228476	TEVA_MDL_A_03228566							
TE-873	09/12/2019	Facilitator Guide - Fentora Finishing the Call Workshop	TEVA_MDL_A_01156937	TEVA_MDL_A_01156961							
TE-874	03/17/2014	FENTORA (fentanyl buccal tablet) CII Regional Brand Plan	TEVA_MDL_A_08680767	TEVA_MDL_A_08680785							
TE-875	07/01/2012	Integrity Principles Policy US Policy - 100	TEVA_MDL_A_00553193	TEVA_MDL_A_00553217							
TE-876		Teva 2014 North America Specialty Medicines President's Club Awards (2014)	TEVA_MDL_A_01086541	TEVA_MDL_A_01086768							
TE-877	05/26/2016	Teva Policy Statement on Suspicious Order Monitoring	TEVA_MDL_A_01037228	TEVA_MDL_A_01037235							
TE-878	02/07/2007	DEA Letter to all entities re controlled substance distribution.	TEVA_MDL_A_01039159	TEVA_MDL_A_01039162							
TE-879	09/27/2006	DEA Letter to All Entities re Responsibilities of Controlled Substance Distribution (Sept. 27, 2006)	TEVA_MDL_A_01039163	TEVA_MDL_A_01039166							
TE-880	12/27/2007	DEA Letter to All Entities re Responsibilities of Controlled Substance Distribution (December 27, 2007)	TEVA_MDL_A_01039167	TEVA_MDL_A_01039168							
TE-881	03/05/2013	SORDS Summary	TEVA_MDL_A_01042796	TEVA_MDL_A_01042796							
TE-882	02/19/2013	Teva SOM Policy Statement	TEVA_MDL_A_01042821	TEVA_MDL_A_01042821							
TE-883	01/23/2013	SORDS - Orders on DEA Hold (screen shots of system)	TEVA_MDL_A_01042832	TEVA_MDL_A_01042844							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-884	01/01/2014	Teva - SOM - SORDS PowerPoint 2014	TEVA_MDL_A_01042847	TEVA_MDL_A_01042847							
TE-885	01/16/2018	2018-01-16 RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01057584	TEVA_MDL_A_01057585							
TE-886	11/04/2013	Teva SOM - Data Tables/Forms to Be Created with Algorithms in SORDS III	TEVA_MDL_A_01060887	TEVA_MDL_A_01060887							
TE-887	01/27/2014	Teva SOM - SORDS III Option 1 Flow Chart	TEVA_MDL_A_01060888	TEVA_MDL_A_01060891							
TE-888	11/04/2013	Teva SOM - SORDS III Proposed Flow Chart	TEVA_MDL_A_01060892	TEVA_MDL_A_01060894							
TE-889	05/09/2014	Controlled Substance SOM SORDS III User Requirements	TEVA_MDL_A_01060897	TEVA_MDL_A_01060914							
TE-890	08/01/2014	TEVA SOP 8278 -(Do Not Ship List) (Aug. 01, 2014),	TEVA_MDL_A_01061094	TEVA_MDL_A_01061098							
TE-891	08/08/2014	TEVA SOP-8277 (DEA Order Holds) (Aug 8 2014)	TEVA_MDL_A_01061099	TEVA_MDL_A_01061106							
TE-892	08/01/2014	TEVA SOP-8279 (Customer Due Diligence)(Aug. 1 2014)	TEVA_MDL_A_01061107	TEVA_MDL_A_01061113							
TE-893	08/01/2014	TEVA SOP-8280 -(Customer Site Visits) (Aug. 01, 2014),	TEVA_MDL_A_01061114	TEVA_MDL_A_01061119							
TE-894	06/18/2018	TEVA SOP-8277 (DEA Order Holds) (Jun 18 2018)	TEVA_MDL_A_01158453	TEVA_MDL_A_01158462							
TE-895	06/18/2018	TEVA SOP 8278 (Do Not Ship List) (June 18, 2018).	TEVA_MDL_A_01158463	TEVA_MDL_A_01158469							
TE-896	06/18/2018	TEVA SOP 8279 (Customer Due Diligence (Jun. 18 2018)	TEVA_MDL_A_01158470	TEVA_MDL_A_01158478							
TE-897	06/18/2018	TEVA SOP-8280 -(Customer Site Visits) (June 18, 2018).	TEVA_MDL_A_01158479	TEVA_MDL_A_01158490							
TE-898	06/18/2018	TEVA SOP-8489 (Jun 18 2018)	TEVA_MDL_A_01158491	TEVA_MDL_A_01158495							
TE-899	03/21/2013	2011 Quota Req and DEA Response Pac 1.pdf	TEVA_MDL_A_01087583	TEVA_MDL_A_01087637							
TE-900	03/21/2013	2011 Quota Req and DEA Response Pac 2.pdf	TEVA_MDL_A_01087638	TEVA_MDL_A_01087683							
TE-901	03/21/2013	2012 Quota Req and DEA Response Pac 1.pdf	TEVA_MDL_A_01087684	TEVA_MDL_A_01087741							
TE-902	12/23/2011	Barr Laboratories RB0234005 12-22-2011.pdf	TEVA_MDL_A_02541088	TEVA_MDL_A_02541089							
TE-903	01/09/2012	2012 SV Quota Approval Methylphen 22Dec2011.pdf	TEVA_MDL_A_07219437	TEVA_MDL_A_07219438							
TE-904	03/20/2012	2012 SV Quota Approval Codeine 19Mar2012.pdf	TEVA_MDL_A_07219534	TEVA_MDL_A_07219535							
TE-905	12/14/2012	2012 VA Quota Approval D L Amphet 09Oct2012.pdf	TEVA_MDL_A_07219822	TEVA_MDL_A_07219823							
TE-906	12/19/2012	2012 VA Quota Denial D Amphet 09Oct2012.pdf	TEVA_MDL_A_07219886	TEVA_MDL_A_07219887							
TE-907	02/08/2013	2012 VA Quota App Morphine 19Sept2012, 113470.pdf	TEVA_MDL_A_07220078	TEVA_MDL_A_07220085							
TE-908	06/26/2013	2012 PO Quota Approval Amphet 13Jan2012.pdf	TEVA_MDL_A_07220343	TEVA_MDL_A_07220344							
TE-909	11/15/2013	2011 Quota Req and DEA Response Pac 1.pdf	TEVA_MDL_A_07228652	TEVA_MDL_A_07228706							
TE-910	11/15/2013	2011 Quota Req and DEA Response Pac 2.pdf	TEVA_MDL_A_07228762	TEVA_MDL_A_07228807							
TE-911	11/15/2013	2012 Quota Req and DEA Response Pac 1.pdf	TEVA_MDL_A_07228854	TEVA_MDL_A_07228911							
TE-912	11/15/2013	2012 Quota Req and DEA Response Pac 2.pdf	TEVA_MDL_A_07228970	TEVA_MDL_A_07229022							
TE-913	08/16/2011	TEVA Pharmaceuticals USA RL0146274 08-12-11.PDF	TEVA_MDL_A_13734192	TEVA_MDL_A_13734192							
TE-914	12/15/2011	Barr Labs RB0234005 12-15-11.pdf	TEVA_MDL_A_13734200	TEVA_MDL_A_13734200							
TE-915	12/23/2011	Barr Laboratories RB0234005 12-22-2011.pdf	TEVA_MDL_A_13734211	TEVA_MDL_A_13734212							
TE-916	12/23/2011	Teva RL0146274 PQ 12-22-11.PDF	TEVA_MDL_A_13734216	TEVA_MDL_A_13734217							
TE-917	03/20/2012	TEVA Pharmaceuticals USA RL0146274 - 03-19-12.PDF	TEVA_MDL_A_13734232	TEVA_MDL_A_13734233							
TE-918	04/18/2012	Teva Pharmaceuticals_RL0146274_04-17-2012.pdf	TEVA_MDL_A_13734254	TEVA_MDL_A_13734255							
TE-919	09/13/2012	Barr Laboratories RB0234005 09-12-2012.pdf	TEVA_MDL_A_13734273	TEVA_MDL_A_13734273							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-920	07/13/2012	Cima Laboratories Inc RC0243256 - 07-12-12.PDF	TEVA_MDL_A_13734460	TEVA_MDL_A_13734460							
TE-921	08/16/2012	Cima Labs RC0243256 08-16-2012.pdf	TEVA_MDL_A_13734497	TEVA_MDL_A_13734497							
TE-922	06/19/2018	2018 Releases Second Check.xlsx	TEVA_MDL_A_13253974	TEVA_MDL_A_13253974							
TE-923	06/07/2018	Holds by Ship To.xlsx	TEVA_MDL_A_13253975	TEVA_MDL_A_13253975							
TE-924	06/07/2018	Holds Over Time.xlsx	TEVA_MDL_A_13253976	TEVA_MDL_A_13253976							
TE-925	06/19/2018	2017 Releases Second Check.xlsx	TEVA_MDL_A_13253977	TEVA_MDL_A_13253977							
TE-926	12/14/2018	SORDS Pended Orders	TEVA_MDL_A_13583538	TEVA_MDL_A_13583538							
TE-927	12/12/2018	SOM Customer Risk Evaluation Database.xlsx	TEVA_MDL_A_13253978	TEVA_MDL_A_13253978							
TE-928	12/12/2018	2018-12-12 OM DEA Suspicious Order Monitoring.xlsx	TEVA_MDL_A_13253979	TEVA_MDL_A_13253979							
TE-929	02/13/2013	2018-12-13 OM DEA Suspicious Order Monitoring.xlsx	TEVA_MDL_A_13583539	TEVA_MDL_A_13583539							
TE-930	05/08/2017	Suspicious Order Report Re: Capital Wholesale	TEVA_MDL_A_01463918	TEVA_MDL_A_01463918							
TE-931	05/08/2017	Suspicious Order Report	TEVA_MDL_A_01056166	TEVA_MDL_A_01056171							
TE-932	05/08/2017	2015-04-18 Osborn Suspicious Order Report.docx	TEVA_MDL_A_01056173	TEVA_MDL_A_01056173							
TE-933	04/16/2018	2015-07-31 Osborn Suspicious Order Report.docx	TEVA_MDL_A_01056175	TEVA_MDL_A_01056175							
TE-934	04/16/2018	2018-01-16 RDC Fairfield Suspicious Order Report.docx	TEVA_MDL_A_01057586	TEVA_MDL_A_01057587							
TE-935	04/16/2018	2018-01-17 RDC Fairfield Suspicious Order Report.docx	TEVA_MDL_A_01057590	TEVA_MDL_A_01057591							
TE-936	04/16/2018	2018-01-18 RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01057593	TEVA_MDL_A_01057594							
TE-937	04/16/2018	2018-01-23 RDC Fairfield Suspicious Order Report.docx	TEVA_MDL_A_01057596	TEVA_MDL_A_01057597							
TE-938	04/16/2018	2018-01-23 RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01057598	TEVA_MDL_A_01057599							
TE-939	04/16/2018	2018-02-06 RDC Fairfield Suspicious Order Report.docx	TEVA_MDL_A_01057601	TEVA_MDL_A_01057601							
TE-940	04/16/2018	2018-02-06 RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01057602	TEVA_MDL_A_01057602							
TE-941	04/16/2018	2018-02-07 RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01057604	TEVA_MDL_A_01057604							
TE-942	04/16/2018	2018-02-13 RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01057606	TEVA_MDL_A_01057606							
TE-943	04/16/2018	2018-02-15 RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01057608	TEVA_MDL_A_01057608							
TE-944	01/16/2018	2018-03-30 RDC Fairfield Suspicious Order Report.docx	TEVA_MDL_A_01057612	TEVA_MDL_A_01057612							
TE-945	01/17/2018	2018-01-16 RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01058103	TEVA_MDL_A_01058104							
TE-946	02/14/2013	2018-04-18 R&S Philadelphia Suspicious Order Report.docx	TEVA_MDL_A_01061044	TEVA_MDL_A_01061045							
TE-947	12/01/2014	DEA Notification Form.doc	TEVA_MDL_A_02331377	TEVA_MDL_A_02331377							
TE-948	08/10/2017	2014-12-01 Richie Suspicious Order Report.docx	TEVA_MDL_A_02345901	TEVA_MDL_A_02345901							
TE-949	01/22/2016	Letter from Joseph Tomkiewicz to Richie Pharmacal	TEVA_MDL_A_01046053	TEVA_MDL_A_01046053							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-950	11/21/2014	Internal Memorandum from Joseph Tomkiewicz to Colleen McGinn	TEVA_MDL_A_02063682	TEVA_MDL_A_02063685							
TE-951	06/25/2015	Letter from Joseph Tomkiewicz to Drug Enforcement Agency	TEVA_MDL_A_02063701	TEVA_MDL_A_02063701							
TE-952	12/01/2014	2014-12-01 Richie Suspicious Order Report.docx	TEVA_MDL_A_02342525	TEVA_MDL_A_02342525							
TE-953	06/04/2015	TEVA SOP - 8489	TEVA_MDL_A_03160173	TEVA_MDL_A_03160175							
TE-954	07/08/2014	Teva Pharmaceuticals North America, Order Management, DEF OPS Enhancements, Functional Design Specification	TEVA_MDL_A_03479111	TEVA_MDL_A_03479127							
TE-955	10/15/2015	Due diligence documents re: Publix	TEVA_MDL_A_01056233	TEVA_MDL_A_01056407							
TE-956	Undated	Due diligence documents re: Publix	TEVA_MDL_A_01056802	TEVA_MDL_A_01057182							
TE-957	Undated	SORDS Database Configuration	TEVA_MDL_A_01060884	TEVA_MDL_A_01060886							
TE-958	04/19/2017	EMED Suspicious Order Report.docx	TEVA_MDL_A_01061035	TEVA_MDL_A_01061035							
TE-959	12/13/2017	R&S Suspicious Order Report.docx	TEVA_MDL_A_01061036	TEVA_MDL_A_01061037							
TE-960	01/16/2018	R&S Suspicious Order Report.docx	TEVA_MDL_A_01061038	TEVA_MDL_A_01061038							
TE-961	01/16/2018	RDC Fairfield Suspicious Order Report.docx	TEVA_MDL_A_01061039	TEVA_MDL_A_01061040							
TE-962	01/16/2018	RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_01061041	TEVA_MDL_A_01061042							
TE-963	01/18/2018	RDC Rochester Suspicious Order Report.docx	TEVA_MDL_A_04205782	TEVA_MDL_A_04205783							
TE-964	03/30/2018	RDC Fairfield Suspicious Order Report.docx	TEVA_MDL_A_01061043	TEVA_MDL_A_01061043							
TE-965	04/18/2018	R&S Philadelphia Suspicious Order Report.docx	TEVA_MDL_A_01061044	TEVA_MDL_A_01061045							
TE-966	01/16/2018	RDC Rochester State Suspicious Order Report.docx	TEVA_MDL_A_01061046	TEVA_MDL_A_01061047							
TE-967	01/18/2018	RDC Rochester State Suspicious Order Report.docx	TEVA_MDL_A_04205784	TEVA_MDL_A_04205785							
TE-968	10/07/2010	Timeline of Events Leading Up to the REMS Requirement for Opioid Analgesics,	TEVA_MDL_A_00349300	TEVA_MDL_A_00349301							
TE-969	06/02/2015	REMS Operations Global Pharmacovigilance & Regulatory Slide Deck	TEVA_MDL_A_01066698	TEVA_MDL_A_01066698							
TE-970	08/03/2018	TIRF REMS Advisory Committee Briefing Document	TEVA_MDL_A_01089148	TEVA_MDL_A_01089248							
TE-971	01/15/2012	Teva REMS – Regulatory Affairs Lunch & Learn (Jan 15 2012)	TEVA_MDL_A_03498285	TEVA_MDL_A_03498285							
TE-972		Distributor enrollment form	TEVA_MDL_A_13748755	TEVA_MDL_A_13748758							
TE-973		TIRF REMS Access Education Program for Prescribers and Pharmacists	TEVA_MDL_A_13747107	TEVA_MDL_A_13747121							
TE-974		TIRF REMS Prescriber Enrollment Form	TEVA_MDL_A_13743867	TEVA_MDL_A_13743869							
TE-975		TIRF REMS Patient-Prescriber Agreement Form	TEVA_MDL_A_13750620	TEVA_MDL_A_13750622							
TE-976		TIRF FREMS Corporate Pharmacy Enrollment Form	TEVA_MDL_A_13751497	TEVA_MDL_A_13751501							
TE-977		TIRF REMS Prescriber Enrollees	TEVA_MDL_A_13755784	TEVA_MDL_A_13755784							
TE-978		TIRF REMS Pharmacy Enrollees	TEVA_MDL_A_13748759	TEVA_MDL_A_13748759							
TE-979		TIRF REMS Patient Enrollees	TEVA_MDL_A_13744290	TEVA_MDL_A_13744290							
TE-980		TIRF REMS Prescriptions	TEVA_MDL_A_13751051	TEVA_MDL_A_13751051							
TE-981	REMOVED	REMOVED	REMOVED	REMOVED							
TE-982		TRIG Database of TIRF REMS Access Program Enrollment Forms, Agreements, and Prescription Data	TRIGMDL00000001	TRIGMDL00355214							
TE-983		TIRF REMS Reporting	TEVA_MDL_A_00446500	TEVA_MDL_A_00446569							
TE-984		TIRF REMS Reporting	TEVA_MDL_A_00446500	TEVA_MDL_A_00446569							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-985		TIRF REMS Reporting	TEVA_MDL_A_00446500	TEVA_MDL_A_00446569							
TE-986		TIRF REMS Reporting	TEVA_MDL_A_00446500	TEVA_MDL_A_00446569							
TE-987		TIRF REMS Reporting	TEVA_MDL_A_00446500	TEVA_MDL_A_00446569							
TE-988		TIRF REMS Reporting	TEVA_MDL_A_00446500	TEVA_MDL_A_00446569							
TE-989		TIRF REMS Reporting	TEVA_MDL_A_00447807	TEVA_MDL_A_00448395							
TE-990		TIRF REMS Reporting	TEVA_MDL_A_00447807	TEVA_MDL_A_00448395							
TE-991		TIRF REMS Reporting	TEVA_MDL_A_00447807	TEVA_MDL_A_00448395							
TE-992		TIRF REMS Reporting	TEVA_MDL_A_00447807	TEVA_MDL_A_00448395							
TE-993		24-month REMS Assessment Report	PAR_OPIOID_MDL_0001217772	PAR_OPIOID_MDL_0001218742							
TE-994		TIRF REMS Reporting	INSYS-MDL-015176326	INSYS-MDL-015176327							
TE-995		IMS Xponent	ALLERGAN_MDL_02485011	ALLERGAN_MDL_02485011							
TE-996		IMS Xponent	ALLERGAN_MDL_03281086	ALLERGAN_MDL_03281086							
TE-997	REMOVED	REMOVED	REMOVED	REMOVED							
TE-998	04/01/2018	21 C.F.R. § 202.1	TEVA_MDL_A_13743915	TEVA_MDL_A_13743925							
TE-999	04/01/2018	21 C.F.R. § 312.2	TEVA_MDL_A_13754803	TEVA_MDL_A_13754805							
TE-1000	05/01/2019	Akinboro, Oladimeji Akinola, Stanley Nwabudike, Camille Edwards, Diana Cirstea, Nana Oduraa Addo-Tabiri, Michael Voisine, . . . Adetola A. Kassim. “Opioid Use Is NOT Associated with in-Hospital Mortality Among Patients with Sickle CELL Disease in the United States: Findings from the National Inpatient Sample.” <i>Blood</i> Vol. 132, Supplement 1: 315 (2018).	TEVA_MDL_A_13745797	TEVA_MDL_A_13745802							
TE-1001	04/11/2018	Bennett, Daniel S., “Breakthrough Pain: Treatment Rationale With Opioids,” https://www.medscape.org/viewarticle/461612 , accessed April 11, 2018.	TEVA_MDL_A_13745223	TEVA_MDL_A_13745237							
TE-1002	02/21/2001	Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341, 351 n.5 (2001)	TEVA_MDL_A_13746976	TEVA_MDL_A_13746983							
TE-1003	05/00/2011	Burton, Beth and Giovambattista Zeppetella. “Assessing the impact of breakthrough cancer pain.” <i>British Journal of Nursing</i> Vol. 20, Supplement 5 (2011): pp. S14-S19.	TEVA_MDL_A_13745528	TEVA_MDL_A_13745532							
TE-1004	12/00/2011	Cephalon, Inc., <i>Special Report: An Integrated Risk Evaluation and Mitigation Strategy for Fentanyl Buccal Tablet (Fentora) and Oral Transmucosal Fentanyl Citrate (Actiq)</i> , 2011.	TEVA_MDL_A_13747854	TEVA_MDL_A_13747865							
TE-1005	12/00/2015	CMS, <i>Pharmacy Self-Auditing</i> , December 2015.	TEVA_MDL_A_13755688	TEVA_MDL_A_13755703							
TE-1006	00/00/2001	Collett, B. J. “Chronic opioid therapy for non-cancer pain.” <i>British Journal of Anaesthesia</i> Vol. 87, No. 1 (2001): pp. 133-43.	TEVA_MDL_A_13751579	TEVA_MDL_A_13751589							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1007	00/00/2005	FDA CDER, <i>MAPP 6700.1: Risk Management Activities in OND and ODS, Manual of Policies and Procedures</i> .	TEVA_MDL_A_13747336	TEVA_MDL_A_13747343							
TE-1008	07/12/2018	FDA, "'Off-Label' and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices - Information Sheet," July 12, 2018, http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm , accessed April 23, 2019.	TEVA_MDL_A_13747677	TEVA_MDL_A_13747679							
TE-1009	04/04/2019	FDA, "A Guide to Safe Use of Pain Medicine," https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm095673.htm , accessed April 4, 2019.	TEVA_MDL_A_13749339	TEVA_MDL_A_13749343							
TE-1010	09/07/2017	FDA, "Approved Risk Evaluation and Mitigation Strategies," September 7, 2017, https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemsDetails.page&REMS=60 , accessed February 14, 2019.	TEVA_MDL_A_13747044	TEVA_MDL_A_13747045							
TE-1011	00/00/2018	FDA, "Development & Approval Process (Drugs)," https://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm , accessed February 14, 2019.	TEVA_MDL_A_13747304	TEVA_MDL_A_13747306							
TE-1012	02/19/2019	FDA, "FDA Approved Drug Products, Fentora," https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppNo=021947 , accessed February 19, 2019.	TEVA_MDL_A_13743383	TEVA_MDL_A_13743387							
TE-1013	02/13/2019	FDA, "FDA's Role in Managing Medication Risks," https://www.fda.gov/Drugs/DrugSafety/REMS/ucm592672.htm , accessed February 13, 2019.	TEVA_MDL_A_13744625	TEVA_MDL_A_13744628							
TE-1014	01/13/2009	FDA, "Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices," January 13, 2009, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-reprint-practices-distribution-medical-journal-articles-and-medical-or-scientific-reference , accessed February 14, 2019.	TEVA_MDL_A_13755642	TEVA_MDL_A_13755647							
TE-1015	00/00/2014	FDA, "Standardizing and Evaluating Risk Evaluation and Mitigation Strategies," 2014.	TEVA_MDL_A_13745803	TEVA_MDL_A_13745832							
TE-1016	08/03/2018	FDA, <i>Addendum to the FDA briefing information to summarize TIRF REMS issues relevant to the August 3, 2018 meeting</i> , July 25, 2018.	TEVA_MDL_A_13751607	TEVA_MDL_A_13751630							
TE-1017	00/00/2006	FDA, <i>An Introduction to the Improved FDA Prescription Drug Labeling</i> , 2006.	TEVA_MDL_A_13747563	TEVA_MDL_A_13747630							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1018	03/00/2005	FDA, <i>Guidance for Industry, Development and Use of Risk Minimization Action Plans</i> , March 2005. https://www.fda.gov/downloads/drugs/guidancecompliance/regulatoryinformation/guidances/ucm071616.pdf .	TEVA_MDL_A_13744094	TEVA_MDL_A_13744120							
TE-1019	05/00/1999	FDA, <i>Managing the Risks From Medical Product Use Creating a Risk Management Framework</i> , May 1999. https://hdl.handle.net/2027/umn.31951d016951490 .	TEVA_MDL_A_13743162	TEVA_MDL_A_13743325							
TE-1020	06/00/2018	FDA, <i>Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers; Guidance for Industry</i> , June 2018. https://www.fda.gov/downloads/drugs/guidancecompliance/regulatoryinformation/guidances/ucm537130.pdf .	TEVA_MDL_A_13743944	TEVA_MDL_A_13743966							
TE-1021	04/00/1982	FDA. “Use of Approved Drugs for Unlabeled Indications.” <i>FDA Drug Bulletin</i> Vol. 12, No. 1 (April, 1982).	TEVA_MDL_A_13749846	TEVA_MDL_A_13749851							
TE-1022	00/00/2008	Fine, Perry G., Christine Miaskowski, and Michael Brennan, <i>SELECT (Stratify, Examine, Listen, Evaluate, Control, Tailor): Opioid-Based Management of Persistent and Breakthrough Pain</i> , 2008.	TEVA_MDL_A_13744263	TEVA_MDL_A_13744274							
TE-1023	00/00/2006	Furlan, Andrea D., Juan A. Sandoval, Angela Mailis-Gagnon, and Eldon Tunks. “Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects.” <i>CMAJ</i> Vol. 174, No. 11 (2006): pp. 1589-94.	TEVA_MDL_A_13744411	TEVA_MDL_A_13744416							
TE-1024	06/27/2018	Gottlieb, Scott., <i>Remarks by Dr. Gottlieb at the FDA Online Opioid Summit</i> , June 27, 2018. https://www.fda.gov/NewsEvents/Speeches/ucm611945.htm .	TEVA_MDL_A_13744139	TEVA_MDL_A_13744144							
TE-1025	03/03/1998	Haythornthwaite, Jennifer A., Lynette A. Menefee, Amy L. Quatrano-Piacentini, and Marco Pappagallo. “Outcome of Chronic Opioid Therapy for Non-Cancer Pain.” <i>Journal of Pain and Symptom Management</i> Vol. 15, No. 3 (1998): pp. 185-94.	TEVA_MDL_A_13743842	TEVA_MDL_A_13743851							
TE-1026	09/00/2010	Jamison, Robert N., Edgar L. Ross, Edward Michna, Li Q. Chen, Caroline Holcomb, and Ajay D. Wasan. “Substance Misuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy: A Randomized Trial.” <i>Pain</i> Vol. 150, No. 3 (2010): pp. 390-400.	TEVA_MDL_A_13744668	TEVA_MDL_A_13744690							
TE-1027	07/29/2011	Jamison, Robert N., Juliana Serrailier, and Edward Michna. “Assessment and Treatment of Abuse Risk in Opioid Prescribing for Chronic Pain.” <i>Pain Research and Treatment</i> Vol. 2011 (2011): pp. 1-12.	TEVA_MDL_A_13748244	TEVA_MDL_A_13748255							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1028	09/14/2004	Kalso, Eija, Jayne E. Edwards, R. Andrew Moore, and Henry J. McQuay. "Opioids in chronic non-cancer pain: systematic review of efficacy and safety." <i>Pain</i> Vol. 112, No. 3 (2004): pp. 372-80.	TEVA_MDL_A_13755623	TEVA_MDL_A_13755631							
TE-1029	09/00/2015	Levy, Benjamin, Leonard Paulozzi, Karin A. Mack, and Christopher M. Jones. "Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012." <i>American Journal of Preventive Medicine</i> Vol. 49, No. 3 (2015): pp. 409-13.	TEVA_MDL_A_13747135	TEVA_MDL_A_13747142							
TE-1030	09/00/2004	Michna, Edward, Edgar L. Ross, Wilfred L. Hynes, Srdjan S. Nedeljkovic, Sharonah Soumekh, David Janfaza, . . . Robert N. Jamison. "Predicting Aberrant Drug Behavior in Patients Treated for Chronic Pain: Importance of Abuse History." <i>Journal of Pain and Symptom Management</i> Vol. 28, No. 3 (2004): pp. 250-58.	TEVA_MDL_A_13750110	TEVA_MDL_A_13750118							
TE-1031	10/00/2013	Nalamachu, Srinivas, David Charles, Kelly Erola, Laura Knobel, Christina Mayville, Wesley Mizutani, . . . Robert Twillman, <i>Prescription Pain Medication: Preserving Patient Access While Curbing Abuse</i> , 2013.	TEVA_MDL_A_13748760	TEVA_MDL_A_13748767							
TE-1032	01/06/2011	Nalamachu, Srinivas, David Hassman, Mark S Wallace, Sam Dumble, Rob Derrick, and Julian Howell. "Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain." <i>Current Medical Research and Opinion</i> Vol. 27, No. 3 (2011): pp. 519-30.	TEVA_MDL_A_13754790	TEVA_MDL_A_13754802							
TE-1033	00/00/2010	Noble, Meredith et al. "Long-term opioid management for chronic noncancer pain." <i>The Cochrane Database of Systematic Reviews</i> Vol. 1 (2010): pp. 1-69.	TEVA_MDL_A_13745457	TEVA_MDL_A_13745527							
TE-1034	00/00/2007	Passik, S. D., and K. L. Kirsh. "Weighing in on the off-label use of Actiq for noncancer-related pain: a recipe for success or a recipe for disaster?" <i>Pain Medicine</i> Vol. 8, No. 2 (2007): pp. 130-3.	TEVA_MDL_A_13748335	TEVA_MDL_A_13748338							
TE-1035	00/00/2011	Passik, Steven D., John Messina, Anthony Golsorkhi, and Fang Xie. "Aberrant Drug-Related Behavior Observed During Clinical Studies Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet for Breakthrough Pain." <i>Journal of Pain and Symptom Management</i> Vol. 41, No. 1 (2011): pp. 116-25.	TEVA_MDL_A_13750557	TEVA_MDL_A_13750566							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1036	10/00/1997	Simpson, Richard K., Everton A. Edmondson, Charles F. Constant, and Connie Collier. "Transdermal fentanyl as treatment for chronic low back pain." <i>Journal of Pain and Symptom Management</i> Vol. 14, No. 4 (1997): pp. 218-24.	TEVA_MDL_A_13750632	TEVA_MDL_A_13750638							
TE-1037	03/06/2019	Substance Abuse and Mental Health Services Administration (SAMHSA), "The CBHSQ Report: How People Obtain the Prescription Pain Relievers they Misuse," 2017. https://www.samhsa.gov/data/sites/default/files/report_2686/ShortReport-2686.html , accessed March 6, 2019.	TEVA_MDL_A_13748396	TEVA_MDL_A_13748401							
TE-1038	03/04/2019	Summit County, Cuyahoga County, and the Cities of Akron and Cleveland, Ohio Plaintiffs' Responses and Objections to Manufacturer Defendants' Fourth Set of Interrogatories, <i>In Re: National Prescription Opiate Litigation</i> , Case No. 17-md-2804, United States District Court for the Northern District of Ohio Eastern Division.									
TE-1039	00/00/2007	Taylor, Donald R., Lynn R. Webster, Steven Y. Chun, Jeffrey Reinking, Mary Stegman, Steven Shoemaker, and Barry V. Fortner. "Impact of Breakthrough Pain on Quality of Life in Patients with Chronic, Noncancer Pain: Patient Perceptions and Effect of Treatment with Oral Transmucosal Fentanyl Citrate (OTFC, ACTIQ)." <i>Pain Medicine</i> Vol. 8, No. 3 (2007): pp. 281-88.	TEVA_MDL_A_13743713	TEVA_MDL_A_13743720							
TE-1040	00/00/2019	TIRF REMS Access, "Frequently Asked Questions," https://www.tirfremssaccess.com/TirfUI/remss/pdf/faq.pdf .	TEVA_MDL_A_13745560	TEVA_MDL_A_13745571							
TE-1041	00/00/2019	TIRF REMS Access, "Knowledge Assessment," https://www.tirfremssaccess.com/TirfUI/remss/pdf/education-and-ka.pdf .	TEVA_MDL_A_13751089	TEVA_MDL_A_13751101							
TE-1042	04/24/2019	U.S. Drug Enforcement Administration, "Practitioner's Manual - Section V - Valid Prescription Requirements," https://www.deadiversion.usdoj.gov/pubs/manuals/pract/section5.htm , accessed April 24, 2019.	TEVA_MDL_A_13751201	TEVA_MDL_A_13751203							
TE-1043	04/24/2019	U.S. Drug Enforcement Agency, "Drug Scheduling," https://www.dea.gov/drug-scheduling , accessed April 24, 2019.	TEVA_MDL_A_13744403	TEVA_MDL_A_13744404							
TE-1044	07/30/1998	Washington Legal Found. v. Friedman, 13 F. Supp. 2d 51, 56 (D.D.C. 1998)	TEVA_MDL_A_13744536	TEVA_MDL_A_13744554							
TE-1045	10/10/2017	Webster, Lynn R. and M. Beth Dove, "Optimizing Opioid Treatment for Breakthrough Pain," 2007. www.medscape.org/viewarticle/563417 , accessed October 10, 2017.	TEVA_MDL_A_13746391	TEVA_MDL_A_13746403							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1046	00/00/2013	Webster, Lynn R., Kieran A. Slevin, Arvind Narayana, Craig Q. Earl, and Ronghua Yang. "Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes." <i>Pain Medicine</i> Vol. 14, No. 9 (2013): pp. 1332-45.	TEVA_MDL_A_13743349	TEVA_MDL_A_13743362							
TE-1047	09/15/2008	Misdeameanor Guilty Plea, US v. Cephalon, Inc., United States District Court for the Eastern District of Pennsylvania, September 15, 2008, available at https://www.justice.gov/civil/file/892071/download .	TEVA_MDL_A_13744417	TEVA_MDL_A_13744429							
TE-1048	00/00/2003	Office of Inspector General, "Compliance Program Guidance for Pharmaceutical Manufacturers," ("OIG Guidance"), 2003, https://oig.hhs.gov/fraud/docs/complianceguidance/042803pharmacymfgnonfr.pdf .	TEVA_MDL_A_13744480	TEVA_MDL_A_13744535							
TE-1049	10/00/2017	"Neurontin (Gabapentin) Label," 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf .	TEVA_MDL_A_13751052	TEVA_MDL_A_13751088							
TE-1050	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1051	04/00/2017	"Fentora Label, April 2017," 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021947s019lbl.pdf .	TEVA_MDL_A_13746757	TEVA_MDL_A_13746783							
TE-1052		"How the opioid crackdown is backfiring," 2018. https://www.politico.com/story/2018/08/28/how-the-opioid-crackdown-is-backfiring-752183 , accessed May 1, 2019.	TEVA_MDL_A_13747652	TEVA_MDL_A_13747660							
TE-1053	09/00/2018	"Hysingla ER Label, September 2018," 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf .	TEVA_MDL_A_13747155	TEVA_MDL_A_13747191							
TE-1054	07/31/2017	"Neonatal Abstinence Syndrome," available at https://medlineplus.gov/ency/article/007313.htm , accessed May 5, 2019.	TEVA_MDL_A_13744132	TEVA_MDL_A_13744136							
TE-1055	06/00/2017	"Trazodone Label," 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf .	TEVA_MDL_A_13743870	TEVA_MDL_A_13743884							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1056	10/14/2018	American Addiction Centers, “Drug Abuse and Chemical Imbalance in the Brain: Dopamine, Serotonin & More,” https://americanaddictioncenters.org/health-complications-addiction/chemical-imbalance , accessed April 26, 2019.	TEVA_MDL_A_13748724	TEVA_MDL_A_13748735							
TE-1057	00/00/2018	American Chronic Pain Association, “ACPA Resource Guide to Chronic Pain Management: An Integrated Guide to Medical, Interventional, Behavioral, Pharmacologic and Rehabilitation Therapies,” 2018. https://www.theacpa.org/wp-content/uploads/2018/03/ACPA_Resource_Guide_2018-Final-v2.pdf .	TEVA_MDL_A_13744691	TEVA_MDL_A_13744842							
TE-1058	00/00/2013	American Psychiatric Association. “Opioid Use Disorder.” <i>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)</i> , 304.00, 2013.	TEVA_MDL_A_13745602	TEVA_MDL_A_13745610							
TE-1059	00/00/2007	American RSDHope, “Medical Articles - Your Doctor and You,” http://www.rsdhope.org/your-doctor-and-you.html , accessed April 26, 2019.	TEVA_MDL_A_13745752	TEVA_MDL_A_13745754							
TE-1060	04/12/2011	American Society of Addiction Medicine, “Definitions Related to the Use of Opioids for the Treatment of Pain: Consensus Statement of the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine,” 2001. https://www.asam.org/docs/default-source/public-policy-statements/1opioid-definitions-consensus-2-011.pdf .	TEVA_MDL_A_13744372	TEVA_MDL_A_13744385							
TE-1061	11/00/2017	Ballantyne, Jane C. “Opioids for the treatment of chronic pain: mistakes made, lessons learned, and future directions.” <i>Anesthesia & Analgesia</i> Vol. 125, No. 5 (2017): pp. 1769-78.	TEVA_MDL_A_13750567	TEVA_MDL_A_13750576							
TE-1062	00/00/2017	Berrettini, Wade. “A brief review of the genetics and pharmacogenetics of opioid use disorders.” <i>Dialogues in Clinical Neuroscience</i> Vol. 19, No. 3 (2017): pp. 229-36, https://www.ncbi.nlm.nih.gov/pubmed/29302220 .	TEVA_MDL_A_13750623	TEVA_MDL_A_13750631							
TE-1063	04/24/2019	Centers for Disease Control and Prevention, “CDC Advises Against Misapplication of the Guideline for Prescribing Opioids for Chronic Pain,” 2019. https://www.cdc.gov/media/releases/2019/s0424-advises-misapplication-guideline-prescribing-opioids.html , accessed April 26, 2019.	TEVA_MDL_A_13750131	TEVA_MDL_A_13750137							
TE-1064	03/08/2019	Centers for Disease Control and Prevention, “Fact Sheets - Alcohol Use and Your Health,” https://www.cdc.gov/alcohol/fact-sheets/alcohol-use.htm , accessed March 8, 2019.	TEVA_MDL_A_13748833	TEVA_MDL_A_13748835							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1065	12/19/2018	Centers for Disease Control and Prevention, “Fentanyl,” https://www.cdc.gov/drugoverdose/opioids/fentanyl.html , accessed March 18, 2019.	TEVA_MDL_A_13750180	TEVA_MDL_A_13750183							
TE-1066	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1067	02/11/2014	Cheatle, Martin D., Thomas Wasser, Carolyn Foster, Akintomi Olugbodi, and Jessica Bryan. “Prevalence of suicidal ideation in patients with chronic non-cancer pain referred to a behaviorally based pain program.” <i>Pain Physician</i> Vol. 17, No. 3 (2014): pp. E359-67.	TEVA_MDL_A_13750138	TEVA_MDL_A_13750147							
TE-1068	03/18/2016	Dowell, Deborah, Tamara Haegerich, and Roger Chou. “CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016.” <i>Morbidity and Mortality Weekly Report</i> Vol. 65, No. 1 (2016): pp. 1-49.	TEVA_MDL_A_13749764	TEVA_MDL_A_13749815							
TE-1069	04/25/2019	Dowell, Deborah, Tamara Haegerich, and Roger Chou. “No Shortcuts to Safer Opioid Prescribing.” <i>New England Journal of Medicine</i> (2019): Online at https://www.nejm.org/doi/full/10.1056/NEJMp1904190 .	TEVA_MDL_A_13743434	TEVA_MDL_A_13743436							
TE-1070	09/00/2016	Dueñas, María, Begona Ojeda, Alejandro Salazar, Juan Antonio Mico, and Inmaculada Failde. “A review of chronic pain impact on patients, their social environment and the health care system.” <i>Journal of Pain Research</i> Vol. 9 (2016): pp. 457-61.	TEVA_MDL_A_13749852	TEVA_MDL_A_13749862							
TE-1071	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1072	03/18/2019	FDA, “Generic Drugs: Questions & Answer,” https://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm , accessed March 18, 2019.	TEVA_MDL_A_13744629	TEVA_MDL_A_13744636							
TE-1073	04/00/2019	FDA, “REMS: FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary, Guidance for Industry,” April 2019. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM521504.pdf .	TEVA_MDL_A_13743930	TEVA_MDL_A_13743942							
TE-1074	08/00/2017	FDA, “Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS),” August 2017. https://www.accessdata.fda.gov/drugsatfda_docs/remis/TIRF_2017-09-07_Full.pdf .	TEVA_MDL_A_13750094	TEVA_MDL_A_13750109							
TE-1075	04/00/2017	Federation of State Medical Boards, “Guidelines for the Chronic Use of Opioid Analgesics,” April 2017. http://www.fsmb.org/siteassets/advocacy/policies/opioid_guidelines_as_adopted_april-2017_final.pdf .	TEVA_MDL_A_13755648	TEVA_MDL_A_13755669							
TE-1076	REMOVED	REMOVED	REMOVED	REMOVED							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1077	03/05/2018	Frakt, Austin. "Overshadowed by the Opioid Crisis: A Comeback by Cocaine." <i>The New York Times</i> , March 5, 2018.	TEVA_MDL_A_13747192	TEVA_MDL_A_13747194							
TE-1078	08/00/2012	Gaskin, Darrell J., and Patrick Richard. "The economic costs of pain in the United States." <i>The Journal of Pain</i> Vol. 13, No. 8 (2012): pp. 715-24.	TEVA_MDL_A_13745110	TEVA_MDL_A_13745119							
TE-1079	00/00/2011	Goldberg, Daniel S., and Summer J. McGee. "Pain as a Global Public Health Priority." <i>BMC Public Health</i> Vol. 11, No. 1 (2011): pp. 770-75.	TEVA_MDL_A_13743885	TEVA_MDL_A_13743889							
TE-1080	01/00/2016	Governor's Cabinet Opiate Action Team, "Ohio Guideline for the Management of Acute Pain Outside of Emergency Departments," 2016. https://mha.ohio.gov/Portals/0/assets/Initiatives/GCOAT/Guidelines-Acute-Pain-20160119.pdf , accessed May 1, 2019.	TEVA_MDL_A_13744137	TEVA_MDL_A_13744138							
TE-1081	01/10/2012	Guarino, Anthony and Martha Cornell. "Breakthrough Pain in Non-Cancer Patients." <i>Practical Pain Management</i> Vol. 6, No. 3 (2012): pp. 1-5.	TEVA_MDL_A_13751600	TEVA_MDL_A_13751606							
TE-1082	03/27/2019	Heubusch, John, "The War on Opioids is Saving Lives. But It's Also Killing People Like Me.," March 27, 2019. https://www.washingtonpost.com/opinions/the-war-on-opioids-is-saving-lives-but-its-also-killing-people-like-me/2019/03/27/cea00af6-50c2-11e9-a3f7-78b7525a8d5f_story.html , accessed April 26, 2019.	TEVA_MDL_A_13743910	TEVA_MDL_A_13743912							
TE-1083	08/30/2006	Højsted, Jette and Per Sjøgren. "Addiction to opioids in chronic pain patients: a literature review." <i>European Journal of Pain</i> Vol. 11, No. 5 (2007): pp. 490-518.	TEVA_MDL_A_13755080	TEVA_MDL_A_13755108							
TE-1084	06/00/2012	Intermountain Healthcare, "Management of Chronic Non-Cancer Pain," 2012. https://intermountainhealthcare.org/ext/Dcmnt?ncid=521023323 .	TEVA_MDL_A_13746687	TEVA_MDL_A_13746714							
TE-1085	07/00/2002	Kosten, Thomas R. and Tony P. George. "The neurobiology of opioid dependence: implications for treatment." <i>Science & Practice Perspectives</i> Vol. 1, No. 1 (2002): p. 13.	TEVA_MDL_A_13745170	TEVA_MDL_A_13745177							
TE-1086	05/00/2011	Ling, Walter, Larissa Mooney, and Maureen Hillhouse. "Prescription opioid abuse, pain and addiction: clinical issues and implications." <i>Drug and Alcohol Review</i> Vol. 30, No. 3 (2011): pp. 300-05.	TEVA_MDL_A_13748181	TEVA_MDL_A_13748190							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1087	12/10/2018	Llorente, Elizabeth, “As doctors taper or end opioid prescriptions, many patients driven to despair, suicide,” December 10, 2018. https://www.foxnews.com/health/as-opioids-become-taboo-doctors-taper-down-or-abandon-pain-patients-driving-many-to-suicide , accessed May 1, 2019.	TEVA_MDL_A_13751184	TEVA_MDL_A_13751200							
TE-1088	05/00/2012	Margarit, Cesar, Joaquim Juliá, Rafael López, Antonio Anton, Yolanda Escobar, Ana Casas, . . . Francisco Zaragoza. “Breakthrough cancer pain—still a challenge.” <i>Journal of Pain Research</i> Vol. 5 (2012): p. 559.	TEVA_MDL_A_13755109	TEVA_MDL_A_13755116							
TE-1089	08/01/2015	Massachusetts Medical Society, “Opioid Therapy and Physician Communication Guidelines,” 2015. http://www.massmed.org/Advocacy/Key-Issues/Opioid-Abuse/Opioid-Therapy-and-Physician-Communication-Guidelines-(pdf)/ , accessed May 1, 2019.	TEVA_MDL_A_13750451	TEVA_MDL_A_13750458							
TE-1090	11/00/2014	Medical Board of California, “Guidelines for Prescribing Controlled Substances for Pain,” 2014. http://www.mbc.ca.gov/licensees/prescribing/pain_guidelines.pdf , accessed May 1, 2019.	TEVA_MDL_A_13744151	TEVA_MDL_A_13744240							
TE-1091	04/01/2019	Medline Plus, “Opiate and Opioid Withdrawal,” https://medlineplus.gov/ency/article/000949.htm , accessed April 23, 2019.	TEVA_MDL_A_13743820	TEVA_MDL_A_13743825							
TE-1092	07/20/2018	Mercadante, Sebastiano, Claudio Adile, Francesco Masedu, Paolo Marchetti, Andrea Costanzi, and Federica Aielli. “Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.” <i>European Journal of Pain</i> Vol. 23, No. 4 (2018): pp. 719-26.	TEVA_MDL_A_13743368	TEVA_MDL_A_13743375							
TE-1093	01/15/2014	Mistry, Chetna, Monica Bawor, Dipika Desai, David C. Marsh, and Zainab Samaan. “Genetics of opioid dependence: a review of the genetic contribution to opioid dependence.” <i>Current Psychiatry Reviews</i> Vol. 10, No. 2 (2014): pp. 156-67.	TEVA_MDL_A_13744275	TEVA_MDL_A_13744286							
TE-1094	03/00/2011	Morasco, Benjamin J., Susan Gritzner, Lynsey Lewis, Robert Oldham, Dennis C. Turk, and Steven K. Dobscha. “Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder.” <i>Pain</i> Vol. 152, No. 3 (2011): pp. 488-97.	TEVA_MDL_A_13744039	TEVA_MDL_A_13744058							
TE-1095	04/26/2019	Multiple Chronic Conditions Resource Center, “Chronic Pain Guidelines,” https://www.multiplechronicconditions.org/chronic-pain-guidelines .	TEVA_MDL_A_13743437	TEVA_MDL_A_13743439							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1096	05/01/2017	Munzing, Timothy. "Physician guide to appropriate opioid prescribing for noncancer pain." <i>The Permanente Journal</i> Vol. 21 (2017): pp. 160-69.	TEVA_MDL_A_13746680	TEVA_MDL_A_13746686							
TE-1097	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1098	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1099	01/00/2019	National Institute on Drug Abuse, "Overdose Death Rates," January 2019. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates , accessed March 8, 2019.	TEVA_MDL_A_13749344	TEVA_MDL_A_13749351							
TE-1100	01/00/2019	National Institute on Drug Abuse, "Treating Opioid Use Disorder during Pregnancy," 2017. https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/treating-opioid-use-disorder-during-pregnancy .	TEVA_MDL_A_13746807	TEVA_MDL_A_13746808							
TE-1101	03/15/2019	NIH National Cancer Institute, "Fentanyl Citrate," https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fentanyl-citrate , accessed March 15, 2019.	TEVA_MDL_A_13746358	TEVA_MDL_A_13746358							
TE-1102	04/24/2019	O'Donnell, Jane and Ken Alltucker. "Feds issue new warning to doctors: Don't skimp too much on opioid pain pills." USA Today, April 24, 2019. https://www.usatoday.com/story/news/health/2019/04/24/opioid-pain-pills-crackdown-doctors-prescriptions-cdc-fda/3562373002/ .	TEVA_MDL_A_13748331	TEVA_MDL_A_13748334							
TE-1103	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1104	10/00/2011	Passik, Steven D., Kenneth L. Kirsh, and Lynn Webster. "Pseudoaddiction revisited: a commentary on clinical and historical considerations." <i>Pain Management</i> Vol. 1, No. 3 (2011): pp. 239-48.	TEVA_MDL_A_13745971	TEVA_MDL_A_13745980							
TE-1105	11/30/2017	Pergolizzi Jr., Joseph V., Jo Ann LeQuang, Robert Taylor Jr., Robert B. Raffa, and NEMA Research Group. "Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin." <i>Postgraduate Medicine</i> Vol. 130, No. 1 (2018): pp. 1-8.	TEVA_MDL_A_13748268	TEVA_MDL_A_13748276							
TE-1106	11/01/2018	Pergolizzi Jr., Joseph V., Meredith Rosenblatt, D. J. Mariano, and J. Bisney. "Tapering opioid therapy: clinical strategies." <i>Pain Management</i> Vol. 8, No. 6 (Nov 1, 2018): pp. 409-13.	TEVA_MDL_A_13748736	TEVA_MDL_A_13748741							
TE-1107	01/15/2007	Pollock, Madelyn, Oralia V. Bazaldua, and Alison E. Dobbie. "Appropriate prescribing of medications: an eight-step approach." <i>American Family Physician</i> Vol. 75, No. 2 (2007): pp. 231-36.	TEVA_MDL_A_13744405	TEVA_MDL_A_13744410							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1108	08/18/1995	Portenoy, Russell K. "Opioid therapy for chronic nonmalignant pain: clinicians' perspective." <i>The Journal of Law, Medicine & Ethics</i> Vol. 24, No. 4 (1996): pp. 296-309.	TEVA_MDL_A_13747122	TEVA_MDL_A_13747134							
TE-1109	06/10/1985	Portenoy, Russell K. and Kathy M. Foley. "Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases." <i>Pain</i> Vol. 25 (1986): pp. 171-86.	TEVA_MDL_A_13755529	TEVA_MDL_A_13755544							
TE-1110	05/08/2006	Radley, David C., Stan N. Finkelstein, and Randall S. Stafford. "Off-label prescribing among office-based physicians." <i>Archives of Internal Medicine</i> Vol. 166, No. 9 (2006): pp. 1021-26.	TEVA_MDL_A_13747143	TEVA_MDL_A_13747148							
TE-1111	09/25/2006	Rappaport, Bob, "FDA Approval Letter for Fentora," September 25, 2006. https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2006/021947s000ltr.pdf .	TEVA_MDL_A_13746325	TEVA_MDL_A_13746329							
TE-1112	11/11/2015	Ray, James B. "Implications of the extended-release/long-acting opioid REMS for managed care." <i>American Journal of Managed Care</i> Vol. 21 (2015): pp. S177a-S87a.	TEVA_MDL_A_13744023	TEVA_MDL_A_13744034							
TE-1113	02/13/2018	Robles, Frances. "Meth, the Forgotten Killer, Is Back. And It's Everywhere." <i>The New York Times</i> , February 13, 2018.	TEVA_MDL_A_13751574	TEVA_MDL_A_13751578							
TE-1114	00/00/2012	Rosenberg, Mark. "Undertreated Pain Epidemic: Multi-Modality Approach to Pain Management." <i>Journal of Managed Care Medicine</i> Vol. 15, No. 1 (2012): pp. 30-37.	TEVA_MDL_A_13745789	TEVA_MDL_A_13745796							
TE-1115	10/00/2008	Rosenblum, Andrew, Lisa A. Marsch, Herman Joseph, and Russell K. Portenoy. "Opioids and the treatment of chronic pain: controversies, current status, and future directions." <i>Experimental and Clinical Psychopharmacology</i> Vol. 16, No. 5 (2008): pp. 405-16.	TEVA_MDL_A_13748367	TEVA_MDL_A_13748388							
TE-1116	02/07/2017	Simeone, Ronald. "Doctor Shopping Behavior and the Diversion of Prescription Opioids." <i>Substance Abuse: Research and Treatment</i> Vol. 11 (2017): pp. 1-10.	TEVA_MDL_A_13755070	TEVA_MDL_A_13755079							
TE-1117	12/00/2014	Stanley, Theodore H. "The Fentanyl Story." <i>The Journal of Pain</i> Vol. 15, No. 12 (2014): pp. 1215-26.	TEVA_MDL_A_13744468	TEVA_MDL_A_13744479							
TE-1118	10/28/2017	Stobbe, Mike. "Today's Opioid Crisis Shares Chilling Similarities with Past Drug Epidemics." <i>The Chicago Tribune</i> , October 28, 2017.	TEVA_MDL_A_13750444	TEVA_MDL_A_13750450							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1119	00/00/2012	Substance Abuse and Mental Health Services Administration (SAMHSA), “Managing Chronic Pain in Adults With or in Recovery from Substance Use Disorders,” 2012. https://store.samhsa.gov/system/files/sma13-4671.pdf .	TEVA_MDL_A_13743516	TEVA_MDL_A_13743643							
TE-1120	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1121	00/00/2013	Substance Abuse and Mental Health Services Administration (SAMHSA), “Treatment Improvement Protocol 63,” https://www.ncbi.nlm.nih.gov/books/NBK535268/pdf/Bookshelf_NBK535268.pdf .	TEVA_MDL_A_13750639	TEVA_MDL_A_13750960							
TE-1122	03/08/2018	Sullum, Jacob, “America’s War on Pain Pills Is Killing Addicts and Leaving Patients in Agony,” <i>Reason</i> , April 2018. https://reason.com/2018/03/08/americas-war-on-pain-pills-is/ , accessed April 26, 2019.	TEVA_MDL_A_13746715	TEVA_MDL_A_13746737							
TE-1123	02/09/2019	Szalavitz, Maia. “When the Cure is Worse than the Disease.” <i>The New York Times</i> , February 9, 2019. https://www.nytimes.com/2019/02/09/opinion/sunday/pain-opioids.html .	TEVA_MDL_A_13743363	TEVA_MDL_A_13743367							
TE-1124	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1125	05/00/2019	TIRF REMS Access, “An Overview for Prescribers,” https://www.tirfremssaccess.com/TirfUI/remss/pdf/prescriber-overview.pdf .	TEVA_MDL_A_13743440	TEVA_MDL_A_13743445							
TE-1126	03/31/2016	Volkow, Nora D., and A. Thomas McLellan. “Opioid abuse in chronic pain—misconceptions and mitigation strategies.” <i>New England Journal of Medicine</i> Vol. 374, No. 13 (2016): pp. 1253-63.	TEVA_MDL_A_13745591	TEVA_MDL_A_13745601							
TE-1127	00/00/2018	WebMD, “8 Specialists Who Treat Pain,” https://www.webmd.com/back-pain/guide/pain-specialists#2 , accessed April 26, 2019.	TEVA_MDL_A_13743826	TEVA_MDL_A_13743841							
TE-1128	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1129	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1130	09/25/2018	Weissman, David E. and J. David Haddox. “Opioid pseudoaddiction—an iatrogenic syndrome.” <i>Pain</i> Vol. 36, No. 3 (1989): pp. 363-66.	TEVA_MDL_A_13750459	TEVA_MDL_A_13750463							
TE-1131	00/00/2014	World Health Organization, “Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy,” 2014. https://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/ .	TEVA_MDL_A_13749870	TEVA_MDL_A_13750093							
TE-1132	11/00/1998	“Actiq Label, November 1998,” 1998. https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/207471bl.pdf .	TEVA_MDL_A_13743487	TEVA_MDL_A_13743515							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1133	09/00/2006	"Fentora Label, September 2006," 2006. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/0219471bl.pdf .	TEVA_MDL_A_13747278	TEVA_MDL_A_13747303							
TE-1134	05/00/2008	Abernethy, Amy P., Jane L. Wheeler, and Barry V. Fortner. "A health economic model of breakthrough pain." <i>American Journal of Managed Care</i> Vol. 14, No. 5 Supplement 1 (2008): pp. S129-40.	TEVA_MDL_A_13747195	TEVA_MDL_A_13747206							
TE-1135	00/00/2005	American Pain Foundation, "Treatment Options: A Guide for People Living with Pain."	TEVA_MDL_A_13745882	TEVA_MDL_A_13745965							
TE-1136	03/00/2011	Ashburn, Michael A., Kieran A. Slevin, John Messina, and Fang Xie. "The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain." <i>Anesthesia & Analgesia</i> Vol. 112, No. 3 (2011): pp. 693-702.	TEVA_MDL_A_13745872	TEVA_MDL_A_13745881							
TE-1137	02/24/2003	Brennan, Michael J., Steven D. Passik, and Kenneth L. Kirsh, "Pharmacologic Management of Breakthrough or Incident Pain," 2003. https://www.medscape.org/viewarticle/449803_print , accessed April 11, 2019.	TEVA_MDL_A_13745981	TEVA_MDL_A_13745988							
TE-1138	03/00/2013	Caraceni, Augusto, Andrew Davies, Philippe Poulain, Hernán Cortés-Funes, Sunil J. Panchal, and Guido Fanelli. "Guidelines for the management of breakthrough pain in patients with cancer." <i>Journal of the National Comprehensive Cancer Network</i> Vol. 11, Supplement 1(2013): pp. S-29-S-36.	TEVA_MDL_A_13747661	TEVA_MDL_A_13747668							
TE-1139	03/30/2001	Cephalon, Inc., Form 10-K405, filed March 30, 2001.	TEVA_MDL_A_13745253	TEVA_MDL_A_13745456							
TE-1140	00/00/2010	Cephalon, Inc., <i>Opioid Medications and REMS: A Patient's Guide</i> , 2010.	TEVA_MDL_A_13743721	TEVA_MDL_A_13743729							
TE-1141	09/00/2015	Chang, Andrew, Eric J. Roeland, Rabia S. Atayee, Carolyn Revta, and Joseph D. Ma. "Transmucosal immediate-release fentanyl for breakthrough cancer pain: opportunities and challenges for use in palliative care." <i>Journal of Pain & Palliative Care Pharmacotherapy</i> Vol. 29, No. 3 (2015): pp. 247-60.	TEVA_MDL_A_13750464	TEVA_MDL_A_13750479							
TE-1142	02/00/2009	Chou, Roger, Gilbert J. Fanciullo, Perry G. Fine, Jeremy A. Adler, Jane C. Ballantyne, Pamela Davies, . . . Jeffrey Fudin. "Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain." <i>The Journal of Pain</i> Vol. 10, No. 2 (2009): pp. 113-30. e22.	TEVA_MDL_A_13745120	TEVA_MDL_A_13745159							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1143	01/00/2001	Coluzzi, Paul H., Lee Schwartzberg, John D. Conroy Jr., Steve Charapata, Mason Gay, Michael A. Busch, . . . Maureen McCracken. “Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®).” <i>Pain</i> Vol. 91, No. 1-2 (2001): pp. 123-30.	TEVA_MDL_A_13745755	TEVA_MDL_A_13745762							
TE-1144	11/00/2010	Fine, Perry G., John Messina, Fang Xie, and James Rathmell. “Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study.” <i>Journal of Pain and Symptom Management</i> Vol. 40, No. 5 (2010): pp. 747-60.	TEVA_MDL_A_13755704	TEVA_MDL_A_13755717							
TE-1145	11/04/2008	Fishbain, David A., Brandly Cole, John Lewis, Hubert L. Rosomoff, and R. Steele Rosomoff. “What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review.” <i>Pain Medicine</i> Vol. 9, No. 4 (2008): pp. 444-59.	TEVA_MDL_A_13746359	TEVA_MDL_A_13746376							
TE-1146	00/00/2007	Fishman, Scott M. <i>Responsible Opioid Prescribing: A Physician’s Guide</i> . Washington, DC: Waterford Life Sciences, 2007.	TEVA_MDL_A_13743746	TEVA_MDL_A_13743819							
TE-1147	02/00/2002	Fortner, Barry V., Theodore A. Okon, and Russell K. Portenoy. “A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain.” <i>The Journal of Pain</i> Vol. 3, No. 1 (2002): pp. 38-44.	TEVA_MDL_A_13751502	TEVA_MDL_A_13751508							
TE-1148	09/20/2012	Kesselheim, Aaron S., Christopher T. Robertson, Jessica A. Myers, Susannah L. Rose, Victoria Gillet, Kathryn M. Ross, . . . Jerry Avorn. “A Randomized Study of How Physicians Interpret Research Funding Disclosures.” <i>New England Journal of Medicine</i> Vol. 367, No. 12 (2012): pp. 1119-27.	TEVA_MDL_A_13745551	TEVA_MDL_A_13745559							
TE-1149	01/00/2011	Lacasse, Jeffrey R. and Jonathan Leo. “Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research.” <i>BMC Research Notes</i> Vol. 4, No. 27 (2011): pp. 1-6.	TEVA_MDL_A_13745624	TEVA_MDL_A_13745630							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1150	07/11/2001	Mercadante, Sebastiano, Lukas Radbruch, Augusto Caraceni, Nathan Cherny, Stein Kaasa, Friedemann Nauck, . . . Steering Committee of the European Association for Palliative Care Research Network. "Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care." <i>Cancer</i> Vol. 94, No. 3 (2002): pp. 832-39.	TEVA_MDL_A_13745833	TEVA_MDL_A_13745840							
TE-1151	12/07/2015	Minkowitz, Harold, Janet Bull, R. Charles Brownlow, Neha Parikh, and Richard Rauck. "Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain." <i>Supportive Care in Cancer</i> Vol. 24, No. 6 (2016): pp. 2669-75.	TEVA_MDL_A_13744914	TEVA_MDL_A_13744920							
TE-1152	00/00/2017	Payne, Richard. "Recognition and diagnosis of breakthrough pain." <i>Pain Medicine</i> Vol. 8, Supplement 1 (2007): pp. S3-S7.	TEVA_MDL_A_13747558	TEVA_MDL_A_13747562							
TE-1153	01/31/2010	Portenoy, Russell K., Daniel Bruns, Bonnie Shoemaker, and Steven A. Shoemaker. "Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics." <i>Journal of Opioid Management</i> Vol. 6, No. 2 (2010): pp. 97-108.	TEVA_MDL_A_13755673	TEVA_MDL_A_13755684							
TE-1154	08/00/2006	Portenoy, Russell K., Daniel S. Bennett, Richard Rauck, Steven Simon, Donald Taylor, Michael Brennan, and Steven A. Shoemaker. "Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain." <i>The Journal of Pain</i> Vol. 7, No. 8 (2006): pp. 583-91.	TEVA_MDL_A_13744430	TEVA_MDL_A_13744438							
TE-1155	00/00/2012	Rudowska, Joanna. "Management of breakthrough pain due to cancer." <i>Contemporary Oncology</i> Vol. 16, No. 6 (2012): pp. 498-501.	TEVA_MDL_A_13750154	TEVA_MDL_A_13750157							
TE-1156	07/28/2016	Schuckit, Marc A. "Treatment of opioid-use disorders." <i>New England Journal of Medicine</i> Vol. 375, No. 4 (2016): pp. 357-68.	TEVA_MDL_A_13743898	TEVA_MDL_A_13743909							
TE-1157	11/06/2014	Shimoyama, N., I. Gomyo, O. Teramoto, K. Kojima, H. Higuchi, N. Yukitoshi, . . . M. Shimoyama. "Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain." <i>Japanese Journal of Clinical Oncology</i> Vol. 45, No. 2 (2014): pp. 189-96.	TEVA_MDL_A_13748256	TEVA_MDL_A_13748263							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1158	03/31/2008	Slatkin, Neal E. and Michele I. Rhiner, “Breakthrough Pain: Improving Recognition and Management to Enhance Quality of Life,” 2008. www.medscape.org/viewarticle/572129 , accessed October 10, 2017.	TEVA_MDL_A_13748354	TEVA_MDL_A_13748366							
TE-1159	00/00/2012	Smith, Howard. “A comprehensive review of rapid-onset opioids for breakthrough pain.” <i>CNS Drugs</i> Vol. 26, No. 6 (2012): pp. 509-35.	TEVA_MDL_A_13748217	TEVA_MDL_A_13748243							
TE-1160	05/00/2019	TIRF REMS Access, “Education Program for Prescribers and Pharmacists,” https://www.tirfremssaccess.com/TirfUI/remss/pdf/education-and-ka.pdf .	TEVA_MDL_A_13745611	TEVA_MDL_A_13745623							
TE-1161	05/00/2019	TIRF REMS Access, “Patient-Prescriber Agreement Form,” https://www.tirfremssaccess.com/TirfUI/remss/pdf/ppaf-form.pdf .	TEVA_MDL_A_13745764	TEVA_MDL_A_13745766							
TE-1162	05/00/2019	TIRF REMS Access, “Prescriber Enrollment Form,” https://www.tirfremssaccess.com/TirfUI/remss/pdf/prescriber-enrollment-form.pdf .	TEVA_MDL_A_13746817	TEVA_MDL_A_13746819							
TE-1163	04/00/2015	Vowles, Kevin E., Mindy L. McEntee, Peter Siyahhan Julnes, Tessa Frohe, John P. Ney, and David N. van der Goes. “Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis.” <i>Pain</i> Vol. 156, No. 4 (2015): pp. 569-76.	TEVA_MDL_A_13745767	TEVA_MDL_A_13745774							
TE-1164	00/00/2012	“Mortality Risk Valuation in Environment, Health and Transport Policies,” OECD, available at https://read.oecd-ilibrary.org/environment/mortality-risk-valuation-in-environment-health-and-transport-policies/recommended-value-of-a-statistical-life-numbers-for-policy-analysis_9789264130807-9-en#page7 (2012)	TEVA_MDL_A_13744121	TEVA_MDL_A_13744129							
TE-1165	08/00/2000	“National Incident-Based Reporting System Volume 1: Data Collection Guidelines,” United States Department of Justice and Federal Bureau of Investigation, 2000	TEVA_MDL_A_13746848	TEVA_MDL_A_13746975							
TE-1166	01/00/2007	“Prescription Drug Pricing in Private Sector,” Congressional Budget Office (CBO), January 2007, available at https://www.cbo.gov/sites/default/files/110th-congress-2007-2008/reports/01-03-prescriptiondrug.pdf	TEVA_MDL_A_13746291	TEVA_MDL_A_13746324							
TE-1167	01/03/2018	“Questions for the Record from Senator Charles E. Grassley To President and CEO of Healthcare Distribution Alliance, U.S. Senate Committee on the Judiciary – Oversight on the Ensuring Patient Access and Drug Enforcement Act,” answered on January 3, 2018	TEVA_MDL_A_13754784	TEVA_MDL_A_13754789							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1168	11/01/2018	“The Underestimated Cost of the Opioid Crisis,” The Council of Economic Advisers, November 2018, available at https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The Underestimated Cost of the Opioid Crisis.pdf	TEVA_MDL_A_13744439	TEVA_MDL_A_13744452							
TE-1169	06/00/2018	“Using International Classification of Diseases (ICD) Codes to Assess Opioid-Related Overdose Deaths,” Substance Abuse and Mental Health Services Administration, available at https://mnprc.org/wp-content/uploads/2019/01/using-icd-10-codes-to-assess-opioid-related-overdose-deaths.pdf	TEVA_MDL_A_13744463	TEVA_MDL_A_13744467							
TE-1170	08/05/2015	“Why Teva Paid \$40.5 Billion for Allergan’s Generic Business,” Knowledge@Wharton, August 5, 2015, available at https://knowledge.wharton.upenn.edu/article/why-teva-paid-40-5-billion-for-allergans-generic-business/	TEVA_MDL_A_13743376	TEVA_MDL_A_13743382							
TE-1171	12/01/2016	Actiq, “Highlights of Prescribing Information,” available at http://www.actiq.com/pdf/ActiqDigitalPIandMedGuide.pdf (December 1, 2016)	TEVA_MDL_A_13743852	TEVA_MDL_A_13743866							
TE-1172	00/00/2016	Adam J. Fein, “Modern Distribution Management (MDM). 2016 MDM market leaders: top pharmaceuticals distributors.” MDM, available at https://www.mdm.com/2016-top-pharmaceuticals-distributors	TEVA_MDL_A_13745178	TEVA_MDL_A_13745184							
TE-1173	11/00/2011	Ajay Kalra et al., “Understanding Responses to Contradictory Information About Products,” Marketing Science, 30(6) (2011)	TEVA_MDL_A_13745572	TEVA_MDL_A_13745589							
TE-1174	03/24/2019	Anesta Corporation, SEC Form 8-K [March 24, 2000]	TEVA_MDL_A_13746788	TEVA_MDL_A_13746791							
TE-1175	09/27/2006	BioSpace, “Barr Pharmaceuticals, Inc. Launches Generic ACTIQ(R) Cancer Pain Management Product,” September 27, 2006, available at https://www.biospace.com/article/releases/barr-pharmaceuticals-inc-launches-generic-actiq-r-cancer-pain-management-product-/	TEVA_MDL_A_13747149	TEVA_MDL_A_13747152							
TE-1176	03/00/2019	Bipartisan Policy Center, “Tracking Federal Funding to Combat the Opioid Crisis,” available at https://bipartisanpolicy.org/wp-content/uploads/2019/03/Tracking-Federal-Funding-to-Combat-the-Opioid-Crisis.pdf	TEVA_MDL_A_13747866	TEVA_MDL_A_13747969							
TE-1177	12/13/1999	CBS News, “FDA OKs ‘Narcotic Lollipop’,” available at https://www.cbsnews.com/news/fda-oks-narcotic-lollipop/ (December 13, 1999)	TEVA_MDL_A_13750158	TEVA_MDL_A_13750179							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1178	08/29/2017	CDC, "Commonly Used Terms," August 29, 2017, available at https://www.cdc.gov/drugoverdose/opioids/prescribed.html	TEVA_MDL_A_13745718	TEVA_MDL_A_13745720							
TE-1179	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1180	12/19/2018	CDC, "Opioid Data Analysis and Resources," available at https://www.cdc.gov/drugoverdose/data/analysis.html (December 19, 2018)	TEVA_MDL_A_13745966	TEVA_MDL_A_13745970							
TE-1181	08/28/2017	CDC, "Opioid Overdose," available at https://www.cdc.gov/drugoverdose/opioids/terms.html (August 28, 2017)	TEVA_MDL_A_13755782	TEVA_MDL_A_13755783							
TE-1182	08/29/2017	CDC, "Prescription Opioids," available at https://www.cdc.gov/drugoverdose/opioids/prescribed.html (August 29, 2017)	TEVA_MDL_A_13755801	TEVA_MDL_A_13755803							
TE-1183	06/28/2010	Center for Disease Control and Prevention, "United States Life Table, 2006," National Vital Statistics Report 58 (June 28, 2010)	TEVA_MDL_A_13745989	TEVA_MDL_A_13746028							
TE-1184	09/28/2011	Center for Disease Control and Prevention, "United States Life Table, 2007," National Vital Statistics Report 59 (September 28, 2011)	TEVA_MDL_A_13751643	TEVA_MDL_A_13751703							
TE-1185	09/24/2012	Center for Disease Control and Prevention, "United States Life Table, 2008," National Vital Statistics Report 61 (September 24, 2012)	TEVA_MDL_A_13746227	TEVA_MDL_A_13746290							
TE-1186	01/06/2014	Center for Disease Control and Prevention, "United States Life Table, 2009," National Vital Statistics Report 62 (January 6, 2014)	TEVA_MDL_A_13751511	TEVA_MDL_A_13751573							
TE-1187	11/06/2014	Center for Disease Control and Prevention, "United States Life Table, 2010," National Vital Statistics Report 63 (November 6, 2014)	TEVA_MDL_A_13748768	TEVA_MDL_A_13748830							
TE-1188	11/22/2015	Center for Disease Control and Prevention, "United States Life Table, 2011," National Vital Statistics Report 64 (November 22, 2015)	TEVA_MDL_A_13751121	TEVA_MDL_A_13751183							
TE-1189	11/28/2016	Center for Disease Control and Prevention, "United States Life Table, 2012," National Vital Statistics Report 65 (November 28, 2016)	TEVA_MDL_A_13743644	TEVA_MDL_A_13743711							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1190	04/11/2017	Center for Disease Control and Prevention, "United States Life Table, 2013," National Vital Statistics Report 66 (April 11, 2017)	TEVA_MDL_A_13744555	TEVA_MDL_A_13744618							
TE-1191	08/14/2017	Center for Disease Control and Prevention, "United States Life Table, 2014," National Vital Statistics Report 66 (August 14, 2017)	TEVA_MDL_A_13755718	TEVA_MDL_A_13755781							
TE-1192	11/13/2018	Center for Disease Control and Prevention, "United States Life Table, 2015," National Vital Statistics Report 67 (November 13, 2018)	TEVA_MDL_A_13744308	TEVA_MDL_A_13744371							
TE-1193	08/31/2018	Center for Disease Control and Prevention, "2018 Annual Surveillance Report Of Drug-Related Risks And Outcomes: United States," available at https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf	TEVA_MDL_A_13744926	TEVA_MDL_A_13745016							
TE-1194	01/13/2012	Centers for Disease Control and Prevention, "CDC Grand Rounds: Prescription Drug Overdoses – a U.S. Epidemic," Mortality and Morbidity Weekly Report, available at https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm (January 13, 2012)	TEVA_MDL_A_13747669	TEVA_MDL_A_13747676							
TE-1195	02/22/2019	Centers for Disease Control and Prevention, "Multiple Cause of Death 1999 – 2017," available at https://wonder.cdc.gov/wonder/help/mcd.html	TEVA_MDL_A_13748277	TEVA_MDL_A_13748328							
TE-1196	07/17/2000	Cephalon Inc. Press Release, "Cephalon and Anesta Announce Merger to Create Stronger, More Profitable Pharmaceutical Business," available at http://phx.corporate-ir.net/phoenix.zhtml?c=81709&p=irol-newsArticle&ID=182729 (July 17, 2000)	TEVA_MDL_A_13751107	TEVA_MDL_A_13751110							
TE-1197	10/10/2000	Cephalon Inc. Press Release, "Cephalon Completes Merger with Anesta," available at http://phx.corporate-ir.net/phoenix.zhtml?c=81709&p=irol-newsArticle&ID=182704 (October 10, 2000)	TEVA_MDL_A_13748329	TEVA_MDL_A_13748330							
TE-1198	03/30/2001	Cephalon, Inc., SEC Form 10-K for period ended December 31, 2000 [March 30, 2001]	TEVA_MDL_A_13745638	TEVA_MDL_A_13745717							
TE-1199	02/28/2008	Cephalon, Inc., SEC Form 10-K for period ended December 31, 2007 [February 28, 2008]	TEVA_MDL_A_13747696	TEVA_MDL_A_13747853							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1200	04/12/2017	Chad M. Brummett et al., “New Persistent Opioid Use after Minor and Major Surgical Procedures in US Adults,” JAMA Surgery, 152(6), pp. 1–9 (2017)	TEVA_MDL_A_13743478	TEVA_MDL_A_13743486							
TE-1201	01/05/2017	CMS, “Opioid Misuse Strategy 2016,” available at https://www.cms.gov/Outreach-and-Education/Outreach/Partnerships/Downloads/CMS-Opioid-Misuse-Strategy-2016.pdf (January 5, 2017)	TEVA_MDL_A_13749816	TEVA_MDL_A_13749845							
TE-1202	00/00/2017	Corwin N. Rhyan, “The Potential Societal Benefit of Eliminating Opioid Overdoses, Deaths, and Substance Use Disorders Exceeds \$95 Billion Per Year,” 2017, Altarum Research Brief, available at https://altarum.org/sites/default/files/uploaded-publication-files/Research-Brief_Opioid-Epidemic-Economic-Burden.pdf (2017)	TEVA_MDL_A_13743926	TEVA_MDL_A_13743929							
TE-1203	00/00/2014	County of Summit ADM Board, “2014 Report to the Community,” available at https://www.admboard.org/Data/Sites/25/2014-annual-report-final.pdf	TEVA_MDL_A_13751102	TEVA_MDL_A_13751106							
TE-1204	00/00/2017	County of Summit ADM Board, “2017 Report to the Community,” available at https://www.admboard.org/Data/Sites/25/18adm04-annualrpt_8.5x11_r8_web.pdf	TEVA_MDL_A_13744453	TEVA_MDL_A_13744460							
TE-1205	00/00/2011	CTK Protex, “Anesta Corp. Licenses Actiq Rights to Elan / Novel Breakthrough Pain Therapy to Be Marketed by Elan Pharma International,” available at http://www.protex.cz/novy/press-release.php?id=1344	TEVA_MDL_A_13754777	TEVA_MDL_A_13754778							
TE-1206	10/00/2016	Curtis S. Florence et al., “The Economic Burden of Prescription Opioid Overdose, Abuse and Dependence in the United States, 2013,” Medical Care, 54(10) (2016)	TEVA_MDL_A_13744619	TEVA_MDL_A_13744624							
TE-1207	00/00/2016	Curtis S. Florence et al., online appendix, “Methodological Assumptions,” available at http://links.lww.com/MLR/B262 (2016)	TEVA_MDL_A_13745198	TEVA_MDL_A_13745220							
TE-1208	00/00/2019	Cuyahoga ADAMHS Board, “Calendar Year 2019: ADAMHS Board – Total Budget Summary,” available at http://adamhsc.org/pdf_adamhsc/en-US/CY2019%20Operating%20Budget.pdf	TEVA_MDL_A_13744035	TEVA_MDL_A_13744038							
TE-1209	00/00/2014	Cuyahoga County Opiate Task Force, “Cuyahoga County Opiate Task Force Report 2014,” available at http://opiatecollaborative.cuyahogacounty.us/pdf_OpiateCollaborative/en-US/CC_OpiateTaskForceReport.pdf (2014)	TEVA_MDL_A_13743730	TEVA_MDL_A_13743745							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1210	10/01/2018	Dailymed, “ACTIQ® (AK-tik): (Fentanyl Citrate) Oral Transmucosal Lozenge, CII,” available at https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a (October 1, 2018)	TEVA_MDL_A_13744059	TEVA_MDL_A_13744070							
TE-1211	09/01/2018	Dailymed, “FENTORA® (fen-tor-a): (Fentanyl) Buccal Tablet, CII,” available at https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=8f549d95-985b-f783-1ebb-ef57bd2ecb05 (September 1, 2018)	TEVA_MDL_A_13744090	TEVA_MDL_A_13744093							
TE-1212	02/00/2012	Darius Lakdawalla and Tomas Philipson, “Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets,” Journal of Law and Economics, 55(1), pp. 151–187 (2012)	TEVA_MDL_A_13745017	TEVA_MDL_A_13745054							
TE-1213	00/00/1997	David M. Cutler and Elizabeth Richardson, “Measuring the Health of the U.S. Population,” Brookings Paper on Economic Activity, Microeconomics (1997)	TEVA_MDL_A_13747051	TEVA_MDL_A_13747106							
TE-1214	01/00/1999	David M. Cutler and Elizabeth Richardson, “Your Money and Your Life: The Value of Health and What Affects It,” Frontiers in Health Policy Research, Volume 2 (1999)	TEVA_MDL_A_13747523	TEVA_MDL_A_13747557							
TE-1215	09/07/2017	DEA Form Reference ID: 4148977, “The TIRF REMS Access Program: Knowledge Assessment,” available at https://www.accessdata.fda.gov/drugsatfda_docs/remis/TIR_F_2017-09-07_Knowledge_Assessment.pdf	TEVA_MDL_A_13744147	TEVA_MDL_A_13744150							
TE-1216	08/16/2018	DEA, "Justice Department, DEA propose significant opioid manufacturing reduction in 2019," available at https://www.dea.gov/press-releases/2018/08/16/justice-department-dea-propose-significant-opioid-manufacturing-reduction	TEVA_MDL_A_13743913	TEVA_MDL_A_13743914							
TE-1217	05/10/2019	DEA, "Missions," available at https://www.dea.gov/mission	TEVA_MDL_A_13744461	TEVA_MDL_A_13744462							
TE-1218	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1219	10/01/2018	DEA, “Fentanyl: (Trade Names: Actiq®, Fentora™, Duragesic®),” available at https://www.deadiversion.usdoj.gov/drug_chem_info/fentanyl.pdf (October 1, 2018)	TEVA_MDL_A_13754774	TEVA_MDL_A_13754774							
TE-1220	09/00/2006	DEA, “Practitioner’s Manual: An Informational Outline of the Controlled Substances Act,” United States Department of Justice Report, available at https://www.deadiversion.usdoj.gov/pubs/manuals/pract/index.html (2006)	TEVA_MDL_A_13744843	TEVA_MDL_A_13744908							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1221	10/01/2018	Department of Justice: U.S. Attorney's Office, Northern District of Ohio, October 1, 2018, available at https://www.justice.gov/usao-ndoh/pr/justice-department-awards-18-million-support-data-sharing-drug-courts-and-other	TEVA_MDL_A_13744287	TEVA_MDL_A_13744289							
TE-1222	06/00/2007	Douglas E. Mager and Emily R. Cox, "Relationship Between Generic and Preferred-Brand Prescription Copayment Differentials and Generic Fill Rate," The American Journal of Managed Care, 13(6), pp. 347–352 (2007)	TEVA_MDL_A_13751115	TEVA_MDL_A_13751120							
TE-1223	08/21/2019	Drug Enforcement Administration, "National Forensic Laboratory Information System," available at https://www.nflis.deadiversion.usdoj.gov/Resources/NFLISPublicResourceLibrary.aspx	TEVA_MDL_A_13750184	TEVA_MDL_A_13750186							
TE-1224	00/00/2008	Enno Freye and Joseph Victor Levy, Opioids in Medicine: A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Pain States, Dordrecht, The Netherlands: Springer (2008)	TEVA_MDL_A_13744921	TEVA_MDL_A_13744925							
TE-1225	09/00/2010	Ernst R. Berndt and Joseph P. Newhouse, "Pricing and Reimbursement in US Pharmaceutical Markets," NBER Working Paper, p. 8 (2010)	TEVA_MDL_A_13750480	TEVA_MDL_A_13750556							
TE-1226	03/00/2001	Ernst R. Berndt, "The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?," Health Affairs, 20(2), pp. 100–114 (2001)	TEVA_MDL_A_13754806	TEVA_MDL_A_13754820							
TE-1227	05/31/2019	FBI, "National Incident-Based Reporting System (NIBRS)," available at https://www.fbi.gov/services/cjis/ucr/nibrs	TEVA_MDL_A_13750990	TEVA_MDL_A_13750996							
TE-1228	11/01/2012	FDA, "A Guide to Drug Safety Terms at FDA," Consumer Health Information Report (November 1, 2012)	TEVA_MDL_A_13750617	TEVA_MDL_A_13750619							
TE-1229	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1230	02/14/2019	FDA, "Approved Risk Evaluation and Mitigation Strategies (REMS)," available at https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm	TEVA_MDL_A_13750187	TEVA_MDL_A_13750189							
TE-1231	02/14/2019	FDA, "Development & Approval Process (Drugs)," available at https://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm (June 13, 2018)	TEVA_MDL_A_13751207	TEVA_MDL_A_13751210							
TE-1232	02/19/2019	FDA, "Drug Approval Process," available at https://www.fda.gov/downloads/drugs/resourcesforyou/consumers/ucm284393.pdf	TEVA_MDL_A_13754775	TEVA_MDL_A_13754776							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1233	10/08/2014	FDA, "Generic Drugs Undergo Rigorous FDA Scrutiny," available at https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm (October 8, 2014)	TEVA_MDL_A_13748173	TEVA_MDL_A_13748176							
TE-1234	00/00/2018	FDA, "Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse," available at https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM566985.pdf	TEVA_MDL_A_13745055	TEVA_MDL_A_13745091							
TE-1235	REMOVED	REMOVED	REMOVED	REMOVED							
TE-1236	07/09/2015	FDA, "Transmucosal Immediate-Release Fentanyl (TIRF) Medicines," available at https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm282110.htm (July 9, 2015)	TEVA_MDL_A_13751590	TEVA_MDL_A_13751591							
TE-1237	02/14/2019	FDA, "What Does FDA Inspect?," available at https://www.fda.gov/AboutFDA/Transparency/Basics/ucm194888.htm	TEVA_MDL_A_13751509	TEVA_MDL_A_13751510							
TE-1238	01/26/2018	FDA, "What's in a REMS?," available at https://www.fda.gov/Drugs/DrugSafety/REMS/ucm592636.htm (January 26, 2018)	TEVA_MDL_A_13755670	TEVA_MDL_A_13755672							
TE-1239	09/25/2006	FDA, Fentora Approval Letter, available at https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021947s000ltr.pdf (September 25, 2006)	TEVA_MDL_A_13747046	TEVA_MDL_A_13747050							
TE-1240	12/04/2009	FDANEWS, "Barr Pharma Wins Right to Sell Generic Fentora in 2018," December 4, 2009, available at https://www.fdanews.com/articles/122567-barr-pharma-wins-right-to-sell-generic-fentora-in-2018	TEVA_MDL_A_13750577	TEVA_MDL_A_13750578							
TE-1241	12/01/2016	Fentora, "Highlights of Prescribing Information," available at http://www.fentora.com/pdfs/pdf100_prescribing_info.pdf (December 1, 2016)	TEVA_MDL_A_13746377	TEVA_MDL_A_13746390							
TE-1242	10/15/2018	Gary Wollenhaupt, "Managing inventory: What retail can learn from pharma," Supply Chain Dive, October 15, 2018, available at https://www.supplychaindive.com/news/retail-pharmaceutical-supply-chain-inventory-spotlight/539696/	TEVA_MDL_A_13744305	TEVA_MDL_A_13744307							
TE-1243	00/00/2002	George Casella and Roger L. Berger "Statistical Inference," Second Edition, Thomson Learning (2002)	TEVA_MDL_A_13747207	TEVA_MDL_A_13747277							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1244	04/00/2018	George Psacharopoulos and Harry Antony Patrinos, "Returns to Investment in Education: A Decennial Review of the Global Literature," Policy Research Working Paper 8402, World Bank Education Global Practice, available at http://documents.worldbank.org/curated/en/442521523465644318/pdf/WPS8402.pdf (April 2018)	TEVA_MDL_A_13748922	TEVA_MDL_A_13748936							
TE-1245	12/01/2017	Jane Tilly et al., "The Opioid Public Health Emergency and Older Adults," available at http://www.nasud.org/hcbs/article/opioid-public-health-emergency-and-older-adults (December 1, 2017)	TEVA_MDL_A_13746738	TEVA_MDL_A_13746756							
TE-1246	00/00/2010	Janet Currie and Cathy S. Widom, "Long-Term Consequences of Child Abuse and Neglect on Adult Economic Well-Being," Child Maltreatment, 15(2), pp. 111–120 (2010)	TEVA_MDL_A_13755785	TEVA_MDL_A_13755794							
TE-1247	00/00/2018	Janet Currie et al., "U.S. Employment and Opioids: Is There a Connection?" National Bureau of Economic Research, available at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3149264 (2018)	TEVA_MDL_A_13743985	TEVA_MDL_A_13744022							
TE-1248	12/20/2017	Jay Soong-Jin Lee et al., "New Persistent Opioid Use Among Patients with Cancer After Curative-Intent Surgery," Journal of Clinical Oncology, 35(36), pp. 4042–4053 (2017)	TEVA_MDL_A_13751631	TEVA_MDL_A_13751642							
TE-1249	00/00/2010	Jeffrey M. Wooldridge, "Single-Equation Linear Model and Ordinary Least Squares Estimation," Econometric Analysis of Cross Section and Panel Data, (Cambridge, London: The MIT Press) (2010)	TEVA_MDL_A_13744909	TEVA_MDL_A_13744913							
TE-1250	11/01/2017	Jessica Webster Sendra, "For 1 in 10 Cancer Patients, Surgery Means Opioid Dependence," Michigan Health Lab, available at https://labblog.uofmhealth.org/rounds/for-1-10-cancer-patients-surgery-means-opioid-dependence (November 1, 2017)	TEVA_MDL_A_13750613	TEVA_MDL_A_13750616							
TE-1251	04/11/2018	Julia Zur and Jennifer Tobert, "The Opioid Epidemic and Medicaid's Role in Facilitating Access to Treatment," The Henry J. Kaiser Family Foundation, available at https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicoids-role-in-facilitating-access-to-treatment/ (April 11, 2018)	TEVA_MDL_A_13750120	TEVA_MDL_A_13750130							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1252	03/01/2005	Kaiser Family Foundation, "Follow the Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain," available at https://www.kff.org/wp-content/uploads/2013/01/follow-the-pill-understanding-the-u-s-commercial-pharmaceutical-supply-chain-report.pdf (March 1, 2005)	TEVA_MDL_A_13743446	TEVA_MDL_A_13743477							
TE-1253	00/00/2016	Kaiser Family Foundation, "2016 Employer Health Benefits Annual Survey," available at http://files.kff.org/attachment/Report-Employer-Health-Benefits-2016-Annual-Survey (2016)	TEVA_MDL_A_13746404	TEVA_MDL_A_13746677							
TE-1254	08/01/2011	Karen A. Goldman et al., "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact," Federal Trade Commission Report, available at https://www.ftc.gov/sites/default/files/documents/reports/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission.pdf (August 1, 2011)	TEVA_MDL_A_13755117	TEVA_MDL_A_13755386							
TE-1255	01/13/2010	Kathryn E. McCollister et al, "The cost of crime to society: New Crime-Specific Estimates for Policy and Program Evaluation," Drug and Alcohol Dependence, 108(1) (2010)	TEVA_MDL_A_13747344	TEVA_MDL_A_13747355							
TE-1256	01/09/1998	Letter from Cynthia McCormick (FDA) to Patricia J. Richards (Anesta Corporation), "NDA 20-747" [January 9, 1998]	TEVA_MDL_A_13747307	TEVA_MDL_A_13747312							
TE-1257	01/09/1998	Letter from Ken Nolan (Center for Drug Evaluation and Research) to Patricia J. Richards (Anesta Corporation), "NDA 20-747" [January 9, 1998]	TEVA_MDL_A_13743326	TEVA_MDL_A_13743348							
TE-1258	08/01/2018	Marcus Dillender, "What Happens When the Insurer Can Say No? Assessing Prior Authorization as a Tool to Prevent High-Risk Prescriptions and to Lower Costs," Journal of Public Economics, 165(1) (2018)	TEVA_MDL_A_13745841	TEVA_MDL_A_13745871							
TE-1259	04/26/2018	Maria A. Oquendo and Nora D. Volkow, "Suicide: A Silent Contributor to Opioid-Overdose Deaths," New England Journal of Medicine, 378(17), available at https://www.nejm.org/doi/10.1056/NEJMp1801417 (2018)	TEVA_MDL_A_13755685	TEVA_MDL_A_13755687							
TE-1260	07/04/2017	Matan C. Dabora et al., "Financing and Distribution of Pharmaceuticals in the United States," JAMA, 318(1) (2017)	TEVA_MDL_A_13745221	TEVA_MDL_A_13745222							
TE-1261	10/19/2018	Michelle Llamas, "Black Box Warnings," Drugwatch, available at https://www.drugwatch.com/fda/black-box-warnings/ (October 19, 2018)	TEVA_MDL_A_13750997	TEVA_MDL_A_13751006							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1262	02/00/2018	Nabarun Dasgupta et al., "Opioid Crisis: No Easy Fix to Its Social and Economic Determinants," American Journal of Public Health, 108(2) (February 2018)	TEVA_MDL_A_13751491	TEVA_MDL_A_13751496							
TE-1263	06/02/2016	Nadia Kounang, "FDA Requires 'Black Box' Warning on Painkillers," CNN, available at https://www.cnn.com/2016/03/22/health/fda-opioid-black-box-warning/index.html (June 2, 2016)	TEVA_MDL_A_13746784	TEVA_MDL_A_13746787							
TE-1264	09/00/2018	Office of Policy Development and Research, "HUD USPS ZIP Crosswalk Files," available at https://www.huduser.gov/portal/datasets/usps_crosswalk.html	TEVA_MDL_A_13748836	TEVA_MDL_A_13748836							
TE-1265	12/11/2019	Office of the Federal Register, "List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness," December 11, 2019, available at https://www.federalregister.gov/documents/2018/12/11/2018-26712/list-of-drug-products-that-have-been-withdrawn-or-removed-from-the-market-for-reasons-of-safety-or	TEVA_MDL_A_13754821	TEVA_MDL_A_13754826							
TE-1266	04/29/2019	Ohio Board of Pharmacy, "Ohio Automated RX Reporting System," available at https://www.ohiopmp.gov/Documents/Brochure.pdf	TEVA_MDL_A_13743967	TEVA_MDL_A_13743968							
TE-1267	06/01/2012	Ohio Bureau of Workers' Compensation Final Rule 4123-6-21.4 ("Coordinated services program"), available at https://www.bwc.ohio.gov/downloads/blankpdf/OAC4123-6-21.4.pdf	TEVA_MDL_A_13750149	TEVA_MDL_A_13750153							
TE-1268	00/00/2019	Ohio Department of Medicaid, "Information on the Coordinated Service Program," available at https://pharmacy.medicaid.ohio.gov/sites/default/files/2019%20CSP%20Brochure.pdf	TEVA_MDL_A_13750119	TEVA_MDL_A_13750119							
TE-1269	02/00/2017	Ohio Development Services Agency, Office of Research, "Educational Attainment: Ohio by the Numbers," February 2017, available at https://development.ohio.gov/files/research/P7006.pdf	TEVA_MDL_A_13751592	TEVA_MDL_A_13751599							
TE-1270	07/22/1998	Ohio Rev. Code Ann. § 4729.38(B)	TEVA_MDL_A_13751204	TEVA_MDL_A_13751206							
TE-1271	08/11/2009	Pradeep K. Chintagunta et al., "Information, Learning, and Drug Diffusion: The Case of Cox-2 Inhibitors," Quantitative Marketing and Economics, 7(4) (2009)	TEVA_MDL_A_13743388	TEVA_MDL_A_13743433							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1272	08/01/2013	Pradip K. Muhuri et al., “Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States,” Center for Behavioral Health Statistics and Quality, available at https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm (August 1, 2013)	TEVA_MDL_A_13748695	TEVA_MDL_A_13748709							
TE-1273	08/20/2016	Priscilla Hunt et al., “The Price of Justice: New National and State-Level Estimates of the Judicial and Legal Costs of Crime to Taxpayers,” American Journal of Criminal Justice, 42(2), pp. 231–254 (2016)	TEVA_MDL_A_13748879	TEVA_MDL_A_13748902							
TE-1274	00/00/2015	PwC, “How can pharmaceutical and life sciences companies monitor their wholesalers to minimise financial losses and distribution risks?,” Global Pharmaceuticals and Life Sciences Industry Group, available at https://www.pwc.com/gx/en/pharma-life-sciences/pdf/pwc-pharma-wholesaler.pdf	TEVA_MDL_A_13747153	TEVA_MDL_A_13747154							
TE-1275	04/10/2016	Raj Chetty et al., “The Association Between Income and Life Expectancy in the United States, 2001-2014,” JAMA, 315(16) (2016)	TEVA_MDL_A_13744386	TEVA_MDL_A_13744402							
TE-1276	09/01/2018	Robin Ghertner and Lincoln Groves, “The Opioid Crisis and Economic Opportunity: Geographic and Economic Trends,” U.S. Department of Health and Human Services: Office of the Assistant Secretary for Planning and Evaluation Research Brief, available at https://aspe.hhs.gov/system/files/pdf/259261/ASPEEconomicOpportunityOpioidCrisis.pdf (September 1, 2018)	TEVA_MDL_A_13754709	TEVA_MDL_A_13754730							
TE-1277	11/06/1998	Rochelle Sharpe, “Medicine for Flare-Ups of Cancer Pain, Anesta’s Actiq, is Approved by the FDA,” The Wall Street Journal, available at https://www.wsj.com/articles/SB910283165711912000 (November 6, 1998)	TEVA_MDL_A_13755621	TEVA_MDL_A_13755622							
TE-1278	01/00/2004	Sachin Kamal-Bahl and Becky Briesacher, “How Do Incentive-Based Formularies Influence Drug Selection And Spending For Hypertension?,” Health Affairs, 23(1), pp. 227–236 (2004)	TEVA_MDL_A_13755632	TEVA_MDL_A_13755641							
TE-1279	11/00/2004	Stanley S. Wallack et al., “Health Plans’ Strategies to Control Prescription Drug Spending,” Health Affairs, 23(6), pp. 141–148 (2004)	TEVA_MDL_A_13746792	TEVA_MDL_A_13746806							
TE-1280	00/00/2017	Stata 15 Documentation, “regress postestimation — Postestimation tools for regress,” available at https://www.stata.com/manuals13/regresspostestimation.pdf	TEVA_MDL_A_13751704	TEVA_MDL_A_13754708							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1281	08/31/2017	State of Ohio, "New Limits On Opiate Prescriptions for Acute Pain Will Save Lives and Fight Addition," available at https://mha.ohio.gov/Portals/0/assets/Initiatives/GCOAT/AcutePrescribingLimits_FINAL.pdf	TEVA_MDL_A_13745590	TEVA_MDL_A_13745590							
TE-1282	00/00/2016	Substance Abuse and Mental Health Data Archive, National Survey on Drug Use and Health: 2-Year RDAS (2016-2017)	TEVA_MDL_A_13743943	TEVA_MDL_A_13743943							
TE-1283	03/28/2013	T. Miller and S. Bhattacharya, "Incidence and Cost of Carbon Monoxide Poisoning for All Ages, Pool and Spa Submersions for Ages 0– 14, and Lead Poisoning for Ages 0-4," PIRE, March 28, 2013, available at https://www.cpsc.gov/s3fs-public/pdfs/IncidenceandCostofCarbonMonoxidePoisoningPoolandSpaSubmersionandLeadPosioning_0.pdf	TEVA_MDL_A_13755574	TEVA_MDL_A_13755620							
TE-1284	06/00/2013	Tat Chan et al., "Treatment Effectiveness and Side Effects: A Model of Physician Learning," Management Science, 59(6) (2013)	TEVA_MDL_A_13745092	TEVA_MDL_A_13745109							
TE-1285	08/02/2016	Teva Pharmaceutical Industries Limited Press Release, "Teva Completes Acquisition of Actavis Generics," available at https://www.tevapharm.com/news/teva_completes_acquisition_of_actavis_generics_08_16.aspx (August 2, 2016)	TEVA_MDL_A_13748748	TEVA_MDL_A_13748752							
TE-1286	10/14/2011	Teva Pharmaceutical Industries Limited Press Release, "Teva Completes Acquisition of Cephalon," available at https://www.tevapharm.com/news/teva_completes_acquisition_of_cephalon_10_11.aspx (October 14, 2011)	TEVA_MDL_A_13748339	TEVA_MDL_A_13748341							
TE-1287	07/27/2015	Teva Pharmaceutical Industries Limited Press Release, "Teva to Acquire Allergan Generics for \$40.5 Billion Creating a Transformative Generics and Specialty Company Well Positioned to Win in Global Healthcare," available at https://www.tevapharm.com/news/teva_to_acquire_allergan_generics_for_40_5_billion_creating_a_transformative_generics_and_specialty_company_well_positioned_to_win_in_global_healthcare_07_15.aspx (July 27, 2015)	TEVA_MDL_A_13749863	TEVA_MDL_A_13749869							
TE-1288	02/12/2018	Teva Pharmaceutical Industries Limited, SEC Form 10-K for period ended December 31, 2017 [February 12, 2018]	TEVA_MDL_A_13751211	TEVA_MDL_A_13751490							
TE-1289	12/31/2016	Teva Pharmaceutical Industries Limited, SEC Form 20-F for period ended December 31, 2006	TEVA_MDL_A_13747356	TEVA_MDL_A_13747519							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1290	12/31/2010	Teva Pharmaceutical Industries Limited, SEC Form 20-F for period ended December 31, 2010	TEVA_MDL_A_13749352	TEVA_MDL_A_13749670							
TE-1291	12/31/2011	Teva Pharmaceutical Industries Limited, SEC Form 20-F for period ended December 31, 2011	TEVA_MDL_A_13746029	TEVA_MDL_A_13746221							
TE-1292	12/31/2012	Teva Pharmaceutical Industries Limited, SEC Form 20-F for period ended December 31, 2012	TEVA_MDL_A_13747970	TEVA_MDL_A_13748172							
TE-1293	12/31/2013	Teva Pharmaceutical Industries Limited, SEC Form 20-F for period ended December 31, 2013	TEVA_MDL_A_13748937	TEVA_MDL_A_13749276							
TE-1294	12/31/2014	Teva Pharmaceutical Industries Limited, SEC Form 20-F for period ended December 31, 2014	TEVA_MDL_A_13748402	TEVA_MDL_A_13748694							
TE-1295	12/31/2015	Teva Pharmaceutical Industries Limited, SEC Form 20-F for period ended December 31, 2015	TEVA_MDL_A_13750190	TEVA_MDL_A_13750406							
TE-1296	12/31/2016	Teva Pharmaceutical Industries Limited, SEC Form 20-F for period ended December 31, 2016	TEVA_MDL_A_13754827	TEVA_MDL_A_13755069							
TE-1297	12/27/2018	Teva, "Full Product Catalog," available at https://www.tevagenics.com/products/product-search (December 27, 2018)	TEVA_MDL_A_13747520	TEVA_MDL_A_13747522							
TE-1298	00/00/2018	Teva, "Who We Are," available at https://www.tevagenics.com/about-teva-generics/who-we-are/	TEVA_MDL_A_13748177	TEVA_MDL_A_13748180							
TE-1299	11/01/2017	The Council of Economic Advisers, "The Underestimated Cost of the Opioid Crisis," available at https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The Underestimated Cost of the Opioid Crisis.pdf (November 1, 2017)	TEVA_MDL_A_13745775	TEVA_MDL_A_13745788							
TE-1300	04/29/2014	The Pew Charitable Trusts, "Implementing a Pharmaceutical Serialization and Traceability in the United States: Stockholder Perspectives and Investments," available at https://www.pewtrusts.org/en/research-and-analysis/articles/2014/04/29/implementing-pharmaceutical-serialization-and-traceability-perspectives-and-investments	TEVA_MDL_A_13746678	TEVA_MDL_A_13746679							
TE-1301	00/00/2014	The State of Ohio Board of Pharmacy, "What is OARRS?," available at https://www.ohiopmp.gov/About.aspx	TEVA_MDL_A_13751111	TEVA_MDL_A_13751114							
TE-1302	02/00/2018	Thomas C. Buchmueller and Colleen Carey, "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," American Economic Journal: Economic Policy, 10(1), pp. 77–112 (2018)	TEVA_MDL_A_13750407	TEVA_MDL_A_13750443							
TE-1303	00/00/2003	Thomas S. Rector et al., "Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications," Medical Care, 41(3) (2003)	TEVA_MDL_A_13744254	TEVA_MDL_A_13744262							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1304	11/21/2018	Tyler Lacoma, "What Is a Pharmaceutical Chargeback?", available at https://bizfluent.com/info-8783464-pharmaceutical-chargeback.html (November 21, 2018)	TEVA_MDL_A_13746222	TEVA_MDL_A_13746226							
TE-1305	09/00/2013	U.S. Department of Health and Human Services, "Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities," available at https://www.cdc.gov/drugoverdose/pdf/hhs_prescription_drug_abuse_report_09.2013.pdf	TEVA_MDL_A_13743116	TEVA_MDL_A_13743151							
TE-1306	00/00/2016	U.S. Department of Health and Human Services: Office of the Assistant Secretary for Planning and Evaluation, "Guidelines for Regulatory Impact Analysis: A Primer," available at https://aspe.hhs.gov/system/files/pdf/242931/HHS_RIAGuidancePrimer.pdf (2016)	TEVA_MDL_A_13744291	TEVA_MDL_A_13744304							
TE-1307	05/31/2019	US FDA, "Advisory Committees," available at https://www.fda.gov/advisory-committees	TEVA_MDL_A_13748389	TEVA_MDL_A_13748395							
TE-1308	00/00/2000	W.Kip Viscusi, "The Value of Life in Legal Contexts: Survey and Critique," American Law and Economics Review, 2(1), pp. 195–222 (2000)	TEVA_MDL_A_13746330	TEVA_MDL_A_13746357							
TE-1309	00/00/1994	World Health Organization Report, "Guide to Good Prescribing: A Practical Manual," Document WHO/DAP/94.11, available https://apps.who.int/medicinedocs/pdf/whozip23e/whozip23e.pdf (1994)	TEVA_MDL_A_13755387	TEVA_MDL_A_13755528							
TE-1310	05/00/2016	Zhou, Chao, et al., "Payments for Opioids Shifted Substantially to Public and Private Insurers While Consumer Spending Declined, 1999–2012," Health Affairs, 35(5) (2016)	TEVA_MDL_A_13748342	TEVA_MDL_A_13748349							
TE-1311	05/10/2019	All appendices, attachments, and exhibits to the Expert Report of Professor Edward Michna, <i>In Re National Prescription Opiate Litigation</i> , MDL No. 2804									
TE-1312	05/10/2019	All appendices, attachments, and exhibits to the expert Report of Professor Howard Dorfman <i>In Re National Prescription Opiate Litigation</i> , MDL No. 2804									
TE-1313	05/10/2019	All appendices, attachments, and exhibits to the expert Report of Melanie H. Rosenblatt, <i>In Re National Prescription Opiate Litigation</i> , MDL No. 2804									
TE-1314	05/10/2019	All appendices, attachments, and exhibits to the expert Report of Sean Nicholson, <i>In Re National Prescription Opiate Litigation</i> , MDL No. 2804									
TE-1315	03/25/2019	Plaintiff's Experts' Data Appendix									

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1316		narne_def_manu_drug_v10	SUMMIT_000087427	SUMMIT_000087427							
TE-1317	Undated	Datamonitor Report, "Stakeholder Insight: Cancer Pain,"	TEVA_MDL_A_07392961	TEVA_MDL_A_07393207							
TE-1318	07/01/2012	"Independent Medical Education Grants (US Policy-205)	TEVA_MDL_A_01261096	TEVA_MDL_A_01261099							
TE-1319	09/24/2004	Identifying Called on Universe of Physicians in Connection with Promotional Activities	TEVA_MDL_A_11892862	TEVA_MDL_A_11892864							
TE-1320	00/00/2005	Berndt, E. (2005). To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs. The New England Journal of Medicine 352, no. 4	TEVA_MDL_A_13745546	TEVA_MDL_A_13745550							
TE-1321	Undated	Anne Case and Angus Deaton, "Mortality and Morbidity in the 21st Century," Brookings Papers on Economic Activity BPEA Conference Drafts	TEVA_MDL_A_13746984	TEVA_MDL_A_13747043							
TE-1322	00/00/2016	Moghe, S (2016). Opioid History: From 'wonder rug' to abuse epidemic	TEVA_MDL_A_13746809	TEVA_MDL_A_13746816							
TE-1323	Undated	Khary K. Rigg et al., "Prescription Drug Abuse & Diversion: Role of the Pain Clinic," Journal of Drug	TEVA_MDL_A_13747631	TEVA_MDL_A_13747651							
TE-1324	Undated	Natalie Mizik and Robert Jacobson, "Are Physicians 'Easy Marks'? Quantifying the Effects of Detailing and Sampling on New Prescriptions," Management Science, 50(12)	TEVA_MDL_A_13744241	TEVA_MDL_A_13744253							
TE-1325	04/30/2011	Federation of State Medical Board House of Delegate Meeting	FSMB_001590	FSMB_001591							
TE-1326	12/03/2018	Federation of State Medical Boards Report of the Board of Directors	FSMB_001389	FSMB_001396							
TE-1327	06/03/2009	Attorney General Janet Mills Remarks to the Maine Medical Association	FSMB_001931	FSMB_001939							
TE-1328	07/29/2011	Letter from Virginia Board of Medicine	FSMB_001966	FSMB_001967							
TE-1329	03/04/2004	Medical Education in Opioid Use	FSMB_001357	FSMB_001364							
TE-1330	02/16/2017	Email Explaining DefOPS Process.	TEVA_MDL_A_13757937	TEVA_MDL_A_13757938							
TE-1331	04/27/2017	Document explaining the benefits of the DefOPS implementation.	TEVA_MDL_A_13757946	TEVA_MDL_A_13757946							
TE-1332	04/27/2017	Document explaining the benefits of the DefOPS implementation.	TEVA_MDL_A_13757947	TEVA_MDL_A_13757947							
TE-1333	04/27/2017	Documents explaining the benefits of the DefOPS implementation.	TEVA_MDL_A_13757948	TEVA_MDL_A_13757952							
TE-1334	1/11/2018	Document describinig Suspicious Order Monitoring process.	TEVA_MDL_A_13757963	TEVA_MDL_A_13757965							
TE-1335	04/27/2018	Email regarding DefOPS procedures.	TEVA_MDL_A_13757990	TEVA_MDL_A_13757993							
TE-1336	2/10/2014	Document describing Suspicious Order Monitoring Policies and Procedures.	TEVA_MDL_A_13758027	TEVA_MDL_A_13758042							
TE-1337	9/11/2014	DefOPS Process Flow.	TEVA_MDL_A_13758082	TEVA_MDL_A_13758082							
TE-1338	02/12/2015	Document describing DefOPS enhancements.	TEVA_MDL_A_13758155	TEVA_MDL_A_13758173							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
TE-1339	08/23/2016	Documents describing DefOPS workbench.	TEVA_MDL_A_13758326	TEVA_MDL_A_13758329							
TE-1340	04/27/2017	Email regarding DefOPS screen mock-up.	TEVA_MDL_A_13758575	TEVA_MDL_A_13758587							
TE-1341	01/10/2018	Powerpoint regarding SOM Process Flow.	TEVA_MDL_A_13758672	TEVA_MDL_A_13758674							
TE-1342	03/14/2013	Email Describing Teva SOM System.	TEVA_MDL_A_13758721	TEVA_MDL_A_13758722							
TE-1343	06/02/2016	Email regarding DEA order hold system.	TEVA_MDL_A_13758909	TEVA_MDL_A_13758916							
TE-1344	04/10/2018	Document listing DefOPS scenarios.	TEVA_MDL_A_13759200	TEVA_MDL_A_13759200							
TE-1345	05/03/2018	Email regarding DEA Customer License Information Form.	TEVA_MDL_A_13759209	TEVA_MDL_A_13759210							
TE-1346	05/29/2018	Spreadsheet regarding DefOPS computer system test script load.	TEVA_MDL_A_13759218	TEVA_MDL_A_13759218							
TE-1347	04/02/2014	Presentation regarding Suspicious Order Monitoring.	TEVA_MDL_A_13759578	TEVA_MDL_A_13759589							
TE-1348	05/14/2012	Memorandum regarding DEA Suspicious Order Monitoring review.	TEVA_MDL_A_13760784	TEVA_MDL_A_13760784							
TE-1349	01/25/2013	Project Plan regarding Suspicious Order Monitoring.	TEVA_MDL_A_13760810	TEVA_MDL_A_13760810							
TE-1350	00/00/1972	37 Fed. Reg. 16,503-16,504	To be produced	To be produced							
TE-1351	00/00/1975	40 Fed. Reg. 15,392, 15,394	To be produced	To be produced							
TE-1352	00/0/1994	59 Fed. Reg. 59,820, 59,821, 59,825	To be produced	To be produced							
TE-1353	00/00/1998	63 Fed. Reg. 31,143, 31,153, 64,556, 64,579	To be produced	To be produced							
TE-1354	00/00/2003	68 Fed. Reg. 6,062, 6,071	To be produced	To be produced							
TE-1355	10/17/2017	From Teddy Roosevelt to Trump: How drug companies triggered an opioid crisis a century ago - https://www.washingtonpost.com/news/retropolis/wp/2017/09/29/the-greatest-drug-fiends-in-the-world-an-american-opioid-crisis-in-1908/	To be produced	To be produced							
TE-1356	12/05/2011	Letter from Susan Franks, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA, Amending Actiq REMS with TIRF Class REMS,	TEVA_MDL_A_00297176	TEVA_MDL_A_00297176							
TE-1357	02/08/2012	Letter from Susan Franks, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA, Proposed REMS/ Modification for Fentora	TEVA_MDL_A_10687983	TEVA_MDL_A_10687983							
TE-1358	06/16/2008	Speaker Program Presentation - Fentora Secure Program	TEVA_MDL_A_06384848	TEVA_MDL_A_06384951							
TE-1359	05/00/2006	SAMHSA Substance Abuse Treatment Advisory: News for the Treatment Field (May 2006) - https://store.samhsa.gov/system/files/sma12-4175.pdf	To be produced	To be produced							
TE-1360	01/00/2012	SAMHSA Review of the Literature: Managing Chronic Pain in Adults With or in Recovery - https://store.samhsa.gov/system/files/tip54_litrev_jan2012.pdf	To be produced	To be produced							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
		Teva, Cephalon, and the Actavis Generic Entities incorporate all other Teva, Cephalon and Actavis expert witness materials given to the Plaintiffs.									
		Teva, Cephalon, and the Actavis Generic Entities incorporate all exhibits listed by any other defendants not otherwise captured on this list.									
		Teva, Cephalon, and the Actavis Generic Entities incorporate all exhibits listed by the Plaintiffs not otherwise captured on this list, unless objected to by the Defendants.									
		Teva, Cephalon, and the Actavis Generic Entities incorporate all documents yet to be produced by the Plaintiffs and not objected to by the Defendants.									
		Teva, Cephalon, and the Actavis Generic Entities reserve the right to use any document or exhibit not included on this list for purposes of impeachment.									

CERTIFICATE OF SERVICE

I hereby certify that on September 25, 2019, a copy of the foregoing Teva, Cephalon and Actavis Generic Defendants' Exhibit List was filed electronically. Notice of this filing will be sent to all parties by operation of the Court's electronic filing system. If electronic notice is not indicated through the court's e-filing system, a true and correct copy of the foregoing document was delivered via electronic mail or U.S. Mail.

Dated: September 25, 2019

/s/ Steven A. Reed
Steven A. Reed